

Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees

The Australian Needle Syringe Program Survey is funded by the Australian Centre for Disease Control. Kirby Institute, UNSW Sydney. July 2026.

© Kirby Institute, UNSW Sydney

ISSN 1448-5915

This publication is available at: **<http://www.kirby.unsw.edu.au>**

Kirby Institute
UNSW Sydney
Sydney NSW 2052
Australia

Telephone: **02 9385 0900** Facsimile: **02 6100 2860** International prefix: **612** Email: **info@kirby.unsw.edu.au**

AUSTRALIAN NSP SURVEY

Prevalence of HIV, HCV and injecting and
sexual behaviour among NSP attendees

NATIONAL DATA REPORT

2021 - 2025

Report prepared by

Sue Heard, Bradley Mathers and Lisa Maher

Kirby Institute

UNSW Sydney
Sydney NSW 2052
Australia

July 2026

Any presentation of these data should include acknowledgement of the Australian Needle Syringe Program Survey, Kirby Institute, UNSW Sydney.

Citation: Heard, S. Mathers, B. & Maher, L. (2026). Australian Needle Syringe Program Survey National Data Report 2021-2025: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: Kirby Institute, UNSW Sydney.

The Australian Needle Syringe Program Survey is funded by the Australian Centre for Disease Control. Kirby Institute, Faculty of Medicine & Health, UNSW Sydney.

ACKNOWLEDGEMENTS

We would like to acknowledge the many people who assist each year in the development and implementation of the Australian Needle Syringe Program Survey (ANSPS), particularly the clients, staff and managers at participating Needle Syringe Program (NSP) services. We also appreciate the dedication and vision of the founding members of the project and the late Dr Margaret MacDonald who was responsible for the initiation and conduct of the ANSPS from 1995 until 2003.

Ethical approvals for the survey are obtained from institutional ethics committees associated with the investigators and participating NSP sites. The Australian Needle Syringe Program Survey is funded by the Australian Centre for Disease Control.

Special thanks go to Associate Professor Philip Cunningham OAM, Chief Research Officer, Mr Mitchell Starr, Senior Hospital Scientist, Mr Andrew Kelly, Research Assistant, Mr Kevin Tran, Research Assistant, Ms Bella Galitsky, Research Assistant, Ms Maeve Hodgson, Research Assistant and Ms Shannen Butterly, Research Assistant at the NSW State Reference Laboratory for HIV at St Vincent's Hospital and St Vincent's Centre for Applied Medical Research. We also appreciate the assistance provided by Ms Rachel McCleave and Ms Lucy O'Shaugnessy from the Kirby Institute.

In 2025, the project received support and input from the following members of the ANSPS National Advisory Group: Mr Phillip Hull (ACT); Ms Annabelle Stephens (NSW); Ms Susannah O'Brien (NT); Ms Kate Kelly (SA); Ms Myf Briggs (TAS); Mr Rob Biviano (VIC); Ms Carla Gorton (QLD); Ms Ele Morrison (Australian Injecting and Illicit Drug Users League); and Ms Sue Heard, Dr Bradley Mathers and Professor Lisa Maher (Kirby Institute). We would particularly like to thank Ms Jude Bevan (WA) for chairing the National Advisory Group.

We also wish to acknowledge and thank Professor Lisa Maher who retired in 2026 after a long and successful career in the harm reduction and research sectors, including more than two decades at the Kirby Institute. During this time Professor Maher led the ANSPS and other important work providing insights that have driven not only advocacy but significant changes in policy and practice that have supported Australia's world leading response to blood-borne virus infections.

ABBREVIATIONS

ACT	Australian Capital Territory
ANSPS	Australian Needle Syringe Program Survey
COVID-19	Coronavirus disease 2019
DAA	Direct acting antiviral
DBS	Dried blood spot
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
NSP	Needle syringe program
NSW	New South Wales
NT	Northern Territory
OAT	Opioid agonist therapy
PIEDs	Performance and image-enhancing drugs
PWID	People who inject drugs
PBS	Pharmaceutical Benefits Scheme
QLD	Queensland
RNA	Ribonucleic acid
SA	South Australia
TAS	Tasmania
VIC	Victoria
WA	Western Australia

TABLE OF CONTENTS

Summary

Key Findings	i
Introduction	1
Methods	1
Findings	2
Sample	2
Demographic characteristics	2
Age at first injection and duration of injecting history	3
Drugs injected	3
Injecting behaviours	6
Drug overdose	7
Naloxone distribution and use	8
Drug treatment	8
Sexual behaviour	9
HIV	9
HIV diagnostic testing	9
HIV antibody prevalence	9
HIV treatment	10
HCV	11
HCV diagnostic testing	11
HCV antibody prevalence	11
HCV RNA prevalence	13
HCV treatment	15
References	17

Tables

1. National	18
2. Australian Capital Territory	46
3. New South Wales	66
4. Northern Territory	94
5. Queensland	114
6. South Australia	142
7. Tasmania	162
8. Victoria	182
9. Western Australia	202

Appendix

A. Participating NSP services	230
B. Methodological notes	232
C. List of tables	235

KEY FINDINGS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor HIV, hepatitis C virus (HCV), injecting-related risks and sexual behaviour among people who inject drugs in Australia.
- In 2025, 1,781 respondents were recruited from 53 participating NSP services nationally. The response rate was 35%. Although sample size has increased from the reduced recruitment observed during the COVID-19 pandemic, it remains lower than in the years preceding the pandemic.

Demographic characteristics

- The median age of survey respondents increased from 44 years in 2021 to 46 years in 2025, consistent with longer-term trends of this survey population.
- The proportion of respondents identifying as Aboriginal and/or Torres Strait Islander increased significantly, from 25% in 2021 to 29% in 2025.
- More than half of respondents in 2025 reported a lifetime history of imprisonment, and 12% reported being in prison in the previous 12 months. Among those imprisoned in the previous 12 months, 42% reported injecting while in prison.
- In 2025, 8% of respondents reported having been paid for sex in the previous month. Among these respondents, 34% reported not using a condom the last time they were paid for sex.

Injecting behaviour and drug use

- The median age at first injection remained 19 years across 2021 to 2025. The median time since first injection was 25 years in 2025, and few (7%) began injecting in the last three years, indicating a population with long injecting histories.
- In 2025, 61% of respondents reported injecting daily or more often, an increase from 44% in 2021.
- Almost half of respondents reported injecting in a public place at least once in the previous month.
- Methamphetamine remained the most commonly reported drug last injected nationally, reported by 54% of respondents in 2025. Heroin was the second most commonly reported drug last injected nationally, reported by 22% of respondents, although the leading drug last injected varied by jurisdiction.
- The proportion of respondents reporting other pharmaceutical opioids as the drug last injected declined significantly, from 7% in 2021 to 2% in 2025. Injecting of opioid agonist therapy medications as the last drug injected also declined over this period.
- In 2025, more than one quarter of respondents reported injecting more than one type of drug in the previous month, including substantial overlap between stimulant and opioid injection.
- Nationally in 2025, 6% of respondents reported performance and image enhancing drugs (PIEDs) as the last drug injected, but this varied by jurisdiction with as many as 17% in New South Wales last injecting PIEDs.
- In 2025, 25% of respondents reported reusing a needle or syringe in the previous month (including their own), and 19% reported using a needle or syringe after someone else had used it.
- In 2025, 36% of respondents reported using ancillary equipment, such as spoons, water, filters or drug mix, after someone else had used it.

Overdose & naloxone use

- Self-reported overdose increased significantly, from 11% in 2021 to 15% in 2025. Among respondents who provided information on the drugs involved in their most recent overdose, three quarters reported using some type of opioid, most commonly heroin, with many reporting use of an opioid in combination with another drug.
- In 2025, 34% of respondents reported obtaining naloxone in the previous 12 months. Respondents were more likely to report obtaining naloxone if they had ever injected opioids or had experienced an overdose themselves in the last 12 months.
- In 2025, 8% of respondents reported having naloxone administered to them in the previous 12 months, and 17% reported administering naloxone to someone else. Among both groups, approximately a third reported that no ambulance was called.

Drug treatment

- In 2025, 30% of respondents reported current engagement in some form of treatment or therapy for drug use, and a further 35% reported previous treatment.
- Among respondents who had ever injected opioids, 38% were currently receiving opioid agonist therapy (OAT) and a further 27% had received OAT in the past.

HIV

- HIV antibody prevalence remained low and stable nationally, at 1.7% in 2025 and between 1.5% and 2.1% across 2021 to 2025.
- In 2025, consistent with previous years, HIV prevalence remained substantially higher among gay men (29.1%) than among bisexual men (7.9%), heterosexual men (0.7%), and women (0.2%).
- Among respondents who tested HIV antibody positive in 2025, 65% reported being aware of their HIV-positive status. Among those who answered the HIV treatment question, 95% reported receiving antiretroviral treatment.

Hepatitis C

- HCV antibody prevalence declined from 45% in 2023 to 32% in 2025. This is the ninth consecutive year that less than half of respondents had this marker indicating exposure to HCV, following two decades of HCV antibody prevalence $\geq 50\%$.
- HCV antibody prevalence remained higher among respondents who had injected for more than three years, those who reported heroin or other opioids as the last drug injected, those injecting daily or more often, those reporting receptive syringe sharing, and those reporting imprisonment in the previous 12 months.
- The proportion of respondents with detectable HCV RNA, indicating active HCV infection, declined significantly from 16% in 2021 to 7% in 2025. This represents a 56% decline in active HCV infection over the five-year period.
- In 2025, 68% of respondents had no evidence of HCV exposure, 25% had evidence of cleared HCV infection, and 7% had active HCV infection.
- Among respondents assessed as eligible for HCV treatment, the proportion who reported a lifetime history of HCV treatment increased over the five-year period, from 62% in 2021 to 81% in 2025.
- Among respondents assessed as eligible for HCV treatment, the proportion who reported recent (last 12 months) treatment increased between 2021 (28%) and 2025 (47%).

INTRODUCTION

The Australian Needle Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antibody prevalence, HCV ribonucleic acid (RNA) prevalence and sexual and injecting risk behaviour among people who inject drugs (PWID) in Australia. Conducted annually since 1995 over a one-two week period in October, all clients attending participating Needle Syringe Program (NSP) services are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV testing. This report presents national and state/territory results for the years 2021 to 2025.

METHODS

NSP sites are selected to participate in the ANSPS based on the number of client occasions of service per week, willingness to participate, and to ensure representation from all jurisdictions.

Previous analyses have demonstrated that inferences derived from ANSPS samples can be reasonably applied to the broader NSP client population and that the ANSPS sample is as representative of Australia's population of people who inject drugs as is practical to obtain.^{1,2}

This report presents results for the years 2021 to 2025. During this period the survey was impacted by the COVID-19 pandemic,³ in particular in 2021 when only 37 sites participated in the survey, including only three each in NSW and Victoria. **Appendix A** provides details of participating NSP services over the period 2021 to 2025.

During the two-week survey implementation period, all clients attending participating NSPs are invited to join the study. NSP staff record the age and gender of both ANSPS respondents and those who decline to participate, as well as whether each individual is a new or repeat client. These records are used to calculate annual ANSPS response rates. Verbal rather than written informed consent was obtained to assure the anonymity of participants. Participation is anonymous and voluntary.

Consenting NSP attendees complete a brief questionnaire and provide a capillary dried blood spot (DBS) for HIV and HCV testing. The questionnaire collects data on demographic characteristics, injecting and sexual behaviours, and history of blood-borne virus testing and treatment, imprisonment and drug dependence treatment. The survey is designed to be self-completed, although assistance for clients is available where necessary.

DBS samples were analysed for HIV and HCV antibodies and HCV RNA by the NSW State Reference Laboratory for HIV at St Vincent's Hospital and St Vincent's Centre for Applied Medical Research, Sydney. Details on laboratory procedures and assays used are described in **Appendix B**. Notably, the assay used for detection of HCV antibodies for the years 2023 to 2025 differed from that used previously. An increase in HCV antibody prevalence observed in 2023 was attributed to the introduction of this new assay and procedure, as discussed further in Appendix B.

Descriptive statistics are presented. Chi-square tests were used to examine differences between groups. Where data showed a linear relationship over time, chi square (Cochran-Armitage) tests for trend were used to assess temporal trends. Statistical significance was set at $p < 0.050$. Percentage values in tables may not add to 100 due to rounding and where data are stratified by gender, totals include respondents who identified as gender other than male or female and respondents who did not report their gender. Results with small sample size, particularly at the jurisdictional level, should be interpreted with caution.

The proportion of the ANSPS sample identifying as Aboriginal and/or Torres Strait Islander has increased substantially over the past 30 years of the survey. Because of this considerable over-representation of Aboriginal and/or Torres Strait Islander people in the survey, the project's Aboriginal research governance structure is in the process of being strengthened and approval from jurisdictional Indigenous health research ethics committees is being sought in order to undertake and report on further analyses of Aboriginal and Torres Strait Islander participant data.

FINDINGS

Sample recruited

In 2025, 1,781 respondents were recruited across 53 participating NSP services (Table 1.1.1). The number of respondents surveyed has remained greater than 1,700 in the years since 2021 when only 1,474 were recruited and COVID-19 related restrictions were in place. Notably, the number of respondents remains substantially lower than in the years preceding the COVID-19 pandemic where the mean sample size was approximately 2,500 for the period 2015 to 2019. A similar decline over the same period was observed in the total number of NSP occasions of service (OOS) nationally, with the number of OOS in 2025 only 73% of 2019 levels.⁴

The pandemic also impacted the composition of the sample by state and territory. In 2021, 33% ($n=485$) of respondents were recruited in WA, 31% ($n=458$) in Queensland, and only 3% ($n=46$) in NSW where COVID-19 related restrictions impacted the number of sites able to participate in the ANSPS. In subsequent years NSW has consistently accounted for a greater proportion of the sample, in 2025 contributing 25% ($n=439$) of the sample with 21% ($n=369$) from WA, 15% ($n=260$) from Queensland, 14% ($n=247$) from Victoria, 12% ($n=218$) from SA, 6% ($n=100$) from ACT and four percent each from NT ($n=69$) and Tasmania ($n=79$).

Thirty-two NSP sites participated in the ANSPS in each of the past five years and accounted for 70% of all respondents recruited in 2025. In 2025, 35% ($n=1,781$) of NSP attendees invited to participate in the study agreed to do so. Over the past five years the response rate varied between 34% ($n=1,781$) in both 2022 & 2025 and 45% ($n=1,474$) in 2021.

Demographic characteristics

Gender

Consistent with previous years, in 2025 the sample was predominantly male, with 32% ($n=573$) female and 1% ($n=19$) identifying as trans or gender diverse.

Age

In 2025, 3% of respondents (n=51) were aged less than 25 years. Between 2021 to 2025, the median age of respondents ranged from 44 to 46 years ($p=0.001$, Table 1.1.1). This is consistent with the overall trend observed since the commencement of the ANSPS in 1995, that the sample recruited each year has become older over time.

Aboriginal and Torres Strait Islander respondents

The proportion of respondents identifying as being of Aboriginal and/or Torres Strait Islander background has consistently increased over the duration of the ANSPS and increased significantly from 25% (n=373) in 2021 to 29% (n=520) in 2025 ($\chi^2 p<0.001$).

Language and country of birth

The majority (89%, n=1,584) of ANSPS respondents were born in Australia (2021-2025 range: 86% to 89%), with New Zealand (3%, n=45) and United Kingdom/Ireland (2%, n=42) the most common countries of birth outside Australia in 2025. In 2025, 5% (n=90) of respondents reported a language other than English spoken at home by their parents (2021-2025 range: 3% to 6%).

Sexual identity

In 2025, the majority (81%, n=1,435) of respondents identified as **heterosexual**, 11% (n=192) identified as **bisexual** and 4% (n=80) as **gay** or **lesbian** (Table 1.1.1). Women were more likely to identify as bisexual than men in each of the past five years, with 20% (n=117) vs 5% (n=64) respectively identifying as bisexual in 2025 ($\chi^2 p < 0.001$).

Incarceration

Over half (54%) of all respondents in 2025 reported having ever been in prison (2021-2025 range: 51% to 54%) with 12% reporting being in prison in the last year (2021-2025 range: 11% to 13%).

Age at first injection and duration of injecting history

The median age at first drug injection was 19 years in all ANSPS samples from 2021 to 2025 (2025 range: 10 years to 66 years).

Among respondents in 2025, the median number of years since first injection was 25 years (2021-2025 range: 23 years to 25 years). In 2025, 7% (n=119) of respondents first injected within the last three years (2021-2025 range: 4% to 7%) and among these newer initiates to injecting drug use, the median age at first injection was 32 years (2021-2025 range: 29 years to 34 years).

Drugs injected

Drug last injected

Nationally, over the past five years, **methamphetamine** has remained the most commonly reported drug last injected, followed by **heroin**, in 2025 reported by 54% (n=954) and 22% (n=383) of respondents, respectively (Table 1.1.2; Figure 1). This differed substantially across states and territories. While methamphetamine was the most frequently reported drug last injected in NSW (39%, n=173), Queensland (54% n=141), South Australia (59%, n=129), Tasmania (73%, n=58), Western Australia (73%, n=269) and the Northern Territory (72%,

n=50), heroin was more frequently reported in ACT (45%, n=45) and Victoria (45%, n=110) (Jurisdiction Tables 2-9.1.2).

Performance and image enhancing drugs (PIEDs; including peptides and anabolic steroids such as testosterone and human growth hormone) were the last drug injected by 6% (n=109) of respondents nationally in 2025 (2021-2025 range: 4% to 7%). PIEDs injection was most prevalent in NSW (17%, n=76), Queensland (7%, n=19) and Tasmania (6%, n=5), less common in Western Australia (2%, n=6) and South Australia (1%, n=3), and was not reported by any respondents in ACT, Victoria and the Northern Territory in 2025.


A small and decreasing proportion of respondents reported last injecting opioid agonist therapy medications nationally over the last five years. In 2025, 2% of respondents reported **methadone** as the drug last injected, 1% **buprenorphine** (Subutex®), and <1% **buprenorphine-naloxone** (Suboxone®) compared to 5%, 4%, and 2%, respectively, in 2021.

Over the past five years, a decreasing proportion of respondents have reported **other pharmaceutical opioids** (such as morphine, oxycodone and fentanyl) as the drug last injected, from 7% in 2021 to 2% in 2025 (χ^2 trend $p<0.001$). In the Northern Territory, pharmaceutical opioids were the second most frequently reported drug last injected (13%, n=9) after methamphetamine in 2025.

Cocaine has been reported as the drug last injected by only 1% of respondents consistently over the past five years.

Notably in 2025, 11% (n=197) of respondents reported injecting **multiple drugs** at last injection, a greater proportion than in the previous four years (2021-2025 range: 5% to 11%).

Figure 1. Drug last injected (%), 2021–2025



Drugs injected in the last month

In 2025 participants were asked to report all drugs they had injected in the last month in addition to the last drug they had injected (Figure 2). This provided an opportunity to examine polydrug use among respondents.

Seventy-one percent (n=1,269) of respondents reported injecting **methamphetamine** in the last month and 7% (n=120) reported injecting **cocaine**.

Forty-three percent of respondents (n=766) reported injecting an **opioid** in the last month. This included 35% (n=621) who reported injecting **heroin**, 6% (n=113) who had injected a **pharmaceutical opioid** (other than an opioid agonist therapy medication), as well as 12% (n=218) who reported injecting an opioid agonist therapy medication, including 8% (n=134) who had injected **methadone**, 5% (n=81) who had injected **buprenorphine** (Subutex®), and 3% (n=60) who had injected **buprenorphine-naloxone** (Suboxone®). Half (n=110) of those who reported injecting an OAT medication in the last month had also injected heroin, and nearly one in five (18%) of those who reported injecting heroin in the last month had also injected an OAT medication.


Sixty-eight percent of respondents (n=1,214) reported having ever injected opioids. Of these respondents, 63% (n=766) had injected opioids in the past month, and 38% (n=465) reported an opioid was the last drug they injected.

Eight percent (n=135) of respondents reported injecting a **performance or image enhancing drug** in the last month.

Fifteen participants (1%) reported injecting other drugs in the last month including ketamine, 3,4-methylenedioxymethamphetamine (MDMA), gamma-hydroxybutyrate (GHB), lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), Ritalin, and Aripiprazole.

Twenty-seven percent (n=478) of respondents reported using more than one drug in the last month. Among the 1,290 respondents who reported injecting a stimulant (either methamphetamine or cocaine) in the last month 30% (n=393) had also injected an opioid (heroin, an OAT medication, or another pharmaceutical opioid). Conversely, among the 766 respondents who reported injecting an opioid in the last month, 51% had also injected a stimulant.

Among respondents reporting they had used a performance or image enhancing drug in the last month, 19% (n=26) reported also injecting another drug in the past month including 16% (n=22) who had also injected methamphetamine, 13% (n=18) who had also injected cocaine, and 13% (n=18) who had also injected an opioid.

Figure 2. Drugs injected in the last month (%), 2025

*Suboxone® = buprenorphine-naloxone

Injecting behaviours

In 2025, 61% (n=1,084) of respondents reported **injecting daily or more often**, an increase from 44% of respondents in 2021 (Table 1.1.2).

Among respondents who reported being in prison in the last 12 months, 42% (n=93) in 2025 reported **injecting while in prison** (2021-2025 range: 31% to 42%; Table 1.1.1).

In 2025, 49% (n=793) of respondents reported **injecting in a public place** (such as a public toilet, the street, a park, the beach, a squat, or a car) on at least one occasion in the past month (2021-2025 range: 44% to 49%).

Use and reuse of injecting equipment


In 2025, 74% (n=1,195) of respondents reported they used **new and sterile needles for all injections** in the past month (2021-2025 range: 73% to 75%), with 25% (396) of respondents reusing a needle-syringe (used previously by themselves or another person) on one or more occasions in the last month (2021-2025 range: 24% to 26%; Table 1.1.3, Figure 3).

In 2025, 19% (n=300) reported using on one or more occasions in the past month a needle/syringe after someone else had used it, referred to as **'receptive syringe sharing'** (2021-2025 range: 18% to 19%). Among those who reported receptive syringe sharing in the past month 25% (n=79) did not know how many people had used the equipment previously. Further, 40% (n=99) reported the other people who had used the equipment included their

regular sex partner, 10% (n=24) a casual sex partner, 37% (n=91) a close friend, 22% (n=54) an acquaintance, 4% (n=11) another person, among respondents providing this information (n=247).

Reuse of any **ancillary injecting equipment** (including spoon, water, filter, and drug mix) after use by someone else in the last month was reported by 36% of respondents in 2025 (2021-2025 range: 30% to 36%). As in previous years, spoons (20%) and water (24%) were the items most commonly reported to have been reused (Table 1.1.3).

Figure 3. Proportion of respondents reporting reuse and receptive sharing of needles and syringes and receptive sharing of ancillary equipment in the last month, 2021–2025



Drug overdose

In 2025, 15% (n=266) of respondents reported they had experienced a drug overdose in the previous 12 months (Table 1.1.2), a significant increase from 11% (n=166) reported in 2021 (χ^2 p=0.001).

Sixty-nine percent of respondents (n=177) reporting an overdose in the last 12 months, provided information on the drug(s) they had used when they last overdosed. Seventy-five percent (n=133) of these respondents reported using some type of opioid when they last overdosed, including 69% (n=122) who had used heroin. Among these individuals experiencing an opioid overdose 3% (n=4) involved heroin in combination with another opioid, 16% (n=20) in combination with a benzodiazepine, 7% (n=8) in combination with alcohol, 5% (n=6) in combination with GHB, and 5% (n=6) in combination with another pharmaceutical such as an antipsychotic.

Among the n=44 respondents who reported an overdose that did not involve an opioid, n=21 reported having used a stimulant such as methamphetamine or cocaine, n=20 had used GHB either alone or in combination with alcohol or another drug, and n=5 had used benzodiazepines.

Naloxone distribution and use

Naloxone is now widely available in all states and territories through the Take Home Naloxone (THN) program funded by the Australian Government since July 2022. Naloxone is distributed through community and hospital-based pharmacies, alcohol and drug treatment centres, needle and syringe programs, and custodial release programs for anyone who may experience or witness an opioid overdose.

In 2025, 34% (n=600) of respondents reported having obtained naloxone in the previous twelve months, compared to 37% in 2024. Respondents who reported ever injecting opioids were more likely to report having obtained naloxone than those who reported never injecting opioids (44% vs. 13%; p-value <0.001). Respondents reporting having overdosed in the last 12 months (66%) were more likely to have obtained naloxone than those who had not (59% vs 29%; p-value <0.001).

Respondents reported obtaining naloxone from NSPs (80%, n=481), chemists (14%, n=85), drug and alcohol services (10%, n=61), friends (5%, n=28), other health services (1%, n=15), or on exiting prison (1%, n=14).

Eight percent of respondents (n=138) reported having naloxone administered to them in the last 12 months. Of these respondents 26% (n=36) reported having naloxone administered four or more times in the last 12 months and 34% (n=47) reported that no ambulance was called.

Seventeen percent (n=297) reported having administered naloxone to someone else in the last 12 months. Of these respondents 24% (n=72) reported administering naloxone to another person four or more times in the last 12 months and 29% (n=85) reported that no ambulance was called. Among these respondents 74% (n=220) reported injecting an opioid in the last month and 90% (n=268) had injected opioids at some time in their life.

Drug treatment

In 2025, 30% (n=534) of respondents reported they were currently engaged in some form of treatment or therapy for drug use (2021-2025 range: 30% to 34%), and an additional 35% (n=619) were not currently receiving treatment but had done so previously (2021-2025 range: 33% to 35%, Table 1.1.4).

In 2025, 27% (n=475) of all ANSPS respondents reported they were currently receiving OAT (2021-2025 range: 26% to 30%) and a further 21% (n=367) had received OAT in the past (2021-2025 range: 20% to 23%). Methadone was the most commonly reported OAT medication currently prescribed, reported by 17% (n=295) of respondents, followed by long-

acting depot buprenorphine (7%, n=131), buprenorphine (6%, n=106), and buprenorphine-suboxone (6%, n=106).

In 2025, among those participants who reported they had ever injected opioids, 38% (n=462) were currently receiving OAT and a further 27% (n=328) had received OAT in the past, consistent with previous years (2021-2025 range: 36% to 41%, and 27% to 29%, respectively).

Sexual behaviour

Half of all respondents (50%, n=899) in 2025 reported being sexually active in the last month (2021-2025 range: 49% to 51%), with 42% (n=744) reporting sex with a regular partner and 17% (n=298) with a non-regular partner (Table 1.1.5).

The majority (75%, n=555) reported never using condoms during sex with a regular partner in the last month (2021-2025 range: 75% to 78%, Table 1.1.5). Only 16% (n=49) of those reporting casual sex in the past month used condoms on every occasion, with 54% (n=162) never using condoms (2021-2025 range: 13% to 23%, and 49% to 56%, respectively).

In 2025, 8% (n=137) of respondents reported having been paid for sex in the last month (2021-2025 range: 5% to 8%), with female (9%, n=53) and trans and gender diverse (37%, n=7) respondents more likely to report having been paid for sex than male respondents (6%, n=71). Among these respondents, 34% (n=47) reported not using a condom the last time they were paid for sex (2021-2025 range: 24% to 38%).

HIV

HIV testing

In 2025, 77% (n=1,373) of respondents reported having ever been tested for HIV, consistent over the last five years (2021-2025 range: 75% to 77%), with 43% (n=766) tested in the previous 12 months (2021-2025 range: 38% to 43%, Table 1.1.6).

HIV antibody prevalence

HIV antibody prevalence among respondents remained low at 1.7% (n=31) nationally in 2025, and stable across the last five years (2021-2025 range: 1.5% to 2.1%, χ^2 trend p=0.704, Table 1.2.1). HIV seroprevalence varied between jurisdictions and in 2025 was highest among respondents from Queensland (3.5%, n=9) and New South Wales (3.0%, n=13), with a combined prevalence among respondents from all other states of 0.8% (n=9); none of the respondents from the Australian Capital Territory (n=100) or the Northern Territory (n=69) tested positive for HIV in 2025. The prevalence of HIV observed among state and territory samples fluctuated over the last five years (Jurisdiction Tables 2-9.2.1).


HIV prevalence among men (2.4%, n=28) was significantly greater than among women (0.2%, n=1, p<0.002) in 2025 and in the previous four years (Figure 4). No female respondents in the Australian Capital Territory, South Australia or Tasmania tested HIV positive in any of the five years 2021 to 2025.

Consistent with previous analyses, in 2025 HIV prevalence remained highest among male respondents who identified as homosexual (29.1%, n=15) compared to those identifying as bisexual (7.9%, n=5) or heterosexual (0.7%, n=7) and compared to female respondents of any sexual identity (Table 1.2.2 and Figure 4). Male homosexual identity remains the strongest independent correlate of HIV antibody-positive serostatus among ANSPS respondents.⁵

In 2025, the median age of respondents living with HIV was 45 years (range 31 to 70 years) and the median time since first injection was 22 years (range 4 to 56 years).

Among the 31 respondents who tested HIV antibody positive in 2025, two thirds (65%, n=20) were aware of their HIV positive status and 16% (n=5) self-reported they were HIV negative; 19% of those who tested seropositive (n=6) did not report their HIV status in the questionnaire.

Figure 4. HIV antibody prevalence (%) by gender and sexual identity, 2021–2025



HIV treatment

In 2025, among the 31 respondents who tested positive for HIV, 61% (n=19) reported receiving antiretroviral treatment, 3% (n=1) reported not receiving treatment, and 35% (n=11) did not respond to the treatment question. The proportion of respondents living with HIV who reported receiving treatment was lower in 2025 than in the previous four years (2021–2024 range: 72%–86%); however, this comparison should be interpreted with caution given the relatively high level of non-response in 2025. Among respondents living with HIV who answered the treatment question, 95% reported receiving treatment, consistent with the previous five years (2021–2025 range: 90%–95%).

HCV

HCV antibody testing


In 2025, 79% (n=1,398) of respondents reported having ever been tested for HCV, consistent over the last five years (2021-2025 range: 78% to 80%), with 48% (n=860) tested in the previous 12 months (2021-2025 range: 47% to 49%, Table 1.1.6).

HCV antibody prevalence

In 2025, 32% of respondents (n=565) tested HCV antibody positive. As noted above, the assay used to detect HCV antibodies from 2023 to 2025 differed from that used in earlier years. The increase in HCV antibody prevalence observed in 2023, compared with preceding years, is likely attributable to changes in laboratory procedures and the enhanced sensitivity of the newer assay (Appendix B). Consequently, HCV antibody results from 2023 onwards should not be directly compared with results from years in which the previous assay was used.

Nationally, HCV antibody prevalence declined between 2023 and 2025 (45% to 32%, χ^2 trend $p<0.001$, Table 1.3.1). Similar declines in prevalence over the last three years were observed across states and territories (Jurisdiction Tables 2-9.3.1, Figure 5). It should be noted that HCV Ab prevalence remains lower compared to ANSPS results in the pre-DAA era.


Figure 5. HCV antibody prevalence (%) by jurisdiction, 2021–2025



Differences in HCV antibody prevalence between male and female respondents across the last five years were not statistically significant. HCV antibody prevalence was significantly higher among heterosexual respondents compared to those identifying as homosexual or bisexual. These differences were statistically significant in the years 2022, 2023, and 2024 (Table 1.3.2).


Across the last five years HCV antibody prevalence was significantly higher among older respondents and those with longer injection histories (Table 1.3.3 and 1.3.4). Figure 6 illustrates the relationship between HCV prevalence and greater time since first injection and longer duration of exposure.

Figure 6. HCV antibody prevalence (%) by time since first injection, 2025



HCV antibody prevalence was higher among respondents reporting heroin or other opioids as the last drug injected, compared to respondents who last injected methamphetamine, consistently from 2021 to 2025 among both male and female respondents (Figure 7, Table 1.3.6).

Figure 7. HCV antibody prevalence (%) by drug last injected and gender, 2021–2025



Further, across each of the last five years, HCV antibody prevalence was significantly higher among respondents who reported injecting daily or more often ($p<0.001$ in 2025, Table 1.3.7), among those who reported receptive syringe sharing ($p<0.001$ in 2025, Table 1.3.5), and among respondents who reported imprisonment in the last 12 months ($p=0.012$ in 2025, Table 1.3.8).


HCV RNA prevalence

The ANSPS commenced HCV RNA testing in 2015, immediately before HCV direct acting antiviral (DAA) therapies were made available through the Australian Government's Pharmaceutical Benefits Scheme (PBS) in March 2016.⁶ The proportion of the ANSPS sample with sufficient DBS for HCV RNA testing has improved over time, with ~90% of respondents tested for HCV RNA in all years since 2020.

The proportion of respondents with detectable HCV RNA decreased from 16% in 2021 to 7% in 2025 (χ^2 trend $p<0.001$, Table 1.3.1), representing a 56% decline in the proportion of respondents with active HCV infection.

HCV RNA prevalence was consistently lower among female than male respondents across the period 2021 to 2025, but this difference was only statistically significant in 2023 ($p=0.025$, Figure 8).

Figure 8. Proportion of respondents (%) with detectable HCV RNA by gender and survey year



In each of the past five years, HCV RNA prevalence was significantly greater among respondents who reported receptive syringe sharing ($p=0.006$ in 2025), and among those who first injected more than three years ago ($p=0.024$ in 2025).

There were no significant differences in HCV RNA prevalence between respondents who last injected an opioid and those who last injected methamphetamine. In 2021, HCV RNA was detected in three respondents who reported the last drug they injected was a performance or image enhancing drug, and none in any subsequent year.

There was no significant difference in HCV RNA prevalence between groups on the basis of sexual identity, age, history of imprisonment in the last 12 months, country of birth or language spoken at home.

Together, results of HCV antibody and HCV RNA testing provide an estimate of HCV infection and viraemic prevalence.⁶ Across the period 2023 to 2025 for which HCV antibody prevalence is comparable (see previous note on introduction of new HCV antibody assay in 2023), the proportion of respondents with a history of HCV but who have cleared infection (HCV antibody positive and HCV RNA negative) decreased from 33% to 25% (χ^2 trend $p < 0.001$), while the proportion of respondents with no evidence of exposure to HCV (HCV antibody negative) increased from 55% in 2023 to 68% in 2025 (χ^2 trend $p < 0.001$, Figure 9).

Figure 9. HCV viraemic status (%) by survey year






Figure 10. HCV viraemic status (%) nationally and by jurisdiction in 2025

HCV treatment

As noted above, DAA therapies for HCV are now widely available through the Australian Government's Pharmaceutical Benefits Scheme (PBS).⁶ Among respondents who tested HCV antibody positive and were aware of their status, and after excluding those who reported spontaneous HCV clearance, the proportion who reported a lifetime history of HCV treatment increased significantly from 62% in 2021 to 81% in 2025 (χ^2 trend $p=0.001$). This increase was observed among both men and women. Similarly, among all those testing HCV antibody positive, irrespective of awareness of status or self-reported clearance, the proportion who reported having ever received HCV treatment increased from 38% in 2021 to 48% in 2025 (χ^2 trend $p=0.001$).

Among respondents who tested HCV antibody positive, and after excluding those who reported spontaneous or treatment-induced clearance more than 12 months previously, the proportion who reported recent (last 12 months) HCV treatment also increased significantly between 2021 (28%) and 2025 (47%, χ^2 trend $p<0.001$, Figure 11). Notably, a significant increase in recent treatment uptake was observed in men (29% in 2021 to 54% in 2025, χ^2 trend $p<0.001$), however the smaller increase observed among women was not statistically significant (24% in 2021 to 33% in 2025, χ^2 trend $p=0.275$).

Figure 11. Proportion of respondents (%) reporting lifetime and recent* HCV treatment among HCV antibody positive respondents who did not report spontaneous clearance by survey year



* The denominator for recent HCV treatment includes respondents reporting treatment in the last 12 months and excludes those who reported prior HCV treatment induced clearance

Figure 12. Lifetime history of HCV treatment (%) nationally and by jurisdiction, 2021-2025



REFERENCES

1. MacDonald M, Wodak AD, Ali R, Crofts N, Cunningham PH, Dolan KA, Kelaher M, Loxley WM, van Beek I & Kaldor JM. HIV prevalence and risk behaviour in needle exchange attenders: a national study. *Medical Journal of Australia* 1997; 166, 237-240.
2. Topp L, Iversen J, Wand H, Day C, Kaldor J & Maher L. Representativeness of injecting drug users who participate in HIV surveillance: Results from Australia's Needle and Syringe Program Survey. *Journal of Acquired Immune Deficiency Syndromes* 2008; 47(5), 632-638.
3. Iversen J, Wand H, Kemp R, Bevan J, Briggs M, Patten K, Heard S & Maher L. Uptake of COVID-19 vaccination among people who inject drugs. *Harm Reduction Journal* 2022;19 (59).
4. Heard S, Mathers B, Kwon JA & Maher L. Needle Syringe Program National Minimum Data Collection: 10 Year National Data Report 2016-2025. Sydney: Kirby Institute, UNSW Sydney; 2025.
5. Iversen J, Wand H, Topp L, Kaldor J & Maher L. Extremely low and sustained HIV incidence among people who inject drugs in a setting of harm reduction. *AIDS* 2014;28(2):275-8.
6. Iversen J, Dore G, Starr M, Catlett B, Cunningham P, Geddes L & Maher L. Estimating the Consensus Hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy. *International Journal of Drug Policy* 2020;83:102837.

National

Table 1.1.1 Number (%) of respondents by demographic characteristics and survey year

National	2021*	2022	2023	2024	2025
Number of sites	37	53	55	54	53
N° surveyed	N=1474	N=1781	N=1991	N=1760	N=1781
Response rate (%)	45%	34%	37%	35%	34%
Gender (%)					
Male	933 (63)	1156 (65)	1276 (64)	1139 (65)	1165 (65)
Female	520 (35)	586 (33)	679 (34)	575 (33)	573 (32)
Other	19 (1)	35 (2)	30 (2)	43 (2)	19 (1)
Not reported	2 (<1)	4 (<1)	6 (<1)	3 (<1)	24 (1)
Age (years)					
Median age	44	45	45	45	46
Age range	16-78	16-73	18-77	18-73	16-76
<25 years	34 (2)	52 (3)	48 (2)	47 (3)	51 (3)
25+ years	1431 (97)	1711 (96)	1926 (97)	1712 (97)	1725 (97)
Not reported	9 (1)	18 (1)	17 (1)	1 (<1)	5 (<1)
Sexual identity (%)					
Heterosexual	1204 (82)	1409 (79)	1579 (79)	1384 (79)	1435 (81)
Bisexual	149 (10)	178 (10)	207 (10)	193 (11)	192 (11)
Gay/Lesbian	65 (4)	87 (5)	86 (4)	87 (5)	80 (4)
Other	45 (3)	93 (5)	99 (5)	89 (5)	12 (1)
Not reported	11 (1)	14 (1)	20 (1)	7 (<1)	62 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	1031 (70)	1312 (74)	1383 (69)	1271 (72)	1233 (69)
Yes	373 (25)	438 (25)	581 (29)	464 (26)	520 (29)
Not reported	70 (5)	31 (2)	27 (1)	25 (1)	28 (2)
Region/country of birth (%)					
Australia	1274 (86)	1541 (87)	1776 (89)	1553 (88)	1584 (89)
Other Oceania	43 (3)	50 (3)	62 (3)	39 (2)	46 (3)
Asia	12 (1)	26 (1)	18 (1)	23 (1)	26 (1)
UK & Ireland	57 (4)	58 (3)	55 (3)	54 (3)	42 (2)
Other	48 (3)	72 (4)	57 (3)	67 (4)	47 (3)
Not reported	40 (3)	34 (2)	23 (1)	24 (1)	36 (2)
Main language spoken at home by parents (%)					
English	1406 (95)	1669 (94)	1876 (94)	1647 (94)	1667 (94)
Non-English	51 (3)	93 (5)	100 (5)	99 (6)	90 (5)
Not reported	17 (1)	19 (1)	15 (1)	14 (1)	24 (1)
Age at first injection and time since first injection (years)					
Median age first injection	19	19	19	19	19
Age range first injection	10-85	10-72	10-72	10-64	10-66
N° not reported	49	99	73	46	78
Median yrs since first injection	23	24	24	25	25
Range yrs since first injection	<1-62	<1-56	<1-56	<1-54	<1-58
<3 years since first injection	65 (4)	97 (5)	103 (5)	108 (6)	119 (7)
3+ years since first injection	1353 (92)	1584 (89)	1812 (91)	1605 (91)	1583 (89)
Not reported	56 (4)	100 (6)	76 (4)	47 (3)	79 (4)

* Implementation of the 2021 ANSPS was impacted by the COVID-19 pandemic

Table 1.1.2 Number (%) of respondents by last drug injected, frequency of injecting, overdose, imprisonment, injection in prison and survey year

National N° surveyed	2021 N=1474	2022 N=1781	2023 N=1991	2024 N=1760	2025 N=1781
Drug last injected (%)					
Cocaine	8 (1)	14 (1)	15 (1)	14 (1)	10 (1)
Methamphetamine	750 (51)	840 (47)	1048 (53)	916 (52)	954 (54)
Heroin	299 (20)	451 (25)	478 (24)	431 (24)	383 (22)
Pharm. opioids	110 (7)	87 (5)	65 (3)	50 (3)	28 (2)
Methadone	70 (5)	75 (4)	91 (5)	68 (4)	41 (2)
Buprenorphine	53 (4)	40 (2)	34 (2)	27 (2)	10 (1)
Buprenorphine/naloxone	33 (2)	23 (1)	21 (1)	13 (1)	3 (<1)
PIEDs	52 (4)	118 (7)	101 (5)	92 (5)	109 (6)
More than one	77 (5)	98 (6)	105 (5)	123 (7)	197 (11)
Other	11 (1)	17 (1)	19 (1)	15 (1)	1 (<1)
Not reported	11 (1)	18 (1)	14 (1)	11 (1)	45 (3)
Ever injected opioids (%)					
No	434 (29)	472 (27)	559 (28)	506 (29)	556 (31)
Yes	1030 (70)	1302 (73)	1422 (71)	1237 (70)	1214 (68)
Not reported	10 (1)	7 (<1)	10 (1)	17 (1)	11 (1)
Frequency of injection last month (%)					
Not last month	186 (13)	165 (9)	202 (10)	142 (8)	128 (7)
Less than weekly	293 (20)	286 (16)	301 (15)	233 (13)	192 (11)
Weekly not daily	312 (21)	393 (22)	426 (21)	350 (20)	333 (19)
Daily or more	654 (44)	902 (51)	1021 (51)	1005 (57)	1084 (61)
Not reported	29 (2)	35 (2)	41 (2)	30 (2)	44 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	1207 (82)	1459 (82)	1603 (81)	1394 (79)	1404 (79)
Yes	234 (16)	286 (16)	297 (15)	306 (17)	311 (17)
Not reported	33 (2)	36 (2)	91 (5)	60 (3)	66 (4)
Overdosed in last 12 months (%)					
No	1265 (86)	1525 (86)	1631 (82)	1421 (81)	1445 (81)
Yes	166 (11)	220 (12)	266 (13)	266 (15)	266 (15)
Not reported	43 (3)	36 (2)	94 (5)	73 (4)	70 (4)
Imprisonment last year (%)					
No	1230 (83)	1508 (85)	1637 (82)	1416 (80)	1446 (81)
Yes	157 (11)	198 (11)	213 (11)	236 (13)	221 (12)
Not reported	87 (6)	75 (4)	141 (7)	108 (6)	114 (6)
Injected while in prison last year					
N° in prison in last year	N=157	N=198	N=213	N=236	N=221
No	101 (64)	125 (63)	137 (64)	148 (63)	122 (55)
Yes	54 (34)	66 (33)	67 (31)	80 (34)	93 (42)
Not reported	2 (1)	7 (4)	9 (4)	8 (3)	6 (3)

Table 1.1.3 Number (%) of respondents by injecting behaviour in the last month and survey year

National	2021	2022	2023	2024	2025
N° injected last month	N=1259	N=1581	N=1748	N=1588	N=1609
Places injected last month (%)					
All private	694 (55)	841 (53)	896 (51)	821 (52)	809 (50)
Any public	559 (44)	734 (46)	843 (48)	759 (48)	793 (49)
Not reported	6 (<1)	6 (<1)	9 (1)	8 (1)	7 (<1)
Use of new and sterile needles and syringes last month (%)					
All injections	941 (75)	1179 (75)	1275 (73)	1153 (73)	1195 (74)
Most of the time	244 (19)	312 (20)	354 (20)	312 (20)	322 (20)
Half of the time	27 (2)	39 (2)	55 (3)	35 (2)	32 (2)
Some of the time	28 (2)	23 (1)	31 (2)	41 (3)	34 (2)
Not last month	10 (1)	9 (1)	13 (1)	11 (1)	8 (1)
Not reported	9 (1)	19 (1)	20 (1)	36 (2)	18 (1)
Re-used someone else's used needle & syringe last month (%)					
None	1030 (82)	1269 (80)	1396 (80)	1277 (80)	1291 (80)
Once	61 (5)	93 (6)	102 (6)	90 (6)	86 (5)
Twice	61 (5)	95 (6)	103 (6)	73 (5)	70 (4)
3-5 times	44 (3)	61 (4)	73 (4)	75 (5)	79 (5)
>5 times	54 (4)	56 (4)	54 (3)	58 (4)	65 (4)
Not reported	9 (1)	7 (<1)	20 (1)	15 (1)	18 (1)
Number of people needle & syringe was re-used after last month (%)					
None	1029 (82)	1269 (80)	1396 (80)	1277 (80)	1291 (80)
One	94 (7)	125 (8)	136 (8)	115 (7)	104 (6)
Two	30 (2)	38 (2)	35 (2)	31 (2)	31 (2)
Three to five	14 (1)	21 (1)	22 (1)	19 (1)	31 (2)
More than five	14 (1)	19 (1)	16 (1)	23 (1)	28 (2)
Don't know	50 (4)	54 (3)	78 (4)	73 (5)	79 (5)
Not reported	28 (2)	55 (3)	65 (4)	50 (3)	45 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	77 (6)	111 (7)	101 (6)	104 (7)	99 (6)
Casual sex partner	12 (1)	13 (1)	21 (1)	17 (1)	24 (1)
Close friend	67 (5)	86 (5)	92 (5)	91 (6)	91 (6)
Acquaintance	42 (3)	40 (3)	58 (3)	44 (3)	54 (3)
Other	17 (1)	28 (2)	19 (1)	34 (2)	11 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	252 (20)	292 (18)	334 (19)	312 (20)	325 (20)
Water	284 (23)	288 (18)	403 (23)	374 (24)	392 (24)
Filter	123 (10)	122 (8)	174 (10)	156 (10)	130 (8)
Drug mix	127 (10)	149 (9)	199 (11)	188 (12)	168 (10)
None	834 (66)	1071 (68)	1148 (66)	1049 (66)	1043 (65)
Injected by someone after that person injected themselves or others last month (%)					
No	1030 (82)	1276 (81)	1429 (82)	1279 (81)	1281 (80)
Yes	219 (17)	288 (18)	306 (18)	287 (18)	312 (19)
Not reported	10 (1)	17 (1)	13 (1)	22 (1)	16 (1)
Source of needle acquisition (%)					
Needle Syringe Program	1071 (85)	1341 (85)	1459 (83)	1393 (88)	1393 (87)
Chemist/Pharmacy	327 (26)	339 (21)	341 (20)	335 (21)	345 (21)
Personal sources	143 (11)	190 (12)	204 (12)	224 (14)	197 (12)
Dispensing/Vending Machine	134 (11)	234 (15)	266 (15)	267 (17)	344 (21)
Other sources	27 (2)	43 (3)	13 (1)	42 (3)	13 (1)

Table 1.1.4 Number (%) of respondents by treatment for drug use and survey year

National	2021	2022	2023	2024	2025
N° surveyed	N=1474	N=1781	N=1991	N=1760	N=1781
Ever any treatment/therapy for drug use (%)					
No	534 (36)	574 (32)	654 (33)	552 (31)	621 (35)
Yes	939 (64)	1204 (68)	1336 (67)	1207 (69)	1153 (65)
Not reported	1 (<1)	3 (<1)	1 (<1)	1 (<1)	7 (<1)
History of methadone maintenance treatment (%)					
Currently	219 (15)	345 (19)	316 (16)	299 (17)	295 (17)
Previously	281 (19)	399 (22)	464 (23)	375 (21)	339 (19)
Never	921 (62)	990 (56)	1116 (56)	1020 (58)	1071 (60)
Not reported	53 (4)	47 (3)	95 (5)	66 (4)	76 (4)
History of buprenorphine (Subutex®) treatment (%)					
Currently	119 (8)	139 (8)	147 (7)	127 (7)	106 (6)
Previously	310 (21)	422 (24)	471 (24)	442 (25)	440 (25)
Never	1001 (68)	1175 (66)	1280 (64)	1127 (64)	1162 (65)
Not reported	44 (3)	45 (3)	93 (5)	64 (4)	73 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	105 (7)	101 (6)	118 (6)	109 (6)	69 (4)
Previously	298 (20)	422 (24)	443 (22)	395 (22)	409 (23)
Never	1053 (71)	1242 (70)	1415 (71)	1243 (71)	1272 (71)
Not reported	18 (1)	16 (1)	15 (1)	13 (1)	31 (2)
History of depot buprenorphine treatment (%)					
Currently	59 (4)	116 (7)	130 (7)	143 (8)	131 (7)
Previously	92 (6)	181 (10)	183 (9)	189 (11)	238 (13)
Never	1280 (87)	1439 (81)	1583 (80)	1368 (78)	1329 (75)
Not reported	43 (3)	45 (3)	95 (5)	60 (3)	83 (5)

Table 1.1.5 Number (%) of respondents by sexual behaviour in the month prior to survey and survey year

National	2021	2022	2023	2024	2025
N° surveyed	N=1474	N=1781	N=1991	N=1760	N=1781
Sex with a regular partner last month (%)					
No	758 (51)	933 (52)	1032 (52)	944 (54)	941 (53)
Yes	631 (43)	774 (43)	849 (43)	736 (42)	744 (42)
Not reported	85 (6)	74 (4)	110 (6)	80 (5)	96 (5)
Condom used with regular partner last month (%)					
N° surveyed	N=631	N=774	N=849	N=736	N=744
Never	479 (76)	604 (78)	653 (77)	570 (77)	555 (75)
Sometimes	68 (11)	74 (10)	90 (11)	67 (9)	89 (12)
Every time	52 (8)	61 (8)	61 (7)	56 (8)	61 (8)
Not reported	32 (5)	35 (5)	45 (5)	43 (6)	39 (5)
Sex with other partner(s) last month (%)					
No	1154 (78)	1409 (79)	1538 (77)	1370 (78)	1364 (77)
Yes	213 (14)	283 (16)	311 (16)	279 (16)	298 (17)
Not reported	107 (7)	89 (5)	142 (7)	111 (6)	119 (7)
Condom used with other partner(s) last month (%)					
N° surveyed	N=213	N=283	N=311	N=279	N=298
Never	104 (49)	152 (54)	174 (56)	153 (55)	162 (54)
Sometimes	47 (22)	70 (25)	66 (21)	73 (26)	72 (24)
Every time	48 (23)	52 (18)	65 (21)	36 (13)	49 (16)
Not reported	14 (7)	9 (3)	6 (2)	17 (6)	15 (5)
Sex work last month (%)					
No	1292 (88)	1579 (89)	1741 (87)	1534 (87)	1519 (85)
Yes	76 (5)	100 (6)	109 (5)	106 (6)	137 (8)
Not reported	106 (7)	102 (6)	141 (7)	120 (7)	125 (7)
Condom used at last sex work (%)					
Yes	43 (57)	70 (70)	67 (61)	60 (57)	76 (55)

Table 1.1.6 Number (%) of respondents by testing for HIV and HCV, HCV treatment by survey year

National	2021	2022	2023	2024	2025
N° surveyed	N=1474	N=1781	N=1991	N=1760	N=1781
Previous HIV test (%)					
Yes, ever	1116 (76)	1360 (76)	1484 (75)	1324 (75)	1373 (77)
Yes, last year	557 (38)	768 (43)	839 (42)	714 (41)	766 (43)
>1 year ago	559 (38)	592 (33)	645 (32)	610 (35)	607 (34)
Never tested	296 (20)	357 (20)	399 (20)	352 (20)	329 (18)
Not reported	62 (4)	64 (4)	108 (5)	84 (5)	79 (4)
Previous HCV test (%)					
Yes, ever	1147 (78)	1417 (80)	1561 (78)	1413 (80)	1398 (79)
Yes, last year	686 (47)	875 (49)	943 (47)	857 (49)	860 (48)
>1 year ago	462 (31)	542 (30)	618 (31)	556 (32)	538 (30)
Never tested	194 (13)	212 (12)	235 (12)	199 (11)	203 (11)
Not reported	132 (9)	152 (9)	195 (10)	148 (8)	180 (10)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=309	N=334	N=403	N=359	N=304
Antiviral treatment	191 (62)	226 (68)	301 (75)	280 (78)	246 (81)
No antiviral treatment	116 (38)	107 (32)	100 (25)	78 (22)	57 (19)
Not reported	2 (1)	1 (<1)	2 (1)	1 (<1)	1 (<1)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=200	N=199	N=224	N=164	N=150
Antiviral treatment	56 (28)	68 (34)	85 (38)	60 (37)	71 (47)
No antiviral treatment	142 (71)	130 (65)	137 (61)	103 (63)	78 (52)
Not reported	2 (1)	1 (1)	2 (1)	1 (1)	1 (1)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

HIV antibody prevalence

Table 1.2.1 HIV antibody prevalence by gender and survey year

National	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021	902	16 (1.8)	514	3 (0.6)	1435	21 (1.5)
2022	1132	28 (2.5)	583	6 (1.0)	1752	37 (2.1)
2023	1049	26 (2.5)	583	4 (0.7)	1662	30 (1.8)
2024	1105	26 (2.4)	569	5 (0.9)	1719	35 (2.0)
2025	1151	28 (2.4)	568	1 (0.2)	1762	31 (1.8)
X ² p trend		0.472		0.352		0.704

Table 1.2.2 HIV antibody prevalence by sexual identity, gender and survey year

National	Male		Female		Total	
Sexual identity	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
Heterosexual	793	4 (0.5)	375	2 (0.5)	1172	7 (0.6)
Bisexual	49	0 (0.0)	96	0 (0.0)	148	0 (0.0)
Homosexual	40	11 (27.5)	16	1 (6.3)	61	13 (21.3)
p value		<0.001		0.201		<0.001
2022						
Heterosexual	973	3 (0.3)	407	4 (1.0)	1387	7 (0.5)
Bisexual	61	2 (3.3)	107	1 (0.9)	177	5 (2.8)
Homosexual	58	22 (37.9)	24	0 (0.0)	84	22 (26.2)
p value		<0.001		0.410		<0.001
2023						
Heterosexual	897	5 (0.6)	413	3 (0.7)	1314	8 (0.6)
Bisexual	60	6 (10.0)	116	1 (0.9)	181	7 (3.9)
Homosexual	51	14 (27.5)	15	0 (0.0)	69	14 (20.3)
p value		<0.001		1.000		<0.001
2024						
Heterosexual	956	5 (0.5)	396	4 (1.0)	1354	9 (0.7)
Bisexual	54	3 (5.6)	114	1 (0.9)	189	7 (3.7)
Homosexual	51	15 (29.4)	23	0 (0.0)	84	15 (17.9)
p value		<0.001		0.997		<0.001
2025						
Heterosexual	1000	7 (0.7)	406	0 (0.0)	1421	7 (0.5)
Bisexual	63	5 (7.9)	116	1 (0.9)	190	7 (3.7)
Homosexual	55	16 (29.1)	18	0 (0.0)	79	16 (20.3)
p value		<0.001		0.573		<0.001

Table 1.2.3 HIV antibody prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
<25 years	21	1 (4.8)	12	0 (0.0)	34	1 (2.9)
25-34 years	122	1 (0.8)	83	0 (0.0)	209	2 (1.0)
35-44 years	306	3 (1.0)	194	2 (1.0)	509	6 (1.2)
45+ years	449	11 (2.5)	221	1 (0.5)	675	12 (1.8)
p value		0.202		0.785		0.483
2022						
<25 years	36	0 (0.0)	12	0 (0.0)	52	0 (0.0)
25-34 years	161	2 (1.2)	84	0 (0.0)	250	2 (0.8)
35-44 years	341	9 (2.6)	213	3 (1.4)	561	13 (2.3)
45+ years	583	16 (2.7)	268	3 (1.1)	871	21 (2.4)
p value		0.720		0.880		0.365
2023						
<25 years	27	0 (0.0)	16	0 (0.0)	43	0 (0.0)
25-34 years	132	2 (1.5)	79	1 (1.3)	218	3 (1.4)
35-44 years	323	8 (2.5)	197	1 (0.5)	526	9 (1.7)
45+ years	561	16 (2.9)	286	2 (0.7)	860	18 (2.1)
p value		0.876		0.664		0.929
2024						
<25 years	29	0 (0.0)	14	0 (0.0)	44	0 (0.0)
25-34 years	143	2 (1.4)	100	0 (0.0)	250	3 (1.2)
35-44 years	312	9 (2.9)	205	2 (1.0)	533	13 (2.4)
45+ years	620	15 (2.4)	250	3 (1.2)	891	19 (2.1)
p value		0.646		0.722		0.519
2025						
<25 years	26	0 (0.0)	21	0 (0.0)	50	0 (0.0)
25-34 years	141	1 (0.7)	67	0 (0.0)	217	1 (0.5)
35-44 years	324	12 (3.7)	184	1 (0.5)	523	13 (2.5)
45+ years	657	15 (2.3)	295	0 (0.0)	967	16 (1.7)
p value		0.198		0.555		0.189

Table 1.2.4 HIV antibody prevalence by last drug injected, gender and survey year

National Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
Heroin	180	2 (1.1)	106	1 (0.9)	292	4 (1.4)
Methamphetamine	419	11 (2.6)	299	2 (0.7)	725	14 (1.9)
Other opioids	187	2 (1.1)	72	0 (0.0)	263	2 (0.8)
PIEDs	51	0 (0.0)	0	0 (0.0)	51	0 (0.0)
Other drugs	59	0 (0.0)	33	0 (0.0)	93	0 (0.0)
p value		0.515		1.000		0.564
2022						
Heroin	262	1 (0.4)	176	2 (1.1)	443	4 (0.9)
Methamphetamine	497	22 (4.4)	308	4 (1.3)	827	26 (3.1)
Other opioids	163	1 (0.6)	54	0 (0.0)	223	1 (0.5)
PIEDs	113	2 (1.8)	4	0 (0.0)	117	2 (1.7)
Other drugs	90	2 (2.2)	33	0 (0.0)	126	3 (2.4)
p value		0.003		1.000		0.023
2023						
Heroin	223	6 (2.7)	141	2 (1.4)	371	8 (2.2)
Methamphetamine	533	16 (3.0)	344	2 (0.6)	891	18 (2.0)
Other opioids	135	4 (3.0)	55	0 (0.0)	194	4 (2.1)
PIEDs	75	0 (0.0)	4	0 (0.0)	80	0 (0.0)
Other drugs	77	0 (0.0)	38	0 (0.0)	116	0 (0.0)
p value		0.382		0.800		0.458
2024						
Heroin	275	2 (0.7)	137	5 (3.7)	425	9 (2.1)
Methamphetamine	541	21 (3.9)	323	0 (0.0)	887	23 (2.6)
Other opioids	110	2 (1.8)	44	0 (0.0)	157	2 (1.3)
PIEDs	89	0 (0.0)	2	0 (0.0)	91	0 (0.7)
Other drugs	85	1 (1.2)	57	0 (0.0)	148	1 (0.7)
p value		0.022		0.003		0.279
2025						
Heroin	241	4 (1.7)	134	0 (0.0)	383	5 (1.3)
Methamphetamine	591	18 (3.1)	330	1 (0.3)	942	20 (2.1)
Other opioids	54	1 (1.9)	23	0 (0.0)	79	1 (1.3)
PIEDs	98	2 (2.0)	4	0 (0.0)	106	2 (1.9)
Other drugs	140	2 (1.4)	61	0 (0.0)	207	2 (1.0)
p value		0.681		0.955		0.724

Table 1.2.5 HIV antibody prevalence by years of injection, gender and survey year

National Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
<3 years	43	0 (0.0)	19	0 (0.0)	64	0 (0.0)
3 to 10 years	108	6 (5.6)	76	0 (0.0)	185	7 (3.8)
11+ years	719	9 (1.3)	397	3 (0.8)	1131	13 (1.2)
p value		0.015		1.000		0.035
2022						
<3 years	69	1 (1.5)	23	0 (0.0)	96	1 (1.0)
3 to 10 years	127	2 (1.6)	77	0 (0.0)	207	2 (1.0)
11+ years	866	23 (2.7)	456	6 (1.3)	1349	32 (2.4)
p value		0.857		0.690		0.478
2023						
<3 years	56	1 (1.8)	29	0 (0.0)	86	1 (1.2)
3 to 10 years	138	4 (2.9)	86	0 (0.0)	229	4 (1.8)
11+ years	818	21 (2.6)	453	4 (0.9)	1287	25 (1.9)
p value		0.921		1.000		1.000
2024						
<3 years	70	0 (0.0)	35	0 (0.0)	107	0 (0.0)
3 to 10 years	141	9 (6.4)	84	0 (0.0)	233	11 (4.7)
11+ years	869	17 (2.0)	434	5 (1.2)	1335	24 (1.8)
p value		0.003		0.501		0.005
2025						
<3 years	76	0 (0.0)	39	0 (0.0)	118	0 (0.0)
3 to 10 years	131	6 (4.6)	81	0 (0.0)	219	6 (2.7)
11+ years	893	22 (2.5)	427	1 (0.2)	1346	24 (1.8)
p value		0.123		0.869		0.193

Table 1.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

National Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
No receptive sharing	638	14 (2.2)	355	2 (0.6)	1003	18 (1.8)
Receptive sharing	135	1 (0.7)	75	1 (1.3)	215	2 (0.9)
p value		0.490		0.438		0.555
2022						
No receptive sharing	814	22 (2.7)	408	2 (0.5)	1249	26 (2.1)
Receptive sharing	189	3 (1.6)	107	1 (0.9)	303	4 (1.3)
p value		0.603		0.504		0.491
2023						
No receptive sharing	714	20 (2.8)	414	3 (0.7)	1149	23 (2.0)
Receptive sharing	196	4 (2.0)	87	0 (0.0)	286	4 (1.4)
p value		0.801		1.000		0.631
2024						
No receptive sharing	803	23 (2.9)	417	5 (1.2)	1246	30 (2.4)
Receptive sharing	188	2 (1.1)	91	0 (0.0)	291	4 (1.4)
p value		0.156		0.294		0.281
2025						
No receptive sharing	850	21 (2.5)	398	1 (0.3)	1274	22 (1.7)
Receptive sharing	186	2 (1.1)	102	0 (0.0)	298	2 (0.7)
p value		0.242		0.612		0.181

Table 1.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

National	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
Less than daily	373	10 (2.7)	209	0 (0.0)	588	10 (1.7)
Daily or more	402	5 (1.2)	228	3 (1.3)	639	10 (1.6)
Not last month	111	0 (0.0)	67	0 (0.0)	180	0 (0.0)
p value		0.118		0.361		0.199
2022						
Less than daily	438	14 (3.2)	214	1 (0.5)	669	15 (2.2)
Daily or more	570	11 (1.9)	303	2 (0.7)	890	15 (1.7)
Not last month	105	3 (2.9)	51	3 (5.9)	158	6 (3.8)
p value		0.391		0.020		0.220
2023						
Less than daily	408	11 (2.7)	205	2 (1.0)	621	13 (2.1)
Daily or more	516	13 (2.5)	300	1 (0.3)	832	14 (1.7)
Not last month	103	2 (1.9)	66	1 (1.5)	172	3 (1.7)
p value		1.000		0.342		0.864
2024						
Less than daily	386	11 (2.9)	168	2 (1.2)	570	15 (2.6)
Daily or more	614	14 (2.3)	345	3 (0.9)	982	19 (1.9)
Not last month	88	1 (1.1)	44	0 (0.0)	138	1 (0.7)
p value		0.614		0.754		0.332
2025						
Less than daily	352	10 (2.8)	156	0 (0.0)	519	11 (2.1)
Daily or more	692	13 (1.9)	352	1 (0.3)	1071	14 (1.3)
Not last month	77	5 (6.5)	49	0 (0.0)	128	5 (3.9)
p value		0.043		0.747		0.078

Table 1.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

National	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
No imprisonment	733	13 (1.8)	447	3 (0.7)	1196	18 (1.5)
Imprisonment	114	1 (0.9)	39	0 (0.0)	154	1 (0.7)
p value		0.707		1.000		0.714
2022						
No imprisonment	938	28 (3.0)	514	3 (0.6)	1484	34 (2.3)
Imprisonment	147	0 (0.0)	48	2 (4.2)	197	2 (1.0)
p value		0.024		0.060		0.427
2023						
No imprisonment	845	23 (2.7)	498	4 (0.8)	1369	27 (2.0)
Imprisonment	132	2 (1.5)	44	0 (0.0)	177	2 (1.1)
p value		0.562		1.000		0.766
2024						
No imprisonment	862	22 (2.6)	479	5 (1.0)	1380	30 (2.2)
Imprisonment	171	3 (1.8)	61	0 (0.0)	234	4 (1.7)
p value		0.535		0.423		0.647
2025						
No imprisonment	914	24 (2.6)	485	1 (0.2)	1430	26 (1.8)
Imprisonment	160	3 (1.9)	53	0 (0.0)	220	3 (1.4)
p value		0.576		0.741		0.633

Table 1.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

National	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
No condom use	267	4 (1.5)	200	0 (0.0)	473	4 (0.9)
Condom use	65	0 (0.0)	48	0 (0.0)	116	1 (0.9)
p value		1.000		--		1.000
2022						
No condom use	353	10 (2.8)	235	2 (0.9)	598	13 (2.2)
Condom use	83	1 (1.2)	45	1 (2.2)	133	3 (2.3)
p value		0.698		0.410		1.000
2023						
No condom use	328	8 (2.4)	228	1 (0.4)	564	9 (1.6)
Condom use	68	3 (4.4)	53	0 (0.0)	123	3 (2.4)
p value		0.411		1.000		0.458
2024						
No condom use	333	12 (3.6)	215	0 (0.0)	558	13 (2.3)
Condom use	69	3 (4.4)	48	1 (2.1)	121	4 (3.3)
p value		0.767		0.034		0.533
2025						
No condom use	345	10 (2.9)	196	0 (0.0)	551	10 (1.8)
Condom use	90	3 (3.3)	49	0 (0.0)	148	3 (2.0)
p value		0.829		--		0.865

Table 1.2.10 HIV antibody prevalence by sex work last month, gender and survey year

National	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
No sex work	820	13 (1.6)	425	3 (0.7)	1259	16 (1.3)
Sex work	27	1 (3.7)	44	0 (0.0)	74	3 (4.1)
p value		0.367		1.000		0.084
2022						
No sex work	1018	22 (2.2)	504	6 (1.2)	1553	31 (2.0)
Sex work	44	5 (11.4)	52	0 (0.0)	100	5 (5.0)
p value		<0.001		1.000		0.046
2023						
No sex work	931	21 (2.3)	508	4 (0.8)	1460	25 (1.7)
Sex work	45	3 (6.7)	35	0 (0.0)	86	3 (3.5)
p value		0.094		1.000		0.201
2024						
No sex work	977	22 (2.3)	490	5 (1.0)	1496	30 (2.0)
Sex work	56	3 (5.4)	38	0 (0.0)	106	4 (3.8)
p value		0.141		0.532		0.222
2025						
No sex work	1010	21 (2.1)	469	1 (0.2)	1504	22 (1.5)
Sex work	69	5 (7.3)	52	0 (0.0)	134	6 (4.5)
p value		0.007		0.739		0.010

Table 1.2.11 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

National	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
English speaking	856	15 (1.8)	495	3 (0.6)	1368	20 (1.5)
Non-English speaking	35	1 (2.9)	14	0 (0.0)	51	1 (2.0)
p value		0.476		1.000		0.539
2022						
English speaking	1052	26 (2.5)	556	6 (1.1)	1643	35 (2.1)
Non-English speaking	68	2 (2.9)	22	0 (0.0)	91	2 (2.2)
p value		0.685		1.000		1.000
2023						
English speaking	987	26 (2.6)	558	4 (0.7)	1573	30 (1.9)
Non-English speaking	56	0 (0.0)	21	0 (0.0)	78	0 (0.0)
p value		0.393		1.000		0.397
2024						
English speaking	1029	25 (2.4)	541	5 (0.9)	1612	34 (2.1)
Non-English speaking	63	1 (1.6)	28	0 (0.0)	93	1 (1.1)
p value		0.670		0.609		0.494
2025						
English speaking	1071	25 (2.3)	540	1 (0.2)	1648	27 (1.6)
Non-English speaking	63	2 (3.2)	24	0 (0.0)	90	2 (2.2)
p value		0.671		0.833		0.674

Table 1.2.12 HIV antibody prevalence by region/country of birth, gender and survey year

National	Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
Australia	776	12 (1.6)	449	3 (0.7)	1241	16 (1.3)
Other Oceania	22	0 (0.0)	18	0 (0.0)	43	1 (2.3)
Asia	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
UK & Ireland	39	0 (0.0)	15	0 (0.0)	54	0 (0.0)
Other	32	3 (9.4)	15	0 (0.0)	47	3 (6.4)
p value		0.080		1.000		0.087
2022						
Australia	968	22 (2.3)	517	6 (1.2)	1518	30 (2.0)
Other Oceania	36	2 (5.6)	13	0 (0.0)	50	2 (4.0)
Asia	12	0 (0.0)	11	0 (0.0)	23	0 (0.0)
UK & Ireland	35	1 (2.9)	22	0 (0.0)	58	1 (1.7)
Other	54	3 (5.6)	14	0 (0.0)	69	3 (4.4)
p value		0.241		1.000		0.352
2023						
Australia	926	25 (2.7)	533	4 (0.8)	1486	29 (2.0)
Other Oceania	28	1 (3.6)	23	0 (0.0)	52	1 (1.9)
Asia	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)
UK & Ireland	33	0 (0.0)	10	0 (0.0)	44	0 (0.0)
Other	37	0 (0.0)	11	0 (0.0)	48	0 (0.0)
p value		0.749		1.000		1.000
2024						
Australia	967	20 (2.1)	517	5 (1.0)	1520	29 (1.9)
Other Oceania	28	3 (10.7)	9	0 (0.0)	37	3 (8.1)
Asia	17	1 (5.9)	4	0 (0.0)	23	1 (4.4)
UK & Ireland	32	0 (0.0)	16	0 (0.0)	50	0 (0.0)
Other	45	1 (2.2)	17	0 (0.0)	65	1 (1.5)
p value		0.029		0.978		0.066
2025						
Australia	1014	25 (2.5)	518	1 (0.2)	1567	26 (1.7)
Other Oceania	28	1 (3.6)	17	0 (0.0)	46	1 (2.2)
Asia	20	0 (0.0)	6	0 (0.0)	26	0 (0.0)
UK & Ireland	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
Other	63	0 (0.0)	19	0 (0.0)	85	1 (1.2)
p value		0.519		0.994		0.888

HCV antibody prevalence

Table 1.3.1 HCV antibody prevalence by gender and survey year

National	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	902	343 (38)	514	173 (34)	1435	522 (36)
2022	1115	350 (31)	573	194 (34)	1724	554 (32)
2023*	1050	473 (45)	583	264 (45)	1663	745 (45)
2024	1109	439 (40)	569	211 (37)	1723	666 (39)
2025	1153	357 (31)	568	196 (35)	1764	565 (32)
X ² p trend^		<0.001		<0.001		<0.001

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

^ X² p trend calculated on years 2023-2025 only

Table 1.3.2 HCV antibody prevalence by sexual identity, gender and survey year

National	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	791	316 (40)	375	118 (31)	1170	436 (37)
Bisexual	49	16 (33)	96	38 (40)	148	54 (36)
Homosexual	42	6 (14)	16	7 (44)	63	13 (21)
p value		0.004		0.216		0.156
2022						
Heterosexual	956	316 (33)	398	141 (35)	1361	463 (34)
Bisexual	60	17 (28)	106	26 (25)	175	43 (25)
Homosexual	59	6 (10)	24	6 (25)	85	13 (15)
p value		0.005		0.018		0.002
2023						
Heterosexual	897	425 (47)	413	189 (46)	1314	614 (47)
Bisexual	61	18 (30)	116	46 (40)	182	65 (36)
Homosexual	51	12 (24)	15	7 (47)	69	19 (28)
p value		0.001		0.309		0.005
2024						
Heterosexual	957	396 (41)	396	150 (38)	1355	546 (40)
Bisexual	55	19 (35)	114	38 (33)	190	66 (35)
Homosexual	52	8 (15)	23	10 (43)	85	19 (22)
p value		0.010		0.824		0.015
2025						
Heterosexual	1001	323 (32)	406	136 (34)	1422	464 (33)
Bisexual	64	15 (23)	116	39 (34)	191	55 (29)
Homosexual	55	7 (13)	18	8 (44)	79	16 (20)
p value		0.021		0.224		0.100

Table 1.3.3 HCV antibody prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<25 years	21	4 (19)	12	3 (25)	34	7 (21)
25-34 years	122	30 (25)	83	25 (30)	209	56 (27)
35-44 years	307	126 (41)	194	60 (31)	510	189 (37)
45+ years	448	183 (41)	221	83 (38)	674	268 (40)
p value		0.001		0.410		0.002
2022						
<25 years	36	5 (14)	11	2 (18)	50	7 (14)
25-34 years	162	27 (17)	83	19 (23)	250	46 (18)
35-44 years	337	102 (30)	210	67 (32)	554	172 (31)
45+ years	569	212 (37)	263	104 (40)	852	322 (38)
p value		<0.001		0.020		<0.001
2023						
<25 years	27	3 (11)	16	4 (25)	43	7 (16)
25-34 years	132	27 (20)	79	26 (33)	218	54 (25)
35-44 years	324	128 (40)	197	91 (46)	527	220 (42)
45+ years	561	310 (55)	286	139 (49)	860	452 (53)
p value		<0.001		0.031		<0.001
2024						
<25 years	29	1 (3)	14	1 (7)	44	3 (7)
25-34 years	143	32 (22)	100	24 (24)	250	59 (24)
35-44 years	314	116 (37)	205	72 (35)	535	190 (36)
45+ years	622	289 (46)	250	114 (46)	893	413 (46)
p value		<0.001		<0.001		<0.001
2025						
<25 years	26	0 (0)	21	2 (10)	50	3 (6)
25-34 years	141	27 (19)	67	14 (21)	217	42 (19)
35-44 years	326	72 (22)	184	55 (30)	525	130 (25)
45+ years	657	258 (39)	295	124 (42)	967	388 (40)
p value		<0.001		<0.001		<0.001

Table 1.3.4 HCV antibody prevalence by years since first injection, gender and survey year

National Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	43	2 (5)	19	3 (16)	64	5 (8)
3 to 10 years	108	19 (18)	76	16 (21)	185	35 (19)
11+ years	719	308 (43)	397	147 (37)	1131	460 (41)
p value		<0.001		0.005		<0.001
2022						
<3 years	69	3 (4)	22	1 (5)	94	4 (4)
3 to 10 years	127	16 (13)	76	12 (16)	206	29 (14)
11+ years	850	310 (36)	448	170 (38)	1325	488 (37)
p value		<0.001		<0.001		<0.001
2023						
<3 years	56	3 (5)	29	4 (14)	86	7 (8)
3 to 10 years	138	23 (17)	86	17 (20)	229	40 (17)
11+ years	819	431 (53)	453	235 (52)	1288	670 (52)
p value		<0.001		<0.001		<0.001
2024						
<3 years	70	2 (3)	35	0 (0)	107	2 (2)
3 to 10 years	141	25 (18)	84	12 (14)	233	39 (17)
11+ years	873	399 (46)	434	195 (45)	1339	606 (45)
p value		<0.001		<0.001		<0.001
2025						
<3 years	76	1 (1)	39	2 (5)	118	3 (3)
3 to 10 years	131	17 (13)	81	13 (16)	219	31 (14)
11+ years	895	322 (36)	427	174 (41)	1348	502 (37)
p value		<0.001		<0.001		<0.001

Table 1.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

National Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	44	3 (7)	924	343 (37)	1003	358 (36)
Receptive sharing	5	2 (40)	202	100 (50)	214	106 (50)
p value		0.075		0.001		<0.001
2022						
No receptive sharing	73	2 (3)	1100	347 (32)	1228	370 (30)
Receptive sharing	6	2 (33)	273	121 (44)	299	130 (43)
p value		0.027		<0.001		<0.001
2023						
No receptive sharing	66	2 (3)	1050	482 (46)	1150	503 (44)
Receptive sharing	12	5 (42)	263	156 (59)	286	166 (58)
p value		0.001		<0.001		<0.001
2024						
No receptive sharing	75	1 (1)	1149	454 (40)	1249	465 (37)
Receptive sharing	17	1 (6)	264	131 (50)	291	138 (47)
p value		0.246		0.003		0.001
2025						
No receptive sharing	91	3 (3)	1145	378 (33)	1276	393 (31)
Receptive sharing	10	0 (0)	265	111 (42)	298	124 (42)
p value		0.560		0.006		<0.001

Table 1.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

National Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heroin	4	1 (25)	277	134 (48)	289	139 (48)
Methamphetamine	39	1 (3)	649	184 (28)	710	193 (27)
Other opioids	8	2 (25)	239	119 (50)	257	125 (49)
PIEDs	8	0 (0)	41	4 (10)	51	4 (8)
Other drugs	2	0 (0)	81	42 (52)	91	45 (49)
p value		0.079		<0.001		<0.001
2022						
Heroin	4	0 (0)	406	185 (46)	424	191 (45)
Methamphetamine	35	3 (9)	725	195 (27)	806	216 (27)
Other opioids	7	1 (14)	196	92 (47)	214	97 (45)
PIEDs	43	0 (0)	63	2 (3)	115	3 (3)
Other drugs	2	0 (0)	107	35 (33)	117	36 (31)
p value		0.255		<0.001		<0.001
2023						
Heroin	3	0 (0)	352	224 (64)	363	231 (64)
Methamphetamine	52	5 (10)	802	316 (39)	878	332 (38)
Other opioids	3	0 (0)	182	103 (57)	192	107 (56)
PIEDs	21	0 (0)	52	0 (0)	79	0 (0)
Other drugs	6	2 (33)	95	53 (56)	108	58 (54)
p value		0.109		<0.001		<0.001
2024						
Heroin	13	1 (8)	401	235 (59)	422	240 (57)
Methamphetamine	44	1 (2)	808	263 (33)	875	277 (32)
Other opioids	4	0 (0)	150	75 (50)	155	76 (49)
PIEDs	36	0 (0)	49	1 (2)	89	1 (1)
Other drugs	9	0 (0)	131	58 (44)	142	58 (41)
p value		0.502		<0.001		<0.001
2025						
Heroin	7	1 (14)	356	191 (54)	377	198 (53)
Methamphetamine	55	2 (4)	838	216 (26)	922	231 (25)
Other opioids	0	0 (0)	72	30 (42)	78	34 (44)
PIEDs	43	0 (0)	57	1 (2)	105	1 (1)
Other drugs	8	0 (0)	175	70 (40)	195	73 (37)
p value		0.154		<0.001		<0.001

Table 1.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

National	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	32	1 (3)	541	160 (30)	589	167 (28)
Daily or more	18	4 (22)	592	286 (48)	637	301 (47)
Not last month	13	0 (0)	160	38 (24)	181	41 (23)
p value		0.041		<0.001		<0.001
2022						
Less than daily	55	1 (2)	575	177 (31)	657	187 (28)
Daily or more	24	3 (13)	802	293 (37)	877	315 (36)
Not last month	13	0 (0)	129	42 (33)	155	44 (28)
p value		0.106		0.079		0.005
2023						
Less than daily	45	3 (7)	562	247 (44)	622	256 (41)
Daily or more	33	4 (12)	769	400 (52)	832	422 (51)
Not last month	7	0 (0)	157	51 (32)	172	52 (30)
p value		0.705		<0.001		<0.001
2024						
Less than daily	41	1 (2)	523	197 (38)	573	200 (35)
Daily or more	51	1 (2)	905	393 (43)	982	408 (42)
Not last month	15	0 (0)	117	44 (38)	139	46 (33)
p value		0.835		0.076		0.013
2025						
Less than daily	37	0 (0)	467	133 (28)	519	137 (26)
Daily or more	66	3 (5)	959	367 (38)	1073	391 (36)
Not last month	13	0 (0)	107	22 (21)	128	24 (19)
p value		0.311		<0.001		<0.001

Table 1.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

National	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	55	4 (7)	1100	395 (36)	1196	413 (35)
Imprisonment	4	0 (0)	142	66 (46)	154	70 (45)
p value		1.000		0.014		0.008
2022						
No imprisonment	85	2 (2)	1298	424 (33)	1459	450 (31)
Imprisonment	7	2 (29)	171	65 (38)	195	74 (38)
p value		0.028		0.163		0.045
2023						
No imprisonment	71	5 (7)	1254	564 (45)	1370	589 (43)
Imprisonment	9	1 (11)	159	92 (58)	177	98 (55)
p value		0.523		0.002		0.002
2024						
No imprisonment	93	2 (2)	1253	489 (39)	1382	507 (37)
Imprisonment	11	0 (0)	219	114 (52)	235	116 (49)
p value		0.623		<0.001		<0.001
2025						
No imprisonment	103	2 (2)	1276	419 (33)	1432	438 (31)
Imprisonment	10	0 (0)	192	76 (40)	220	86 (39)
p value		0.657		0.065		0.012

Table 1.3.9 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

National	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
English speaking	856	326 (38)	495	163 (33)	1368	494 (36)
Non-English speaking	35	14 (40)	14	7 (50)	51	22 (43)
p value		0.819		0.182		0.306
2022						
English speaking	1038	318 (31)	547	188 (34)	1619	516 (32)
Non-English speaking	66	28 (42)	21	5 (24)	88	33 (38)
p value		0.045		0.316		0.271
2023						
English speaking	988	450 (46)	558	250 (45)	1574	707 (45)
Non-English speaking	56	19 (34)	21	12 (57)	78	31 (40)
p value		0.089		0.265		0.370
2024						
English speaking	1033	407 (39)	541	204 (38)	1616	625 (39)
Non-English speaking	63	24 (38)	28	7 (25)	93	32 (34)
p value		0.837		0.175		0.411
2025						
English speaking	1073	340 (32)	540	184 (34)	1650	533 (32)
Non-English speaking	63	13 (21)	24	11 (46)	90	24 (27)
p value		0.065		0.236		0.264

Table 1.3.10 HCV antibody prevalence by region/country of birth, gender and survey year

National	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Australia	775	292 (38)	449	147 (33)	1240	445 (36)
Other Oceania	22	12 (55)	18	8 (44)	43	20 (47)
Asia	7	1 (14)	5	3 (60)	12	4 (33)
UK & Ireland	39	12 (31)	15	3 (20)	54	15 (28)
Other	33	14 (42)	15	7 (47)	48	21 (44)
p value		0.270		0.264		0.293
2022						
Australia	951	293 (31)	508	173 (34)	1491	475 (32)
Other Oceania	36	16 (44)	13	4 (31)	50	21 (42)
Asia	12	2 (17)	11	3 (27)	23	5 (22)
UK & Ireland	35	7 (20)	22	7 (32)	58	14 (24)
Other	54	19 (35)	13	2 (15)	68	21 (31)
p value		0.169		0.739		0.280
2023						
Australia	927	423 (46)	533	232 (44)	1487	662 (45)
Other Oceania	28	11 (39)	23	12 (52)	52	23 (44)
Asia	12	4 (33)	2	0 (0)	14	4 (29)
UK & Ireland	33	18 (55)	10	8 (80)	44	26 (59)
Other	37	10 (27)	11	8 (73)	48	18 (38)
p value		0.122		0.023		0.194
2024						
Australia	970	384 (40)	517	194 (38)	1523	589 (39)
Other Oceania	29	7 (24)	9	3 (33)	38	10 (26)
Asia	17	9 (53)	4	2 (50)	23	13 (57)
UK & Ireland	32	7 (22)	16	4 (25)	50	12 (24)
Other	45	22 (49)	17	5 (29)	65	28 (43)
p value		0.041		0.770		0.032
2025						
Australia	1016	325 (32)	518	181 (35)	1569	514 (33)
Other Oceania	28	6 (21)	17	6 (35)	46	12 (26)
Asia	20	1 (5)	6	1 (17)	26	2 (8)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	63	17 (27)	19	6 (32)	85	24 (28)
p value		0.037		0.811		0.032

HCV RNA prevalence

Table 1.4.1 HCV RNA prevalence by gender and survey year

National	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	835	148 (18)	474	62 (13)	1328	214 (16)
2022	1065	137 (13)	552	58 (11)	1653	200 (12)
2023	1038	140 (13)	578	56 (10)	1646	197 (12)
2024	1084	98 (9)	560	37 (7)	1687	137 (8)
2025	1102	79 (7)	555	35 (6)	1699	114 (7)
X ² p trend		<0.001		<0.001		<0.001

Totals include respondents where gender was reported as other or not reported

Table 1.4.2 HCV RNA prevalence by sexual identity, gender and survey year

National	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	736	136 (18)	345	41 (12)	1085	179 (16)
Bisexual	43	8 (19)	90	11 (12)	136	19 (14)
Homosexual	37	1 (3)	16	4 (25)	58	5 (9)
p value		0.049		0.298		0.226
2022						
Heterosexual	914	122 (13)	386	47 (12)	1307	171 (13)
Bisexual	58	7 (12)	100	5 (5)	166	12 (7)
Homosexual	54	3 (6)	21	1 (5)	77	5 (6)
p value		0.314		0.311		0.102
2023						
Heterosexual	887	128 (14)	410	44 (11)	1301	172 (13)
Bisexual	60	8 (13)	115	7 (6)	180	16 (9)
Homosexual	50	3 (6)	14	0 (0)	67	3 (4)
p value		0.327		0.307		0.149
2024						
Heterosexual	938	89 (9)	391	23 (6)	1331	112 (8)
Bisexual	54	3 (6)	112	10 (9)	186	14 (8)
Homosexual	51	4 (8)	23	0 (0)	84	5 (6)
p value		0.682		0.343		0.753
2025						
Heterosexual	955	71 (7)	399	27 (7)	1369	98 (7)
Bisexual	61	6 (10)	113	6 (5)	185	12 (6)
Homosexual	54	0 (0)	16	0 (0)	76	0 (0)
p value		0.357		0.099		0.211

Table 1.4.3 HCV RNA prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<25 years	21	2 (10)	12	2 (17)	34	4 (12)
25-34 years	113	21 (19)	78	10 (13)	195	33 (17)
35-44 years	281	55 (20)	174	18 (10)	464	74 (16)
45+ years	416	70 (17)	206	31 (15)	627	102 (16)
p value		0.593		0.573		0.899
2022						
<25 years	35	3 (9)	12	1 (8)	51	4 (8)
25-34 years	158	14 (9)	79	8 (10)	242	22 (9)
35-44 years	326	39 (12)	201	18 (9)	534	59 (11)
45+ years	535	80 (15)	254	31 (12)	808	114 (14)
p value		0.181		0.731		0.103
2023						
<25 years	27	1 (4)	16	1 (6)	43	2 (5)
25-34 years	132	13 (10)	78	10 (13)	217	24 (11)
35-44 years	320	40 (13)	195	17 (9)	521	57 (11)
45+ years	553	84 (15)	284	27 (10)	850	111 (13)
p value		0.169		0.758		0.306
2024						
<25 years	29	1 (3)	14	1 (7)	44	2 (5)
25-34 years	142	7 (5)	100	6 (6)	248	13 (5)
35-44 years	310	27 (9)	200	13 (7)	526	40 (8)
45+ years	602	63 (10)	246	17 (7)	868	82 (9)
p value		0.136		0.991		0.125
2025						
<25 years	26	1 (4)	21	1 (5)	50	2 (4)
25-34 years	137	8 (6)	65	6 (9)	211	14 (7)
35-44 years	311	15 (5)	180	10 (6)	506	25 (5)
45+ years	626	55 (9)	288	18 (6)	929	73 (8)
p value		0.121		0.754		0.167

Table 1.4.4 HCV RNA prevalence by years since first injection, gender and survey year

National Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	42	1 (2)	17	1 (6)	61	2 (3)
3 to 10 years	103	21 (20)	67	9 (13)	171	31 (18)
11+ years	660	122 (18)	368	48 (13)	1043	172 (16)
p value		0.024		0.680		0.018
2022						
<3 years	67	2 (3)	23	0 (0)	94	2 (2)
3 to 10 years	126	12 (10)	75	8 (11)	204	20 (10)
11+ years	807	115 (14)	427	48 (11)	1260	168 (13)
p value		0.009		0.271		0.001
2023						
<3 years	56	0 (0)	29	2 (7)	86	2 (2)
3 to 10 years	137	10 (7)	86	12 (14)	228	22 (10)
11+ years	809	125 (15)	448	40 (9)	1273	166 (13)
p value		<0.001		0.325		0.002
2024						
<3 years	68	0 (0)	35	1 (3)	105	1 (1)
3 to 10 years	139	11 (8)	84	4 (5)	231	15 (6)
11+ years	854	86 (10)	425	32 (8)	1309	120 (9)
p value		0.018		0.414		0.008
2025						
<3 years	76	1 (1)	38	1 (3)	117	2 (2)
3 to 10 years	128	7 (5)	81	3 (4)	216	10 (5)
11+ years	849	66 (8)	416	31 (7)	1291	97 (8)
p value		0.082		0.275		0.024

Table 1.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

National Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	588	101 (17)	325	39 (12)	923	142 (15)
Receptive sharing	124	36 (29)	72	15 (21)	201	52 (26)
p value		0.002		0.048		<0.001
2022						
No receptive sharing	769	95 (12)	385	30 (8)	1180	127 (11)
Receptive sharing	175	34 (19)	101	22 (22)	283	59 (21)
p value		0.014		<0.001		<0.001
2023						
No receptive sharing	707	93 (13)	411	40 (10)	1139	133 (12)
Receptive sharing	193	37 (19)	86	11 (13)	282	49 (17)
p value		0.035		0.395		0.010
2024						
No receptive sharing	788	71 (9)	411	26 (6)	1225	98 (8)
Receptive sharing	181	21 (12)	88	7 (8)	280	29 (10)
p value		0.283		0.577		0.200
2025						
No receptive sharing	814	49 (6)	391	24 (6)	1231	73 (6)
Receptive sharing	178	24 (13)	100	6 (6)	288	30 (10)
p value		0.001		0.959		0.006

Table 1.4.6 HCV RNA prevalence by last drug injected, gender and survey year

National Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heroin	164	29 (18)	95	14 (15)	265	45 (17)
Methamphetamine	382	72 (19)	267	28 (10)	656	100 (15)
Other opioids	173	32 (18)	67	11 (16)	244	44 (18)
PIEDs	48	3 (6)	0	0 (0)	48	3 (6)
Other drugs	50	7 (14)	32	7 (22)	82	14 (17)
p value		0.264		0.198		0.320
2022						
Heroin	228	28 (12)	158	22 (14)	391	50 (13)
Methamphetamine	470	73 (16)	292	25 (9)	783	100 (13)
Other opioids	158	21 (13)	52	8 (15)	216	32 (15)
PIEDs	111	0 (0)	3	0 (0)	114	0 (0)
Other drugs	77	12 (16)	25	2 (8)	104	14 (13)
p value		<0.001		0.304		0.001
2023						
Heroin	215	33 (15)	136	16 (12)	358	49 (14)
Methamphetamine	521	76 (15)	337	30 (9)	872	107 (12)
Other opioids	132	18 (14)	54	3 (6)	190	21 (11)
PIEDs	74	0 (0)	4	0 (0)	79	0 (0)
Other drugs	70	10 (14)	34	6 (18)	105	16 (15)
p value		0.013		0.305		0.011
2024						
Heroin	272	27 (10)	136	8 (6)	421	37 (9)
Methamphetamine	517	46 (9)	309	16 (5)	848	62 (7)
Other opioids	107	15 (14)	42	4 (10)	152	19 (13)
PIEDs	86	0 (0)	2	0 (0)	88	0 (0)
Other drugs	80	8 (10)	53	5 (9)	138	13 (9)
p value		0.016		0.646		0.010
2025						
Heroin	223	20 (9)	130	5 (4)	361	25 (7)
Methamphetamine	546	42 (8)	320	23 (7)	885	65 (7)
Other opioids	53	3 (6)	23	1 (4)	78	4 (5)
PIEDs	96	0 (0)	4	0 (0)	104	0 (0)
Other drugs	130	9 (7)	55	2 (4)	191	11 (6)
p value		0.061		0.587		0.066

Table 1.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

National	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	352	56 (16)	196	20 (10)	554	76 (14)
Daily or more	362	81 (22)	206	35 (17)	577	119 (21)
Not last month	106	6 (6)	62	5 (8)	170	11 (6)
p value		<0.001		0.060		<0.001
2022						
Less than daily	424	47 (11)	206	18 (9)	647	67 (10)
Daily or more	525	82 (16)	281	34 (12)	822	119 (14)
Not last month	100	5 (5)	50	5 (10)	152	10 (7)
p value		0.006		0.487		0.005
2023						
Less than daily	407	47 (12)	205	19 (9)	620	66 (11)
Daily or more	507	85 (17)	296	32 (11)	819	118 (14)
Not last month	103	5 (5)	65	4 (6)	171	9 (5)
p value		0.002		0.558		0.002
2024						
Less than daily	379	35 (9)	164	12 (7)	559	47 (8)
Daily or more	599	58 (10)	340	21 (6)	961	81 (8)
Not last month	89	3 (3)	44	1 (2)	138	4 (3)
p value		0.149		0.468		0.072
2025						
Less than daily	338	15 (4)	154	14 (9)	503	29 (6)
Daily or more	662	60 (9)	345	17 (5)	1034	77 (7)
Not last month	74	1 (1)	48	2 (4)	124	3 (2)
p value		0.004		0.167		0.070

Table 1.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

National	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	680	110 (16)	412	50 (12)	1108	163 (15)
Imprisonment	107	23 (21)	36	6 (17)	144	29 (20)
p value		0.172		0.431		0.089
2022						
No imprisonment	882	105 (12)	486	50 (10)	1399	160 (11)
Imprisonment	141	24 (17)	46	7 (15)	189	31 (16)
p value		0.089		0.302		0.049
2023						
No imprisonment	834	115 (14)	496	49 (10)	1356	164 (12)
Imprisonment	132	13 (10)	41	2 (5)	174	16 (9)
p value		0.215		0.411		0.264
2024						
No imprisonment	849	75 (9)	472	34 (7)	1359	110 (8)
Imprisonment	165	19 (12)	59	2 (3)	226	22 (10)
p value		0.277		0.272		0.409
2025						
No imprisonment	877	55 (6)	475	31 (7)	1382	86 (6)
Imprisonment	155	19 (12)	51	1 (2)	213	20 (9)
p value		0.008		0.195		0.084

Table 1.4.9 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
English speaking	794	140 (18)	459	56 (12)	1270	199 (16)
Non-English speaking	32	7 (22)	13	4 (31)	47	12 (26)
p value		0.538		0.047		0.070
2022						
English speaking	993	124 (12)	527	55 (10)	1555	184 (12)
Non-English speaking	61	12 (20)	20	2 (10)	81	14 (17)
p value		0.104		1.000		0.143
2023						
English speaking	977	136 (14)	553	50 (9)	1558	187 (12)
Non-English speaking	56	4 (7)	21	6 (29)	78	10 (13)
p value		0.225		0.003		0.829
2024						
English speaking	1009	91 (9)	532	35 (7)	1581	128 (8)
Non-English speaking	63	6 (10)	28	2 (7)	93	8 (9)
p value		0.892		0.907		0.862
2025						
English speaking	1026	75 (7)	527	32 (6)	1590	107 (7)
Non-English speaking	60	3 (5)	24	3 (13)	87	6 (7)
p value		0.501		0.207		0.952

Table 1.4.10 HCV RNA prevalence by region/country of birth, gender and survey year

National	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Australia	718	126 (18)	416	52 (13)	1150	181 (16)
Other Oceania	20	7 (35)	15	4 (27)	38	12 (32)
Asia	6	1 (17)	5	2 (40)	11	3 (27)
UK & Ireland	36	6 (17)	14	1 (7)	50	7 (14)
Other	30	5 (17)	14	2 (14)	44	7 (16)
p value		0.391		0.187		0.093
2022						
Australia	912	111 (12)	489	52 (11)	1434	167 (12)
Other Oceania	34	6 (18)	12	1 (8)	47	8 (17)
Asia	12	2 (17)	10	1 (10)	22	3 (14)
UK & Ireland	32	3 (9)	22	2 (9)	55	5 (9)
Other	51	9 (18)	13	1 (8)	64	10 (16)
p value		0.512		1.000		0.559
2023						
Australia	917	124 (14)	528	52 (10)	1472	177 (12)
Other Oceania	28	2 (7)	23	1 (4)	52	3 (6)
Asia	12	1 (8)	2	0 (0)	14	1 (7)
UK & Ireland	32	9 (28)	10	0 (0)	43	9 (21)
Other	37	2 (5)	11	1 (9)	48	3 (6)
p value		0.056		0.870		0.162
2024						
Australia	948	83 (9)	509	35 (7)	1492	119 (8)
Other Oceania	28	2 (7)	9	0 (0)	37	2 (5)
Asia	15	4 (27)	4	1 (25)	20	5 (25)
UK & Ireland	32	2 (6)	15	0 (0)	49	3 (6)
Other	45	5 (11)	17	1 (6)	65	6 (9)
p value		0.168		0.417		0.077
2025						
Australia	968	71 (7)	506	33 (7)	1509	104 (7)
Other Oceania	26	2 (8)	16	1 (6)	43	3 (7)
Asia	20	0 (0)	6	1 (17)	26	1 (4)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	62	6 (10)	19	0 (0)	84	6 (7)
p value		0.555		0.500		0.944

Australian Capital Territory

Table 2.1.1 Number (%) of respondents by demographic characteristics and survey year

Australian Capital Territory	2021*	2022	2023	2024	2025
Number of sites	1	1	1	1	1
N° surveyed	N=100	N=100	N=109	N=99	N=100
Response rate (%)	68%	67%	56%	64%	67%
Gender (%)					
Male	68 (68)	67 (67)	68 (62)	64 (65)	67 (67)
Female	32 (32)	32 (32)	38 (35)	29 (29)	30 (30)
Other	0 (0)	1 (1)	3 (3)	6 (6)	1 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
Age (years)					
Median age	42.5	45	46	46	46
Age range	21-65	25-62	23-68	21-71	16-72
<25 years	2 (2)	0 (0)	1 (1)	3 (3)	2 (2)
25+ years	98 (98)	100 (100)	107 (98)	96 (97)	98 (98)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	87 (87)	81 (81)	85 (78)	81 (82)	82 (82)
Bisexual	7 (7)	11 (11)	11 (10)	9 (9)	8 (8)
Gay/Lesbian	4 (4)	1 (1)	4 (4)	5 (5)	3 (3)
Other	1 (1)	7 (7)	9 (8)	4 (4)	1 (1)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	6 (6)
Aboriginal and Torres Strait Islander origin (%)					
No	68 (68)	71 (71)	77 (71)	79 (80)	75 (75)
Yes	29 (29)	27 (27)	30 (28)	20 (20)	25 (25)
Not reported	3 (3)	2 (2)	2 (2)	0 (0)	0 (0)
Region/country of birth (%)					
Australia	91 (91)	85 (85)	100 (92)	89 (90)	84 (84)
Other Oceania	2 (2)	5 (5)	1 (1)	2 (2)	4 (4)
Asia	0 (0)	2 (2)	2 (2)	3 (3)	2 (2)
UK & Ireland	3 (3)	4 (4)	1 (1)	1 (1)	2 (2)
Other	4 (4)	1 (1)	3 (3)	3 (3)	4 (4)
Not reported	0 (0)	3 (3)	2 (2)	1 (1)	4 (4)
Main language spoken at home by parents (%)					
English	95 (95)	94 (94)	102 (94)	95 (96)	92 (92)
Non-English	5 (5)	4 (4)	6 (6)	3 (3)	7 (7)
Not reported	0 (0)	2 (2)	1 (1)	1 (1)	1 (1)
Age at first injection and time since first injection (years)					
Median age at first injection	19	19	19	19	19
Age range at first injection	12-65	10-60	10-49	10-45	10-52
N° not reported	4	3	4	2	6
Median yrs since first injection	23	23	25	26	26
Range yrs since first injection	<1-43	<1-42	<1-47	1-51	<1-52
<3 years since first injection	10 (10)	8 (8)	4 (4)	2 (2)	5 (5)
3+ years since first injection	86 (86)	89 (89)	101 (93)	95 (96)	89 (89)
Not reported	4 (4)	3 (3)	4 (4)	2 (2)	6 (6)

* Implementation of the 2021 ANSPS was impacted by the COVID-19 pandemic

Table 2.1.2 Number (%) of respondents by last drug injected, frequency of injecting, overdose, imprisonment, injection in prison and survey year

Australian Capital Territory	2021	2022	2023	2024	2025
N° surveyed	N=100	N=100	N=109	N=99	N=100
Drug last injected (%)					
Cocaine	1 (1)	0 (0)	1 (1)	1 (1)	0 (0)
Methamphetamine	40 (40)	42 (42)	52 (48)	46 (46)	38 (38)
Heroin	44 (44)	44 (44)	48 (44)	42 (42)	45 (45)
Pharm. opioids	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Methadone	6 (6)	2 (2)	2 (2)	0 (0)	1 (1)
Buprenorphine	0 (0)	0 (0)	2 (2)	0 (0)	1 (1)
Buprenorphine/naloxone	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
PIEDs	1 (1)	1 (1)	1 (1)	0 (0)	0 (0)
More than one	7 (7)	7 (7)	2 (2)	5 (5)	13 (13)
Other	0 (0)	3 (3)	0 (0)	2 (2)	0 (0)
Not reported	1 (1)	1 (1)	0 (0)	2 (2)	2 (2)
Ever injected opioids (%)					
No	15 (15)	14 (14)	16 (15)	11 (11)	21 (21)
Yes	84 (84)	86 (86)	91 (83)	88 (89)	79 (79)
Not reported	1 (1)	0 (0)	2 (2)	0 (0)	0 (0)
Frequency of injection last month (%)					
Not last month	7 (7)	3 (3)	6 (6)	9 (9)	8 (8)
Less than weekly	16 (16)	17 (17)	14 (13)	8 (8)	10 (10)
Weekly not daily	17 (17)	24 (24)	28 (26)	20 (20)	17 (17)
Daily or more	58 (58)	54 (54)	58 (53)	61 (62)	64 (64)
Not reported	2 (2)	2 (2)	3 (3)	1 (1)	1 (1)
Present when someone injected for the first time in the last 12 months (%)					
No	83 (83)	90 (90)	93 (85)	74 (75)	78 (78)
Yes	16 (16)	9 (9)	13 (12)	25 (25)	21 (21)
Not reported	1 (1)	1 (1)	3 (3)	0 (0)	1 (1)
Overdosed in last 12 months (%)					
No	79 (79)	80 (80)	88 (81)	77 (78)	77 (77)
Yes	19 (19)	18 (18)	20 (18)	22 (22)	23 (23)
Not reported	2 (2)	2 (2)	1 (1)	0 (0)	0 (0)
Imprisonment last year (%)					
No	81 (81)	89 (89)	96 (88)	85 (86)	87 (87)
Yes	12 (12)	9 (9)	8 (7)	10 (10)	12 (12)
Not reported	7 (7)	2 (2)	5 (5)	4 (4)	1 (1)
Injected while in prison last year					
N° in prison last year	N=12	N=9	N=8	N=10	N=12
No	4 (33)	6 (67)	2 (25)	6 (60)	3 (25)
Yes	8 (67)	3 (33)	5 (63)	3 (30)	9 (75)
Not reported	0 (0)	0 (0)	1 (13)	1 (10)	0 (0)

Table 2.1.3 Number (%) of respondents by injecting behaviour in the last month and survey year

Australian Capital Territory	2021	2022	2023	2024	2025
N° injected last month	N=91	N=95	N=100	N=89	N=91
Places injected last month (%)					
All private	56 (62)	52 (55)	53 (53)	32 (36)	46 (51)
Any public	35 (38)	43 (45)	47 (47)	57 (64)	45 (49)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	70 (77)	74 (78)	65 (65)	58 (65)	61 (67)
Most of the time	20 (22)	17 (18)	29 (29)	23 (26)	25 (27)
Half of the time	0 (0)	3 (3)	3 (3)	4 (4)	4 (4)
Some of the time	1 (1)	1 (1)	2 (2)	1 (1)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
Not reported	0 (0)	0 (0)	1 (1)	2 (2)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	71 (78)	80 (84)	74 (74)	74 (83)	67 (74)
Once	4 (4)	1 (1)	11 (11)	4 (4)	7 (8)
Twice	6 (7)	4 (4)	5 (5)	3 (3)	6 (7)
3-5 times	1 (1)	5 (5)	6 (6)	5 (6)	5 (5)
>5 times	8 (9)	5 (5)	4 (4)	3 (3)	6 (7)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	71 (78)	80 (84)	74 (74)	74 (83)	67 (74)
One	7 (8)	5 (5)	9 (9)	7 (8)	5 (5)
Two	3 (3)	3 (3)	2 (2)	1 (1)	3 (3)
Three to five	0 (0)	2 (2)	1 (1)	1 (1)	3 (3)
More than five	2 (2)	0 (0)	2 (2)	1 (1)	4 (4)
Don't know	6 (7)	3 (3)	11 (11)	5 (6)	7 (8)
Not reported	2 (2)	2 (2)	1 (1)	0 (0)	2 (2)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	8 (9)	7 (7)	7 (7)	7 (8)	8 (9)
Casual sex partner	1 (1)	0 (0)	2 (2)	2 (2)	2 (2)
Close friend	4 (4)	1 (1)	9 (9)	4 (4)	6 (7)
Acquaintance	2 (2)	2 (2)	7 (7)	3 (3)	2 (2)
Other	1 (1)	3 (3)	4 (4)	0 (0)	1 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	29 (32)	29 (31)	23 (23)	26 (29)	26 (29)
Water	21 (23)	14 (15)	17 (17)	22 (25)	20 (22)
Filter	12 (13)	9 (9)	8 (8)	6 (7)	10 (11)
Drug mix	11 (12)	16 (17)	10 (10)	6 (7)	11 (12)
None	58 (64)	63 (66)	69 (69)	58 (65)	59 (65)
Injected by someone after that person injected themselves or others last month (%)					
No	74 (81)	82 (86)	82 (82)	75 (84)	74 (81)
Yes	16 (18)	13 (14)	18 (18)	13 (15)	17 (19)
Not reported	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)
Source of needle acquisition (%)					
Needle Syringe Program	75 (82)	84 (88)	93 (93)	82 (92)	80 (88)
Chemist/Pharmacy	25 (27)	23 (24)	28 (28)	30 (34)	29 (32)
Personal sources	14 (15)	19 (20)	22 (22)	24 (27)	5 (5)
Dispensing/Vending Machine	9 (10)	16 (17)	16 (16)	18 (20)	18 (20)
Other sources	3 (3)	2 (2)	0 (0)	5 (6)	1 (1)

Table 2.1.4 Number (%) of respondents by treatment for drug use and survey year

Australian Capital Territory	2021	2022	2023	2024	2025
N° surveyed	N=100	N=100	N=109	N=99	N=100
Ever any treatment/therapy for drug use (%)					
No	20 (20)	26 (26)	17 (16)	21 (21)	27 (27)
Yes	80 (80)	74 (74)	92 (84)	78 (79)	73 (73)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	39 (39)	37 (37)	25 (23)	24 (24)	28 (28)
Previously	26 (26)	18 (18)	40 (37)	35 (35)	24 (24)
Never	33 (33)	44 (44)	43 (39)	39 (39)	48 (48)
Not reported	2 (2)	1 (1)	1 (1)	1 (1)	0 (0)
History of buprenorphine (Subutex®) treatment (%)					
Currently	5 (5)	9 (9)	12 (11)	11 (11)	10 (10)
Previously	38 (38)	28 (28)	42 (39)	28 (28)	32 (32)
Never	56 (56)	63 (63)	53 (49)	59 (60)	57 (57)
Not reported	1 (1)	0 (0)	2 (2)	1 (1)	1 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	5 (5)	5 (5)	7 (6)	9 (9)	5 (5)
Previously	34 (34)	31 (31)	44 (40)	26 (26)	30 (30)
Never	60 (60)	63 (63)	57 (52)	64 (65)	65 (65)
Not reported	1 (1)	1 (1)	1 (1)	0 (0)	0 (0)
History of depot buprenorphine treatment (%)					
Currently	9 (9)	16 (16)	16 (15)	15 (15)	14 (14)
Previously	10 (10)	13 (13)	17 (16)	16 (16)	19 (19)
Never	80 (80)	71 (71)	74 (68)	68 (69)	66 (66)
Not reported	1 (1)	0 (0)	2 (2)	0 (0)	1 (1)

Table 2.1.5 Number (%) of respondents by sexual behaviour in the month prior to survey and survey year

Australian Capital Territory	2021	2022	2023	2024	2025
N° surveyed	N=100	N=100	N=109	N=99	N=100
Sex with a regular partner last month (%)					
No	62 (62)	59 (59)	69 (63)	68 (69)	64 (64)
Yes	35 (35)	41 (41)	39 (36)	30 (30)	31 (31)
Not reported	3 (3)	0 (0)	1 (1)	1 (1)	5 (5)
Condom used with regular partner last month (%)					
N° surveyed	N=35	N=41	N=39	N=30	N=31
Never	23 (66)	32 (78)	29 (74)	27 (90)	21 (68)
Sometimes	1 (3)	5 (12)	6 (15)	2 (7)	2 (6)
Every time	6 (17)	3 (7)	3 (8)	1 (3)	5 (16)
Not reported	5 (14)	1 (2)	1 (3)	0 (0)	3 (10)
Sex with other partner(s) last month (%)					
No	86 (86)	91 (91)	97 (89)	85 (86)	80 (80)
Yes	10 (10)	5 (5)	10 (9)	9 (9)	18 (18)
Not reported	4 (4)	4 (4)	2 (2)	5 (5)	2 (2)
Condom used with other partner(s) last month (%)					
N° surveyed	N=10	N=5	N=10	N=9	N=18
Never	5 (50)	3 (60)	5 (50)	3 (33)	12 (67)
Sometimes	2 (20)	0 (0)	4 (40)	4 (44)	3 (17)
Every time	3 (30)	2 (40)	1 (10)	1 (11)	3 (17)
Not reported	0 (0)	0 (0)	0 (0)	1 (11)	0 (0)
Sex work last month (%)					
No	93 (93)	98 (98)	98 (90)	90 (91)	86 (86)
Yes	5 (5)	2 (2)	5 (5)	7 (7)	11 (11)
Not reported	2 (2)	0 (0)	6 (6)	2 (2)	3 (3)
Condom used at last sex work (%)					
Yes	1 (20)	2 (100)	4 (80)	4 (57)	9 (82)

Table 2.1.6 Number (%) of respondents by testing for HIV and HCV, HCV treatment by survey year

Australian Capital Territory N° surveyed	2021 N=100	2022 N=100	2023 N=109	2024 N=99	2025 N=100
Previous HIV test (%)					
Yes, ever	82 (82)	83 (83)	93 (85)	80 (81)	85 (85)
Yes, last year	44 (44)	51 (51)	52 (48)	45 (45)	59 (59)
>1 year ago	38 (38)	32 (32)	41 (38)	35 (35)	26 (26)
Never tested	16 (16)	17 (17)	13 (12)	18 (18)	14 (14)
Not reported	2 (2)	0 (0)	3 (3)	1 (1)	1 (1)
Previous HCV test (%)					
Yes, ever	80 (80)	85 (85)	95 (87)	85 (86)	86 (86)
Yes, last year	46 (46)	58 (58)	60 (55)	60 (61)	65 (65)
>1 year ago	34 (34)	27 (27)	35 (32)	25 (25)	21 (21)
Never tested	7 (7)	11 (11)	5 (5)	8 (8)	6 (6)
Not reported	13 (13)	4 (4)	9 (8)	6 (6)	8 (8)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=24	N=23	N=36	N=30	N=21
Antiviral treatment	11 (46)	16 (70)	27 (75)	23 (77)	18 (86)
No antiviral treatment	13 (54)	7 (30)	9 (25)	7 (23)	3 (14)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)^{**}					
N° self-reported HCV diagnosis	N=18	N=15	N=17	N=15	N=12
Antiviral treatment	4 (22)	6 (40)	4 (24)	2 (13)	8 (67)
No antiviral treatment	14 (78)	9 (60)	13 (76)	13 (87)	4 (33)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance^{*} excludes people who reported treatment induced clearance more than 12 months previously

HIV antibody prevalence

Table 2.2.1 HIV antibody prevalence by gender and survey year

Aust. Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021	67	0 (0.0)	32	0 (0.0)	99	0 (0.0)
2022	66	1 (1.5)	32	0 (0.0)	99	1 (1.0)
2023	65	0 (0.0)	34	0 (0.0)	101	0 (0.0)
2024	64	0 (0.0)	29	0 (0.0)	99	0 (0.0)
2025	67	0 (0.0)	30	0 (0.0)	100	0 (0.0)
X ² p trend		0.484		--		0.477

HCV antibody prevalence

Table 2.3.1 HCV antibody prevalence by gender and survey year

Aust. Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	67	27 (40)	32	9 (28)	99	36 (36)
2022	67	25 (37)	32	10 (31)	100	35 (35)
2023*	65	45 (69)	34	22 (65)	101	68 (67)
2024	64	29 (45)	29	17 (59)	99	49 (49)
2025	67	23 (34)	30	12 (40)	100	35 (35)
X ² p trend^		<0.001		0.050		<0.001

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

^ X² p trend calculated on years 2023-2025 only

Table 2.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	62	25 (40)	24	7 (29)	86	32 (37)
Bisexual	3	2 (67)	4	2 (50)	7	4 (57)
Homosexual	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.490		0.717		0.260
2022						
Heterosexual	60	23 (38)	21	7 (33)	81	30 (37)
Bisexual	3	0 (0)	8	2 (25)	11	2 (18)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.124		0.557		0.187
2023						
Heterosexual	57	40 (70)	22	15 (68)	79	55 (70)
Bisexual	3	1 (33)	8	4 (50)	11	5 (45)
Homosexual	1	1 (100)	2	1 (50)	3	2 (67)
p value		0.396		0.833		0.327
2024						
Heterosexual	59	27 (46)	22	14 (64)	81	41 (51)
Bisexual	2	1 (50)	4	2 (50)	9	5 (56)
Homosexual	0	0 (0)	2	1 (50)	5	2 (40)
p value		0.833		0.609		0.678
2025						
Heterosexual	58	22 (38)	21	8 (38)	82	30 (37)
Bisexual	3	0 (0)	5	2 (40)	8	2 (25)
Homosexual	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.600		0.580		0.811

Table 2.3.3 HCV antibody prevalence by age group, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<25 years	0	0 (0)	2	1 (50)	2	1 (50)
25-34 years	15	5 (33)	5	1 (20)	20	6 (30)
35-44 years	23	11 (48)	11	4 (36)	34	15 (44)
45+ years	29	11 (38)	14	3 (21)	43	14 (33)
p value		0.634		0.764		0.579
2022						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	8	1 (13)	9	1 (11)	18	2 (11)
35-44 years	23	11 (48)	8	2 (25)	31	13 (42)
45+ years	36	13 (36)	15	7 (47)	51	20 (39)
p value		0.232		0.204		0.053
2023						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	6	1 (17)	7	6 (86)	14	7 (50)
35-44 years	19	16 (84)	13	8 (62)	32	24 (75)
45+ years	39	28 (72)	14	8 (57)	53	36 (68)
p value		0.006		0.525		0.160
2024						
<25 years	3	0 (0)	0	0 (0)	3	0 (0)
25-34 years	3	0 (0)	8	3 (38)	12	3 (25)
35-44 years	20	7 (35)	8	4 (50)	30	12 (40)
45+ years	38	22 (58)	13	10 (77)	54	34 (63)
p value		0.041		0.173		0.013
2025						
<25 years	1	0 (0)	1	0 (0)	2	0 (0)
25-34 years	7	0 (0)	4	1 (25)	11	1 (9)
35-44 years	21	6 (29)	7	4 (57)	29	10 (34)
45+ years	38	17 (45)	18	7 (39)	58	24 (41)
p value		0.097		0.592		0.147

Table 2.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	5	1 (20)	5	2 (40)	10	3 (30)
3 to 10 years	4	1 (25)	4	1 (25)	8	2 (25)
11+ years	57	24 (42)	20	6 (30)	77	30 (39)
p value		0.649		1.000		0.785
2022						
<3 years	4	0 (0)	4	0 (0)	8	0 (0)
3 to 10 years	6	0 (0)	6	3 (50)	12	3 (25)
11+ years	57	25 (44)	20	6 (30)	77	31 (40)
p value		0.031		0.344		0.046
2023						
<3 years	2	1 (50)	1	0 (0)	3	1 (33)
3 to 10 years	6	3 (50)	5	3 (60)	11	6 (55)
11+ years	56	40 (71)	28	19 (68)	84	59 (70)
p value		0.328		0.565		0.228
2024						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3 to 10 years	5	1 (20)	3	1 (33)	11	2 (18)
11+ years	57	27 (47)	24	16 (67)	84	46 (55)
p value		0.332		0.241		0.027
2025						
<3 years	2	0 (0)	3	1 (33)	5	1 (20)
3 to 10 years	8	0 (0)	7	2 (29)	15	2 (13)
11+ years	53	21 (40)	18	8 (44)	74	29 (39)
p value		0.051		0.747		0.124

Table 2.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Aust. Capital Territory	<3 years		3+ years		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	7	2 (29)	60	24 (40)	70	27 (39)
Receptive sharing	2	1 (50)	17	8 (47)	19	9 (47)
p value		1.000		0.602		0.488
2022						
No receptive sharing	7	0 (0)	70	24 (34)	80	25 (31)
Receptive sharing	0	0 (0)	15	8 (53)	15	8 (53)
p value		--		0.167		0.099
2023						
No receptive sharing	2	0 (0)	62	38 (61)	67	40 (60)
Receptive sharing	1	1 (100)	25	22 (88)	26	23 (88)
p value		0.333		0.020		0.007
2024						
No receptive sharing	2	0 (0)	70	33 (47)	74	34 (46)
Receptive sharing	0	0 (0)	15	10 (67)	15	10 (67)
p value		--		0.170		0.143
2025						
No receptive sharing	5	1 (20)	60	17 (28)	67	19 (28)
Receptive sharing	0	0 (0)	22	13 (59)	24	15 (63)
p value		--		0.010		0.003

Table 2.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Aust. Capital Territory	<3 years		3+ years		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heroin	2	0 (0)	39	14 (36)	43	15 (35)
Methamphetamine	5	0 (0)	32	12 (38)	39	12 (31)
Other opioids	2	2 (100)	3	1 (33)	5	3 (60)
Other drugs	0	0 (0)	9	5 (56)	9	5 (56)
p value		0.011		0.738		0.361
2022						
Heroin	1	0 (0)	42	22 (52)	44	22 (50)
Methamphetamine	6	0 (0)	33	7 (21)	41	8 (20)
Other opioids	0	0 (0)	2	1 (50)	2	1 (50)
Other drugs	1	0 (0)	9	2 (22)	10	2 (20)
p value		--		0.033		0.019
2023						
Heroin	0	0 (0)	44	36 (82)	44	36 (82)
Methamphetamine	2	1 (50)	41	20 (49)	45	22 (49)
Other opioids	0	0 (0)	4	3 (75)	5	4 (80)
Other drugs	1	0 (0)	3	3 (100)	4	3 (75)
p value		0.386		0.007		0.010
2024						
Heroin	2	0 (0)	39	25 (64)	41	25 (61)
Methamphetamine	0	0 (0)	44	16 (36)	46	17 (37)
Other opioids	0	0 (0)	1	1 (100)	1	1 (100)
Other drugs	0	0 (0)	8	4 (50)	8	4 (50)
p value		--		0.061		0.108
2025						
Heroin	3	1 (33)	40	22 (55)	45	25 (56)
Methamphetamine	2	0 (0)	32	4 (13)	38	5 (13)
Other opioids	0	0 (0)	2	1 (50)	2	1 (50)
Other drugs	0	0 (0)	12	4 (33)	12	4 (33)
p value		0.361		0.003		0.001

Table 2.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Aust. Capital Territory	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	4	1 (25)	27	5 (19)	32	6 (19)
Daily or more	5	2 (40)	51	27 (53)	58	30 (52)
Not last month	1	0 (0)	5	0 (0)	7	0 (0)
p value		1.000		0.001		0.001
2022						
Less than daily	4	0 (0)	35	15 (43)	41	16 (39)
Daily or more	3	0 (0)	50	17 (34)	54	17 (31)
Not last month	1	0 (0)	2	1 (50)	3	1 (33)
p value		--		0.627		0.782
2023						
Less than daily	2	1 (50)	36	18 (50)	39	19 (49)
Daily or more	1	0 (0)	51	42 (82)	54	44 (81)
Not last month	0	0 (0)	5	2 (40)	5	2 (40)
p value		1.000		0.002		0.001
2024						
Less than daily	0	0 (0)	27	12 (44)	28	12 (43)
Daily or more	2	0 (0)	58	31 (53)	61	32 (52)
Not last month	0	0 (0)	9	5 (56)	9	5 (56)
p value		--		0.712		0.660
2025						
Less than daily	2	0 (0)	25	10 (40)	27	10 (37)
Daily or more	3	1 (33)	57	20 (35)	64	24 (38)
Not last month	0	0 (0)	6	1 (17)	8	1 (13)
p value		0.361		0.561		0.370

Table 2.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Aust. Capital Territory	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	8	3 (38)	68	25 (37)	80	29 (36)
Imprisonment	1	0 (0)	11	3 (27)	12	3 (25)
p value		1.000		0.738		0.532
2022						
No imprisonment	8	0 (0)	78	30 (38)	89	31 (35)
Imprisonment	0	0 (0)	9	3 (33)	9	3 (33)
p value		--		1.000		1.000
2023						
No imprisonment	3	1 (33)	85	56 (66)	90	59 (66)
Imprisonment	0	0 (0)	7	7 (100)	7	7 (100)
p value		--		0.093		0.093
2024						
No imprisonment	2	0 (0)	81	42 (52)	85	43 (51)
Imprisonment	0	0 (0)	10	6 (60)	10	6 (60)
p value		--		0.626		0.573
2025						
No imprisonment	4	1 (25)	80	26 (33)	87	27 (31)
Imprisonment	1	0 (0)	8	5 (63)	12	8 (67)
p value		0.576		0.090		0.016

Table 2.3.9 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
English speaking	65	26 (40)	29	7 (24)	94	33 (35)
Non-English speaking	2	1 (50)	3	2 (67)	5	3 (60)
p value		1.000		0.184		0.350
2022						
English speaking	63	22 (35)	31	10 (32)	94	32 (34)
Non-English speaking	3	2 (67)	1	0 (0)	4	2 (50)
p value		0.548		1.000		0.608
2023						
English speaking	60	40 (67)	32	20 (63)	94	61 (65)
Non-English speaking	4	4 (100)	2	2 (100)	6	6 (100)
p value		0.300		0.529		0.174
2024						
English speaking	61	27 (44)	29	17 (59)	95	47 (49)
Non-English speaking	2	1 (50)	0	0 (0)	3	1 (33)
p value		0.872		--		0.582
2025						
English speaking	60	22 (37)	29	11 (38)	92	33 (36)
Non-English speaking	6	0 (0)	1	1 (100)	7	1 (14)
p value		0.069		0.213		0.246

Table 2.3.10 HCV antibody prevalence by region/country of birth, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Australia	62	23 (37)	28	7 (25)	90	30 (33)
Other Oceania	2	2 (100)	0	0 (0)	2	2 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	1	0 (0)	3	1 (33)
Other	1	1 (100)	3	2 (67)	4	3 (75)
p value		0.128		0.421		0.070
2022						
Australia	56	19 (34)	28	9 (32)	85	28 (33)
Other Oceania	5	3 (60)	0	0 (0)	5	3 (60)
Asia	1	0 (0)	1	0 (0)	2	0 (0)
UK & Ireland	2	0 (0)	2	0 (0)	4	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.402		1.000		0.177
2023						
Australia	58	40 (69)	32	21 (66)	92	62 (67)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	1	1 (100)	1	0 (0)	2	1 (50)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	2	0 (0)	1	1 (100)	3	1 (33)
p value		0.312		0.588		0.713
2024						
Australia	56	24 (43)	28	17 (61)	89	44 (49)
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)
Asia	3	3 (100)	0	0 (0)	3	3 (100)
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)
Other	2	1 (50)	0	0 (0)	3	1 (33)
p value		0.287		0.226		0.361
2025						
Australia	56	19 (34)	25	11 (44)	84	30 (36)
Other Oceania	2	0 (0)	2	1 (50)	4	1 (25)
Asia	1	0 (0)	1	0 (0)	2	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	4	2 (50)	2	0 (0)	6	2 (33)
p value		0.571		0.522		0.736

HCV RNA prevalence

Table 2.4.1 HCV RNA prevalence by gender and survey year

Australian Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	62	14 (23)	32	6 (19)	94	20 (21)
2022	65	7 (11)	31	3 (10)	97	10 (10)
2023	63	17 (27)	34	5 (15)	99	22 (22)
2024	64	10 (16)	29	4 (14)	99	15 (15)
2025	67	6 (9)	30	1 (3)	100	7 (7)
X ² p trend		0.028		0.414		0.009

Totals include respondents where gender was reported as other or not reported

Table 2.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Australian Capital Territory	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	57	13 (23)	24	4 (17)	81	17 (21)
Bisexual	3	1 (33)	4	2 (50)	7	3 (43)
Homosexual	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.676		0.233		0.226
2022						
Heterosexual	58	6 (10)	20	2 (10)	78	8 (10)
Bisexual	3	0 (0)	8	1 (13)	11	1 (9)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.394		1.000		0.533
2023						
Heterosexual	56	15 (27)	22	5 (23)	78	20 (26)
Bisexual	3	1 (33)	8	0 (0)	11	1 (9)
Homosexual	1	0 (0)	2	0 (0)	3	0 (0)
p value		0.780		0.635		0.657
2024						
Heterosexual	59	9 (15)	22	3 (14)	81	12 (15)
Bisexual	2	1 (50)	4	1 (25)	9	2 (22)
Homosexual	0	0 (0)	2	0 (0)	5	1 (20)
p value		0.502		0.825		0.884
2025						
Heterosexual	58	6 (10)	21	1 (5)	82	7 (9)
Bisexual	3	0 (0)	5	0 (0)	8	0 (0)
Homosexual	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.969		0.983		0.916

Table 2.4.3 HCV RNA prevalence by age group, gender and survey year

Australian Capital Territory	Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<25 years	0	0 (0)	2	1 (50)	2	1 (50)
25-34 years	14	5 (36)	5	1 (20)	19	6 (32)
35-44 years	21	5 (24)	11	2 (18)	32	7 (22)
45+ years	27	4 (15)	14	2 (14)	41	6 (15)
p value		0.312		0.689		0.351
2022						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	8	0 (0)	8	1 (13)	17	1 (6)
35-44 years	22	3 (14)	8	1 (13)	30	4 (13)
45+ years	35	4 (11)	15	1 (7)	50	5 (10)
p value		0.861		1.000		0.820
2023						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	6	0 (0)	7	1 (14)	14	1 (7)
35-44 years	19	6 (32)	13	2 (15)	32	8 (25)
45+ years	37	11 (30)	14	2 (14)	51	13 (25)
p value		0.512		1.000		0.500
2024						
<25 years	3	0 (0)	0	0 (0)	3	0 (0)
25-34 years	3	0 (0)	8	1 (13)	12	1 (8)
35-44 years	20	4 (20)	8	0 (0)	30	4 (13)
45+ years	38	6 (16)	13	3 (23)	54	10 (19)
p value		0.705		0.327		0.677
2025						
<25 years	1	0 (0)	1	0 (0)	2	0 (0)
25-34 years	7	0 (0)	4	0 (0)	11	0 (0)
35-44 years	21	0 (0)	7	1 (14)	29	1 (3)
45+ years	38	6 (16)	18	0 (0)	58	6 (10)
p value		0.170		0.334		0.469

Table 2.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Australian Capital Territory	Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	5	0 (0)	5	1 (20)	10	1 (10)
3 to 10 years	4	1 (25)	4	1 (25)	8	2 (25)
11+ years	52	12 (23)	20	4 (20)	72	16 (22)
p value		0.476		0.974		0.648
2022						
<3 years	4	0 (0)	4	0 (0)	8	0 (0)
3 to 10 years	6	0 (0)	6	1 (17)	12	1 (8)
11+ years	55	7 (13)	19	2 (11)	74	9 (12)
p value		1.000		1.000		0.840
2023						
<3 years	2	0 (0)	1	0 (0)	3	0 (0)
3 to 10 years	6	1 (17)	5	1 (20)	11	2 (18)
11+ years	54	16 (30)	28	4 (14)	82	20 (24)
p value		0.824		1.000		1.000
2024						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3 to 10 years	5	1 (20)	3	1 (33)	11	2 (18)
11+ years	57	9 (16)	24	3 (13)	84	13 (15)
p value		0.881		0.572		0.807
2025						
<3 years	2	0 (0)	3	0 (0)	5	0 (0)
3 to 10 years	8	0 (0)	7	1 (14)	15	1 (7)
11+ years	53	5 (9)	18	0 (0)	74	5 (7)
p value		0.599		0.211		0.835

Table 2.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Australian Capital Territory	Male		Female		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	44	9 (20)	22	3 (14)	66	12 (18)
Receptive sharing	12	5 (42)	6	3 (50)	18	8 (44)
p value		0.133		0.054		0.020
2022						
No receptive sharing	50	5 (10)	26	2 (8)	77	7 (9)
Receptive sharing	11	1 (9)	4	1 (25)	15	2 (13)
p value		1.000		0.360		0.637
2023						
No receptive sharing	42	12 (29)	23	3 (13)	67	15 (22)
Receptive sharing	16	3 (19)	8	2 (25)	24	5 (21)
p value		0.522		0.583		0.875
2024						
No receptive sharing	46	6 (13)	23	4 (17)	74	11 (15)
Receptive sharing	13	3 (23)	1	0 (0)	15	3 (20)
p value		0.374		0.648		0.618
2025						
No receptive sharing	43	1 (2)	22	0 (0)	67	1 (1)
Receptive sharing	17	5 (29)	6	1 (17)	24	6 (25)
p value		0.002		0.051		<0.001

Table 2.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Australian Capital Territory	Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heroin	28	5 (18)	14	2 (14)	42	7 (17)
Methamphetamine	25	7 (28)	11	2 (18)	36	9 (25)
Other opioids	4	0 (0)	1	1 (100)	5	1 (20)
Other drugs	4	2 (50)	4	1 (25)	8	3 (38)
p value		0.306		0.224		0.569
2022						
Heroin	24	3 (13)	19	3 (16)	43	6 (14)
Methamphetamine	29	2 (7)	10	0 (0)	40	2 (5)
Other opioids	2	0 (0)	0	0 (0)	2	0 (0)
Other drugs	8	1 (13)	1	0 (0)	9	1 (11)
p value		0.856		0.381		0.541
2023						
Heroin	28	8 (29)	16	3 (19)	44	11 (25)
Methamphetamine	31	6 (19)	13	1 (8)	45	7 (16)
Other opioids	1	0 (0)	1	0 (0)	3	0 (0)
Other drugs	1	1 (100)	3	1 (33)	4	2 (50)
p value		0.252		0.643		0.253
2024						
Heroin	22	6 (27)	15	1 (7)	41	8 (20)
Methamphetamine	31	3 (10)	13	2 (15)	46	5 (11)
Other opioids	1	1 (100)	0	0 (0)	1	1 (100)
Other drugs	8	0 (0)	0	0 (0)	8	0 (0)
p value		0.021		0.457		0.036
2025						
Heroin	31	5 (16)	14	1 (7)	45	6 (13)
Methamphetamine	25	1 (4)	10	0 (0)	38	1 (3)
Other opioids	2	0 (0)	0	0 (0)	2	0 (0)
Other drugs	7	0 (0)	5	0 (0)	12	0 (0)
p value		0.322		0.574		0.187

Table 2.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Australian Capital Territory	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	19	3 (16)	12	0 (0)	31	3 (10)
Daily or more	37	11 (30)	17	6 (35)	54	17 (31)
Not last month	5	0 (0)	2	0 (0)	7	0 (0)
p value		0.223		0.047		0.022
2022						
Less than daily	26	3 (12)	15	1 (7)	41	4 (10)
Daily or more	35	3 (9)	15	2 (13)	51	5 (10)
Not last month	3	0 (0)	0	0 (0)	3	0 (0)
p value		1.000		1.000		1.000
2023						
Less than daily	24	4 (17)	14	3 (21)	39	7 (18)
Daily or more	34	11 (32)	17	2 (12)	52	13 (25)
Not last month	3	0 (0)	2	0 (0)	5	0 (0)
p value		0.339		0.739		0.497
2024						
Less than daily	18	1 (6)	8	2 (25)	28	3 (11)
Daily or more	41	8 (20)	16	2 (13)	61	11 (18)
Not last month	4	1 (25)	5	0 (0)	9	1 (11)
p value		0.352		0.434		0.629
2025						
Less than daily	16	1 (6)	10	1 (10)	27	2 (7)
Daily or more	44	5 (11)	18	0 (0)	64	5 (8)
Not last month	6	0 (0)	2	0 (0)	8	0 (0)
p value		0.597		0.355		0.716

Table 2.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Australian Capital Territory	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	48	9 (19)	28	6 (21)	76	15 (20)
Imprisonment	8	1 (13)	3	0 (0)	11	1 (9)
p value		0.669		0.372		0.394
2022						
No imprisonment	56	7 (13)	29	2 (7)	86	9 (10)
Imprisonment	7	0 (0)	2	1 (50)	9	1 (11)
p value		1.000		0.187		1.000
2023						
No imprisonment	56	17 (30)	31	5 (16)	88	22 (25)
Imprisonment	5	0 (0)	2	0 (0)	7	0 (0)
p value		0.309		1.000		0.195
2024						
No imprisonment	52	10 (19)	27	4 (15)	85	15 (18)
Imprisonment	9	0 (0)	1	0 (0)	10	0 (0)
p value		0.150		0.678		0.148
2025						
No imprisonment	56	3 (5)	28	1 (4)	87	4 (5)
Imprisonment	10	3 (30)	2	0 (0)	12	3 (25)
p value		0.013		0.786		0.010

Table 2.4.9 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Australian Capital Territory		Male		Female		Total	
Main language spoken	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
at home by parents							
2021							
English speaking	60	13 (22)	29	5 (17)	89	18 (20)	
Non-English speaking	2	1 (50)	3	1 (33)	5	2 (40)	
p value		0.346		0.497		0.293	
2022							
English speaking	61	6 (10)	30	3 (10)	91	9 (10)	
Non-English speaking	3	1 (33)	1	0 (0)	4	1 (25)	
p value		0.298		1.000		0.364	
2023							
English speaking	59	14 (24)	32	4 (13)	93	18 (19)	
Non-English speaking	4	3 (75)	2	1 (50)	6	4 (67)	
p value		0.057		0.276		0.021	
2024							
English speaking	61	9 (15)	29	4 (14)	95	14 (15)	
Non-English speaking	2	1 (50)	0	0 (0)	3	1 (33)	
p value		0.180		--		0.378	
2025							
English speaking	60	5 (8)	29	1 (3)	92	6 (7)	
Non-English speaking	6	0 (0)	1	0 (0)	7	0 (0)	
p value		0.462		0.850		0.486	

Table 2.4.10 HCV RNA prevalence by region/country of birth, gender and survey year

Australian Capital Territory		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Australia	57	14 (25)	28	5 (18)	85	19 (22)	
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	2	0 (0)	1	0 (0)	3	0 (0)	
Other	1	0 (0)	3	1 (33)	4	1 (25)	
p value		0.663		0.717		0.695	
2022							
Australia	54	5 (9)	27	3 (11)	82	8 (10)	
Other Oceania	5	1 (20)	0	0 (0)	5	1 (20)	
Asia	1	0 (0)	1	0 (0)	2	0 (0)	
UK & Ireland	2	0 (0)	2	0 (0)	4	0 (0)	
Other	1	1 (100)	0	0 (0)	1	1 (100)	
p value		0.145		1.000		0.162	
2023							
Australia	57	14 (25)	32	5 (16)	91	19 (21)	
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)	
Asia	1	1 (100)	1	0 (0)	2	1 (50)	
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)	
Other	2	0 (0)	1	0 (0)	3	0 (0)	
p value		0.059		1.000		0.063	
2024							
Australia	56	8 (14)	28	4 (14)	89	13 (15)	
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)	
Asia	3	2 (67)	0	0 (0)	3	2 (67)	
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)	
Other	2	0 (0)	0	0 (0)	3	0 (0)	
p value		0.084		0.684		0.125	
2025							
Australia	56	6 (11)	25	1 (4)	84	7 (8)	
Other Oceania	2	0 (0)	2	0 (0)	4	0 (0)	
Asia	1	0 (0)	1	0 (0)	2	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	4	0 (0)	2	0 (0)	6	0 (0)	
p value		0.843		0.976		0.782	

New South Wales

Table 3.1.1 Number (%) of respondents by demographic characteristics and survey year

New South Wales	2021*	2022	2023	2024	2025
Number of sites	3	18	19	19	18
N° surveyed	N=46	N=420	N=415	N=463	N=439
Response rate (%)	40%	23%	22%	26%	27%
Gender (%)					
Male	29 (63)	275 (65)	277 (67)	318 (69)	313 (71)
Female	16 (35)	133 (32)	131 (32)	137 (30)	118 (27)
Other	1 (2)	10 (2)	6 (1)	7 (2)	5 (1)
Not reported	0 (0)	2 (<1)	1 (<1)	1 (<1)	3 (1)
Age (years)					
Median age	49	45	45	45	44
Age range	27-66	17-71	20-71	18-71	18-71
<25 years	0 (0)	21 (5)	17 (4)	12 (3)	18 (4)
25+ years	46 (100)	397 (95)	396 (95)	451 (97)	419 (95)
Not reported	0 (0)	2 (<1)	2 (<1)	0 (0)	2 (<1)
Sexual identity (%)					
Heterosexual	32 (70)	327 (78)	326 (79)	358 (77)	334 (76)
Bisexual	5 (11)	45 (11)	43 (10)	51 (11)	48 (11)
Gay/Lesbian	7 (15)	31 (7)	29 (7)	31 (7)	41 (9)
Other	2 (4)	15 (4)	12 (3)	21 (5)	3 (1)
Not reported	0 (0)	2 (<1)	5 (1)	2 (<1)	13 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	31 (67)	315 (75)	295 (71)	336 (73)	311 (71)
Yes	11 (24)	94 (22)	115 (28)	119 (26)	124 (28)
Not reported	4 (9)	11 (3)	5 (1)	8 (2)	4 (1)
Region/country of birth (%)					
Australia	36 (78)	358 (85)	365 (88)	415 (90)	394 (90)
Other Oceania	3 (7)	14 (3)	15 (4)	10 (2)	7 (2)
Asia	1 (2)	8 (2)	5 (1)	4 (1)	7 (2)
UK & Ireland	2 (4)	9 (2)	11 (3)	8 (2)	7 (2)
Other	2 (4)	26 (6)	17 (4)	22 (5)	17 (4)
Not reported	2 (4)	5 (1)	2 (<1)	4 (1)	7 (2)
Main language spoken at home by parents (%)					
English	43 (93)	391 (93)	397 (96)	430 (93)	418 (95)
Non-English	2 (4)	22 (5)	17 (4)	30 (6)	16 (4)
Not reported	1 (2)	7 (2)	1 (<1)	3 (1)	5 (1)
Age at first injection and time since first injection (years)					
Median age at first injection	20	20	20	20	20
Age range at first injection	13-45	10-55	10-56	10-56	10-65
N° not reported	1	28	24	15	20
Median yrs since first injection	26	24	24	24	22
Range yrs since first injection	4-49	<1-56	<1-56	<1-53	<1-56
<3 years since first injection	0 (0)	37 (9)	22 (5)	46 (10)	48 (11)
3+ years since first injection	45 (98)	355 (85)	368 (89)	402 (87)	371 (85)
Not reported	1 (2)	28 (7)	25 (6)	15 (3)	20 (5)

* Implementation of the 2021 ANSPS was impacted by the COVID-19 pandemic

Table 3.1.2 Number (%) of respondents by last drug injected, frequency of injecting, overdose, imprisonment, injection in prison and survey year

New South Wales	2021	2022	2023	2024	2025
N° surveyed	N=46	N=420	N=415	N=463	N=439
Drug last injected (%)					
Cocaine	1 (2)	9 (2)	5 (1)	6 (1)	4 (1)
Methamphetamine	25 (54)	143 (34)	177 (43)	197 (43)	173 (39)
Heroin	16 (35)	126 (30)	98 (24)	114 (25)	87 (20)
Pharm. opioids	1 (2)	6 (1)	10 (2)	5 (1)	1 (<1)
Methadone	2 (4)	32 (8)	35 (8)	48 (10)	26 (6)
Buprenorphine	0 (0)	4 (1)	1 (<1)	3 (1)	1 (<1)
Buprenorphine/naloxone	0 (0)	1 (<1)	1 (<1)	3 (1)	0 (0)
PIEDs	1 (2)	69 (16)	62 (15)	58 (13)	76 (17)
More than one	0 (0)	20 (5)	18 (4)	21 (5)	49 (11)
Other	0 (0)	3 (1)	5 (1)	4 (1)	1 (<1)
Not reported	0 (0)	7 (2)	3 (1)	4 (1)	21 (5)
Ever injected opioids (%)					
No	12 (26)	113 (27)	121 (29)	134 (29)	152 (35)
Yes	34 (74)	305 (73)	293 (71)	325 (70)	285 (65)
Not reported	0 (0)	2 (<1)	1 (<1)	4 (1)	2 (<1)
Frequency of injection last month (%)					
Not last month	11 (24)	66 (16)	51 (12)	65 (14)	48 (11)
Less than weekly	9 (20)	72 (17)	56 (13)	70 (15)	42 (10)
Weekly not daily	12 (26)	97 (23)	105 (25)	100 (22)	90 (21)
Daily or more	14 (30)	175 (42)	196 (47)	224 (48)	252 (57)
Not reported	0 (0)	10 (2)	7 (2)	4 (1)	7 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	40 (87)	340 (81)	326 (79)	360 (78)	354 (81)
Yes	6 (13)	71 (17)	59 (14)	82 (18)	67 (15)
Not reported	0 (0)	9 (2)	30 (7)	21 (5)	18 (4)
Overdosed in last 12 months (%)					
No	39 (85)	363 (86)	335 (81)	382 (83)	370 (84)
Yes	7 (15)	48 (11)	48 (12)	57 (12)	48 (11)
Not reported	0 (0)	9 (2)	32 (8)	24 (5)	21 (5)
Imprisonment last year (%)					
No	41 (89)	367 (87)	336 (81)	373 (81)	359 (82)
Yes	4 (9)	37 (9)	39 (9)	61 (13)	46 (10)
Not reported	1 (2)	16 (4)	40 (10)	29 (6)	34 (8)
Injected while in prison last year					
N° in prison last year	N=4	N=37	N=39	N=61	N=46
No	3 (75)	24 (65)	24 (62)	29 (48)	21 (46)
Yes	1 (25)	10 (27)	13 (33)	30 (49)	24 (52)
Not reported	0 (0)	3 (8)	2 (5)	2 (3)	1 (2)

Table 3.1.3 Number (%) of respondents by injecting behaviour in the last month and survey year

New South Wales	2021	2022	2023	2024	2025
N° injected last month	N=35	N=344	N=357	N=394	N=384
Places injected last month (%)					
All private	25 (71)	220 (64)	236 (66)	261 (66)	235 (61)
Any public	10 (29)	122 (35)	119 (33)	131 (33)	147 (38)
Not reported	0 (0)	2 (1)	2 (1)	2 (1)	2 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	29 (83)	273 (79)	279 (78)	322 (82)	321 (84)
Most of the time	4 (11)	55 (16)	59 (17)	46 (12)	44 (11)
Half of the time	1 (3)	5 (1)	5 (1)	7 (2)	4 (1)
Some of the time	1 (3)	4 (1)	7 (2)	8 (2)	10 (3)
Not last month	0 (0)	1 (<1)	4 (1)	4 (1)	0 (0)
Not reported	0 (0)	6 (2)	3 (1)	7 (2)	5 (1)
Re-used someone else's used needle & syringe last month (%)					
None	31 (89)	288 (84)	305 (85)	349 (89)	326 (85)
Once	2 (6)	17 (5)	16 (4)	14 (4)	15 (4)
Twice	1 (3)	12 (3)	16 (4)	6 (2)	15 (4)
3-5 times	1 (3)	14 (4)	4 (1)	7 (2)	14 (4)
>5 times	0 (0)	9 (3)	7 (2)	12 (3)	8 (2)
Not reported	0 (0)	4 (1)	9 (3)	6 (2)	6 (2)
Number of people needle & syringe was re-used after last month (%)					
None	31 (89)	288 (84)	305 (85)	349 (89)	326 (85)
One	2 (6)	19 (6)	19 (5)	7 (2)	13 (3)
Two	0 (0)	2 (1)	5 (1)	1 (<1)	9 (2)
Three to five	0 (0)	3 (1)	0 (0)	6 (2)	2 (1)
More than five	0 (0)	5 (1)	3 (1)	4 (1)	6 (2)
Don't know	1 (3)	13 (4)	10 (3)	16 (4)	15 (4)
Not reported	1 (3)	14 (4)	15 (4)	11 (3)	13 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	0 (0)	19 (6)	15 (4)	10 (3)	19 (5)
Casual sex partner	0 (0)	3 (1)	1 (<1)	2 (1)	3 (1)
Close friend	0 (0)	9 (3)	10 (3)	6 (2)	15 (4)
Acquaintance	2 (6)	4 (1)	8 (2)	10 (3)	8 (2)
Other	1 (3)	9 (3)	4 (1)	5 (1)	1 (<1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	4 (11)	60 (17)	62 (17)	79 (20)	72 (19)
Water	3 (9)	50 (15)	60 (17)	69 (18)	65 (17)
Filter	1 (3)	23 (7)	33 (9)	35 (9)	23 (6)
Drug mix	2 (6)	36 (10)	33 (9)	44 (11)	29 (8)
None	32 (91)	245 (71)	260 (73)	282 (72)	276 (72)
Injected by someone after that person injected themselves or others last month (%)					
No	30 (86)	286 (83)	301 (84)	321 (81)	333 (87)
Yes	5 (14)	53 (15)	53 (15)	65 (17)	44 (11)
Not reported	0 (0)	5 (1)	3 (1)	8 (2)	7 (2)
Source of needle acquisition (%)					
Needle Syringe Program	32 (91)	296 (86)	288 (81)	340 (86)	336 (88)
Chemist/Pharmacy	3 (9)	49 (14)	36 (10)	52 (13)	39 (10)
Personal sources	3 (9)	34 (10)	37 (10)	32 (8)	30 (8)
Dispensing/Vending Machine	12 (34)	97 (28)	98 (27)	97 (25)	106 (28)
Other sources	2 (6)	12 (3)	1 (<1)	7 (2)	5 (1)

Table 3.1.4 Number (%) of respondents by treatment for drug use and survey year

New South Wales	2021	2022	2023	2024	2025
N° surveyed	N=46	N=420	N=415	N=463	N=439
Ever any treatment/therapy for drug use (%)					
No	11 (24)	127 (30)	135 (33)	137 (30)	158 (36)
Yes	35 (76)	293 (70)	280 (67)	325 (70)	278 (63)
Not reported	0 (0)	0 (0)	0 (0)	1 (<1)	3 (1)
History of methadone maintenance treatment (%)					
Currently	13 (28)	115 (27)	102 (25)	106 (23)	104 (24)
Previously	6 (13)	97 (23)	89 (21)	85 (18)	72 (16)
Never	24 (52)	195 (46)	192 (46)	255 (55)	240 (55)
Not reported	3 (7)	13 (3)	32 (8)	17 (4)	23 (5)
History of buprenorphine (Subutex®) treatment (%)					
Currently	2 (4)	29 (7)	18 (4)	24 (5)	18 (4)
Previously	10 (22)	98 (23)	105 (25)	113 (24)	101 (23)
Never	30 (65)	283 (67)	261 (63)	306 (66)	299 (68)
Not reported	4 (9)	10 (2)	31 (7)	20 (4)	21 (5)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	0 (0)	18 (4)	18 (4)	23 (5)	22 (5)
Previously	10 (22)	94 (22)	72 (17)	80 (17)	73 (17)
Never	33 (72)	304 (72)	324 (78)	356 (77)	336 (77)
Not reported	3 (7)	4 (1)	1 (<1)	4 (1)	8 (2)
History of depot buprenorphine treatment (%)					
Currently	2 (4)	33 (8)	30 (7)	31 (7)	33 (8)
Previously	4 (9)	37 (9)	34 (8)	41 (9)	54 (12)
Never	36 (78)	341 (81)	323 (78)	370 (80)	330 (75)
Not reported	4 (9)	9 (2)	28 (7)	21 (5)	22 (5)

Table 3.1.5 Number (%) of respondents by sexual behaviour in the month prior to survey and survey year

New South Wales	2021	2022	2023	2024	2025
N° surveyed	N=46	N=420	N=415	N=463	N=439
Sex with a regular partner last month (%)					
No	30 (65)	222 (53)	209 (50)	231 (50)	220 (50)
Yes	11 (24)	182 (43)	175 (42)	212 (46)	197 (45)
Not reported	5 (11)	16 (4)	31 (7)	20 (4)	22 (5)
Condom used with regular partner last month (%)					
N° surveyed	N=11	N=182	N=175	N=212	N=197
Never	9 (82)	134 (74)	130 (74)	167 (79)	133 (68)
Sometimes	2 (18)	18 (10)	20 (11)	20 (9)	37 (19)
Every time	0 (0)	21 (12)	16 (9)	14 (7)	18 (9)
Not reported	0 (0)	9 (5)	9 (5)	11 (5)	9 (5)
Sex with other partner(s) last month (%)					
No	37 (80)	317 (75)	304 (73)	351 (76)	331 (75)
Yes	5 (11)	85 (20)	77 (19)	86 (19)	76 (17)
Not reported	4 (9)	18 (4)	34 (8)	26 (6)	32 (7)
Condom used with other partner(s) last month (%)					
N° surveyed	N=5	N=85	N=77	N=86	N=76
Never	2 (40)	43 (51)	48 (62)	49 (57)	27 (36)
Sometimes	2 (40)	21 (25)	10 (13)	23 (27)	23 (30)
Every time	1 (20)	20 (24)	18 (23)	11 (13)	22 (29)
Not reported	0 (0)	1 (1)	1 (1)	3 (3)	4 (5)
Sex work last month (%)					
No	40 (87)	364 (87)	355 (86)	395 (85)	364 (83)
Yes	1 (2)	29 (7)	22 (5)	30 (6)	40 (9)
Not reported	5 (11)	27 (6)	38 (9)	38 (8)	35 (8)
Condom used at last sex work (%)					
Yes	1 (100)	20 (69)	13 (59)	20 (67)	20 (50)

Table 3.1.6 Number (%) of respondents by testing for HIV and HCV, HCV treatment by survey year

New South Wales	2021	2022	2023	2024	2025
N° surveyed	N=46	N=420	N=415	N=463	N=439
Previous HIV test (%)					
Yes, ever	38 (83)	336 (80)	305 (73)	345 (75)	341 (78)
Yes, last year	22 (48)	204 (49)	182 (44)	196 (42)	172 (39)
>1 year ago	16 (35)	132 (31)	123 (30)	149 (32)	169 (39)
Never tested	4 (9)	68 (16)	80 (19)	94 (20)	77 (18)
Not reported	4 (9)	16 (4)	30 (7)	24 (5)	21 (5)
Previous HCV test (%)					
Yes, ever	38 (83)	329 (78)	312 (75)	374 (81)	345 (79)
Yes, last year	29 (63)	204 (49)	195 (47)	243 (52)	194 (44)
>1 year ago	9 (20)	125 (30)	117 (28)	131 (28)	151 (34)
Never tested	2 (4)	49 (12)	49 (12)	49 (11)	49 (11)
Not reported	6 (13)	42 (10)	54 (13)	40 (9)	45 (10)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=9	N=78	N=91	N=98	N=70
Antiviral treatment	5 (56)	58 (74)	74 (81)	76 (78)	62 (89)
No antiviral treatment	4 (44)	19 (24)	16 (18)	22 (22)	8 (11)
Not reported	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)^{**}					
N° self-reported HCV diagnosis	N=8	N=43	N=40	N=44	N=30
Antiviral treatment	4 (50)	19 (44)	16 (40)	17 (39)	17 (57)
No antiviral treatment	4 (50)	23 (53)	23 (58)	27 (61)	13 (43)
Not reported	0 (0)	1 (2)	1 (3)	0 (0)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance^{*} excludes people who reported treatment induced clearance more than 12 months previously

HIV antibody prevalence

Table 3.2.1 HIV antibody prevalence by gender and survey year

New South Wales	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021	27	2 (7.4)	16	1 (6.3)	44	3 (6.8)
2022	270	15 (5.6)	133	4 (3.0)	415	22 (5.3)
2023	247	10 (4.1)	127	1 (0.8)	380	11 (2.9)
2024	310	14 (4.5)	137	2 (1.5)	455	19 (4.2)
2025	311	11 (3.5)	116	1 (0.9)	435	13 (3.0)
X ² p trend		0.222		0.115		0.107

Table 3.2.2 HIV antibody prevalence by sexual identity, gender and survey year

New South Wales	Male		Female		Total	
Sexual identity	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
Heterosexual	21	0 (0.0)	10	1 (10.0)	31	1 (3.2)
Bisexual	1	0 (0.0)	3	0 (0.0)	5	0 (0.0)
Homosexual	5	2 (40.0)	1	0 (0.0)	6	2 (33.3)
p value		0.043		1.000		0.204
2022						
Heterosexual	226	1 (0.4)	96	2 (2.1)	323	3 (0.9)
Bisexual	15	2 (13.3)	25	1 (4.0)	45	5 (11.1)
Homosexual	23	12 (52.2)	5	0 (0.0)	30	12 (40.0)
p value		<0.001		0.174		<0.001
2023						
Heterosexual	205	0 (0.0)	90	1 (1.1)	296	1 (0.3)
Bisexual	16	1 (6.3)	24	0 (0.0)	42	1 (2.4)
Homosexual	21	9 (42.9)	4	0 (0.0)	26	9 (34.6)
p value		<0.001		1.000		<0.001
2024						
Heterosexual	260	2 (0.8)	92	1 (1.1)	352	3 (0.9)
Bisexual	14	1 (7.1)	32	1 (3.1)	51	4 (7.8)
Homosexual	25	10 (40.0)	5	0 (0.0)	30	10 (33.3)
p value		<0.001		0.972		<0.001
2025						
Heterosexual	254	1 (0.4)	75	0 (0.0)	331	1 (0.3)
Bisexual	17	3 (17.7)	28	1 (3.6)	48	4 (8.3)
Homosexual	31	7 (22.6)	8	0 (0.0)	41	7 (17.1)
p value		<0.001		0.541		<0.001

Table 3.2.3 HIV antibody prevalence by age group, gender and survey year

New South Wales		Male		Female		Total	
Age group	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
<25 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
25-34 years	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)	
35-44 years	7	2 (28.6)	3	1 (33.3)	10	3 (30.0)	
45+ years	17	0 (0.0)	10	0 (0.0)	28	0 (0.0)	
p value		0.128		0.375		0.011	
2022							
<25 years	15	0 (0.0)	5	0 (0.0)	21	0 (0.0)	
25-34 years	45	1 (2.2)	17	0 (0.0)	63	1 (1.6)	
35-44 years	69	3 (4.4)	44	2 (4.6)	116	6 (5.2)	
45+ years	139	10 (7.2)	67	2 (3.0)	213	14 (6.6)	
p value		0.570		0.831		0.406	
2023							
<25 years	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)	
25-34 years	35	1 (2.9)	20	0 (0.0)	56	1 (1.8)	
35-44 years	72	6 (8.3)	36	1 (2.8)	108	7 (6.5)	
45+ years	128	3 (2.3)	66	0 (0.0)	198	3 (1.5)	
p value		0.225		0.480		0.117	
2024							
<25 years	10	0 (0.0)	2	0 (0.0)	12	0 (0.0)	
25-34 years	47	0 (0.0)	18	0 (0.0)	66	0 (0.0)	
35-44 years	93	5 (5.4)	52	1 (1.9)	149	8 (5.4)	
45+ years	160	9 (5.6)	65	1 (1.5)	228	11 (4.8)	
p value		0.346		0.945		0.244	
2025							
<25 years	13	0 (0.0)	4	0 (0.0)	17	0 (0.0)	
25-34 years	49	1 (2.0)	13	0 (0.0)	67	1 (1.5)	
35-44 years	97	6 (6.2)	40	1 (2.5)	138	7 (5.1)	
45+ years	151	4 (2.7)	59	0 (0.0)	211	4 (1.9)	
p value		0.372		0.590		0.240	

Table 3.2.4 HIV antibody prevalence by last drug injected, gender and survey year

New South Wales		Male		Female		Total	
Last drug injected	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
Heroin	9	0 (0.0)	7	0 (0.0)	16	0 (0.0)	
Methamphetamine	14	2 (14.3)	8	1 (12.5)	23	3 (13.0)	
Other opioids	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
PIEDs	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
Other drugs	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
p value		0.641		1.000		0.486	
2022							
Heroin	69	0 (0.0)	53	0 (0.0)	124	1 (0.8)	
Methamphetamine	84	13 (15.5)	52	4 (7.7)	41	17 (12.1)	
Other opioids	28	0 (0.0)	13	0 (0.0)	43	0 (0.0)	
PIEDs	64	1 (1.6)	4	0 (0.0)	68	1 (1.5)	
Other drugs	22	1 (4.6)	8	0 (0.0)	32	2 (6.3)	
p value		<0.001		0.213		<0.001	
2023							
Heroin	57	2 (3.5)	39	0 (0.0)	97	2 (2.1)	
Methamphetamine	98	8 (8.2)	61	1 (1.6)	163	9 (5.5)	
Other opioids	25	0 (0.0)	16	0 (0.0)	41	0 (0.0)	
PIEDs	49	0 (0.0)	1	0 (0.0)	50	0 (0.0)	
Other drugs	17	0 (0.0)	9	0 (0.0)	26	0 (0.0)	
p value		0.149		1.000		0.206	
2024							
Heroin	69	0 (0.0)	43	2 (4.7)	113	3 (2.7)	
Methamphetamine	121	13 (10.7)	65	0 (0.0)	191	15 (7.9)	
Other opioids	39	1 (2.6)	17	0 (0.0)	58	1 (1.7)	
PIEDs	57	0 (0.0)	1	0 (0.0)	58	0 (0.0)	
Other drugs	22	0 (0.0)	9	0 (0.0)	31	0 (0.0)	
p value		0.001		0.362		0.019	
2025							
Heroin	55	3 (5.5)	31	0 (0.0)	87	3 (3.5)	
Methamphetamine	123	7 (5.7)	47	1 (2.1)	172	9 (5.2)	
Other opioids	18	0 (0.0)	7	0 (0.0)	27	0 (0.0)	
PIEDs	69	1 (1.5)	2	0 (0.0)	74	1 (1.4)	
Other drugs	31	0 (0.0)	23	0 (0.0)	54	0 (0.0)	
p value		0.321		0.852		0.206	

Table 3.2.5 HIV antibody prevalence by years of injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
<3 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
3 to 10 years	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
11+ years	24	2 (8.3)	13	1 (7.7)	38	3 (7.9)
p value		1.000		1.000		1.000
2022						
<3 years	30	0 (0.0)	5	0 (0.0)	36	0 (0.0)
3 to 10 years	36	1 (2.8)	13	0 (0.0)	49	1 (2.0)
11+ years	183	12 (6.6)	109	4 (3.7)	302	19 (6.3)
p value		0.414		1.000		0.222
2023						
<3 years	15	0 (0.0)	3	0 (0.0)	19	0 (0.0)
3 to 10 years	41	1 (2.4)	17	0 (0.0)	58	1 (1.7)
11+ years	177	9 (5.1)	102	1 (1.0)	281	10 (3.6)
p value		0.844		1.000		0.835
2024						
<3 years	37	0 (0.0)	9	0 (0.0)	46	0 (0.0)
3 to 10 years	47	4 (8.5)	17	0 (0.0)	65	5 (7.7)
11+ years	216	10 (4.6)	106	2 (1.9)	329	14 (4.3)
p value		0.185		0.780		0.144
2025						
<3 years	38	0 (0.0)	9	0 (0.0)	47	0 (0.0)
3 to 10 years	46	2 (4.4)	6	0 (0.0)	55	2 (3.6)
11+ years	214	9 (4.2)	96	1 (1.0)	313	10 (3.2)
p value		0.434		0.924		0.447

Table 3.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

New South Wales Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
No receptive sharing	18	1 (5.6)	11	1 (9.1)	30	2 (6.7)
Receptive sharing	2	1 (50.0)	2	0 (0.0)	4	1 (25.0)
p value		0.195		1.000		0.322
2022						
No receptive sharing	188	12 (6.4)	88	1 (1.1)	285	15 (5.3)
Receptive sharing	33	2 (6.1)	17	1 (5.9)	52	3 (5.8)
p value		1.000		0.299		0.747
2023						
No receptive sharing	184	9 (4.9)	92	1 (1.1)	279	10 (3.6)
Receptive sharing	23	1 (4.4)	15	0 (0.0)	39	1 (2.6)
p value		1.000		1.000		1.000
2024						
No receptive sharing	238	14 (5.9)	103	2 (1.9)	344	18 (5.2)
Receptive sharing	27	0 (0.0)	10	0 (0.0)	39	1 (2.6)
p value		0.195		0.657		0.467
2025						
No receptive sharing	235	9 (3.8)	82	1 (1.2)	322	10 (3.1)
Receptive sharing	29	1 (3.5)	21	0 (0.0)	52	1 (1.9)
p value		0.919		0.611		0.640

Table 3.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

New South Wales		Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
Less than daily	13	1 (7.7)	7	0 (0.0)	20	1 (5.0)	
Daily or more	7	1 (14.3)	6	1 (16.7)	0	0 (0.0)	
Not last month	7	0 (0.0)	3	0 (0.0)	10	0 (0.0)	
p value		1.000		0.562		0.444	
2022							
Less than daily	117	8 (6.8)	47	1 (2.1)	168	9 (5.4)	
Daily or more	107	6 (5.6)	59	1 (1.7)	173	9 (5.2)	
Not last month	42	1 (2.4)	22	2 (9.1)	64	3 (4.7)	
p value		0.678		0.229		1.000	
2023							
Less than daily	106	8 (7.6)	39	1 (2.6)	147	9 (6.1)	
Daily or more	107	2 (1.9)	70	0 (0.0)	179	2 (1.1)	
Not last month	30	0 (0.0)	16	0 (0.0)	47	0 (0.0)	
p value		0.079		0.440		0.022	
2024							
Less than daily	131	7 (5.3)	35	1 (2.9)	168	10 (6.0)	
Daily or more	137	7 (5.1)	81	1 (1.2)	221	9 (4.1)	
Not last month	39	0 (0.0)	20	0 (0.0)	62	0 (0.0)	
p value		0.342		0.672		0.136	
2025							
Less than daily	107	6 (5.6)	20	0 (0.0)	130	6 (4.6)	
Daily or more	161	4 (2.5)	85	1 (1.2)	250	5 (2.0)	
Not last month	37	1 (2.7)	11	0 (0.0)	48	1 (2.1)	
p value		0.386		0.832		0.325	

Table 3.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

New South Wales		Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
No imprisonment	24	1 (4.2)	14	1 (7.1)	39	2 (5.1)	
Imprisonment	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)	
p value		1.000		1.000		1.000	
2022							
No imprisonment	236	15 (6.4)	116	2 (1.7)	363	20 (5.5)	
Imprisonment	24	0 (0.0)	12	2 (16.7)	37	2 (5.4)	
p value		0.374		0.044		1.000	
2023							
No imprisonment	203	10 (4.9)	102	1 (1.0)	311	11 (3.5)	
Imprisonment	23	0 (0.0)	13	0 (0.0)	36	0 (0.0)	
p value		0.604		1.000		0.613	
2024							
No imprisonment	245	13 (5.3)	117	2 (1.7)	367	17 (4.6)	
Imprisonment	46	1 (2.2)	13	0 (0.0)	60	2 (3.3)	
p value		0.632		0.635		0.651	
2025							
No imprisonment	252	11 (4.4)	96	1 (1.0)	355	13 (3.7)	
Imprisonment	35	0 (0.0)	10	0 (0.0)	46	0 (0.0)	
p value		0.208		0.746		0.187	

Table 3.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

New South Wales		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
No condom use	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)	
Condom use	0	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
p value		--		--		--	
2022							
No condom use	79	7 (8.9)	50	2 (4.0)	133	10 (7.5)	
Condom use	25	0 (0.0)	12	0 (0.0)	39	1 (2.6)	
p value		0.192		1.000		0.460	
2023							
No condom use	82	2 (2.4)	40	1 (2.5)	124	3 (2.4)	
Condom use	19	2 (10.5)	12	0 (0.0)	31	2 (6.5)	
p value		0.159		1.000		0.261	
2024							
No condom use	112	8 (7.1)	50	0 (0.0)	165	9 (5.5)	
Condom use	24	2 (8.3)	10	0 (0.0)	34	2 (5.9)	
p value		0.839		--		0.921	
2025							
No condom use	100	2 (2.0)	32	0 (0.0)	133	2 (1.5)	
Condom use	32	3 (9.4)	16	0 (0.0)	53	3 (5.7)	
p value		0.057		--		0.114	

Table 3.2.10 HIV antibody prevalence by sex work last month, gender and survey year

New South Wales		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
No sex work	23	1 (4.4)	14	1 (7.1)	38	2 (5.3)	
Sex work	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)	
p value		--		1.000		1.000	
2022							
No sex work	238	9 (3.8)	112	4 (3.6)	360	16 (4.4)	
Sex work	11	5 (45.5)	16	0 (0.0)	29	5 (17.2)	
p value		<0.001		1.000		0.003	
2023							
No sex work	215	6 (2.8)	108	1 (0.9)	328	7 (2.1)	
Sex work	10	3 (30.0)	9	0 (0.0)	19	3 (15.8)	
p value		0.005		1.000		0.013	
2024							
No sex work	266	12 (4.5)	119	2 (1.7)	388	16 (4.1)	
Sex work	19	2 (10.5)	8	0 (0.0)	30	3 (10.0)	
p value		0.241		0.712		0.137	
2025							
No sex work	273	9 (3.3)	84	1 (1.2)	360	10 (2.8)	
Sex work	16	2 (12.5)	19	0 (0.0)	40	3 (7.5)	
p value		0.061		0.633		0.110	

Table 3.2.11 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

New South Wales		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
English speaking	25	2 (8.0)	15	1 (6.7)	41	3 (7.3)	
Non-English speaking	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)	
p value		1.000		--		1.000	
2022							
English speaking	248	14 (5.7)	127	4 (3.2)	387	21 (5.4)	
Non-English speaking	16	1 (6.3)	5	0 (0.0)	21	1 (4.8)	
p value		1.000		1.000		1.000	
2023							
English speaking	234	10 (4.3)	124	1 (0.8)	363	11 (3.0)	
Non-English speaking	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)	
p value		1.000		1.000		1.000	
2024							
English speaking	290	14 (4.8)	126	2 (1.6)	424	19 (4.5)	
Non-English speaking	17	0 (0.0)	11	0 (0.0)	28	0 (0.0)	
p value		0.354		0.674		0.252	
2025							
English speaking	295	11 (3.7)	113	1 (0.9)	414	12 (2.9)	
Non-English speaking	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)	
p value		0.478		0.870		0.490	

Table 3.2.12 HIV antibody prevalence by region/country of birth, gender and survey year

New South Wales		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
Australia	21	1 (4.8)	14	1 (7.1)	35	2 (5.7)	
Other Oceania	1	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
UK & Ireland	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
Other	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
p value		1.000		1.000		1.000	
2022							
Australia	224	10 (4.5)	121	4 (3.3)	355	16 (4.5)	
Other Oceania	12	2 (16.7)	1	0 (0.0)	14	2 (14.3)	
Asia	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)	
UK & Ireland	7	1 (14.3)	2	0 (0.0)	9	1 (11.1)	
Other	19	2 (10.5)	6	0 (0.0)	25	2 (8.0)	
p value		0.115		1.000		0.196	
2023							
Australia	214	9 (4.2)	112	1 (0.9)	331	10 (3.0)	
Other Oceania	8	1 (12.5)	7	0 (0.0)	15	1 (6.7)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)	
Other	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)	
p value		0.617		1.000		0.640	
2024							
Australia	281	12 (4.3)	123	2 (1.6)	410	17 (4.2)	
Other Oceania	5	1 (20.0)	3	0 (0.0)	8	1 (12.5)	
Asia	2	1 (50.0)	1	0 (0.0)	4	1 (25.0)	
UK & Ireland	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)	
Other	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)	
p value		0.010		0.994		0.140	
2025							
Australia	279	10 (3.6)	106	1 (0.9)	390	11 (2.8)	
Other Oceania	6	1 (16.7)	1	0 (0.0)	7	1 (14.3)	
Asia	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
UK & Ireland	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
Other	16	0 (0.0)	6	0 (0.0)	23	0 (0.0)	
p value		0.285		0.995		0.236	

HCV antibody prevalence

Table 3.3.1 HCV antibody prevalence by gender and survey year

New South Wales	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	28	7 (25)	16	6 (38)	45	13 (29)
2022	257	68 (26)	125	50 (40)	393	121 (31)
2023*	247	96 (39)	127	61 (48)	380	159 (42)
2024	312	118 (38)	137	57 (42)	457	177 (39)
2025	311	80 (26)	116	44 (38)	435	127 (29)
X ² p trend^		<0.001		0.110		<0.001

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

^ X² p trend calculated on years 2023-2025 only

Table 3.3.2 HCV antibody prevalence by sexual identity, gender and survey year

New South Wales	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	21	6 (29)	10	5 (50)	31	11 (35)
Bisexual	1	0 (0)	3	1 (33)	5	1 (20)
Homosexual	6	1 (17)	1	0 (0)	7	1 (14)
p value		1.000		1.000		0.787
2022						
Heterosexual	212	61 (29)	89	41 (46)	302	103 (34)
Bisexual	15	3 (20)	24	6 (25)	44	9 (20)
Homosexual	24	1 (4)	5	0 (0)	31	2 (6)
p value		0.009		0.041		0.001
2023						
Heterosexual	205	83 (40)	90	42 (47)	296	125 (42)
Bisexual	16	4 (25)	24	11 (46)	42	15 (36)
Homosexual	21	6 (29)	4	2 (50)	26	8 (31)
p value		0.539		0.526		0.338
2024						
Heterosexual	261	104 (40)	92	41 (45)	353	145 (41)
Bisexual	14	6 (43)	32	10 (31)	51	17 (33)
Homosexual	25	4 (16)	5	2 (40)	30	6 (20)
p value		0.163		0.474		0.188
2025						
Heterosexual	254	70 (28)	75	26 (35)	331	97 (29)
Bisexual	17	3 (18)	28	12 (43)	48	16 (33)
Homosexual	31	4 (13)	8	4 (50)	41	8 (20)
p value		0.162		0.584		0.309

Table 3.3.3 HCV antibody prevalence by age group, gender and survey year

New South Wales		Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
<25 years	0	0 (0)	0	0 (0)	0	0 (0)	
25-34 years	3	0 (0)	3	0 (0)	6	0 (0)	
35-44 years	8	2 (25)	3	1 (33)	11	3 (27)	
45+ years	17	5 (29)	10	5 (50)	28	10 (36)	
p value		0.831		0.494		0.253	
2022							
<25 years	15	0 (0)	4	1 (25)	19	1 (5)	
25-34 years	45	3 (7)	16	6 (38)	62	9 (15)	
35-44 years	66	15 (23)	42	12 (29)	111	27 (24)	
45+ years	129	48 (37)	63	31 (49)	199	82 (41)	
p value		<0.001		0.169		<0.001	
2023							
<25 years	11	0 (0)	5	1 (20)	16	1 (6)	
25-34 years	35	3 (9)	20	3 (15)	56	6 (11)	
35-44 years	72	24 (33)	36	17 (47)	108	41 (38)	
45+ years	128	68 (53)	66	40 (61)	198	109 (55)	
p value		<0.001		0.001		<0.001	
2024							
<25 years	10	1 (10)	2	0 (0)	12	1 (8)	
25-34 years	47	7 (15)	18	5 (28)	66	13 (20)	
35-44 years	94	28 (30)	52	19 (37)	150	47 (31)	
45+ years	161	82 (51)	65	33 (51)	229	116 (51)	
p value		<0.001		0.131		<0.001	
2025							
<25 years	13	0 (0)	4	0 (0)	17	0 (0)	
25-34 years	49	5 (10)	13	3 (23)	67	9 (13)	
35-44 years	97	17 (18)	40	14 (35)	138	31 (22)	
45+ years	151	58 (38)	59	27 (46)	211	86 (41)	
p value		<0.001		0.148		<0.001	

Table 3.3.4 HCV antibody prevalence by years since first injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	3	1 (33)	2	0 (0)	5	1 (20)
11+ years	25	6 (24)	13	6 (46)	39	12 (31)
p value		1.000		0.486		1.000
2022						
<3 years	30	0 (0)	4	0 (0)	34	0 (0)
3 to 10 years	36	2 (6)	12	2 (17)	48	4 (8)
11+ years	171	62 (36)	103	44 (43)	284	109 (38)
p value		<0.001		0.064		<0.001
2023						
<3 years	15	0 (0)	3	1 (33)	19	1 (5)
3 to 10 years	41	5 (12)	17	0 (0)	58	5 (9)
11+ years	177	88 (50)	102	57 (56)	281	145 (52)
p value		<0.001		<0.001		<0.001
2024						
<3 years	37	1 (3)	9	0 (0)	46	1 (2)
3 to 10 years	47	9 (19)	17	4 (24)	65	13 (20)
11+ years	218	105 (48)	106	51 (48)	331	158 (48)
p value		<0.001		0.005		<0.001
2025						
<3 years	38	1 (3)	9	1 (11)	47	2 (4)
3 to 10 years	46	4 (9)	6	1 (17)	55	6 (11)
11+ years	214	72 (34)	96	42 (44)	313	114 (36)
p value		<0.001		0.080		<0.001

Table 3.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

New South Wales Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	--	-- --	29	9 (31)	30	9 (30)
Receptive sharing	--	-- --	4	2 (50)	4	2 (50)
p value		--		0.586		0.580
2022						
No receptive sharing	26	0 (0)	233	70 (30)	268	74 (28)
Receptive sharing	2	0 (0)	44	29 (66)	50	31 (62)
p value		--		<0.001		<0.001
2023						
No receptive sharing	15	0 (0)	251	110 (44)	279	117 (42)
Receptive sharing	1	1 (100)	35	20 (57)	39	21 (54)
p value		0.062		0.138		0.160
2024						
No receptive sharing	33	0 (0)	305	130 (43)	345	133 (39)
Receptive sharing	5	1 (20)	31	15 (48)	39	18 (46)
p value		0.009		0.537		0.357
2025						
No receptive sharing	34	2 (6)	277	90 (32)	322	95 (30)
Receptive sharing	2	0 (0)	46	20 (43)	52	21 (43)
p value		0.724		0.145		0.145

Table 3.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

New South Wales	<3 years		3+ years		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heroin	--	-- --	16	5 (31)	16	5 (31)
Methamphetamine	--	-- --	23	6 (26)	24	6 (26)
Other opioids	--	-- --	3	2 (67)	3	2 (67)
PIEDs	--	-- --	1	0 (0)	1	0 (0)
Other drugs	--	-- --	1	0 (0)	1	0 (0)
p value		--		0.561		0.538
2022						
Heroin	1	0 (0)	111	49 (44)	115	50 (43)
Methamphetamine	4	0 (0)	120	33 (28)	132	37 (28)
Other opioids	0	0 (0)	37	21 (57)	37	21 (57)
PIEDs	28	0 (0)	32	1 (3)	66	2 (3)
Other drugs	0	0 (0)	26	8 (31)	29	9 (31)
p value		--		<0.001		<0.001
2023						
Heroin	0	0 (0)	94	56 (60)	95	57 (60)
Methamphetamine	4	0 (0)	151	60 (40)	163	64 (39)
Other opioids	2	0 (0)	36	20 (56)	41	22 (54)
PIEDs	11	0 (0)	33	0 (0)	49	0 (0)
Other drugs	2	1 (50)	21	11 (52)	24	12 (50)
p value		0.030		<0.001		<0.001
2024						
Heroin	4	0 (0)	108	65 (60)	113	66 (58)
Methamphetamine	11	1 (9)	175	65 (37)	191	69 (36)
Other opioids	1	0 (0)	56	26 (46)	58	27 (47)
PIEDs	26	0 (0)	27	1 (4)	57	1 (2)
Other drugs	4	0 (0)	26	12 (46)	30	12 (40)
p value		0.516		<0.001		<0.001
2025						
Heroin	2	0 (0)	80	33 (41)	86	35 (41)
Methamphetamine	9	2 (22)	156	46 (29)	169	49 (29)
Other opioids	0	0 (0)	25	9 (36)	27	10 (37)
PIEDs	31	0 (0)	41	1 (2)	74	1 (1)
Other drugs	4	0 (0)	42	22 (52)	51	22 (43)
p value		0.035		<0.001		<0.001

Table 3.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

New South Wales	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	--	-- --	19	6 (32)	20	6 (30)
Daily or more	--	-- --	14	5 (36)	14	5 (36)
Not last month	--	-- --	11	2 (18)	11	2 (18)
p value		--		0.645		0.644
2022						
Less than daily	21	0 (0)	130	39 (30)	159	41 (26)
Daily or more	7	0 (0)	149	60 (40)	163	64 (39)
Not last month	5	0 (0)	49	14 (29)	61	15 (25)
p value		--		0.127		0.016
2023						
Less than daily	10	0 (0)	130	55 (42)	147	58 (39)
Daily or more	6	1 (17)	164	80 (49)	179	85 (47)
Not last month	3	0 (0)	41	12 (29)	47	12 (26)
p value		0.474		0.071		0.020
2024						
Less than daily	19	0 (0)	147	62 (42)	169	62 (37)
Daily or more	19	1 (5)	195	85 (44)	221	91 (41)
Not last month	8	0 (0)	51	22 (43)	63	22 (35)
p value		0.484		0.966		0.538
2025						
Less than daily	15	0 (0)	112	28 (25)	130	29 (22)
Daily or more	21	2 (10)	217	86 (40)	250	91 (36)
Not last month	11	0 (0)	34	5 (15)	48	5 (10)
p value		0.274		0.002		<0.001

Table 3.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

New South Wales	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	0	0 (0)	39	12 (31)	40	12 (30)
Imprisonment	0	0 (0)	4	0 (0)	4	0 (0)
p value		--		0.563		0.562
2022						
No imprisonment	32	0 (0)	288	93 (32)	342	99 (29)
Imprisonment	1	0 (0)	31	14 (45)	36	15 (42)
p value		--		0.149		0.114
2023						
No imprisonment	17	1 (6)	279	119 (43)	311	124 (40)
Imprisonment	0	0 (0)	31	17 (55)	36	21 (58)
p value		--		0.195		0.033
2024						
No imprisonment	40	1 (3)	317	125 (39)	367	130 (35)
Imprisonment	5	0 (0)	52	36 (69)	61	37 (61)
p value		0.721		<0.001		<0.001
2025						
No imprisonment	42	1 (2)	299	91 (30)	355	96 (27)
Imprisonment	3	0 (0)	41	16 (39)	46	17 (37)
p value		0.787		0.267		0.160

Table 3.3.9 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

New South Wales		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
English speaking	26	6 (23)	15	5 (33)	42	11 (26)	
Non-English speaking	2	1 (50)	0	0 (0)	2	1 (50)	
p value		0.444		--		0.476	
2022							
English speaking	236	61 (26)	119	49 (41)	366	113 (31)	
Non-English speaking	16	5 (31)	5	1 (20)	21	6 (29)	
p value		0.634		0.647		0.824	
2023							
English speaking	234	95 (41)	124	59 (48)	363	155 (43)	
Non-English speaking	13	1 (8)	3	2 (67)	16	3 (19)	
p value		0.018		0.608		0.070	
2024							
English speaking	292	113 (39)	126	54 (43)	426	169 (40)	
Non-English speaking	17	3 (18)	11	3 (27)	28	6 (21)	
p value		0.081		0.315		0.055	
2025							
English speaking	295	77 (26)	113	42 (37)	414	120 (29)	
Non-English speaking	13	2 (15)	3	2 (67)	16	4 (25)	
p value		0.387		0.299		0.730	

Table 3.3.10 HCV antibody prevalence by region/country of birth, gender and survey year

New South Wales		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Australia	21	5 (24)	14	6 (43)	35	11 (31)	
Other Oceania	1	0 (0)	1	0 (0)	3	0 (0)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	2	1 (50)	0	0 (0)	2	1 (50)	
p value		0.764		1.000		0.720	
2022							
Australia	210	60 (29)	114	46 (40)	333	108 (32)	
Other Oceania	12	3 (25)	1	0 (0)	14	4 (29)	
Asia	5	1 (20)	2	1 (50)	7	2 (29)	
UK & Ireland	7	0 (0)	2	1 (50)	9	1 (11)	
Other	20	4 (20)	5	1 (20)	25	5 (20)	
p value		0.557		0.950		0.544	
2023							
Australia	214	87 (41)	112	51 (46)	331	139 (42)	
Other Oceania	8	4 (50)	7	3 (43)	15	7 (47)	
Asia	4	1 (25)	0	0 (0)	4	1 (25)	
UK & Ireland	8	3 (38)	3	3 (100)	11	6 (55)	
Other	12	1 (8)	5	4 (80)	17	5 (29)	
p value		0.184		0.159		0.689	
2024							
Australia	282	108 (38)	123	49 (40)	411	158 (38)	
Other Oceania	6	0 (0)	3	2 (67)	9	2 (22)	
Asia	2	0 (0)	1	1 (100)	4	2 (50)	
UK & Ireland	6	2 (33)	2	2 (100)	8	4 (50)	
Other	13	5 (38)	8	3 (38)	21	8 (38)	
p value		0.294		0.267		0.794	
2025							
Australia	279	73 (26)	106	40 (38)	390	114 (29)	
Other Oceania	6	1 (17)	1	0 (0)	7	1 (14)	
Asia	6	0 (0)	1	0 (0)	7	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	16	4 (25)	6	4 (67)	23	8 (35)	
p value		0.499		0.350		0.263	

HCV RNA prevalence

Table 3.4.1 HCV RNA prevalence by gender and survey year

New South Wales	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	26	2 (8)	14	2 (14)	41	4 (10)
2022	262	19 (7)	131	14 (11)	405	35 (9)
2023	240	16 (7)	126	7 (6)	372	23 (6)
2024	310	25 (8)	136	5 (4)	453	30 (7)
2025	307	14 (5)	114	4 (4)	428	18 (4)
X ² p trend		0.289		0.006		0.011

Totals include respondents where gender was reported as other or not reported

Table 3.4.2 HCV RNA prevalence by sexual identity, gender and survey year

New South Wales	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	21	2 (10)	9	2 (22)	30	4 (13)
Bisexual	1	0 (0)	2	0 (0)	4	0 (0)
Homosexual	4	0 (0)	1	0 (0)	5	0 (0)
p value		0.773		0.670		0.512
2022						
Heterosexual	221	19 (9)	95	14 (15)	317	33 (10)
Bisexual	14	0 (0)	25	0 (0)	44	0 (0)
Homosexual	21	0 (0)	4	0 (0)	27	1 (3)
p value		0.591		0.347		0.165
2023						
Heterosexual	200	14 (7)	90	4 (4)	291	18 (6)
Bisexual	15	1 (7)	23	1 (4)	40	2 (5)
Homosexual	20	1 (5)	4	0 (0)	25	1 (4)
p value		1.000		0.051		0.171
2024						
Heterosexual	261	23 (9)	92	3 (3)	353	26 (7)
Bisexual	14	1 (7)	31	1 (3)	50	2 (4)
Homosexual	24	1 (4)	5	0 (0)	29	1 (3)
p value		0.954		0.540		0.930
2025						
Heterosexual	251	12 (5)	73	4 (5)	326	16 (5)
Bisexual	16	2 (13)	28	0 (0)	47	2 (4)
Homosexual	31	0 (0)	8	0 (0)	41	0 (0)
p value		0.548		0.696		0.867

Table 3.4.3 HCV RNA prevalence by age group, gender and survey year

New South Wales		Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
<25 years	0	0 (0)	0	0 (0)	0	0 (0)	
25-34 years	3	0 (0)	2	0 (0)	5	0 (0)	
35-44 years	6	1 (17)	3	0 (0)	9	1 (11)	
45+ years	17	1 (6)	9	2 (22)	27	3 (11)	
p value		0.604		0.523		0.735	
2022							
<25 years	14	0 (0)	5	0 (0)	20	0 (0)	
25-34 years	45	2 (4)	17	2 (12)	63	4 (6)	
35-44 years	67	3 (4)	42	3 (7)	112	6 (5)	
45+ years	134	14 (10)	67	9 (13)	208	25 (12)	
p value		0.323		0.786		0.103	
2023							
<25 years	11	0 (0)	5	0 (0)	16	0 (0)	
25-34 years	35	1 (3)	19	1 (5)	55	2 (4)	
35-44 years	70	8 (11)	36	2 (6)	106	10 (9)	
45+ years	123	7 (6)	66	4 (6)	193	11 (6)	
p value		0.340		1.000		0.420	
2024							
<25 years	10	1 (10)	2	0 (0)	12	1 (8)	
25-34 years	47	1 (2)	18	0 (0)	65	1 (2)	
35-44 years	94	7 (7)	51	2 (4)	149	9 (6)	
45+ years	159	16 (10)	65	3 (5)	227	19 (8)	
p value		0.363		0.817		0.264	
2025							
<25 years	13	0 (0)	4	0 (0)	17	0 (0)	
25-34 years	48	2 (4)	13	0 (0)	66	2 (3)	
35-44 years	95	2 (2)	40	2 (5)	136	4 (3)	
45+ years	150	10 (7)	57	2 (4)	208	12 (6)	
p value		0.324		0.830		0.429	

Table 3.4.4 HCV RNA prevalence by years since first injection, gender and survey year

New South Wales		Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
<3 years	0	0 (0)	0	0 (0)	0	0 (0)	
3 to 10 years	3	1 (33)	1	0 (0)	4	1 (25)	
11+ years	23	1 (4)	12	2 (17)	36	3 (8)	
p value		0.076		0.657		0.292	
2022							
<3 years	29	0 (0)	5	0 (0)	35	0 (0)	
3 to 10 years	36	1 (3)	13	1 (8)	49	2 (4)	
11+ years	177	18 (10)	107	13 (12)	294	33 (11)	
p value		0.083		1.000		0.034	
2023							
<3 years	15	0 (0)	3	0 (0)	19	0 (0)	
3 to 10 years	40	2 (5)	17	0 (0)	57	2 (4)	
11+ years	172	14 (8)	101	6 (6)	275	20 (7)	
p value		0.717		0.650		0.429	
2024							
<3 years	37	0 (0)	9	0 (0)	46	0 (0)	
3 to 10 years	47	4 (9)	17	1 (6)	65	5 (8)	
11+ years	216	20 (9)	105	4 (4)	327	24 (7)	
p value		0.157		0.758		0.161	
2025							
<3 years	38	1 (3)	9	0 (0)	47	1 (2)	
3 to 10 years	45	2 (4)	6	0 (0)	54	2 (4)	
11+ years	211	10 (5)	94	4 (4)	308	14 (5)	
p value		0.844		0.718		0.730	

Table 3.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

New South Wales		Male		Female		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
No receptive sharing	17	0 (0)	10	2 (20)	28	2 (7)	
Receptive sharing	1	1 (100)	2	0 (0)	3	1 (33)	
p value		<0.001		0.488		0.145	
2022							
No receptive sharing	182	12 (7)	87	10 (11)	278	23 (8)	
Receptive sharing	33	5 (15)	16	4 (25)	51	10 (20)	
p value		0.094		0.225		0.013	
2023							
No receptive sharing	179	13 (7)	91	5 (5)	273	18 (7)	
Receptive sharing	22	3 (14)	15	1 (7)	38	4 (11)	
p value		0.393		1.000		0.325	
2024							
No receptive sharing	238	18 (8)	102	4 (4)	343	22 (6)	
Receptive sharing	26	4 (15)	10	1 (10)	37	5 (14)	
p value		0.171		0.374		0.110	
2025							
No receptive sharing	233	12 (5)	81	3 (4)	319	15 (5)	
Receptive sharing	28	2 (7)	21	1 (5)	51	3 (6)	
p value				0.824		0.716	

Table 3.4.6 HCV RNA prevalence by last drug injected, gender and survey year

New South Wales		Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Heroin	9	1 (11)	5	1 (20)	14	2 (14)	
Methamphetamine	13	1 (8)	8	1 (13)	22	2 (9)	
Other opioids	2	0 (0)	1	0 (0)	3	0 (0)	
PIEDs	1	0 (0)	0	0 (0)	1	0 (0)	
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)	
p value		0.975		0.852		0.928	
2022							
Heroin	66	9 (14)	51	7 (14)	119	16 (13)	
Methamphetamine	80	5 (6)	50	3 (6)	135	8 (6)	
Other opioids	27	3 (11)	13	4 (31)	42	9 (21)	
PIEDs	62	0 (0)	3	0 (0)	65	0 (0)	
Other drugs	22	2 (9)	7	0 (0)	30	2 (7)	
p value		0.050		0.095		0.001	
2023							
Heroin	56	8 (14)	38	0 (0)	95	8 (8)	
Methamphetamine	93	7 (8)	61	4 (7)	158	11 (7)	
Other opioids	25	1 (4)	16	2 (13)	41	3 (7)	
PIEDs	48	0 (0)	1	0 (0)	49	0 (0)	
Other drugs	15	0 (0)	7	0 (0)	22	0 (0)	
p value		0.040		0.316		0.208	
2024							
Heroin	69	10 (14)	43	1 (2)	113	11 (10)	
Methamphetamine	119	6 (5)	65	3 (5)	188	9 (5)	
Other opioids	39	4 (10)	17	1 (6)	58	5 (9)	
PIEDs	56	0 (0)	1	0 (0)	57	0 (0)	
Other drugs	22	4 (18)	7	0 (0)	29	4 (14)	
p value		0.008		0.925		0.045	
2025							
Heroin	53	4 (8)	30	1 (3)	84	5 (6)	
Methamphetamine	118	7 (6)	47	1 (2)	166	8 (5)	
Other opioids	18	1 (6)	7	0 (0)	27	1 (4)	
PIEDs	69	0 (0)	2	0 (0)	74	0 (0)	
Other drugs	28	2 (7)	22	1 (5)	50	3 (6)	
p value		0.293		0.961		0.352	

Table 3.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

New South Wales		Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Less than daily	12	0 (0)	7	1 (14)	19	1 (5)	
Daily or more	6	1 (17)	5	1 (20)	12	2 (17)	
Not last month	8	1 (13)	2	0 (0)	10	1 (10)	
p value		0.379		0.792		0.581	
2022							
Less than daily	114	5 (4)	46	5 (11)	164	10 (6)	
Daily or more	104	12 (12)	58	9 (16)	169	23 (14)	
Not last month	40	2 (5)	22	0 (0)	62	2 (3)	
p value		0.139		0.137		0.016	
2023							
Less than daily	104	7 (7)	39	2 (5)	145	9 (6)	
Daily or more	103	9 (9)	69	4 (6)	174	13 (7)	
Not last month	30	0 (0)	16	0 (0)	47	0 (0)	
p value		0.300		1.000		0.144	
2024							
Less than daily	131	11 (8)	34	2 (6)	167	13 (8)	
Daily or more	136	11 (8)	81	3 (4)	219	14 (6)	
Not last month	40	2 (5)	20	0 (0)	63	2 (3)	
p value		0.773		0.543		0.447	
2025							
Less than daily	105	1 (1)	20	1 (5)	128	2 (2)	
Daily or more	160	13 (8)	84	3 (4)	248	16 (6)	
Not last month	36	0 (0)	10	0 (0)	46	0 (0)	
p value		0.009		0.780		0.027	

Table 3.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

New South Wales		Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
No imprisonment	24	2 (8)	12	2 (17)	37	4 (11)	
Imprisonment	2	0 (0)	2	0 (0)	4	0 (0)	
p value		0.671		0.533		0.489	
2022							
No imprisonment	228	15 (7)	114	13 (11)	353	30 (9)	
Imprisonment	24	2 (8)	12	1 (8)	37	3 (8)	
p value		0.669		1.000		1.000	
2023							
No imprisonment	197	14 (7)	102	7 (7)	305	21 (7)	
Imprisonment	23	1 (4)	12	0 (0)	35	1 (3)	
p value		1.000		1.000		0.713	
2024							
No imprisonment	245	16 (7)	116	5 (4)	366	21 (6)	
Imprisonment	46	9 (20)	13	0 (0)	60	9 (15)	
p value		0.004		0.445		0.009	
2025							
No imprisonment	250	10 (4)	94	4 (4)	350	14 (4)	
Imprisonment	34	4 (12)	10	0 (0)	45	4 (9)	
p value		0.050		0.506		0.139	

Table 3.4.9 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

New South Wales		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
English speaking	24	2 (8)	13	1 (8)	38	3 (8)	
Non-English speaking	2	0 (0)	0	0 (0)	2	0 (0)	
p value		0.671		--		0.679	
2022							
English speaking	240	18 (8)	125	14 (11)	377	34 (9)	
Non-English speaking	16	1 (6)	5	0 (0)	21	1 (5)	
p value		1.000		1.000		1.000	
2023							
English speaking	227	16 (7)	123	7 (6)	355	23 (6)	
Non-English speaking	13	0 (0)	3	0 (0)	16	0 (0)	
p value		1.000		1.000		0.612	
2024							
English speaking	290	22 (8)	125	5 (4)	422	27 (6)	
Non-English speaking	17	2 (12)	11	0 (0)	28	2 (7)	
p value		0.533		0.499		0.876	
2025							
English speaking	291	14 (5)	111	4 (4)	408	18 (4)	
Non-English speaking	13	0 (0)	3	0 (0)	16	0 (0)	
p value		0.418		0.738		0.391	

Table 3.4.10 HCV RNA prevalence by region/country of birth, gender and survey year

New South Wales		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Australia	20	2 (10)	12	2 (17)	32	4 (13)	
Other Oceania	1	0 (0)	1	0 (0)	3	0 (0)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	2	0 (0)	0	0 (0)	2	0 (0)	
p value		0.969		0.823		0.893	
2022							
Australia	216	18 (8)	119	14 (12)	345	33 (10)	
Other Oceania	11	0 (0)	1	0 (0)	13	1 (8)	
Asia	5	1 (20)	2	0 (0)	7	1 (14)	
UK & Ireland	7	0 (0)	2	0 (0)	9	0 (0)	
Other	20	0 (0)	6	0 (0)	26	0 (0)	
p value		0.416		1.000		0.383	
2023							
Australia	208	15 (7)	111	7 (6)	324	22 (7)	
Other Oceania	8	0 (0)	7	0 (0)	15	0 (0)	
Asia	4	0 (0)	0	0 (0)	4	0 (0)	
UK & Ireland	7	1 (14)	3	0 (0)	10	1 (10)	
Other	12	0 (0)	5	0 (0)	17	0 (0)	
p value		0.672		1.000		0.643	
2024							
Australia	281	22 (8)	122	5 (4)	409	27 (7)	
Other Oceania	5	0 (0)	3	0 (0)	8	0 (0)	
Asia	2	0 (0)	1	0 (0)	3	0 (0)	
UK & Ireland	6	1 (17)	2	0 (0)	8	1 (13)	
Other	13	1 (8)	8	0 (0)	21	1 (5)	
p value		0.870		0.964		0.852	
2025							
Australia	275	13 (5)	104	4 (4)	384	17 (4.343)	
Other Oceania	6	1 (17)	1	0 (0)	7	1 (14)	
Asia	6	0 (0)	1	0 (0)	7	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	16	0 (0)	6	0 (0)	23	0 (0)	
p value		0.384		0.956		0.380	

Northern Territory

Table 4.1.1 Number (%) of respondents by demographic characteristics and survey year

Northern Territory	2021*	2022	2023	2024	2025
Number of sites	3	3	3	3	3
N° surveyed	N=40	N=20	N=50	N=44	N=69
Response rate (%)	18%	15%	34%	20%	28%
Gender (%)					
Male	25 (63)	14 (70)	32 (64)	32 (73)	45 (65)
Female	15 (38)	4 (20)	16 (32)	12 (27)	20 (29)
Other	0 (0)	2 (10)	2 (4)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	4 (6)
Age (years)					
Median age	50	47.5	47	47	48
Age range	31-65	34-68	26-71	21-71	21-72
<25 years	0 (0)	0 (0)	0 (0)	1 (2)	1 (1)
25+ years	40 (100)	20 (100)	50 (100)	42 (95)	68 (99)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
Sexual identity (%)					
Heterosexual	29 (73)	15 (75)	38 (76)	39 (89)	54 (78)
Bisexual	7 (18)	3 (15)	10 (20)	2 (5)	8 (12)
Gay/Lesbian	2 (5)	0 (0)	0 (0)	2 (5)	1 (1)
Other	2 (5)	2 (10)	2 (4)	1 (2)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	6 (9)
Aboriginal and Torres Strait Islander origin (%)					
No	20 (50)	15 (75)	30 (60)	28 (64)	34 (49)
Yes	20 (50)	4 (20)	20 (40)	15 (34)	33 (48)
Not reported	0 (0)	1 (5)	0 (0)	1 (2)	2 (3)
Region/country of birth (%)					
Australia	39 (98)	19 (95)	46 (92)	40 (91)	64 (93)
Other Oceania	0 (0)	0 (0)	3 (6)	2 (5)	0 (0)
Asia	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
UK & Ireland	0 (0)	1 (5)	1 (2)	0 (0)	2 (3)
Other	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Not reported	1 (3)	0 (0)	0 (0)	1 (2)	2 (3)
Main language spoken at home by parents (%)					
English	39 (98)	20 (100)	49 (98)	42 (95)	61 (88)
Non-English	1 (3)	0 (0)	0 (0)	2 (5)	4 (6)
Not reported	0 (0)	0 (0)	1 (2)	0 (0)	4 (6)
Age at first injection and time since first injection (years)					
Median age at first injection	17	18.5	19	18	19
Age range at first injection	10-42	10-38	13-45	11-52	13-44
N° not reported	1	2	0	1	7
Median yrs since first injection	29	27	27	28	26.5
Range yrs since first injection	1-50	13-51	<1-49	1-54	<1-58
<3 years since first injection	1 (3)	0 (0)	1 (2)	3 (7)	6 (9)
3+ years since first injection	38 (95)	18 (90)	49 (98)	40 (91)	56 (81)
Not reported	1 (3)	2 (10)	0 (0)	1 (2)	7 (10)

* Implementation of the 2021 ANSPS was impacted by the COVID-19 pandemic

Table 4.1.2 Number (%) of respondents by last drug injected, frequency of injecting, overdose, imprisonment, injection in prison and survey year

Northern Territory	2021	2022	2023	2024	2025
N° surveyed	N=40	N=20	N=50	N=44	N=69
Drug last injected (%)					
Cocaine	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	27 (68)	11 (55)	36 (72)	28 (64)	50 (72)
Heroin	1 (3)	0 (0)	2 (4)	1 (2)	1 (1)
Pharm. opioids	4 (10)	6 (30)	6 (12)	9 (20)	9 (13)
Methadone	3 (8)	0 (0)	0 (0)	1 (2)	1 (1)
Buprenorphine	1 (3)	1 (5)	1 (2)	2 (5)	2 (3)
Buprenorphine/naloxone	0 (0)	0 (0)	1 (2)	0 (0)	1 (1)
PIEDs	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
More than one	1 (3)	2 (10)	3 (6)	3 (7)	3 (4)
Other	1 (3)	0 (0)	1 (2)	0 (0)	0 (0)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	2 (3)
Ever injected opioids (%)					
No	11 (28)	3 (15)	17 (34)	15 (34)	26 (38)
Yes	29 (73)	17 (85)	33 (66)	28 (64)	42 (61)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	1 (1)
Frequency of injection last month (%)					
Not last month	5 (13)	1 (5)	7 (14)	5 (11)	8 (12)
Less than weekly	10 (25)	6 (30)	10 (20)	4 (9)	8 (12)
Weekly not daily	7 (18)	5 (25)	9 (18)	7 (16)	15 (22)
Daily or more	16 (40)	8 (40)	22 (44)	26 (59)	36 (52)
Not reported	2 (5)	0 (0)	2 (4)	2 (5)	2 (3)
Present when someone injected for the first time in the last 12 months (%)					
No	31 (78)	17 (85)	43 (86)	37 (84)	48 (70)
Yes	9 (23)	3 (15)	3 (6)	6 (14)	17 (25)
Not reported	0 (0)	0 (0)	4 (8)	1 (2)	4 (6)
Overdosed in last 12 months (%)					
No	35 (88)	18 (90)	43 (86)	38 (86)	58 (84)
Yes	4 (10)	1 (5)	4 (8)	4 (9)	5 (7)
Not reported	1 (3)	1 (5)	3 (6)	2 (5)	6 (9)
Imprisonment last year (%)					
No	36 (90)	19 (95)	42 (84)	38 (86)	51 (74)
Yes	4 (10)	0 (0)	3 (6)	3 (7)	13 (19)
Not reported	0 (0)	1 (5)	5 (10)	3 (7)	5 (7)
Injected while in prison last year					
N° in prison last year	N=4	N=0	N=3	N=3	N=13
No	4 (100)	0 (0)	2 (67)	3 (100)	10 (77)
Yes	0 (0)	0 (0)	1 (33)	0 (0)	2 (15)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)

Table 4.1.3 Number (%) of respondents by injecting behaviour in the last month and survey year

Northern Territory	2021	2022	2023	2024	2025
N° injected last month	N=33	N=19	N=41	N=37	N=59
Places injected last month (%)					
All private	15 (45)	13 (68)	20 (49)	21 (57)	33 (56)
Any public	18 (55)	6 (32)	21 (51)	15 (41)	26 (44)
Not reported	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	27 (82)	18 (95)	34 (83)	29 (78)	45 (76)
Most of the time	4 (12)	1 (5)	5 (12)	7 (19)	11 (19)
Half of the time	1 (3)	0 (0)	2 (5)	0 (0)	2 (3)
Some of the time	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Not reported	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	28 (85)	19 (100)	35 (85)	30 (81)	43 (73)
Once	0 (0)	0 (0)	2 (5)	2 (5)	6 (10)
Twice	2 (6)	0 (0)	1 (2)	3 (8)	5 (8)
3-5 times	1 (3)	0 (0)	2 (5)	1 (3)	3 (5)
>5 times	2 (6)	0 (0)	1 (2)	0 (0)	2 (3)
Not reported	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	28 (85)	19 (100)	35 (85)	30 (81)	43 (73)
One	1 (3)	0 (0)	1 (2)	3 (8)	3 (5)
Two	2 (6)	0 (0)	1 (2)	0 (0)	0 (0)
Three to five	0 (0)	0 (0)	1 (2)	0 (0)	2 (3)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Don't know	2 (6)	0 (0)	3 (7)	1 (3)	6 (10)
Not reported	0 (0)	0 (0)	0 (0)	3 (8)	4 (7)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	0 (0)	0 (0)	4 (10)	1 (3)	3 (5)
Casual sex partner	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
Close friend	4 (12)	0 (0)	3 (7)	1 (3)	6 (10)
Acquaintance	1 (3)	0 (0)	0 (0)	0 (0)	3 (5)
Other	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	2 (6)	0 (0)	6 (15)	3 (8)	6 (10)
Water	6 (18)	1 (5)	9 (22)	4 (11)	17 (29)
Filter	3 (9)	0 (0)	3 (7)	1 (3)	7 (12)
Drug mix	1 (3)	0 (0)	3 (7)	3 (8)	7 (12)
None	22 (67)	18 (95)	30 (73)	24 (65)	39 (66)
Injected by someone after that person injected themselves or others last month (%)					
No	28 (85)	18 (95)	35 (85)	27 (73)	49 (83)
Yes	5 (15)	1 (5)	6 (15)	8 (22)	9 (15)
Not reported	0 (0)	0 (0)	0 (0)	2 (5)	1 (2)
Source of needle acquisition (%)					
Needle Syringe Program	30 (91)	18 (95)	38 (93)	35 (95)	44 (75)
Chemist/Pharmacy	2 (6)	2 (11)	4 (10)	1 (3)	11 (19)
Personal sources	4 (12)	1 (5)	4 (10)	3 (8)	7 (12)
Dispensing/Vending Machine	3 (9)	3 (16)	7 (17)	5 (14)	18 (31)
Other sources	1 (3)	0 (0)	0 (0)	1 (3)	0 (0)

Table 4.1.4 Number (%) of respondents by treatment for drug use and survey year

Northern Territory	2021	2022	2023	2024	2025
N° surveyed	N=40	N=20	N=50	N=44	N=69
Ever any treatment/therapy for drug use (%)					
No	20 (50)	6 (30)	22 (44)	20 (45)	31 (45)
Yes	20 (50)	14 (70)	28 (56)	24 (55)	38 (55)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	6 (15)	1 (5)	3 (6)	2 (5)	2 (3)
Previously	4 (10)	4 (20)	9 (18)	5 (11)	9 (13)
Never	29 (73)	14 (70)	34 (68)	36 (82)	51 (74)
Not reported	1 (3)	1 (5)	4 (8)	1 (2)	7 (10)
History of buprenorphine (Subutex®) treatment (%)					
Currently	3 (8)	2 (10)	3 (6)	3 (7)	4 (6)
Previously	2 (5)	6 (30)	9 (18)	5 (11)	16 (23)
Never	35 (88)	10 (50)	33 (66)	34 (77)	45 (65)
Not reported	0 (0)	2 (10)	5 (10)	2 (5)	4 (6)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	1 (3)	1 (5)	1 (2)	2 (5)	2 (3)
Previously	4 (10)	7 (35)	11 (22)	7 (16)	17 (25)
Never	35 (88)	11 (55)	38 (76)	35 (80)	48 (70)
Not reported	0 (0)	1 (5)	0 (0)	0 (0)	2 (3)
History of depot buprenorphine treatment (%)					
Currently	3 (8)	0 (0)	1 (2)	2 (5)	5 (7)
Previously	0 (0)	0 (0)	3 (6)	1 (2)	8 (12)
Never	37 (93)	19 (95)	41 (82)	39 (89)	49 (71)
Not reported	0 (0)	1 (5)	5 (10)	2 (5)	7 (10)

Table 4.1.5 Number (%) of respondents by sexual behaviour in the month prior to survey and survey year

Northern Territory	2021	2022	2023	2024	2025
N° surveyed	N=40	N=20	N=50	N=44	N=69
Sex with a regular partner last month (%)					
No	25 (63)	12 (60)	28 (56)	29 (66)	42 (61)
Yes	14 (35)	7 (35)	17 (34)	12 (27)	23 (33)
Not reported	1 (3)	1 (5)	5 (10)	3 (7)	4 (6)
Condom used with regular partner last month (%)					
N° surveyed	N=14	N=7	N=17	N=12	N=23
Never	8 (57)	6 (86)	14 (82)	9 (75)	18 (78)
Sometimes	1 (7)	0 (0)	3 (18)	2 (17)	1 (4)
Every time	5 (36)	1 (14)	0 (0)	1 (8)	3 (13)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)
Sex with other partner(s) last month (%)					
No	29 (73)	15 (75)	38 (76)	34 (77)	45 (65)
Yes	10 (25)	5 (25)	7 (14)	6 (14)	17 (25)
Not reported	1 (3)	0 (0)	5 (10)	4 (9)	7 (10)
Condom used with other partner(s) last month (%)					
N° surveyed	N=10	N=5	N=7	N=6	N=17
Never	3 (30)	2 (40)	0 (0)	2 (33)	7 (41)
Sometimes	0 (0)	1 (20)	3 (43)	1 (17)	5 (29)
Every time	6 (60)	1 (20)	2 (29)	2 (33)	4 (24)
Not reported	1 (10)	1 (20)	2 (29)	1 (17)	1 (6)
Sex work last month (%)					
No	32 (80)	16 (80)	40 (80)	39 (89)	58 (84)
Yes	8 (20)	1 (5)	4 (8)	2 (5)	6 (9)
Not reported	0 (0)	3 (15)	6 (12)	3 (7)	5 (7)
Condom used at last sex work (%)					
Yes	7 (88)	1 (100)	4 (100)	2 (100)	5 (83)

Table 4.1.6 Number (%) of respondents by testing for HIV and HCV, HCV treatment by survey year

Northern Territory	2021	2022	2023	2024	2025
N° surveyed	N=40	N=20	N=50	N=44	N=69
Previous HIV test (%)					
Yes, ever	34 (85)	16 (80)	35 (70)	30 (68)	49 (71)
Yes, last year	18 (45)	6 (30)	16 (32)	15 (34)	19 (28)
>1 year ago	16 (40)	10 (50)	19 (38)	15 (34)	30 (43)
Never tested	6 (15)	2 (10)	10 (20)	10 (23)	15 (22)
Not reported	0 (0)	2 (10)	5 (10)	4 (9)	5 (7)
Previous HCV test (%)					
Yes, ever	34 (85)	17 (85)	34 (68)	33 (75)	43 (62)
Yes, last year	20 (50)	9 (45)	18 (36)	19 (43)	20 (29)
>1 year ago	14 (35)	8 (40)	16 (32)	14 (32)	23 (33)
Never tested	4 (10)	1 (5)	10 (20)	6 (14)	13 (19)
Not reported	2 (5)	2 (10)	6 (12)	5 (11)	13 (19)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=6	N=4	N=10	N=3	N=5
Antiviral treatment	3 (50)	1 (25)	9 (90)	3 (100)	5 (100)
No antiviral treatment	3 (50)	3 (75)	1 (10)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)^{**}					
N° self-reported HCV diagnosis	N=4	N=4	N=5	N=0	N=1
Antiviral treatment	0 (0)	1 (25)	1 (20)	0 (0)	0 (0)
No antiviral treatment	4 (100)	3 (75)	4 (80)	0 (0)	1 (100)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance^{*} excludes people who reported treatment induced clearance more than 12 months previously

HIV antibody prevalence

Table 4.2.1 HIV antibody prevalence by gender and survey year

Northern Territory	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021	25	1 (4.0)	14	1 (7.1)	39	2 (5.1)
2022	14	0 (0.0)	4	0 (0.0)	20	0 (0.0)
2023	27	1 (3.7)	13	0 (0.0)	41	1 (2.4)
2024	32	1 (3.1)	12	0 (0.0)	44	1 (2.3)
2025	45	0 (0.0)	18	0 (0.0)	67	0 (0.0)
X ² p trend		0.374		0.132		0.122

HCV antibody prevalence

Table 4.3.1 HCV antibody prevalence by gender and survey year

Northern Territory	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	24	7 (29)	14	2 (14)	38	9 (24)
2022	14	5 (36)	4	0 (0)	20	5 (25)
2023*	27	11 (41)	13	5 (38)	41	16 (39)
2024	32	6 (19)	12	2 (17)	44	8 (18)
2025	45	9 (20)	18	1 (6)	67	11 (16)
X ² p trend^		0.071		0.022		0.010

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

^ X² p trend calculated on years 2023-2025 only

Table 4.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Northern Territory	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	18	6 (33)	9	1 (11)	27	7 (26)
Bisexual	4	1 (25)	3	0 (0)	7	1 (14)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
p value		1.000		0.308		0.790
2022						
Heterosexual	12	4 (33)	3	0 (0)	15	4 (27)
Bisexual	2	1 (50)	1	0 (0)	3	1 (33)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		--		1.000
2023						
Heterosexual	22	8 (36)	9	4 (44)	31	12 (39)
Bisexual	4	3 (75)	4	1 (25)	8	4 (50)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.273		1.000		0.888
2024						
Heterosexual	29	5 (17)	10	2 (20)	39	7 (18)
Bisexual	1	0 (0)	1	0 (0)	2	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.184		0.787		0.145
2025						
Heterosexual	42	9 (21)	9	0 (0)	52	10 (19)
Bisexual	3	0 (0)	4	0 (0)	8	0 (0)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.370		0.093		0.654

Table 4.3.3 HCV antibody prevalence by age group, gender and survey year

Northern Territory		Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
<25 years	0	0 (0)	0	0 (0)	0	0 (0)	
25-34 years	2	0 (0)	0	0 (0)	2	0 (0)	
35-44 years	7	2 (29)	4	1 (4)	11	3 (27)	
45+ years	15	5 (33)	10	1 (10)	25	6 (24)	
p value		1.000		0.505		1.000	
2022							
<25 years	0	0 (0)	0	0 (0)	0	0 (0)	
25-34 years	1	0 (0)	0	0 (0)	1	0 (0)	
35-44 years	4	1 (25)	1	0 (0)	5	1 (20)	
45+ years	9	4 (44)	3	0 (0)	14	4 (29)	
p value		1.000		--		1.000	
2023							
<25 years	0	0 (0)	0	0 (0)	0	0 (0)	
25-34 years	3	0 (0)	2	0 (0)	5	0 (0)	
35-44 years	8	3 (38)	3	1 (33)	11	4 (36)	
45+ years	16	8 (50)	8	4 (50)	25	12 (48)	
p value		0.276		0.739		0.158	
2024							
<25 years	1	0 (0)	0	0 (0)	1	0 (0)	
25-34 years	2	0 (0)	2	0 (0)	4	0 (0)	
35-44 years	11	0 (0)	3	0 (0)	14	0 (0)	
45+ years	17	5 (29)	7	2 (29)	24	7 (29)	
p value		0.179		0.424		0.085	
2025							
<25 years	0	0 (0)	1	0 (0)	1	0 (0)	
25-34 years	5	1 (20)	3	0 (0)	9	1 (11)	
35-44 years	13	2 (15)	6	0 (0)	21	2 (10)	
45+ years	27	6 (22)	8	1 (13)	36	8 (22)	
p value		0.880		0.724		0.574	

Table 4.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Northern Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	22	7 (32)	14	2 (14)	36	9 (25)
p value		1		--		1.000
2022						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	12	4 (33)	4	0 (0)	18	4 (22)
p value		--		--		--
2023						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	1	0 (0)	2	0 (0)	3	0 (0)
11+ years	26	11 (42)	10	5 (50)	37	16 (43)
p value		1		0.674		0.372
2024						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	3	0 (0)	2	0 (0)	5	0 (0)
11+ years	27	5 (19)	8	2 (25)	35	7 (20)
p value		0.643		0.549		0.385
2025						
<3 years	3	0 (0)	3	0 (0)	6	0 (0)
3 to 10 years	5	0 (0)	2	0 (0)	7	0 (0)
11+ years	32	7 (22)	12	1 (8)	47	8 (17)
p value		0.346		0.801		0.279

Table 4.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Northern Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	0	0 (0)	26	5 (19)	26	5 (19)
Receptive sharing	0	0 (0)	5	2 (40)	5	2 (40)
p value		--		0.562		0.562
2022						
No receptive sharing	0	0 (0)	18	4 (22)	19	5 (26)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2023						
No receptive sharing	1	0 (0)	29	12 (41)	30	12 (40)
Receptive sharing	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		1.000		1.000
2024						
No receptive sharing	1	0 (0)	29	7 (24)	30	7 (23)
Receptive sharing	1	0 (0)	4	0 (0)	6	1 (17)
p value		--		0.268		0.720
2025						
No receptive sharing	3	0 (0)	35	4 (11)	41	5 (12)
Receptive sharing	1	0 (0)	11	3 (27)	16	5 (31)
p value		--		0.202		0.089

Table 4.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Northern Territory		<3 years		3+ years		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Methamphetamine	1	0 (0)	23	3 (13)	24	3 (13)	
Pharm. Opioids	0	0 (0)	4	1 (25)	4	1 (25)	
OAT*	0	0 (0)	4	2 (50)	4	2 (50)	
Other drugs	0	0 (0)	4	2 (50)	4	2 (50)	
p value		--		0.203			0.179
2022							
Methamphetamine	0	0 (0)	9	2 (22)	11	3 (27)	
Pharm. Opioids	0	0 (0)	6	1 (17)	6	1 (17)	
OAT*	0	0 (0)	1	1 (100)	1	1 (100)	
Other drugs	0	0 (0)	2	0 (0)	2	0 (0)	
p value		--		0.243			0.27
2023							
Methamphetamine	1	0 (0)	26	12 (46)	27	12 (44)	
Pharm. Opioids	0	0 (0)	6	2 (33)	6	2 (33)	
OAT*	0	0 (0)	2	1 (50)	2	1 (50)	
Other drugs	0	0 (0)	4	0 (0)	4	0 (0)	
p value		--		0.35			0.378
2024							
Methamphetamine	3	0 (0)	23	4 (17)	27	5 (19)	
Pharm. Opioids	0	0 (0)	9	3 (33)	9	3 (33)	
OAT*	0	0 (0)	3	0 (0)	3	0 (0)	
Other drugs	0	0 (0)	3	0 (0)	3	0 (0)	
p value		--		0.44			0.456
2025							
Methamphetamine	5	0 (0)	38	4 (11)	47	6 (13)	
Pharm. Opioids	0	0 (0)	8	3 (38)	9	3 (33)	
OAT*	0	0 (0)	3	0 (0)	4	1 (25)	
Other drugs	0	0 (0)	3	1 (33)	3	1 (33)	
p value		--		0.173			0.396

*OAT = methadone, buprenorphine or buprenorphine/naloxone

Table 4.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Northern Territory Frequency of injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	0	0 (0)	17	2 (12)	17	2 (12)
Daily or more	0	0 (0)	14	5 (36)	14	5 (36)
Not last month	1	0 (0)	4	1 (25)	5	1 (20)
p value		--		0.220		0.345
2022						
Less than daily	0	0 (0)	10	2 (20)	11	3 (27)
Daily or more	0	0 (0)	8	2 (25)	8	2 (25)
Not last month	0	0 (0)	0	0 (0)	1	0 (0)
p value		--		1.000		1.000
2023						
Less than daily	0	0 (0)	16	9 (56)	16	9 (56)
Daily or more	1	0 (0)	16	4 (25)	17	4 (24)
Not last month	0	0 (0)	6	2 (33)	6	2 (33)
p value		--		0.242		0.160
2024						
Less than daily	0	0 (0)	11	4 (36)	11	4 (36)
Daily or more	2	0 (0)	23	3 (13)	26	4 (15)
Not last month	1	0 (0)	4	0 (0)	5	0 (0)
p value		--		0.157		0.170
2025						
Less than daily	1	0 (0)	20	2 (10)	22	2 (9)
Daily or more	3	0 (0)	26	5 (19)	35	8 (23)
Not last month	1	0 (0)	7	1 (14)	8	1 (13)
p value		--		0.685		0.378

Table 4.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Northern Territory Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	1	0 (0)	32	9 (28)	34	9 (26)
Imprisonment	0	0 (0)	4	0 (0)	4	0 (0)
p value		--		0.553		0.554
2022						
No imprisonment	0	0 (0)	17	4 (24)	19	5 (26)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2023						
No imprisonment	1	0 (0)	34	12 (35)	35	12 (34)
Imprisonment	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
2024						
No imprisonment	2	0 (0)	35	6 (17)	38	7 (18)
Imprisonment	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		0.435		0.414
2025						
No imprisonment	5	0 (0)	41	8 (20)	49	9 (18)
Imprisonment	1	0 (0)	9	0 (0)	13	1 (8)
p value		--		0.148		0.352

Table 4.3.9 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Northern Territory		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
English speaking	23	6 (26)	14	2 (14)	37	8 (22)	
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)	
p value		0.292		--		0.237	
2022							
English speaking	14	5 (36)	4	0 (0)	20	5 (25)	
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2023							
English speaking	27	11 (41)	12	5 (42)	40	16 (40)	
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2024							
English speaking	31	6 (19)	11	2 (18)	42	8 (19)	
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)	
p value		0.625		0.640		0.495	
2025							
English speaking	42	9 (21)	15	1 (7)	59	11 (19)	
Non-English speaking	0	0 (0)	2	0 (0)	4	0 (0)	
p value		--		0.707		0.342	

Table 4.3.10 HCV antibody prevalence by region/country of birth, gender and survey year

Northern Territory		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Australia	23	7 (30)	14	2 (14)	37	9 (24)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2022							
Australia	13	5 (38)	4	0 (0)	19	5 (26)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		--		1.000	
2023							
Australia	26	10 (38)	13	5 (38)	39	15 (38)	
Other Oceania	0	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.407		--		0.634	
2024							
Australia	29	5 (17)	11	2 (18)	40	7 (18)	
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)	
Asia	0	0 (0)	1	0 (0)	1	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.521		0.640		0.731	
2025							
Australia	41	9 (22)	18	1 (6)	62	10 (16)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	2	0 (0)	0	0 (0)	3	1 (33)	
p value		0.456		--		0.438	

HCV RNA prevalence

Table 4.4.1 HCV RNA prevalence by gender and survey year

Northern Territory		Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021	22	3 (14)	11	0 (0)	33	3 (9)	
2022	14	3 (21)	4	0 (0)	20	3 (15)	
2023	27	3 (11)	13	1 (8)	41	4 (10)	
2024	32	1 (3)	12	0 (0)	44	1 (2)	
2025	39	0 (0)	17	0 (0)	60	0 (0)	
X ² p trend		0.006		0.808		0.008	

Totals include respondents where gender was reported as other or not reported

Table 4.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Northern Territory		Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Heterosexual	17	2 (12)	8	0 (0)	25	2 (8)	
Bisexual	3	1 (33)	2	0 (0)	5	1 (20)	
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)	
p value		0.564		--		0.629	
2022							
Heterosexual	12	3 (25)	3	0 (0)	15	3 (20)	
Bisexual	2	0 (0)	1	0 (0)	3	0 (0)	
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		--		1.000	
2023							
Heterosexual	22	3 (14)	9	1 (11)	31	4 (13)	
Bisexual	4	0 (0)	4	0 (0)	8	0 (0)	
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		1.000		0.645	
2024							
Heterosexual	29	1 (3)	10	0 (0)	39	1 (3)	
Bisexual	1	0 (0)	1	0 (0)	2	0 (0)	
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)	
p value		0.991		--		0.988	
2025							
Heterosexual	36	0 (0)	9	0 (0)	46	0 (0)	
Bisexual	3	0 (0)	4	0 (0)	8	0 (0)	
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)	
p value		--		--		--	

Table 4.4.3 HCV RNA prevalence by age group, gender and survey year

Northern Territory	Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	0 (0)	0	0 (0)	2	0 (0)
35-44 years	6	1 (17)	4	0 (0)	10	1 (10)
45+ years	14	2 (14)	7	0 (0)	21	2 (10)
p value		0.832		--		0.898
2022						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	1	0 (0)	0	0 (0)	1	0 (0)
35-44 years	4	0 (0)	1	0 (0)	5	0 (0)
45+ years	9	3 (33)	3	0 (0)	14	3 (21)
p value		0.604		--		0.601
2023						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	3	0 (0)	2	0 (0)	5	0 (0)
35-44 years	8	0 (0)	3	1 (33)	11	1 (9)
45+ years	16	3 (19)	8	0 (0)	25	3 (12)
p value		0.672		0.385		1.000
2024						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	2	0 (0)	2	0 (0)	4	0 (0)
35-44 years	11	1 (9)	3	0 (0)	14	1 (7)
45+ years	17	0 (0)	7	0 (0)	24	0 (0)
p value		0.598		--		0.548
2025						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	5	0 (0)	2	0 (0)	8	0 (0)
35-44 years	10	0 (0)	6	0 (0)	18	0 (0)
45+ years	24	0 (0)	8	0 (0)	33	0 (0)
p value		--		--		--

Table 4.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Northern Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	20	3 (15)	11	0 (0)	31	3 (10)
p value		0.676		--		0.744
2022						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	12	3 (25)	4	0 (0)	18	3 (17)
p value		--		--		--
2023						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	1	0 (0)	2	1 (50)	3	1 (33)
11+ years	26	3 (12)	10	0 (0)	37	3 (8)
p value		1.000		0.231		0.348
2024						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	3	0 (0)	2	0 (0)	5	0 (0)
11+ years	27	1 (4)	8	0 (0)	35	1 (3)
p value		0.926		--		0.890
2025						
<3 years	3	0 (0)	3	0 (0)	6	0 (0)
3 to 10 years	5	0 (0)	2	0 (0)	7	0 (0)
11+ years	26	0 (0)	11	0 (0)	40	0 (0)
p value		--		--		--

Table 4.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Northern Territory Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	14	1 (7)	10	0 (0)	24	1 (4)
Receptive sharing	4	1 (25)	1	0 (0)	5	1 (20)
p value		0.316		--		0.204
2022						
No receptive sharing	13	3 (23)	4	0 (0)	19	3 (16)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2023						
No receptive sharing	18	2 (11)	12	1 (8)	30	3 (10)
Receptive sharing	3	0 (0)	0	0 (0)	3	0 (0)
p value		1.000		--		1.000
2024						
No receptive sharing	23	1 (4)	7	0 (0)	30	1 (3)
Receptive sharing	3	0 (0)	3	0 (0)	6	0 (0)
p value		0.713		--		0.650
2025						
No receptive sharing	24	0 (0)	8	0 (0)	36	0 (0)
Receptive sharing	10	0 (0)	4	0 (0)	14	0 (0)
p value		--		--		--

Table 4.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Northern Territory		Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Methamphetamine	11	1 (9)	10	0 (0)	21	1 (5)	
Pharm. Opioids	3	0 (0)	0	0 (0)	3	0 (0)	
OAT	4	1 (25)	0	0 (0)	4	1 (25)	
Other drugs	2	0 (0)	1	0 (0)	3	0 (0)	
p value		0.667		--		0.425	
2022							
Methamphetamine	7	2 (29)	3	0 (0)	11	2 (18)	
Pharm. Opioids	5	1 (20)	1	0 (0)	6	1 (17)	
OAT	1	0 (0)	0	0 (0)	1	0 (0)	
Other drugs	1	0 (0)	0	0 (0)	2	0 (0)	
p value		0.858		--		0.890	
2023							
Methamphetamine	16	2 (13)	10	1 (10)	27	3 (11)	
Pharm. Opioids	5	1 (20)	1	0 (0)	6	1 (17)	
OAT	1	0 (0)	1	0 (0)	2	0 (0)	
Other drugs	3	0 (0)	1	0 (0)	4	0 (0)	
p value		0.837		0.955		0.807	
2024							
Methamphetamine	19	0 (0)	8	0 (0)	27	0 (0)	
Pharm. Opioids	7	0 (0)	2	0 (0)	9	0 (0)	
OAT	3	0 (0)	0	0 (0)	3	0 (0)	
Other drugs	2	1 (50)	1	0 (0)	3	1 (0)	
p value		0.002		--		0.004	
2025							
Methamphetamine	26	0 (0)	11	0 (0)	41	0 (0)	
Pharm. Opioids	6	0 (0)	3	0 (0)	9	0 (0)	
OAT	3	0 (0)	1	0 (0)	4	0 (0)	
Other drugs	3	0 (0)	0	0 (0)	3	0 (0)	
p value		--		--		--	

OAT: methadone, buprenorphine or buprenorphine/naloxone

Table 4.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Northern Territory		Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Less than daily	9	1 (11)	7	0 (0)	16	1 (6)	
Daily or more	9	1 (11)	4	0 (0)	13	1 (8)	
Not last month	2	0 (0)	0	0 (0)	2	0 (0)	
p value		0.884		--		0.918	
2022							
Less than daily	6	2 (33)	3	0 (0)	11	2 (18)	
Daily or more	7	1 (14)	1	0 (0)	8	1 (13)	
Not last month	1	0 (0)	0	0 (0)	1	0 (0)	
p value		0.654		--		1.000	
2023							
Less than daily	10	2 (20)	6	1 (17)	16	3 (19)	
Daily or more	11	0 (0)	6	0 (0)	17	0 (0)	
Not last month	4	1 (25)	1	0 (0)	6	1 (17)	
p value		0.259		1.000		0.147	
2024							
Less than daily	8	1 (13)	3	0 (0)	11	1 (9)	
Daily or more	19	0 (0)	7	0 (0)	26	0 (0)	
Not last month	4	0 (0)	1	0 (0)	5	0 (0)	
p value		0.226		--		0.236	
2025							
Less than daily	14	0 (0)	5	0 (0)	20	0 (0)	
Daily or more	20	0 (0)	7	0 (0)	30	0 (0)	
Not last month	4	0 (0)	4	0 (0)	8	0 (0)	
p value		--		--		--	

Table 4.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Northern Territory		Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
No imprisonment	19	3 (16)	10	0 (0)	29	3 (10)	
Imprisonment	3	0 (0)	1	0 (0)	4	0 (0)	
p value		0.459		--		0.500	
2022							
No imprisonment	14	3 (21)	3	0 (0)	19	3 (16)	
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2023							
No imprisonment	21	2 (10)	13	1 (8)	35	3 (9)	
Imprisonment	2	0 (0)	0	0 (0)	2	0 (0)	
p value		1.000		--		1.000	
2024							
No imprisonment	30	1 (0)	8	0 (0)	38	1 (3)	
Imprisonment	2	0 (0)	1	0 (0)	3	0 (0)	
p value		0.793		--		0.776	
2025							
No imprisonment	28	0 (0)	13	0 (0)	43	0 (0)	
Imprisonment	7	0 (0)	4	0 (0)	12	0 (0)	
p value		--		--		--	

Table 4.4.9 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Northern Territory		Male		Female		Total	
Main language spoken	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
at home by parents							
2021							
English speaking	21	3 (14)	11	0 (0)	32	3 (9)	
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)	
p value		0.684		--		0.748	
2022							
English speaking	14	3 (21)	4	0 (0)	20	3 (15)	
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2023							
English speaking	27	3 (11)	12	1 (8)	40	4 (10)	
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2024							
English speaking	31	1 (3)	11	0 (0)	42	1 (2)	
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)	
p value		0.855		--		0.825	
2025							
English speaking	36	0 (0)	14	0 (0)	52	0 (0)	
Non-English speaking	0	0 (0)	2	0 (0)	4	0 (0)	
p value		--		--		--	

Table 4.4.10 HCV RNA prevalence by region/country of birth, gender and survey year

Northern Territory		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Australia	21	3 (14)	11	0 (0)	32	3 (9)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2022							
Australia	13	3 (23)	4	0 (0)	19	3 (16)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		--		1.000	
2023							
Australia	26	2 (8)	13	1 (8)	39	3 (8)	
Other Oceania	0	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.111		--		0.188	
2024							
Australia	29	1 (3)	11	0 (0)	40	1 (0)	
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)	
Asia	0	0 (0)	1	0 (0)	1	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.790		--		0.962	
2025							
Australia	35	0 (0)	17	0 (0)	55	0 (0)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	2	0 (0)	0	0 (0)	3	0 (0)	
p value		--		--		--	

Queensland

Table 5.1.1 Number (%) of respondents by demographic characteristics and survey year

Queensland	2021*	2022	2023	2024	2025
Number of sites	11	10	10	10	9
N° surveyed	N=458	N=328	N=359	N=312	N=260
Response rate (%)	31%	26%	39%	30%	27%
Gender (%)					
Male	307 (67)	229 (70)	230 (64)	195 (63)	157 (60)
Female	145 (32)	92 (28)	124 (35)	105 (34)	93 (36)
Other	6 (1)	6 (2)	4 (1)	11 (4)	5 (2)
Not reported	0 (0)	1 (<1)	1 (<1)	1 (<1)	5 (2)
Age (years)					
Median age	42	43	43	42	44
Age range	16-72	16-71	18-72	18-73	16-76
<25 years	20 (4)	15 (5)	14 (4)	16 (5)	16 (6)
25+ years	438 (96)	310 (95)	345 (96)	296 (95)	244 (94)
Not reported	0 (0)	3 (<1)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	382 (83)	254 (77)	276 (77)	236 (76)	191 (73)
Bisexual	42 (9)	34 (10)	47 (13)	43 (14)	48 (18)
Gay/Lesbian	24 (5)	20 (6)	22 (6)	18 (6)	11 (4)
Other	9 (2)	16 (5)	11 (3)	14 (4)	2 (1)
Not reported	1 (<1)	4 (1)	3 (1)	1 (<1)	8 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	365 (80)	268 (82)	288 (80)	249 (80)	191 (73)
Yes	79 (17)	55 (17)	69 (19)	57 (18)	66 (25)
Not reported	14 (3)	5 (2)	2 (1)	6 (2)	3 (1)
Region/country of birth (%)					
Australia	407 (89)	293 (89)	331 (92)	275 (88)	231 (89)
Other Oceania	11 (2)	11 (3)	10 (3)	11 (4)	5 (2)
Asia	3 (1)	1 (<1)	1 (<1)	1 (<1)	3 (1)
UK & Ireland	11 (2)	8 (2)	9 (3)	10 (3)	8 (3)
Other	14 (3)	8 (2)	5 (1)	8 (3)	6 (2)
Not reported	12 (3)	7 (2)	3 (1)	7 (2)	7 (3)
Main language spoken at home by parents (%)					
English	441 (96)	316 (96)	351 (98)	307 (98)	245 (94)
Non-English	11 (2)	12 (4)	7 (2)	5 (2)	13 (5)
Not reported	6 (1)	0 (0)	1 (<1)	0 (0)	2 (1)
Age at first injection and time since first injection (years)					
Median age at first injection	19	19	20	19	19
Age range at first injection	12-52	10-55	10-65	11-53	10-62
N° not reported	14	17	5	5	14
Median yrs since first injection	22	22	21	21	21
Range yrs since first injection	<1-58	<1-51	<1-54	<1-52	<1-57
<3 years since first injection	27 (6)	21 (6)	24 (7)	22 (7)	20 (8)
3+ years since first injection	415 (91)	290 (88)	330 (92)	285 (91)	226 (87)
Not reported	16 (3)	17 (5)	5 (1)	5 (2)	14 (5)

* Implementation of the 2021 ANSPS was impacted by the COVID-19 pandemic

Table 5.1.2 Number (%) of respondents by last drug injected, frequency of injecting, overdose, imprisonment, injection in prison and survey year

Queensland N° surveyed	2021 N=458	2022 N=328	2023 N=359	2024 N=312	2025 N=260
Drug last injected (%)					
Cocaine	2 (<1)	3 (1)	4 (1)	5 (2)	0 (0)
Methamphetamine	194 (42)	142 (43)	185 (52)	159 (51)	141 (54)
Heroin	72 (16)	61 (19)	50 (14)	55 (18)	37 (14)
Pharm. opioids	73 (16)	40 (12)	23 (6)	22 (7)	11 (4)
Methadone	20 (4)	13 (4)	21 (6)	8 (3)	1 (<1)
Buprenorphine	25 (5)	12 (4)	18 (5)	10 (3)	2 (1)
Buprenorphine/naloxone	12 (3)	8 (2)	7 (2)	6 (2)	1 (<1)
PIEDs	34 (7)	30 (9)	24 (7)	24 (8)	19 (7)
More than one	15 (3)	11 (3)	16 (4)	18 (6)	43 (17)
Other	4 (1)	3 (1)	6 (2)	4 (1)	0 (0)
Not reported	7 (2)	5 (2)	5 (1)	1 (<1)	5 (2)
Ever injected opioids (%)					
No	120 (26)	99 (30)	114 (32)	106 (34)	84 (32)
Yes	333 (73)	227 (69)	241 (67)	201 (64)	176 (68)
Not reported	5 (1)	2 (1)	4 (1)	5 (2)	0 (0)
Frequency of injection last month (%)					
Not last month	73 (16)	35 (11)	40 (11)	17 (5)	9 (3)
Less than weekly	75 (16)	63 (19)	59 (16)	38 (12)	33 (13)
Weekly not daily	89 (19)	68 (21)	82 (23)	70 (22)	44 (17)
Daily or more	215 (47)	157 (48)	169 (47)	181 (58)	168 (65)
Not reported	6 (1)	5 (2)	9 (3)	6 (2)	6 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	377 (82)	284 (87)	291 (81)	246 (79)	204 (78)
Yes	73 (16)	39 (12)	58 (16)	54 (17)	46 (18)
Not reported	8 (2)	5 (2)	10 (3)	12 (4)	10 (4)
Overdosed in last 12 months (%)					
No	400 (87)	290 (88)	303 (84)	249 (80)	201 (77)
Yes	49 (11)	34 (10)	45 (13)	48 (15)	50 (19)
Not reported	9 (2)	4 (1)	11 (3)	15 (5)	9 (3)
Imprisonment last year (%)					
No	385 (84)	288 (88)	303 (84)	254 (81)	206 (79)
Yes	46 (10)	29 (9)	36 (10)	39 (13)	38 (15)
Not reported	27 (6)	11 (3)	20 (6)	19 (6)	16 (6)
Injected while in prison last year					
N° in prison last year	N=46	N=29	N=36	N=39	N=38
No	19 (41)	15 (52)	19 (53)	21 (54)	13 (34)
Yes	27 (59)	12 (41)	14 (39)	17 (44)	23 (61)
Not reported	0 (0)	2 (7)	3 (8)	1 (3)	2 (5)

Table 5.1.3 Number (%) of respondents by injecting behaviour in the last month and survey year

Queensland	2021	2022	2023	2024	2025
N° injected last month	N=379	N=288	N=310	N=289	N=245
Places injected last month (%)					
All private	249 (66)	187 (65)	183 (59)	162 (56)	126 (51)
Any public	128 (34)	101 (35)	126 (41)	126 (44)	118 (48)
Not reported	2 (1)	0 (0)	1 (<1)	1 (<1)	1 (<1)
Use of new and sterile needles and syringes last month (%)					
All injections	306 (81)	221 (77)	235 (76)	209 (72)	166 (68)
Most of the time	57 (15)	52 (18)	61 (20)	56 (19)	60 (24)
Half of the time	9 (2)	9 (3)	3 (1)	6 (2)	7 (3)
Some of the time	5 (1)	2 (1)	5 (2)	10 (3)	9 (4)
Not last month	2 (1)	2 (1)	2 (1)	3 (1)	0 (0)
Not reported	0 (0)	2 (1)	4 (1)	5 (2)	3 (1)
Re-used someone else's used needle & syringe last month (%)					
None	327 (86)	247 (86)	257 (83)	232 (80)	182 (74)
Once	12 (3)	18 (6)	21 (7)	14 (5)	13 (5)
Twice	13 (3)	12 (4)	16 (5)	10 (3)	9 (4)
3-5 times	14 (4)	5 (2)	7 (2)	20 (7)	23 (9)
>5 times	12 (3)	6 (2)	6 (2)	10 (3)	14 (6)
Not reported	1 (<1)	0 (0)	3 (1)	3 (1)	4 (2)
Number of people needle & syringe was re-used after last month (%)					
None	327 (86)	247 (86)	257 (83)	232 (80)	182 (74)
One	22 (6)	13 (5)	17 (5)	20 (7)	25 (10)
Two	4 (1)	7 (2)	6 (2)	6 (2)	5 (2)
Three to five	2 (1)	1 (<1)	4 (1)	4 (1)	8 (3)
More than five	4 (1)	3 (1)	1 (<1)	4 (1)	5 (2)
Don't know	13 (3)	7 (2)	14 (5)	11 (4)	13 (5)
Not reported	7 (2)	10 (3)	11 (4)	12 (4)	7 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	15 (4)	13 (5)	17 (5)	14 (5)	18 (7)
Casual sex partner	3 (1)	3 (1)	5 (2)	4 (1)	7 (3)
Close friend	14 (4)	11 (4)	9 (3)	15 (5)	23 (9)
Acquaintance	10 (3)	6 (2)	13 (4)	8 (3)	10 (4)
Other	7 (2)	1 (<1)	2 (1)	8 (3)	1 (<1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	74 (20)	50 (17)	50 (16)	55 (19)	59 (24)
Water	65 (17)	45 (16)	57 (18)	72 (25)	82 (33)
Filter	36 (10)	19 (7)	30 (10)	38 (13)	25 (10)
Drug mix	38 (10)	20 (7)	29 (9)	37 (13)	28 (11)
None	274 (72)	210 (73)	219 (71)	185 (64)	136 (56)
Injected by someone after that person injected themselves or others last month (%)					
No	325 (86)	237 (82)	266 (86)	227 (79)	175 (71)
Yes	53 (14)	47 (16)	42 (14)	60 (21)	67 (27)
Not reported	1 (<1)	4 (1)	2 (1)	2 (1)	3 (1)
Source of needle acquisition (%)					
Needle Syringe Program	339 (89)	242 (84)	263 (85)	251 (87)	220 (90)
Chemist/Pharmacy	96 (25)	69 (24)	75 (24)	80 (28)	82 (33)
Personal sources	37 (10)	20 (7)	41 (13)	46 (16)	38 (16)
Dispensing/Vending Machine	47 (12)	26 (9)	42 (14)	53 (18)	54 (22)
Other sources	9 (2)	11 (4)	2 (1)	2 (1)	2 (1)

Table 5.1.4 Number (%) of respondents by treatment for drug use and survey year

Queensland	2021	2022	2023	2024	2025
N° surveyed	N=458	N=328	N=359	N=312	N=260
Ever any treatment/therapy for drug use (%)					
No	152 (33)	113 (34)	127 (35)	114 (37)	97 (37)
Yes	305 (67)	214 (65)	232 (65)	198 (63)	162 (62)
Not reported	1 (<1)	1 (<1)	0 (0)	0 (0)	1 (<1)
History of methadone maintenance treatment (%)					
Currently	42 (9)	44 (13)	42 (12)	32 (10)	24 (9)
Previously	101 (22)	65 (20)	70 (20)	50 (16)	47 (18)
Never	297 (65)	210 (64)	236 (66)	213 (68)	179 (69)
Not reported	18 (4)	9 (3)	11 (3)	17 (5)	10 (4)
History of buprenorphine (Subutex®) treatment (%)					
Currently	52 (11)	31 (9)	40 (11)	28 (9)	17 (7)
Previously	93 (20)	67 (20)	61 (17)	74 (24)	70 (27)
Never	299 (65)	221 (67)	247 (69)	197 (63)	162 (62)
Not reported	14 (3)	9 (3)	11 (3)	13 (4)	11 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	36 (8)	16 (5)	23 (6)	17 (5)	5 (2)
Previously	100 (22)	73 (22)	70 (20)	78 (25)	75 (29)
Never	317 (69)	234 (71)	265 (74)	215 (69)	175 (67)
Not reported	5 (1)	5 (2)	1 (<1)	2 (1)	5 (2)
History of depot buprenorphine treatment (%)					
Currently	22 (5)	10 (3)	11 (3)	23 (7)	17 (7)
Previously	18 (4)	27 (8)	25 (7)	28 (9)	41 (16)
Never	404 (88)	279 (85)	309 (86)	249 (80)	192 (74)
Not reported	14 (3)	12 (4)	14 (4)	12 (4)	10 (4)

Table 5.1.5 Number (%) of respondents by sexual behaviour in the month prior to survey and survey year

Queensland	2021	2022	2023	2024	2025
N° surveyed	N=458	N=328	N=359	N=312	N=260
Sex with a regular partner last month (%)					
No	234 (51)	172 (52)	166 (46)	144 (46)	115 (44)
Yes	210 (46)	149 (45)	175 (49)	148 (47)	132 (51)
Not reported	14 (3)	7 (2)	18 (5)	20 (6)	13 (5)
Condom used with regular partner last month (%)					
N° surveyed	N=210	N=149	N=175	N=148	N=132
Never	161 (77)	116 (78)	146 (83)	114 (77)	104 (79)
Sometimes	28 (13)	17 (11)	13 (7)	15 (10)	12 (9)
Every time	14 (7)	8 (5)	12 (7)	8 (5)	11 (8)
Not reported	7 (3)	8 (5)	4 (2)	11 (7)	5 (4)
Sex with other partner(s) last month (%)					
No	366 (80)	265 (81)	269 (75)	239 (77)	189 (73)
Yes	70 (15)	48 (15)	67 (19)	54 (17)	54 (21)
Not reported	22 (5)	15 (5)	23 (6)	19 (6)	17 (7)
Condom used with other partner(s) last month (%)					
N° surveyed	N=70	N=48	N=67	N=54	N=54
Never	31 (44)	26 (54)	40 (60)	28 (52)	39 (72)
Sometimes	22 (31)	14 (29)	10 (15)	15 (28)	12 (22)
Every time	12 (17)	6 (13)	16 (24)	6 (11)	1 (2)
Not reported	5 (7)	2 (4)	1 (1)	5 (9)	2 (4)
Sex work last month (%)					
No	422 (92)	304 (93)	317 (88)	268 (86)	229 (88)
Yes	14 (3)	9 (3)	18 (5)	23 (7)	19 (7)
Not reported	22 (5)	15 (5)	24 (7)	21 (7)	12 (5)
Condom used at last sex work (%)					
Yes	8 (57)	7 (78)	10 (56)	10 (43)	7 (37)

Table 5.1.6 Number (%) of respondents by testing for HIV and HCV, HCV treatment by survey year

Queensland	2021	2022	2023	2024	2025
N° surveyed	N=458	N=328	N=359	N=312	N=260
Previous HIV test (%)					
Yes, ever	350 (76)	251 (77)	256 (71)	219 (70)	196 (75)
Yes, last year	146 (32)	118 (36)	147 (41)	101 (32)	122 (47)
>1 year ago	204 (45)	133 (41)	109 (30)	118 (38)	74 (28)
Never tested	95 (21)	68 (21)	86 (24)	74 (24)	51 (20)
Not reported	13 (3)	9 (3)	17 (5)	19 (6)	13 (5)
Previous HCV test (%)					
Yes, ever	367 (80)	267 (81)	286 (80)	236 (76)	203 (78)
Yes, last year	198 (43)	144 (44)	164 (46)	133 (43)	141 (54)
>1 year ago	169 (37)	123 (38)	122 (34)	103 (33)	62 (24)
Never tested	59 (13)	41 (13)	44 (12)	50 (16)	24 (9)
Not reported	32 (7)	20 (6)	29 (8)	26 (8)	33 (13)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=107	N=54	N=81	N=51	N=34
Antiviral treatment	80 (75)	33 (61)	57 (70)	35 (69)	28 (82)
No antiviral treatment	25 (23)	21 (39)	24 (30)	15 (29)	6 (18)
Not reported	2 (2)	0 (0)	0 (0)	1 (2)	0 (0)
Treatment for HCV in past 12 months (%)^{##}					
N° self-reported HCV diagnosis	N=54	N=33	N=50	N=27	N=19
Antiviral treatment	20 (37)	11 (33)	18 (36)	8 (30)	11 (58)
No antiviral treatment	32 (59)	22 (67)	32 (64)	18 (67)	8 (42)
Not reported	2 (4)	0 (0)	0 (0)	1 (4)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance^{*} excludes people who reported treatment induced clearance more than 12 months previously

HIV antibody prevalence

Table 5.2.1 HIV antibody prevalence by gender and survey year

Queensland	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021	304	7 (2.3)	145	0 (0.0)	455	8 (1.8)
2022	227	7 (3.1)	91	0 (0.0)	325	7 (2.2)
2023	207	8 (3.9)	115	1 (0.9)	327	9 (2.8)
2024	194	6 (3.1)	105	0 (0.0)	311	6 (1.9)
2025	154	9 (5.8)	93	0 (0.0)	257	9 (3.5)
X ² p trend		0.088		0.909		0.229

Table 5.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Queensland	Male		Female		Total	
Sexual identity	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
Heterosexual	267	1 (0.4)	110	0 (0.0)	379	1 (0.3)
Bisexual	18	0 (0.0)	24	0 (0.0)	42	0 (0.0)
Homosexual	15	5 (33.3)	6	0 (0.0)	24	6 (25.0)
p value		<0.001		--		<0.001
2022						
Heterosexual	192	0 (0.0)	59	0 (0.0)	252	0 (0.0)
Bisexual	13	0 (0.0)	19	0 (0.0)	34	0 (0.0)
Homosexual	15	7 (46.7)	5	0 (0.0)	20	7 (35.0)
p value		<0.001		--		<0.001
2023						
Heterosexual	170	1 (0.6)	82	0 (0.0)	253	1 (0.4)
Bisexual	17	3 (17.7)	26	1 (3.9)	44	4 (9.1)
Homosexual	15	4 (26.7)	4	0 (0.0)	19	4 (21.1)
p value		<0.001		0.287		<0.001
2024						
Heterosexual	165	1 (0.6)	69	0 (0.0)	236	1 (0.4)
Bisexual	14	0 (0.0)	24	0 (0.0)	42	0 (0.0)
Homosexual	9	4 (44.4)	5	0 (0.0)	18	4 (22.2)
p value		<0.001		--		<0.001
2025						
Heterosexual	130	2 (1.5)	56	0 (0.0)	189	2 (1.1)
Bisexual	12	1 (8.3)	31	0 (0.0)	47	1 (2.1)
Homosexual	9	6 (66.7)	1	0 (0.0)	11	6 (54.6)
p value		<0.001		--		<0.001

Table 5.2.3 HIV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
<25 years	14	0 (0.0)	5	0 (0.0)	20	0 (0.0)
25-34 years	49	0 (0.0)	30	0 (0.0)	80	0 (0.0)
35-44 years	108	0 (0.0)	49	0 (0.0)	161	1 (0.6)
45+ years	133	7 (5.3)	61	0 (0.0)	194	7 (3.6)
p value		0.496		--		0.120
2022						
<25 years	9	0 (0.0)	3	0 (0.0)	15	0 (0.0)
25-34 years	36	0 (0.0)	17	0 (0.0)	55	0 (0.0)
35-44 years	71	3 (4.2)	39	0 (0.0)	111	3 (2.7)
45+ years	109	4 (3.7)	31	0 (0.0)	141	4 (2.8)
p value		0.761		--		0.775
2023						
<25 years	9	0 (0.0)	5	0 (0.0)	14	0 (0.0)
25-34 years	29	1 (3.5)	13	1 (7.7)	44	2 (4.6)
35-44 years	70	1 (1.4)	44	0 (0.0)	115	1 (0.9)
45+ years	99	6 (6.1)	53	0 (0.0)	154	6 (3.9)
p value		0.523		0.157		0.316
2024						
<25 years	7	0 (0.0)	8	0 (0.0)	16	0 (0.0)
25-34 years	36	0 (0.0)	21	0 (0.0)	58	0 (0.0)
35-44 years	57	2 (3.5)	40	0 (0.0)	103	2 (1.9)
45+ years	94	4 (4.3)	36	0 (0.0)	134	4 (3.0)
p value		0.609		--		0.523
2025						
<25 years	5	0 (0.0)	9	0 (0.0)	16	0 (0.0)
25-34 years	24	0 (0.0)	14	0 (0.0)	40	0 (0.0)
35-44 years	45	4 (8.9)	27	0 (0.0)	77	4 (5.2)
45+ years	80	5 (6.3)	43	0 (0.0)	124	5 (4.0)
p value		0.461		--		0.425

Table 5.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Queensland	Male		Female		Total	
Last drug injected	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
Heroin	48	0 (0.0)	22	0 (0.0)	71	0 (0.0)
Methamphetamine	108	5 (4.6)	82	0 (0.0)	193	6 (3.1)
Other opioids	94	2 (2.1)	33	0 (0.0)	129	2 (1.6)
PIEDs	34	0 (0.0)	0	0 (0.0)	34	0 (0.0)
Other drugs	16	0 (0.0)	5	0 (0.0)	21	0 (0.0)
p value		0.496		--		0.585
2022						
Heroin	40	0 (0.0)	21	0 (0.0)	61	0 (0.0)
Methamphetamine	87	5 (5.8)	46	0 (0.0)	140	5 (3.6)
Other opioids	58	1 (1.7)	15	0 (0.0)	73	1 (1.4)
PIEDs	30	0 (0.0)	0	0 (0.0)	30	0 (0.0)
Other drugs	11	1 (9.1)	6	0 (0.0)	17	1 (5.9)
p value		0.200		--		0.329
2023						
Heroin	25	0 (0.0)	23	0 (0.0)	48	0 (0.0)
Methamphetamine	105	7 (6.7)	62	1 (1.6)	170	8 (4.7)
Other opioids	44	1 (2.3)	21	0 (0.0)	66	1 (1.5)
PIEDs	18	0 (0.0)	1	0 (0.0)	20	0 (0.0)
Other drugs	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)
p value		0.574		1.000		0.494
2024						
Heroin	36	0 (0.0)	15	0 (0.0)	55	0 (0.0)
Methamphetamine	87	5 (5.8)	67	0 (0.0)	158	5 (3.2)
Other opioids	33	1 (3.0)	12	0 (0.0)	46	1 (2.2)
PIEDs	24	0 (0.0)	0	0 (0.0)	24	0 (0.0)
Other drugs	13	0 (0.0)	11	0 (0.0)	27	0 (0.0)
p value		0.360		--		0.499
2025						
Heroin	26	0 (0.0)	10	0 (0.0)	37	0 (0.0)
Methamphetamine	71	7 (9.9)	64	0 (0.0)	140	7 (5.0)
Other opioids	10	1 (10.0)	5	0 (0.0)	15	1 (6.7)
PIEDs	17	0 (0.0)	1	0 (0.0)	18	0 (0.0)
Other drugs	28	1 (3.6)	11	0 (0.0)	42	1 (2.4)
p value		0.262		--		0.484

Table 5.2.5 HIV antibody prevalence by years of injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
<3 years	20	0 (0.0)	6	0 (0.0)	27	0 (0.0)
3 to 10 years	47	2 (4.3)	20	0 (0.0)	67	2 (3.0)
11+ years	228	5 (2.2)	112	0 (0.0)	345	6 (1.7)
p value		0.600		--		0.773
2022						
<3 years	13	1 (7.7)	5	0 (0.0)	21	1 (4.8)
3 to 10 years	28	0 (0.0)	21	0 (0.0)	50	0 (0.0)
11+ years	172	6 (3.5)	62	0 (0.0)	237	6 (2.5)
p value		0.278		--		0.328
2023						
<3 years	16	1 (6.3)	6	0 (0.0)	22	1 (4.6)
3 to 10 years	38	2 (5.3)	18	0 (0.0)	58	2 (3.5)
11+ years	151	5 (3.3)	90	1 (1.1)	244	6 (2.5)
p value		0.536		1.000		0.551
2024						
<3 years	12	0 (0.0)	9	0 (0.0)	22	0 (0.0)
3 to 10 years	30	3 (10.0)	30	0 (0.0)	62	3 (4.8)
11+ years	149	3 (2.0)	65	0 (0.0)	222	3 (1.4)
p value		0.059		--		0.170
2025						
<3 years	12	0 (0.0)	7	0 (0.0)	20	0 (0.0)
3 to 10 years	23	3 (13.0)	22	0 (0.0)	48	3 (6.3)
11+ years	110	6 (5.5)	59	0 (0.0)	175	6 (3.4)
p value		0.253		--		0.432

Table 5.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Queensland Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
No receptive sharing	225	7 (3.1)	95	0 (0.0)	324	8 (2.5)
Receptive sharing	32	0 (0.0)	19	0 (0.0)	51	0 (0.0)
p value		0.602		--		0.605
2022						
No receptive sharing	180	4 (2.2)	59	0 (0.0)	245	4 (1.6)
Receptive sharing	25	1 (4.0)	16	0 (0.0)	41	1 (2.4)
p value		0.482		--		0.541
2023						
No receptive sharing	147	5 (3.4)	86	1 (1.2)	236	6 (2.5)
Receptive sharing	39	2 (5.1)	6	0 (0.0)	46	2 (4.4)
p value		0.638		1.000		0.621
2024						
No receptive sharing	143	5 (3.5)	78	0 (0.0)	231	5 (2.2)
Receptive sharing	34	1 (2.9)	19	0 (0.0)	54	1 (1.9)
p value		0.872		--		0.885
2025						
No receptive sharing	108	5 (4.6)	66	0 (0.0)	179	5 (2.8)
Receptive sharing	38	1 (2.6)	19	0 (0.0)	59	1 (1.7)
p value		0.594		--		0.641

Table 5.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Queensland	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
Less than daily	121	4 (3.3)	40	0 (0.0)	162	4 (2.5)
Daily or more	136	3 (2.2)	75	0 (0.0)	214	4 (1.9)
Not last month	42	0 (0.0)	29	0 (0.0)	73	0 (0.0)
p value		0.670		--		0.498
2022						
Less than daily	100	3 (3.0)	25	0 (0.0)	131	3 (2.3)
Daily or more	105	2 (1.9)	50	0 (0.0)	155	2 (1.3)
Not last month	21	2 (9.5)	12	0 (0.0)	34	2 (5.9)
p value		0.195		--		0.214
2023						
Less than daily	82	2 (2.4)	45	1 (2.2)	129	3 (2.3)
Daily or more	107	5 (4.7)	47	0 (0.0)	156	5 (3.2)
Not last month	15	1 (6.7)	19	0 (0.0)	35	1 (2.9)
p value		0.433		0.577		0.894
2024						
Less than daily	69	3 (4.4)	30	0 (0.0)	107	3 (2.8)
Daily or more	110	3 (2.7)	68	0 (0.0)	181	3 (1.7)
Not last month	10	0 (0.0)	6	0 (0.0)	17	0 (0.0)
p value		0.702		--		0.664
2025						
Less than daily	51	3 (5.9)	23	0 (0.0)	76	3 (4.0)
Daily or more	97	3 (3.1)	63	0 (0.0)	166	3 (1.8)
Not last month	4	3 (75.0)	4	0 (0.0)	9	3 (33.3)
p value		<0.001		--		<0.001

Table 5.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Queensland	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
No imprisonment	252	7 (2.8)	126	0 (0.0)	383	8 (2.1)
Imprisonment	36	0 (0.0)	9	0 (0.0)	45	0 (0.0)
p value		0.602		--		1.000
2022						
No imprisonment	197	7 (3.6)	82	0 (0.0)	285	7 (2.5)
Imprisonment	22	0 (0.0)	7	0 (0.0)	29	0 (0.0)
p value		1.000		--		1.000
2023						
No imprisonment	167	7 (4.2)	100	1 (1.0)	272	8 (2.9)
Imprisonment	28	0 (0.0)	7	0 (0.0)	35	0 (0.0)
p value		0.596		1.000		0.604
2024						
No imprisonment	152	5 (3.3)	89	0 (0.0)	253	5 (2.0)
Imprisonment	26	0 (0.0)	13	0 (0.0)	39	0 (0.0)
p value		0.348		--		0.376
2025						
No imprisonment	123	5 (4.1)	74	0 (0.0)	204	5 (2.5)
Imprisonment	24	3 (12.5)	12	0 (0.0)	38	3 (7.9)
p value		0.096		--		0.085

Table 5.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Queensland		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
No condom use	106	1 (0.9)	54	0 (0.0)	160	1 (0.6)	
Condom use	26	0 (0.0)	15	0 (0.0)	42	1 (2.4)	
p value		1.000		--		0.373	
2022							
No condom use	73	1 (1.4)	41	0 (0.0)	115	1 (0.9)	
Condom use	18	1 (5.6)	5	0 (0.0)	25	1 (4.0)	
p value		0.358		--		0.326	
2023							
No condom use	82	5 (6.1)	54	0 (0.0)	138	5 (3.6)	
Condom use	11	0 (0.0)	7	0 (0.0)	19	0 (0.0)	
p value		1.000		--		1.000	
2024							
No condom use	64	2 (3.1)	46	0 (0.0)	113	2 (1.8)	
Condom use	10	0 (0.0)	11	0 (0.0)	23	0 (0.0)	
p value		0.571		--		0.520	
2025							
No condom use	60	4 (6.7)	39	0 (0.0)	102	4 (3.9)	
Condom use	13	0 (0.0)	7	0 (0.0)	23	0 (0.0)	
p value		0.338		--		0.334	

Table 5.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Queensland		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
No sex work	285	7 (2.5)	131	0 (0.0)	420	7 (1.7)	
Sex work	8	0 (0.0)	5	0 (0.0)	14	1 (7.1)	
p value		1.000		--		0.232	
2022							
No sex work	209	7 (3.4)	85	0 (0.0)	301	7 (2.3)	
Sex work	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)	
p value		1.000		--		1.000	
2023							
No sex work	186	8 (4.3)	100	1 (1.0)	290	9 (3.1)	
Sex work	10	0 (0.0)	4	0 (0.0)	15	0 (0.0)	
p value		1.000		1.000		1.000	
2024							
No sex work	165	5 (3.0)	92	0 (0.0)	267	5 (1.9)	
Sex work	12	0 (0.0)	9	0 (0.0)	23	0 (0.0)	
p value		0.541		--		0.508	
2025							
No sex work	139	6 (4.3)	84	0 (0.0)	228	6 (2.6)	
Sex work	9	2 (22.2)	5	0 (0.0)	18	2 (11.1)	
p value		0.021		--		0.051	

Table 5.2.11 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Queensland	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
English speaking	292	7 (2.4)	143	0 (0.0)	439	8 (1.8)
Non-English speaking	8	0 (0.0)	1	0 (0.0)	11	0 (0.0)
p value		1.000		--		1.000
2022						
English speaking	216	7 (3.2)	90	0 (0.0)	313	7 (2.2)
Non-English speaking	11	0 (0.0)	1	0 (0.0)	12	0 (0.0)
p value		1.000		--		1.000
2023						
English speaking	204	8 (3.9)	113	1 (0.9)	322	9 (2.8)
Non-English speaking	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
p value		1.000		1.000		1.000
2024						
English speaking	190	6 (3.2)	104	0 (0.0)	306	6 (2.0)
Non-English speaking	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
p value		0.718		--		0.752
2025						
English speaking	142	7 (4.9)	90	0 (0.0)	242	7 (2.9)
Non-English speaking	10	1 (10.0)	3	0 (0.0)	13	1 (7.7)
p value		0.488		--		0.333

Table 5.2.12 HIV antibody prevalence by region/country of birth, gender and survey year

Queensland		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
Australia	273	6 (2.2)	127	0 (0.0)	405	7 (1.7)	
Other Oceania	7	0 (0.0)	3	0 (0.0)	11	0 (0.0)	
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
UK & Ireland	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)	
Other	10	1 (10.0)	4	0 (0.0)	14	1 (7.1)	
p value		0.487		--		0.524	
2022							
Australia	200	7 (3.5)	83	0 (0.0)	290	7 (2.4)	
Other Oceania	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
Asia	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)	
UK & Ireland	7	0 (0.0)	1	0 (0.0)	8	0 (0.0)	
Other	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)	
p value		1.000		--		1.000	
2023							
Australia	187	8 (4.3)	111	1 (0.9)	303	9 (3.0)	
Other Oceania	7	0 (0.0)	3	0 (0.0)	10	0 (0.0)	
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
UK & Ireland	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
Other	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
p value		1.000		1.000		1.000	
2024							
Australia	168	3 (1.8)	94	0 (0.0)	274	3 (1.1)	
Other Oceania	9	2 (22.2)	2	0 (0.0)	11	2 (18.2)	
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
UK & Ireland	7	0 (0.0)	3	0 (0.0)	10	0 (0.0)	
Other	6	1 (16.7)	2	0 (0.0)	8	1 (12.5)	
p value		0.004		--		<0.001	
2025							
Australia	133	7 (5.3)	86	0 (0.0)	228	7 (3.1)	
Other Oceania	4	0 (0.0)	0	0 (0.0)	5	0 (0.0)	
Asia	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)	
UK & Ireland	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
Other	9	0 (0.0)	5	0 (0.0)	14	0 (0.0)	
p value		0.856		--		0.874	

HCV antibody prevalence

Table 5.3.1 HCV antibody prevalence by gender and survey year

Queensland	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	304	120 (39)	145	51 (35)	455	172 (38)
2022	227	53 (23)	91	30 (33)	325	84 (26)
2023*	208	81 (39)	115	41 (36)	328	122 (37)
2024	195	68 (35)	105	31 (30)	312	101 (32)
2025	156	42 (27)	93	23 (25)	259	66 (25)
X ² p trend^		0.018		0.087		0.003

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

^ X² p trend calculated on years 2023-2025 only

Table 5.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Queensland	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	267	111 (42)	110	39 (35)	379	151 (40)
Bisexual	18	5 (28)	24	7 (29)	42	12 (29)
Homosexual	15	3 (20)	6	4 (67)	24	7 (29)
p value		0.238		0.466		0.333
2022						
Heterosexual	192	48 (25)	59	20 (34)	252	69 (27)
Bisexual	13	3 (23)	19	5 (26)	34	8 (24)
Homosexual	15	2 (13)	5	1 (20)	20	3 (15)
p value		0.891		0.303		0.144
2023						
Heterosexual	170	74 (44)	82	32 (39)	253	106 (42)
Bisexual	18	3 (17)	26	7 (27)	45	10 (22)
Homosexual	15	3 (20)	4	2 (50)	19	5 (26)
p value		0.046		0.601		0.055
2024						
Heterosexual	165	59 (36)	69	19 (28)	236	78 (33)
Bisexual	15	6 (40)	24	7 (29)	43	14 (33)
Homosexual	9	2 (22)	5	2 (40)	18	4 (22)
p value		0.649		0.942		0.815
2025						
Heterosexual	131	36 (27)	56	16 (29)	190	53 (28)
Bisexual	13	4 (31)	31	7 (23)	48	11 (23)
Homosexual	9	1 (11)	1	0 (0)	11	1 (9)
p value		0.735		0.774		0.452

Table 5.3.3 HCV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<25 years	14	2 (14)	5	1 (20)	20	3 (15)
25-34 years	49	14 (29)	30	12 (40)	80	26 (33)
35-44 years	108	47 (44)	49	17 (35)	161	65 (40)
45+ years	133	57 (43)	61	21 (34)	194	78 (40)
p value		0.055		0.865		0.092
2022						
<25 years	9	1 (11)	3	1 (33)	15	2 (13)
25-34 years	36	5 (14)	17	4 (24)	55	9 (16)
35-44 years	71	16 (23)	39	12 (31)	111	29 (26)
45+ years	109	31 (28)	31	12 (39)	141	43 (31)
p value		0.285		0.756		0.154
2023						
<25 years	9	2 (22)	5	1 (20)	14	3 (21)
25-34 years	29	8 (28)	13	2 (15)	44	10 (23)
35-44 years	71	23 (32)	44	15 (34)	116	38 (33)
45+ years	99	48 (48)	53	23 (43)	154	71 (46)
p value		0.059		0.252		0.009
2024						
<25 years	7	0 (0)	8	1 (13)	16	2 (13)
25-34 years	36	11 (31)	21	5 (24)	58	16 (28)
35-44 years	58	23 (40)	40	11 (28)	104	35 (34)
45+ years	94	34 (36)	36	14 (39)	134	48 (36)
p value		0.195		0.385		0.231
2025						
<25 years	5	0 (0)	9	0 (0)	16	0 (0)
25-34 years	24	9 (38)	14	1 (7)	40	10 (25)
35-44 years	47	12 (26)	27	8 (30)	79	20 (25)
45+ years	80	21 (26)	43	14 (33)	124	36 (29)
p value		0.352		0.070		0.098

Table 5.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Queensland	Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	20	0 (0)	6	0 (0)	27	0 (0)
3 to 10 years	47	4 (9)	20	4 (20)	67	8 (12)
11+ years	228	111 (49)	112	45 (40)	345	157 (46)
p value		<0.001		0.043		<0.001
2022						
<3 years	13	0 (0)	5	0 (0)	21	0 (0)
3 to 10 years	28	5 (18)	21	3 (14)	50	8 (16)
11+ years	172	44 (26)	62	26 (42)	237	71 (30)
p value		0.070		0.018		0.001
2023						
<3 years	16	1 (6)	6	0 (0)	22	1 (5)
3 to 10 years	38	5 (13)	18	3 (17)	58	8 (14)
11+ years	152	73 (48)	90	38 (42)	245	111 (45)
p value		<0.001		0.017		<0.001
2024						
<3 years	12	0 (0)	9	0 (0)	22	0 (0)
3 to 10 years	30	4 (13)	30	4 (13)	62	9 (15)
11+ years	150	61 (41)	65	27 (42)	223	88 (39)
p value		0.001		0.002		<0.001
2025						
<3 years	12	0 (0)	7	0 (0)	20	0 (0)
3 to 10 years	23	6 (26)	22	2 (9)	48	8 (17)
11+ years	112	31 (28)	59	19 (32)	177	51 (29)
p value		0.110		0.029		0.007

Table 5.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	19	0 (0)	295	113 (38)	324	118 (36)
Receptive sharing	1	0 (0)	49	26 (53)	51	26 (51)
p value		--		0.051		0.047
2022						
No receptive sharing	17	0 (0)	217	59 (27)	245	63 (26)
Receptive sharing	0	0 (0)	36	11 (31)	41	12 (29)
p value		--		0.676		0.632
2023						
No receptive sharing	18	0 (0)	218	86 (39)	237	87 (37)
Receptive sharing	1	1 (100)	44	24 (55)	46	26 (57)
p value		0.053		0.064		0.012
2024						
No receptive sharing	16	0 (0)	213	63 (30)	232	65 (28)
Receptive sharing	3	0 (0)	49	27 (55)	54	29 (54)
p value		--		0.001		<0.001
2025						
No receptive sharing	16	0 (0)	158	37 (23)	181	39 (22)
Receptive sharing	2	0 (0)	51	18 (35)	59	22 (37)
p value		--		0.094		0.016

Table 5.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heroin	0	0 (0)	71	41 (58)	71	41 (58)
Methamphetamine	17	0 (0)	168	46 (27)	190	49 (26)
Other opioids	2	0 (0)	120	64 (53)	127	65 (51)
PIEDs	6	0 (0)	27	3 (11)	34	3 (9)
Other drugs	1	0 (0)	15	7 (47)	20	9 (45)
p value		--		<0.001		<0.001
2022						
Heroin	1	0 (0)	57	26 (46)	60	27 (45)
Methamphetamine	8	0 (0)	121	21 (17)	137	24 (18)
Other opioids	2	0 (0)	67	25 (37)	73	26 (36)
PIEDs	8	0 (0)	21	1 (5)	30	1 (3)
Other drugs	1	0 (0)	14	6 (43)	16	6 (38)
p value		--		<0.001		<0.001
2023						
Heroin	1	0 (0)	46	24 (52)	47	24 (51)
Methamphetamine	12	1 (8)	153	48 (31)	166	50 (30)
Other opioids	1	0 (0)	64	36 (56)	65	36 (55)
PIEDs	6	0 (0)	14	0 (0)	20	0 (0)
Other drugs	2	0 (0)	18	10 (56)	21	11 (52)
p value		0.928		<0.001		<0.001
2024						
Heroin	2	0 (0)	51	29 (57)	55	31 (56)
Methamphetamine	12	0 (0)	142	36 (25)	157	38 (24)
Other opioids	0	0 (0)	44	22 (50)	44	22 (50)
PIEDs	7	0 (0)	17	0 (0)	24	0 (0)
Other drugs	1	0 (0)	24	7 (29)	25	7 (28)
p value		--		<0.001		<0.001
2025						
Heroin	1	0 (0)	34	17 (50)	37	18 (49)
Methamphetamine	8	0 (0)	125	23 (18)	136	25 (18)
Other opioids	0	0 (0)	12	6 (50)	14	8 (57)
PIEDs	7	0 (0)	9	0 (0)	18	0 (0)
Other drugs	2	0 (0)	39	13 (33)	43	14 (33)
p value		--		<0.001		<0.001

Table 5.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	15	0 (0)	143	38 (27)	162	40 (25)
Daily or more	5	0 (0)	202	102 (51)	214	105 (49)
Not last month	7	0 (0)	61	22 (36)	73	24 (33)
p value		--		<0.001		<0.001
2022						
Less than daily	13	0 (0)	113	28 (25)	131	30 (23)
Daily or more	4	0 (0)	140	42 (30)	155	45 (29)
Not last month	3	0 (0)	30	9 (30)	34	9 (26)
p value		--		0.631		0.502
2023						
Less than daily	9	0 (0)	121	37 (31)	130	37 (28)
Daily or more	10	1 (10)	144	74 (51)	156	77 (49)
Not last month	3	0 (0)	32	8 (25)	35	8 (23)
p value		1.000		<0.001		<0.001
2024						
Less than daily	9	0 (0)	97	28 (29)	108	29 (27)
Daily or more	10	0 (0)	168	64 (38)	181	67 (37)
Not last month	3	0 (0)	14	2 (14)	17	2 (12)
p value		--		0.089		0.037
2025						
Less than daily	9	0 (0)	62	14 (23)	76	15 (20)
Daily or more	10	0 (0)	150	43 (29)	168	48 (29)
Not last month	0	0 (0)	9	2 (22)	9	2 (22)
p value		--		0.629		0.333

Table 5.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	25	0 (0)	345	124 (36)	383	129 (34)
Imprisonment	0	0 (0)	44	31 (70)	45	32 (71)
p value		--		<0.001		<0.001
2022						
No imprisonment	17	0 (0)	254	70 (28)	285	74 (26)
Imprisonment	3	0 (0)	24	6 (25)	29	7 (24)
p value		--		0.788		0.83
2023						
No imprisonment	19	0 (0)	251	94 (37)	273	96 (35)
Imprisonment	2	1 (50)	33	14 (42)	35	15 (43)
p value		0.095		0.58		0.372
2024						
No imprisonment	21	0 (0)	228	69 (30)	254	73 (29)
Imprisonment	1	0 (0)	38	18 (47)	39	18 (46)
p value		--		0.037		0.029
2025						
No imprisonment	17	0 (0)	177	41 (23)	206	46 (22)
Imprisonment	1	0 (0)	36	15 (42)	38	16 (42)
p value		--		0.022		0.010

Table 5.3.9 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Queensland		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
English speaking	292	118 (40)	143	49 (34)	439	167 (38)	
Non-English speaking	8	2 (25)	1	1 (100)	11	4 (36)	
p value		0.483		0.347		1.000	
2022							
English speaking	216	48 (22)	90	30 (33)	313	79 (25)	
Non-English speaking	11	5 (45)	1	0 (0)	12	5 (42)	
p value		0.076		1.000		0.202	
2023							
English speaking	205	80 (39)	113	41 (36)	323	121 (37)	
Non-English speaking	3	1 (33)	2	0 (0)	5	1 (20)	
p value		1.000		0.537		0.622	
2024							
English speaking	191	66 (35)	104	30 (29)	307	98 (32)	
Non-English speaking	4	2 (50)	1	1 (100)	5	3 (60)	
p value		0.521		0.121		0.183	
2025							
English speaking	144	41 (28)	90	23 (26)	244	65 (27)	
Non-English speaking	10	1 (10)	3	0 (0)	13	1 (8)	
p value		0.205		0.313		0.128	

Table 5.3.10 HCV antibody prevalence by region/country of birth, gender and survey year

Queensland	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Australia	273	108 (40)	127	41 (32)	405	150 (37)
Other Oceania	7	3 (43)	3	3 (100)	11	6 (55)
Asia	2	0 (0)	1	1 (100)	3	1 (33)
UK & Ireland	8	3 (38)	3	1 (33)	11	4 (36)
Other	10	5 (50)	4	2 (50)	14	7 (50)
p value		0.857		0.049		0.637
2022						
Australia	200	44 (22)	83	29 (35)	290	74 (26)
Other Oceania	7	2 (29)	4	1 (25)	11	3 (27)
Asia	0	0 (0)	1	0 (0)	1	0 (0)
UK & Ireland	7	1 (14)	1	0 (0)	8	1 (13)
Other	6	1 (17)	2	0 (0)	8	1 (13)
p value		0.953		0.919		0.894
2023						
Australia	188	74 (39)	111	39 (35)	304	113 (37)
Other Oceania	7	2 (29)	3	2 (67)	10	4 (40)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	6	4 (67)	1	0 (0)	7	4 (57)
Other	4	0 (0)	0	0 (0)	4	0 (0)
p value		0.248		0.545		0.431
2024						
Australia	169	63 (37)	94	27 (29)	275	92 (33)
Other Oceania	9	2 (22)	2	1 (50)	11	3 (27)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	7	0 (0)	3	0 (0)	10	0 (0)
Other	6	2 (33)	2	1 (50)	8	3 (38)
p value		0.253		0.553		0.227
2025						
Australia	135	38 (28)	86	23 (27)	230	62 (27)
Other Oceania	4	1 (25)	0	0 (0)	5	1 (20)
Asia	1	0 (0)	2	0 (0)	3	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	9	1 (11)	5	0 (0)	14	1 (7)
p value		0.654		0.288		0.277

HCV RNA prevalence

Table 5.4.1 HCV RNA prevalence by gender and survey year

Queensland	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	291	32 (11)	143	15 (10)	440	48 (11)
2022	223	22 (10)	91	9 (10)	321	32 (10)
2023	208	24 (12)	115	11 (10)	328	35 (11)
2024	192	13 (7)	104	8 (8)	307	21 (7)
2025	153	10 (7)	91	6 (7)	254	16 (6)
X ² p trend		0.075		0.259		0.018

Totals include respondents where gender was reported as other or not reported

Table 5.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Queensland	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	256	30 (12)	108	11 (10)	366	42 (11)
Bisexual	17	2 (12)	24	1 (4)	41	3 (7)
Homosexual	15	0 (0)	6	2 (33)	24	2 (8)
p value		0.372		0.106		0.661
2022						
Heterosexual	187	19 (10)	59	7 (12)	247	27 (11)
Bisexual	13	2 (15)	19	1 (5)	34	3 (9)
Homosexual	15	1 (7)	5	0 (0)	20	1 (5)
p value		0.863		0.628		0.833
2023						
Heterosexual	170	22 (13)	82	10 (12)	253	32 (13)
Bisexual	18	1 (6)	26	1 (4)	45	2 (4)
Homosexual	15	1 (7)	4	0 (0)	19	1 (5)
p value		0.862		0.656		0.600
2024						
Heterosexual	162	9 (6)	68	4 (6)	232	13 (6)
Bisexual	15	1 (7)	24	3 (13)	42	4 (10)
Homosexual	9	2 (22)	5	0 (0)	18	2 (11)
p value		0.118		0.234		0.440
2025						
Heterosexual	128	8 (6)	55	4 (7)	186	12 (6)
Bisexual	13	1 (8)	30	2 (7)	47	3 (6)
Homosexual	9	0 (0)	1	0 (0)	11	0 (0)
p value		0.940		0.989		0.942

Table 5.4.3 HCV RNA prevalence by age group, gender and survey year

Queensland	Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<25 years	14	0 (0)	5	0 (0)	20	0 (0)
25-34 years	47	9 (19)	29	3 (10)	77	12 (16)
35-44 years	102	16 (16)	49	6 (12)	155	23 (15)
45+ years	128	7 (5)	60	6 (10)	188	13 (7)
p value		0.011		0.858		0.021
2022						
<25 years	9	1 (11)	3	1 (33)	15	2 (13)
25-34 years	36	3 (8)	17	2 (12)	55	5 (9)
35-44 years	70	9 (13)	39	3 (8)	110	13 (12)
45+ years	106	9 (8)	31	3 (10)	138	12 (9)
p value		0.716		0.470		0.788
2023						
<25 years	9	1 (11)	5	1 (20)	14	2 (14)
25-34 years	29	3 (10)	13	0 (0)	44	3 (7)
35-44 years	71	6 (8)	44	3 (7)	116	9 (8)
45+ years	99	14 (14)	53	7 (13)	154	21 (14)
p value		0.718		0.269		0.326
2024						
<25 years	7	0 (0)	8	1 (13)	16	1 (6)
25-34 years	35	1 (3)	21	2 (10)	57	3 (5)
35-44 years	58	5 (9)	39	4 (10)	103	9 (9)
45+ years	92	7 (8)	36	1 (3)	131	8 (6)
p value		0.621		0.584		0.82
2025						
<25 years	5	0 (0)	9	0 (0)	16	0 (0)
25-34 years	24	3 (13)	14	2 (14)	40	5 (13)
35-44 years	45	4 (9)	27	1 (4)	77	5 (6)
45+ years	79	3 (4)	41	3 (7)	121	6 (5)
p value		0.373		0.497		0.256

Table 5.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	20	0 (0)	6	0 (0)	27	0 (0)
3 to 10 years	47	5 (11)	19	0 (0)	66	5 (8)
11+ years	215	27 (13)	111	15 (14)	331	43 (13)
p value		0.235		0.150		0.071
2022						
<3 years	13	0 (0)	5	0 (0)	21	0 (0)
3 to 10 years	29	5 (17)	21	3 (14)	51	8 (16)
11+ years	167	16 (10)	62	6 (10)	232	23 (10)
p value		0.255		0.819		0.125
2023						
<3 years	16	0 (0)	6	0 (0)	22	0 (0)
3 to 10 years	38	1 (3)	18	2 (11)	58	3 (5)
11+ years	152	22 (14)	90	9 (10)	245	31 (13)
p value		0.041		1.000		0.058
2024						
<3 years	12	0 (0)	9	0 (0)	22	0 (0)
3 to 10 years	29	2 (7)	30	1 (3)	61	3 (5)
11+ years	148	11 (7)	64	7 (11)	219	18 (8)
p value		0.620		0.290		0.276
2025						
<3 years	12	0 (0)	7	1 (14)	20	1 (5)
3 to 10 years	23	1 (4)	22	0 (0)	48	1 (2)
11+ years	109	8 (7)	57	5 (9)	172	13 (8)
p value		0.559		0.285		0.372

Table 5.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Queensland Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	214	24 (11)	94	10 (11)	312	35 (11)
Receptive sharing	30	6 (20)	19	1 (5)	49	7 (14)
p value		0.170		0.471		0.534
2022						
No receptive sharing	177	16 (9)	59	5 (8)	242	22 (9)
Receptive sharing	25	5 (20)	16	2 (13)	41	7 (17)
p value		0.093		0.637		0.119
2023						
No receptive sharing	148	20 (14)	86	11 (13)	237	31 (13)
Receptive sharing	39	4 (10)	6	0 (0)	46	4 (9)
p value		0.789		1.000		0.624
2024						
No receptive sharing	142	11 (8)	77	4 (5)	229	15 (7)
Receptive sharing	33	1 (3)	19	3 (16)	53	4 (8)
p value		0.334		0.112		0.794
2025						
No receptive sharing	109	6 (6)	64	5 (8)	178	11 (6)
Receptive sharing	37	4 (11)	19	1 (5)	58	5 (9)
p value		0.270		0.706		0.521

Table 5.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Queensland	Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heroin	46	4 (9)	22	2 (9)	69	7 (10)
Methamphetamine	103	10 (10)	80	6 (8)	186	16 (9)
Other opioids	86	13 (15)	33	7 (21)	121	20 (17)
PIEDs	34	2 (6)	0	0 (0)	34	2 (6)
Other drugs	15	2 (13)	5	0 (0)	20	2 (10)
p value		0.571		0.149		0.208
2022						
Heroin	38	4 (11)	20	3 (15)	58	7 (12)
Methamphetamine	86	10 (12)	44	3 (7)	137	14 (10)
Other opioids	57	7 (12)	15	3 (20)	72	10 (14)
PIEDs	30	0 (0)	0	0 (0)	30	0 (0)
Other drugs	11	1 (9)	5	0 (0)	16	1 (6)
p value		0.410		0.386		0.291
2023						
Heroin	25	2 (8)	22	2 (9)	47	4 (9)
Methamphetamine	103	12 (12)	60	6 (10)	166	18 (11)
Other opioids	44	8 (18)	20	1 (5)	65	9 (14)
PIEDs	18	0 (0)	1	0 (0)	20	0 (0)
Other drugs	13	2 (15)	8	2 (25)	21	4 (19)
p value		0.327		0.608		0.318
2024						
Heroin	36	3 (8)	15	3 (20)	55	6 (11)
Methamphetamine	84	4 (5)	67	3 (4)	155	7 (5)
Other opioids	31	5 (16)	11	2 (18)	43	7 (16)
PIEDs	24	0 (0)	0	0 (0)	24	0 (0)
Other drugs	11	0 (0)	10	0 (0)	23	0 (0)
p value		0.098		0.084		0.014
2025						
Heroin	25	3 (12)	10	0 (0)	36	3 (8)
Methamphetamine	69	5 (7)	59	5 (8)	132	10 (8)
Other opioids	9	1 (11)	5	0 (0)	14	1 (7)
PIEDs	17	0 (0)	1	0 (0)	18	0 (0)
Other drugs	29	1 (3)	11	1 (9)	43	2 (5)
p value		0.534		0.830		0.749

Table 5.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Queensland	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	115	9 (8)	40	2 (5)	156	11 (7)
Daily or more	129	21 (16)	73	9 (12)	205	31 (15)
Not last month	42	1 (2)	29	4 (14)	73	5 (7)
p value		0.017		0.392		0.025
2022						
Less than daily	100	6 (6)	25	1 (4)	131	8 (6)
Daily or more	102	15 (15)	50	6 (12)	152	21 (14)
Not last month	21	1 (5)	12	2 (17)	34	3 (9)
p value		0.103		0.316		0.100
2023						
Less than daily	83	8 (10)	45	4 (9)	130	12 (9)
Daily or more	107	16 (15)	47	7 (15)	156	23 (15)
Not last month	15	0 (0)	19	0 (0)	35	0 (0)
p value		0.232		0.214		0.018
2024						
Less than daily	69	5 (7)	30	2 (7)	107	7 (7)
Daily or more	108	7 (6)	67	5 (7)	178	12 (7)
Not last month	10	0 (0)	6	1 (17)	16	1 (6)
p value		0.682		0.697		0.996
2025						
Less than daily	50	2 (4)	23	4 (17)	75	6 (8)
Daily or more	98	8 (8)	61	2 (3)	165	10 (6)
Not last month	3	0 (0)	4	0 (0)	8	0 (0)
p value		0.564		0.063		0.640

Table 5.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Queensland	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	243	21 (9)	124	13 (10)	372	34 (9)
Imprisonment	34	10 (29)	9	2 (22)	43	12 (28)
p value		<0.001		0.282		<0.001
2022						
No imprisonment	194	16 (8)	82	6 (7)	282	23 (8)
Imprisonment	22	5 (23)	7	2 (29)	29	7 (24)
p value		0.030		0.119		0.006
2023						
No imprisonment	168	18 (11)	100	9 (9)	273	27 (10)
Imprisonment	28	3 (11)	7	1 (14)	35	4 (11)
p value		1.000		0.507		0.766
2024						
No imprisonment	151	11 (7)	88	7 (8)	250	18 (7)
Imprisonment	26	2 (8)	13	1 (8)	39	3 (8)
p value		0.941		0.974		0.912
2025						
No imprisonment	123	7 (6)	73	5 (7)	203	12 (6)
Imprisonment	23	3 (13)	11	0 (0)	36	3 (8)
p value		0.200		0.371		0.581

Table 5.4.9 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Queensland	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
English speaking	279	31 (11)	142	15 (11)	425	46 (11)
Non-English speaking	8	1 (13)	1	0 (0)	11	2 (18)
p value		0.902		0.731		0.441
2022						
English speaking	212	19 (9)	90	9 (10)	309	29 (9)
Non-English speaking	11	3 (27)	1	0 (0)	12	3 (25)
p value		0.082		1.000		0.106
2023						
English speaking	205	24 (12)	113	11 (10)	323	35 (11)
Non-English speaking	3	0 (0)	2	0 (0)	5	0 (0)
p value		1.000		1.000		1.000
2024						
English speaking	188	13 (7)	103	8 (8)	302	21 (7)
Non-English speaking	4	0 (0)	1	0 (0)	5	0 (0)
p value		0.586		0.772		0.541
2025						
English speaking	141	10 (7)	88	6 (7)	239	16 (7)
Non-English speaking	10	0 (0)	3	0 (0)	13	0 (0)
p value		0.383		0.640		0.335

Table 5.4.10 HCV RNA prevalence by region/country of birth, gender and survey year

Queensland		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Australia	261	27 (10)	126	13 (10)	392	41 (10)	
Other Oceania	6	1 (17)	3	1 (33)	10	2 (20)	
Asia	2	0 (0)	1	0 (0)	3	0 (0)	
UK & Ireland	8	1 (13)	3	0 (0)	11	1 (9)	
Other	10	3 (30)	4	1 (25)	14	4 (29)	
p value		0.379		0.576		0.224	
2022							
Australia	197	16 (8)	83	9 (11)	287	26 (9)	
Other Oceania	7	1 (14)	4	0 (0)	11	1 (9)	
Asia	0	0 (0)	1	0 (0)	1	0 (0)	
UK & Ireland	7	0 (0)	1	0 (0)	8	0 (0)	
Other	6	1 (17)	2	0 (0)	8	1 (13)	
p value		0.437		1.000		0.858	
2023							
Australia	188	23 (12)	111	11 (10)	304	34 (11)	
Other Oceania	7	0 (0)	3	0 (0)	10	0 (0)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	6	0 (0)	1	0 (0)	7	0 (0)	
Other	4	0 (0)	0	0 (0)	4	0 (0)	
p value		1.000		1.000		0.811	
2024							
Australia	166	11 (7)	93	8 (9)	270	19 (7)	
Other Oceania	9	1 (11)	2	0 (0)	11	1 (9)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	7	0 (0)	3	0 (0)	10	0 (0)	
Other	6	1 (17)	2	0 (0)	8	1 (13)	
p value		0.780		0.884		0.866	
2025							
Australia	132	10 (8)	84	6 (7)	225	16 (7)	
Other Oceania	4	0 (0)	0	0 (0)	5	0 (0)	
Asia	1	0 (0)	2	0 (0)	3	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	9	0 (0)	5	0 (0)	14	0 (0)	
p value		0.768		0.765		0.643	

South Australia

Table 6.1.1 Number (%) of respondents by demographic characteristics and survey year

South Australia	2021*	2022	2023	2024	2025
Number of sites	8	8	8	8	8
N° surveyed	N=210	N=279	N=283	N=232	N=218
Response rate (%)	50%	49%	61%	53%	55%
Gender (%)					
Male	133 (63)	168 (60)	173 (61)	127 (55)	133 (61)
Female	70 (33)	102 (37)	102 (36)	99 (43)	81 (37)
Other	7 (3)	9 (3)	8 (3)	5 (2)	1 (<1)
Not reported	0 (0)	0 (0)	0 (0)	1 (<1)	3 (1)
Age (years)					
Median age	45	48	47	49	48
Age range	19-78	22-68	18-71	25-69	22-70
<25 years	3 (1)	4 (1)	10 (4)	0 (0)	1 (<1)
25+ years	206 (98)	269 (96)	270 (95)	232 (100)	217 (100)
Not reported	1 (<1)	6 (2)	3 (1)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	166 (79)	219 (78)	226 (80)	183 (79)	186 (85)
Bisexual	23 (11)	28 (10)	27 (10)	28 (12)	24 (11)
Gay/Lesbian	10 (5)	11 (4)	10 (4)	8 (3)	4 (2)
Other	9 (4)	17 (6)	18 (6)	11 (5)	0 (0)
Not reported	2 (1)	4 (1)	2 (1)	2 (1)	4 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	138 (66)	200 (72)	189 (67)	157 (68)	150 (69)
Yes	55 (26)	75 (27)	87 (31)	71 (31)	65 (30)
Not reported	17 (8)	4 (1)	7 (2)	4 (2)	3 (1)
Region/country of birth (%)					
Australia	181 (86)	238 (85)	256 (90)	213 (92)	194 (89)
Other Oceania	3 (1)	4 (1)	9 (3)	1 (<1)	4 (2)
Asia	3 (1)	10 (4)	2 (1)	5 (2)	10 (5)
UK & Ireland	12 (6)	13 (5)	9 (3)	7 (3)	6 (3)
Other	5 (2)	6 (2)	4 (1)	2 (1)	3 (1)
Not reported	6 (3)	8 (3)	3 (1)	4 (2)	1 (<1)
Main language spoken at home by parents (%)					
English	200 (95)	259 (93)	269 (95)	218 (94)	199 (91)
Non-English	7 (3)	16 (6)	12 (4)	11 (5)	17 (8)
Not reported	3 (1)	4 (1)	2 (1)	3 (1)	2 (1)
Age at first injection and time since first injection (years)					
Median age at first injection	19	20	19	20	20
Age range at first injection	12-46	10-54	11-55	10-60	11-66
N° not reported	10	15	14	8	9
Median yrs since first injection	25	27	24	26	25
Range yrs since first injection	<1-62	<1-51	<1-52	1-52	<1-52
<3 years since first injection	3 (1)	11 (4)	11 (4)	5 (2)	11 (5)
3+ years since first injection	196 (93)	252 (90)	258 (91)	218 (94)	198 (91)
Not reported	11 (5)	16 (6)	14 (5)	9 (4)	9 (4)

* Implementation of the 2021 ANSPS was impacted by the COVID-19 pandemic

Table 6.1.2 Number (%) of respondents by last drug injected, frequency of injecting, overdose, imprisonment, injection in prison and survey year

South Australia	2021	2022	2023	2024	2025
N° surveyed	N=210	N=279	N=283	N=232	N=218
Drug last injected (%)					
Cocaine	2 (1)	0 (0)	4 (1)	2 (1)	1 (<1)
Methamphetamine	115 (55)	134 (48)	169 (60)	144 (62)	129 (59)
Heroin	57 (27)	83 (30)	62 (22)	62 (27)	53 (24)
Pharm. opioids	5 (2)	8 (3)	8 (3)	4 (2)	1 (<1)
Methadone	9 (4)	7 (3)	13 (5)	5 (2)	5 (2)
Buprenorphine	1 (<1)	6 (2)	0 (0)	0 (0)	0 (0)
Buprenorphine/naloxone	0 (0)	4 (1)	4 (1)	0 (0)	1 (<1)
PIEDs	5 (2)	2 (1)	8 (3)	1 (0)	3 (1)
More than one	16 (8)	30 (11)	14 (5)	12 (5)	21 (10)
Other	0 (0)	3 (1)	1 (<1)	0 (0)	0 (0)
Not reported	0 (0)	2 (1)	0 (0)	2 (1)	4 (2)
Ever injected opioids (%)					
No	84 (40)	71 (25)	88 (31)	83 (36)	68 (31)
Yes	126 (60)	205 (73)	195 (69)	145 (63)	148 (68)
Not reported	0 (0)	3 (1)	0 (0)	4 (2)	2 (1)
Frequency of injection last month (%)					
Not last month	38 (18)	19 (7)	42 (15)	16 (7)	20 (9)
Less than weekly	43 (20)	29 (10)	46 (16)	40 (17)	25 (11)
Weekly not daily	40 (19)	68 (24)	52 (18)	42 (18)	51 (23)
Daily or more	83 (40)	157 (56)	140 (49)	129 (56)	119 (55)
Not reported	6 (3)	6 (2)	3 (1)	5 (2)	3 (1)
Present when someone injected for the first time in the last 12 months (%)					
No	175 (83)	229 (82)	228 (81)	183 (79)	181 (83)
Yes	26 (12)	44 (16)	44 (16)	38 (16)	30 (14)
Not reported	9 (4)	6 (2)	11 (4)	11 (5)	7 (3)
Overdosed in last 12 months (%)					
No	185 (88)	254 (91)	253 (89)	198 (85)	191 (88)
Yes	15 (7)	20 (7)	20 (7)	26 (11)	20 (9)
Not reported	10 (5)	5 (2)	10 (4)	8 (3)	7 (3)
Imprisonment last year (%)					
No	176 (84)	234 (84)	237 (84)	198 (85)	176 (81)
Yes	20 (10)	37 (13)	26 (9)	21 (9)	26 (12)
Not reported	14 (7)	8 (3)	20 (7)	13 (6)	16 (7)
Injected while in prison last year					
N° in prison last year	N=20	N=37	N=26	N=21	N=26
No	18 (90)	27 (73)	21 (81)	14 (67)	16 (62)
Yes	2 (10)	10 (27)	5 (19)	5 (24)	10 (38)
Not reported	0 (0)	0 (0)	0 (0)	2 (10)	0 (0)

Table 6.1.3 Number (%) of respondents by injecting behaviour in the last month and survey year

South Australia	2021	2022	2023	2024	2025
N° injected last month	N=166	N=254	N=238	N=211	N=195
Places injected last month (%)					
All private	86 (52)	125 (49)	123 (52)	124 (59)	99 (51)
Any public	80 (48)	129 (51)	113 (47)	87 (41)	95 (49)
Not reported	0 (0)	0 (0)	2 (1)	0 (0)	1 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	135 (81)	202 (80)	191 (80)	170 (81)	157 (81)
Most of the time	23 (14)	41 (16)	33 (14)	32 (15)	34 (17)
Half of the time	2 (1)	2 (1)	6 (3)	1 (<1)	0 (0)
Some of the time	3 (2)	3 (1)	1 (<1)	3 (1)	0 (0)
Not last month	1 (1)	0 (0)	3 (1)	0 (0)	4 (2)
Not reported	2 (1)	6 (2)	4 (2)	5 (2)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	141 (85)	210 (83)	198 (83)	182 (86)	171 (88)
Once	7 (4)	13 (5)	10 (4)	12 (6)	12 (6)
Twice	6 (4)	16 (6)	14 (6)	5 (2)	2 (1)
3-5 times	5 (3)	6 (2)	7 (3)	5 (2)	7 (4)
>5 times	4 (2)	7 (3)	7 (3)	6 (3)	3 (2)
Not reported	3 (2)	2 (1)	2 (1)	1 (<1)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	141 (85)	210 (83)	198 (83)	182 (86)	171 (88)
One	10 (6)	19 (7)	17 (7)	13 (6)	7 (4)
Two	3 (2)	8 (3)	5 (2)	4 (2)	2 (1)
Three to five	1 (1)	1 (<1)	1 (<1)	1 (<1)	6 (3)
More than five	1 (1)	3 (1)	2 (1)	3 (1)	2 (1)
Don't know	5 (3)	9 (4)	12 (5)	4 (2)	5 (3)
Not reported	5 (3)	4 (2)	3 (1)	4 (2)	2 (1)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	9 (5)	17 (7)	12 (5)	10 (5)	10 (5)
Casual sex partner	2 (1)	2 (1)	3 (1)	1 (<1)	4 (2)
Close friend	9 (5)	15 (6)	12 (5)	13 (6)	7 (4)
Acquaintance	1 (1)	7 (3)	4 (2)	2 (1)	4 (2)
Other	1 (1)	2 (1)	0 (0)	1 (<1)	2 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	29 (17)	43 (17)	35 (15)	27 (13)	25 (13)
Water	36 (22)	56 (22)	49 (21)	33 (16)	48 (25)
Filter	11 (7)	21 (8)	20 (8)	10 (5)	12 (6)
Drug mix	11 (7)	18 (7)	24 (10)	12 (6)	19 (10)
None	107 (64)	167 (66)	163 (68)	160 (76)	134 (69)
Injected by someone after that person injected themselves or others last month (%)					
No	138 (83)	196 (77)	198 (83)	183 (87)	153 (78)
Yes	25 (15)	55 (22)	37 (16)	25 (12)	42 (22)
Not reported	3 (2)	3 (1)	3 (1)	3 (1)	0 (0)
Source of needle acquisition (%)					
Needle Syringe Program	142 (86)	228 (90)	198 (83)	190 (90)	173 (89)
Chemist/Pharmacy	25 (15)	33 (13)	28 (12)	21 (10)	25 (13)
Personal sources	18 (11)	40 (16)	23 (10)	27 (13)	23 (12)
Dispensing/Vending Machine	36 (22)	35 (14)	31 (13)	37 (18)	62 (32)
Other sources	3 (2)	2 (1)	2 (1)	2 (1)	0 (0)

Table 6.1.4 Number (%) of respondents by treatment for drug use and survey year

South Australia	2021	2022	2023	2024	2025
N° surveyed	N=210	N=279	N=283	N=232	N=218
Ever any treatment/therapy for drug use (%)					
No	87 (41)	92 (33)	106 (37)	81 (35)	74 (34)
Yes	123 (59)	186 (67)	176 (62)	151 (65)	144 (66)
Not reported	0 (0)	1 (<1)	1 (<1)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	34 (16)	53 (19)	37 (13)	36 (16)	37 (17)
Previously	44 (21)	66 (24)	50 (18)	56 (24)	36 (17)
Never	120 (57)	149 (53)	183 (65)	132 (57)	139 (64)
Not reported	12 (6)	11 (4)	13 (5)	8 (3)	6 (3)
History of buprenorphine (Subutex®) treatment (%)					
Currently	8 (4)	17 (6)	18 (6)	14 (6)	6 (3)
Previously	56 (27)	76 (27)	66 (23)	54 (23)	61 (28)
Never	138 (66)	175 (63)	188 (66)	156 (67)	146 (67)
Not reported	8 (4)	11 (4)	11 (4)	8 (3)	5 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	24 (11)	18 (6)	18 (6)	19 (8)	4 (2)
Previously	44 (21)	75 (27)	51 (18)	48 (21)	56 (26)
Never	142 (68)	185 (66)	210 (74)	162 (70)	154 (71)
Not reported	0 (0)	1 (<1)	4 (1)	3 (1)	4 (2)
History of depot buprenorphine treatment (%)					
Currently	4 (2)	16 (6)	13 (5)	13 (6)	5 (2)
Previously	18 (9)	32 (11)	14 (5)	16 (7)	28 (13)
Never	180 (86)	223 (80)	243 (86)	194 (84)	178 (82)
Not reported	8 (4)	8 (3)	13 (5)	9 (4)	7 (3)

Table 6.1.5 Number (%) of respondents by sexual behaviour in the month prior to survey and survey year

South Australia	2021	2022	2023	2024	2025
N° surveyed	N=210	N=279	N=283	N=232	N=218
Sex with a regular partner last month (%)					
No	116 (55)	148 (53)	161 (57)	122 (53)	118 (54)
Yes	83 (40)	120 (43)	113 (40)	102 (44)	89 (41)
Not reported	11 (5)	11 (4)	9 (3)	8 (3)	11 (5)
Condom used with regular partner last month (%)					
N° surveyed	N=83	N=120	N=113	N=102	N=89
Never	58 (70)	103 (86)	84 (74)	76 (75)	70 (79)
Sometimes	17 (20)	9 (8)	10 (9)	10 (10)	11 (12)
Every time	5 (6)	4 (3)	7 (6)	8 (8)	5 (6)
Not reported	3 (4)	4 (3)	12 (11)	8 (8)	3 (3)
Sex with other partner(s) last month (%)					
No	165 (79)	231 (83)	233 (82)	194 (84)	179 (82)
Yes	33 (16)	35 (13)	32 (11)	23 (10)	27 (12)
Not reported	12 (6)	13 (5)	18 (6)	15 (6)	12 (6)
Condom used with other partner(s) last month (%)					
N° surveyed	N=33	N=35	N=32	N=23	N=27
Never	17 (52)	23 (66)	18 (56)	6 (26)	13 (48)
Sometimes	5 (15)	6 (17)	9 (28)	12 (52)	6 (22)
Every time	9 (27)	5 (14)	4 (13)	4 (17)	6 (22)
Not reported	2 (6)	1 (3)	1 (3)	1 (4)	2 (7)
Sex work last month (%)					
No	186 (89)	244 (87)	253 (89)	204 (88)	186 (85)
Yes	11 (5)	19 (7)	14 (5)	15 (6)	15 (7)
Not reported	13 (6)	16 (6)	16 (6)	13 (6)	17 (8)
Condom used at last sex work (%)					
Yes	8 (73)	14 (74)	11 (79)	8 (53)	11 (73)

Table 6.1.6 Number (%) of respondents by testing for HIV and HCV, HCV treatment by survey year

South Australia	2021	2022	2023	2024	2025
N° surveyed	N=210	N=279	N=283	N=232	N=218
Previous HIV test (%)					
Yes, ever	136 (65)	186 (67)	191 (67)	167 (72)	161 (74)
Yes, last year	59 (28)	94 (34)	78 (28)	58 (25)	69 (32)
>1 year ago	77 (37)	92 (33)	113 (40)	109 (47)	92 (42)
Never tested	63 (30)	79 (28)	80 (28)	55 (24)	46 (21)
Not reported	11 (5)	14 (5)	12 (4)	10 (4)	11 (5)
Previous HCV test (%)					
Yes, ever	139 (66)	203 (73)	215 (76)	173 (75)	166 (76)
Yes, last year	66 (31)	123 (44)	97 (34)	75 (32)	93 (43)
>1 year ago	73 (35)	80 (29)	118 (42)	98 (42)	73 (33)
Never tested	51 (24)	52 (19)	46 (16)	37 (16)	37 (17)
Not reported	20 (10)	24 (9)	22 (8)	22 (9)	15 (7)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=23	N=54	N=38	N=32	N=33
Antiviral treatment	18 (78)	40 (74)	31 (82)	27 (84)	27 (82)
No antiviral treatment	5 (22)	14 (26)	6 (16)	5 (16)	5 (15)
Not reported	0 (0)	0 (0)	1 (3)	0 (0)	1 (3)
Treatment for HCV in past 12 months (%)^{**}					
N° self-reported HCV diagnosis	N=11	N=21	N=13	N=9	N=10
Antiviral treatment	3 (27)	5 (24)	6 (46)	4 (44)	4 (40)
No antiviral treatment	8 (73)	16 (76)	6 (46)	5 (56)	5 (50)
Not reported	0 (0)	0 (0)	1 (8)	0 (0)	1 (10)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance^{*} excludes people who reported treatment induced clearance more than 12 months previously

HIV antibody prevalence

Table 6.2.1 HIV antibody prevalence by gender and survey year

South Australia	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021	116	0 (0.0)	67	0 (0.0)	188	0 (0.0)
2022	163	1 (0.6)	102	0 (0.0)	273	1 (0.4)
2023	127	0 (0.0)	81	0 (0.0)	215	0 (0.0)
2024	116	1 (0.9)	98	1 (1.0)	220	2 (0.9)
2025	130	1 (0.8)	80	0 (0.0)	214	1 (0.5)
X ² p trend		0.385		0.484		0.274

HCV antibody prevalence

Table 6.3.1 HCV antibody prevalence by gender and survey year

South Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	116	36 (31)	67	20 (30)	188	57 (30)
2022	162	54 (33)	102	36 (35)	272	93 (34)
2023*	127	42 (33)	81	30 (37)	215	75 (35)
2024	116	44 (38)	98	28 (29)	220	74 (34)
2025	130	27 (21)	80	27 (34)	214	58 (27)
X ² p trend^		0.031		0.654		0.084

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

^ X² p trend calculated on years 2023-2025 only

Table 6.3.2 HCV antibody prevalence by sexual identity, gender and survey year

South Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	100	31 (31)	49	13 (27)	149	44 (30)
Bisexual	7	4 (57)	14	4 (29)	22	8 (36)
Homosexual	7	1 (14)	0	0 (0)	8	1 (13)
p value		0.361		0.749		0.828
2022						
Heterosexual	135	50 (37)	75	26 (35)	213	78 (37)
Bisexual	11	4 (36)	16	7 (44)	28	11 (39)
Homosexual	7	0 (0)	4	1 (25)	11	1 (9)
p value		0.158		0.780		0.287
2023						
Heterosexual	110	41 (37)	55	17 (31)	165	58 (35)
Bisexual	5	0 (0)	17	8 (47)	24	9 (38)
Homosexual	5	0 (0)	3	1 (33)	9	1 (11)
p value		0.123		0.193		0.650
2024						
Heterosexual	101	41 (41)	72	20 (28)	173	61 (35)
Bisexual	7	2 (29)	19	6 (32)	27	9 (33)
Homosexual	3	0 (0)	3	2 (67)	8	2 (25)
p value		0.496		0.573		0.841
2025						
Heterosexual	121	27 (22)	61	20 (33)	183	48 (26)
Bisexual	7	0 (0)	16	6 (38)	23	6 (26)
Homosexual	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.282		0.735		0.015

Table 6.3.3 HCV antibody prevalence by age group, gender and survey year

South Australia	Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<25 years	3	1 (33)	0	0 (0)	3	1 (33)
25-34 years	15	2 (13)	9	2 (22)	24	4 (17)
35-44 years	37	16 (43)	28	9 (32)	67	25 (37)
45+ years	61	17 (28)	30	9 (30)	94	27 (29)
p value		0.142		0.936		0.232
2022						
<25 years	4	0 (0)	0	0 (0)	4	0 (0)
25-34 years	14	1 (7)	10	2 (20)	24	3 (13)
35-44 years	42	11 (26)	27	8 (30)	69	19 (28)
45+ years	98	41 (42)	64	25 (39)	169	68 (40)
p value		0.014		0.409		0.008
2023						
<25 years	4	0 (0)	4	1 (25)	8	1 (13)
25-34 years	10	1 (10)	3	0 (0)	16	2 (13)
35-44 years	37	7 (19)	28	10 (36)	66	17 (26)
45+ years	75	33 (44)	44	17 (39)	122	52 (43)
p value		0.008		0.742		0.011
2024						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	6	0 (0)	15	0 (0)	21	0 (0)
35-44 years	26	7 (27)	30	11 (37)	58	18 (31)
45+ years	84	37 (44)	53	17 (32)	141	56 (40)
p value		0.042		0.026		0.001
2025						
<25 years	0	0 (0)	1	1 (100)	1	1 (100)
25-34 years	13	1 (8)	8	1 (13)	21	2 (10)
35-44 years	33	1 (3)	29	6 (21)	64	9 (14)
45+ years	84	25 (30)	42	19 (45)	128	46 (36)
p value		0.003		0.041		0.001

Table 6.3.4 HCV antibody prevalence by years since first injection, gender and survey year

South Australia		Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
<3 years	1	1 (100)	1	0 (0)	2	1 (50)	
3 to 10 years	10	3 (30)	9	0 (0)	19	3 (16)	
11+ years	98	28 (29)	54	19 (35)	157	48 (31)	
p value		0.405		0.064		0.256	
2022							
<3 years	9	0 (0)	2	1 (50)	11	1 (9)	
3 to 10 years	14	2 (14)	10	1 (10)	25	4 (16)	
11+ years	128	49 (38)	86	33 (38)	220	83 (38)	
p value		0.013		0.139		0.016	
2023							
<3 years	4	0 (0)	4	1 (25)	8	1 (13)	
3 to 10 years	11	0 (0)	12	0 (0)	25	0 (0)	
11+ years	107	41 (38)	60	27 (45)	172	71 (41)	
p value		0.006		0.004		<0.001	
2024							
<3 years	4	0 (0)	0	0 (0)	5	0 (0)	
3 to 10 years	11	0 (0)	12	1 (8)	23	1 (4)	
11+ years	98	42 (43)	82	27 (33)	184	71 (39)	
p value		0.006		0.082		0.001	
2025							
<3 years	8	0 (0)	3	0 (0)	11	0 (0)	
3 to 10 years	13	2 (15)	11	2 (18)	24	4 (17)	
11+ years	103	23 (22)	64	25 (39)	170	51 (30)	
p value		0.286		0.177		0.046	

Table 6.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

South Australia		<3 years		3+ years		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
No receptive sharing	2	1 (50)	118	40 (34)	127	44 (35)	
Receptive sharing	0	0 (0)	17	4 (24)	19	5 (26)	
p value		--		0.581		0.473	
2022							
No receptive sharing	9	1 (11)	190	65 (34)	205	69 (34)	
Receptive sharing	1	0 (0)	36	14 (39)	41	14 (34)	
p value		1.000		0.589		0.952	
2023							
No receptive sharing	4	0 (0)	138	52 (38)	146	54 (37)	
Receptive sharing	3	1 (33)	25	12 (48)	29	13 (45)	
p value		0.429		0.331		0.428	
2024							
No receptive sharing	3	0 (0)	165	60 (36)	172	60 (35)	
Receptive sharing	1	0 (0)	24	9 (38)	27	10 (37)	
p value		--		0.914		0.828	
2025							
No receptive sharing	10	0 (0)	152	50 (33)	167	51 (31)	
Receptive sharing	1	0 (0)	21	3 (14)	24	4 (17)	
p value		--		0.083		0.161	

Table 6.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

South Australia	<3 years		3+ years		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heroin	0	0 (0)	47	20 (43)	51	22 (43)
Methamphetamine	2	1 (50)	92	20 (22)	99	23 (23)
Other opioids	0	0 (0)	13	4 (31)	14	5 (36)
Other drugs	0	0 (0)	19	5 (26)	19	5 (26)
p value		--		0.083		0.083
2022						
Heroin	0	0 (0)	75	37 (49)	79	40 (51)
Methamphetamine	7	1 (14)	120	31 (26)	131	32 (24)
Other opioids	1	0 (0)	19	9 (47)	22	9 (41)
Other drugs	2	0 (0)	27	8 (30)	32	8 (25)
p value		0.788		0.005		0.001
2023						
Heroin	0	0 (0)	38	20 (53)	41	23 (56)
Methamphetamine	7	1 (14)	123	37 (30)	133	38 (29)
Other opioids	0	0 (0)	18	8 (44)	19	8 (42)
Other drugs	1	0 (0)	15	5 (33)	19	5 (26)
p value		0.686		0.071		0.009
2024						
Heroin	0	0 (0)	60	36 (60)	60	36 (60)
Methamphetamine	3	0 (0)	120	29 (24)	129	30 (23)
Other opioids	0	0 (0)	9	2 (22)	9	2 (22)
Other drugs	2	0 (0)	13	5 (38)	15	5 (33)
p value		--		<0.001		<0.001
2025						
Heroin	0	0 (0)	50	25 (50)	52	25 (48)
Methamphetamine	9	0 (0)	110	25 (23)	123	27 (22)
Other opioids	0	0 (0)	7	3 (43)	7	3 (43)
Other drugs	2	0 (0)	20	1 (5)	25	2 (8)
p value		--		<0.001		<0.001

Table 6.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

South Australia	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	1	0 (0)	72	17 (24)	75	18 (24)
Daily or more	1	1 (100)	66	29 (44)	74	33 (45)
Not last month	0	0 (0)	33	3 (9)	34	4 (12)
p value		1.000		0.001		0.001
2022						
Less than daily	8	1 (13)	84	27 (32)	94	28 (30)
Daily or more	2	0 (0)	143	53 (37)	154	56 (36)
Not last month	1	0 (0)	15	5 (33)	18	5 (28)
p value		1.000		0.747		0.493
2023						
Less than daily	6	1 (17)	68	28 (41)	76	29 (38)
Daily or more	1	0 (0)	97	37 (38)	101	39 (39)
Not last month	1	0 (0)	29	5 (17)	35	6 (17)
p value		1.000		0.067		0.054
2024						
Less than daily	3	0 (0)	72	25 (35)	77	26 (34)
Daily or more	1	0 (0)	118	44 (37)	123	44 (36)
Not last month	1	0 (0)	13	3 (23)	15	3 (20)
p value		--		0.588		0.476
2025						
Less than daily	4	0 (0)	69	19 (28)	74	19 (26)
Daily or more	7	0 (0)	104	34 (33)	117	36 (31)
Not last month	0	0 (0)	18	2 (11)	20	3 (15)
p value		--		0.168		0.314

Table 6.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

South Australia	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	1	0 (0)	149	43 (29)	156	47 (30)
Imprisonment	0	0 (0)	16	1 (6)	19	1 (5)
p value		--		0.072		0.027
2022						
No imprisonment	10	1 (10)	207	76 (37)	228	80 (35)
Imprisonment	1	0 (0)	31	7 (23)	36	8 (22)
p value		1.000		0.124		0.128
2023						
No imprisonment	8	1 (13)	163	54 (33)	178	57 (32)
Imprisonment	0	0 (0)	19	8 (42)	21	8 (38)
p value		--		0.435		0.575
2024						
No imprisonment	5	0 (0)	176	62 (35)	187	62 (33)
Imprisonment	0	0 (0)	20	6 (30)	21	7 (33)
p value		--		0.642		0.987
2025						
No imprisonment	8	0 (0)	157	47 (30)	173	49 (28)
Imprisonment	3	0 (0)	22	6 (27)	26	7 (27)
p value		--		0.798		0.882

Table 6.3.9 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

South Australia		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
English speaking	110	35 (32)	63	19 (30)	178	55 (31)	
Non-English speaking	3	1 (33)	4	1 (25)	7	2 (29)	
p value		1.000		1.000		1.000	
2022							
English speaking	150	49 (33)	95	34 (36)	252	86 (34)	
Non-English speaking	10	5 (50)	5	1 (20)	16	6 (38)	
p value		0.262		0.655		0.783	
2023							
English speaking	117	39 (33)	79	29 (37)	203	71 (35)	
Non-English speaking	9	2 (22)	1	0 (0)	10	2 (20)	
p value		0.717		1.000		0.500	
2024							
English speaking	107	40 (37)	95	28 (29)	207	69 (33)	
Non-English speaking	7	2 (29)	3	0 (0)	10	2 (20)	
p value		0.640		0.266		0.380	
2025							
English speaking	115	27 (23)	76	26 (34)	195	57 (29)	
Non-English speaking	13	0 (0)	4	1 (25)	17	1 (3)	
p value		0.049		0.704		0.038	

Table 6.3.10 HCV antibody prevalence by region/country of birth, gender and survey year

South Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Australia	99	29 (29)	58	14 (24)	162	44 (27)	
Other Oceania	1	1 (100)	2	2 (100)	3	3 (100)	
Asia	2	1 (50)	1	1 (100)	3	2 (67)	
UK & Ireland	7	2 (29)	3	2 (67)	10	4 (40)	
Other	3	0 (0)	2	1 (50)	5	1 (20)	
p value		0.419		0.013		0.029	
2022							
Australia	140	44 (31)	86	29 (34)	233	76 (33)	
Other Oceania	2	2 (100)	2	1 (50)	4	3 (75)	
Asia	5	1 (20)	3	1 (33)	8	2 (25)	
UK & Ireland	5	2 (40)	8	5 (63)	13	7 (54)	
Other	3	1 (33)	2	0 (0)	6	1 (17)	
p value		0.340		0.412		0.161	
2023							
Australia	109	35 (32)	75	26 (35)	191	64 (34)	
Other Oceania	5	3 (60)	3	1 (33)	8	4 (50)	
Asia	2	0 (0)	0	0 (0)	2	0 (0)	
UK & Ireland	5	2 (40)	3	3 (100)	8	5 (63)	
Other	3	0 (0)	0	0 (0)	3	0 (0)	
p value		0.435		0.093		0.209	
2024							
Australia	104	40 (38)	93	27 (29)	202	68 (34)	
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)	
Asia	5	2 (40)	0	0 (0)	5	2 (40)	
UK & Ireland	3	0 (0)	3	1 (33)	6	1 (17)	
Other	1	0 (0)	1	0 (0)	2	0 (0)	
p value		0.483		0.839		0.671	
2025							
Australia	112	24 (21)	75	26 (35)	191	54 (28)	
Other Oceania	2	1 (50)	2	0 (0)	4	1 (25)	
Asia	9	0 (0)	1	0 (0)	10	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	6	1 (17)	2	1 (50)	8	2 (25)	
p value		0.316		0.617		0.273	

HCV RNA prevalence

Table 6.4.1 HCV RNA prevalence by gender and survey year

South Australia		Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021	87	16 (18)	54	5 (9)	146	22 (15)	
2022	149	19 (13)	87	13 (15)	243	32 (13)	
2023	128	9 (7)	80	1 (1)	215	11 (5)	
2024	110	8 (7)	97	4 (4)	213	12 (6)	
2025	125	8 (6)	80	5 (6)	209	13 (6)	
X ² p trend		0.002		0.048		<0.001	

Totals include respondents where gender was reported as other or not reported

Table 6.4.2 HCV RNA prevalence by sexual identity, gender and survey year

South Australia		Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Heterosexual	76	14 (18)	38	3 (8)	114	17 (15)	
Bisexual	4	2 (50)	13	1 (8)	18	3 (17)	
Homosexual	5	0 (0)	0	0 (0)	6	0 (0)	
p value		0.156		0.981		0.576	
2022							
Heterosexual	122	17 (14)	63	10 (16)	188	27 (14)	
Bisexual	11	2 (18)	14	2 (14)	25	4 (16)	
Homosexual	7	0 (0)	3	0 (0)	10	0 (0)	
p value		0.859		1.000		0.865	
2023							
Heterosexual	110	9 (8)	55	1 (2)	165	10 (6)	
Bisexual	5	0 (0)	17	0 (0)	24	1 (4)	
Homosexual	5	0 (0)	2	0 (0)	8	0 (0)	
p value		1.000		1.000		1.000	
2024							
Heterosexual	96	8 (8)	71	3 (4)	167	11 (7)	
Bisexual	7	0 (0)	19	1 (5)	27	1 (4)	
Homosexual	3	0 (0)	3	0 (0)	8	0 (0)	
p value		0.782		0.996		0.916	
2025							
Heterosexual	116	8 (7)	61	3 (5)	178	11 (6)	
Bisexual	7	0 (0)	16	2 (13)	23	2 (9)	
Homosexual	2	0 (0)	2	0 (0)	4	0 (0)	
p value		0.718		0.694		0.942	

Table 6.4.3 HCV RNA prevalence by age group, gender and survey year

South Australia		Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
<25 years	3	1 (33)	0	0 (0)	3	1 (33)	
25-34 years	11	2 (18)	9	1 (11)	20	3 (15)	
35-44 years	28	5 (18)	20	1 (5)	50	6 (12)	
45+ years	45	8 (18)	25	3 (12)	73	12 (16)	
p value		0.927		0.707		0.739	
2022							
<25 years	4	0 (0)	0	0 (0)	4	0 (0)	
25-34 years	14	0 (0)	9	1 (11)	23	1 (4)	
35-44 years	41	4 (10)	24	3 (13)	65	7 (11)	
45+ years	86	14 (16)	53	9 (17)	145	23 (16)	
p value		0.358		0.903		0.428	
2023							
<25 years	4	0 (0)	4	0 (0)	8	0 (0)	
25-34 years	10	0 (0)	3	0 (0)	16	1 (6)	
35-44 years	37	2 (5)	27	1 (4)	65	3 (5)	
45+ years	76	7 (9)	44	0 (0)	123	7 (6)	
p value		0.904		0.436		1.000	
2024							
<25 years	0	0 (0)	0	0 (0)	0	0 (0)	
25-34 years	6	0 (0)	15	0 (0)	21	0 (0)	
35-44 years	24	2 (8)	30	1 (3)	56	3 (5)	
45+ years	80	6 (8)	52	3 (6)	136	9 (7)	
p value		0.772		0.592		0.470	
2025							
<25 years	0	0 (0)	1	1 (100)	1	1 (100)	
25-34 years	13	0 (0)	8	0 (0)	21	0 (0)	
35-44 years	33	1 (3)	29	2 (7)	64	3 (5)	
45+ years	79	7 (9)	42	2 (5)	123	9 (7)	
p value		0.315		0.001		0.001	

Table 6.4.4 HCV RNA prevalence by years since first injection, gender and survey year

South Australia	Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	1	1 (100)	1	0 (0)	2	1 (50)
3 to 10 years	8	3 (38)	8	1 (13)	16	4 (25)
11+ years	73	11 (15)	42	4 (10)	120	16 (13)
p value		0.031		0.915		0.183
2022						
<3 years	9	0 (0)	2	0 (0)	11	0 (0)
3 to 10 years	14	1 (7)	10	1 (10)	25	2 (8)
11+ years	116	17 (15)	71	12 (17)	192	29 (15)
p value		0.675		1.000		0.415
2023						
<3 years	4	0 (0)	4	0 (0)	8	0 (0)
3 to 10 years	11	0 (0)	12	0 (0)	25	0 (0)
11+ years	108	9 (8)	59	1 (2)	172	11 (6)
p value		1.000		1.000		0.595
2024						
<3 years	3	0 (0)	0	0 (0)	4	0 (0)
3 to 10 years	11	0 (0)	12	1 (8)	23	1 (4)
11+ years	94	8 (9)	81	3 (4)	179	11 (6)
p value		0.526		0.461		0.830
2025						
<3 years	8	0 (0)	3	0 (0)	11	0 (0)
3 to 10 years	13	1 (8)	11	1 (9)	24	2 (8)
11+ years	98	7 (7)	64	4 (6)	165	11 (7)
p value		0.732		0.844		0.636

Table 6.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

South Australia	Male		Female		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	62	16 (26)	33	4 (12)	98	20 (20)
Receptive sharing	7	0 (0)	4	0 (0)	13	1 (8)
p value		0.125		0.461		0.271
2022						
No receptive sharing	112	17 (15)	64	6 (9)	181	23 (13)
Receptive sharing	20	1 (5)	16	5 (31)	37	6 (16)
p value		0.307		0.023		0.567
2023						
No receptive sharing	81	2 (2)	60	1 (2)	147	3 (2)
Receptive sharing	17	4 (24)	10	0 (0)	28	5 (18)
p value		0.008		1.000		0.003
2024						
No receptive sharing	81	8 (10)	81	4 (5)	166	12 (7)
Receptive sharing	20	0 (0)	5	0 (0)	26	0 (0)
p value		0.143		0.611		0.157
2025						
No receptive sharing	99	8 (8)	62	4 (6)	164	12 (7)
Receptive sharing	14	0 (0)	8	0 (0)	23	0 (0)
p value		0.270		0.459		0.180

Table 6.4.6 HCV RNA prevalence by last drug injected, gender and survey year

South Australia		Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Heroin	21	5 (24)	14	2 (14)	37	7 (19)	
Methamphetamine	51	9 (18)	29	1 (3)	82	10 (12)	
Other opioids	8	1 (13)	3	0 (0)	12	2 (17)	
Other drugs	7	1 (14)	4	1 (25)	11	2 (18)	
p value		0.875		0.334		0.784	
2022							
Heroin	37	5 (14)	30	7 (23)	69	12 (17)	
Methamphetamine	70	10 (14)	47	4 (9)	121	14 (12)	
Other opioids	16	0 (0)	4	0 (0)	21	0 (0)	
Other drugs	19	3 (16)	5	2 (40)	24	5 (21)	
p value		0.444		0.098		0.124	
2023							
Heroin	16	1 (6)	21	0 (0)	41	1 (2)	
Methamphetamine	81	7 (9)	51	1 (2)	134	9 (7)	
Other opioids	14	1 (7)	4	0 (0)	19	1 (5)	
Other drugs	14	0 (0)	4	0 (0)	18	0 (0)	
p value		0.715		0.902		0.522	
2024							
Heroin	31	1 (3)	27	0 (0)	60	1 (2)	
Methamphetamine	68	7 (10)	52	4 (8)	123	11 (9)	
Other opioids	5	0 (0)	4	0 (0)	9	0 (0)	
Other drugs	5	0 (0)	8	0 (0)	14	0 (0)	
p value		0.487		0.371		0.139	
2025							
Heroin	21	1 (5)	28	1 (4)	51	2 (4)	
Methamphetamine	76	6 (8)	43	4 (9)	121	10 (8)	
Other opioids	4	1 (25)	3	0 (0)	7	1 (14)	
Other drugs	19	0 (0)	5	0 (0)	24	0 (0)	
p value		0.281		0.673		0.309	

Table 6.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

South Australia	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	37	6 (16)	25	2 (8)	65	8 (12)
Daily or more	32	10 (31)	14	2 (14)	48	13 (27)
Not last month	18	0 (0)	11	0 (0)	29	0 (0)
p value		0.021		0.426		0.004
2022						
Less than daily	56	7 (13)	33	4 (12)	90	11 (12)
Daily or more	78	11 (14)	47	7 (15)	130	18 (14)
Not last month	10	0 (0)	6	2 (33)	17	2 (12)
p value		0.678		0.347		0.953
2023						
Less than daily	45	2 (4)	31	0 (0)	77	2 (3)
Daily or more	55	5 (9)	39	1 (3)	100	7 (7)
Not last month	25	2 (8)	10	0 (0)	35	2 (6)
p value		0.665		1.000		0.450
2024						
Less than daily	33	3 (9)	39	1 (3)	73	4 (5)
Daily or more	68	5 (7)	48	3 (6)	120	8 (7)
Not last month	8	0 (0)	6	0 (0)	15	0 (0)
p value		0.676		0.607		0.575
2025						
Less than daily	46	3 (7)	27	2 (7)	73	5 (7)
Daily or more	67	5 (7)	43	2 (5)	114	7 (6)
Not last month	10	0 (0)	10	1 (10)	20	1 (5)
p value		0.671		0.783		0.951

Table 6.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

South Australia		Male		Female		Total	
Imprisonment last year	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	Nº tested	Nº with HCV (%)	
2021							
No imprisonment	71	11 (15)	46	2 (4)	122	14 (11)	
Imprisonment	9	0 (0)	5	0 (0)	14	0 (0)	
p value		0.204		0.634		0.181	
2022							
No imprisonment	119	15 (13)	80	13 (16)	203	28 (14)	
Imprisonment	26	3 (12)	6	0 (0)	33	3 (9)	
p value		1.000		0.585		0.586	
2023							
No imprisonment	99	7 (7)	74	1 (1)	178	8 (4)	
Imprisonment	17	1 (6)	2	0 (0)	20	2 (10)	
p value		1.000		1.000		0.267	
2024							
No imprisonment	90	8 (9)	86	4 (5)	182	12 (7)	
Imprisonment	15	0 (0)	4	0 (0)	19	0 (0)	
p value		0.230		0.659		0.248	
2025							
No imprisonment	95	8 (8)	71	4 (6)	169	12 (7)	
Imprisonment	19	0 (0)	6	1 (17)	26	1 (4)	
p value		0.190		0.292		0.536	

Table 6.4.9 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

South Australia		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
English speaking	84	15 (18)	51	4 (8)	140	20 (14)	
Non-English speaking	2	1 (50)	3	1 (33)	5	2 (40)	
p value		0.248		0.139		0.115	
2022							
English speaking	138	16 (12)	81	13 (16)	226	29 (13)	
Non-English speaking	9	3 (33)	4	0 (0)	13	3 (23)	
p value		0.093		1.000		0.391	
2023							
English speaking	118	9 (8)	78	1 (1)	203	11 (5)	
Non-English speaking	9	0 (0)	1	0 (0)	10	0 (0)	
p value		1.000		1.000		1.000	
2024							
English speaking	101	8 (8)	94	4 (4)	200	12 (6)	
Non-English speaking	7	0 (0)	3	0 (0)	10	0 (0)	
p value		0.439		0.715		0.425	
2025							
English speaking	112	8 (7)	76	5 (7)	192	13 (7)	
Non-English speaking	11	0 (0)	4	0 (0)	15	0 (0)	
p value		0.359		0.596		0.298	

Table 6.4.10 HCV RNA prevalence by region/country of birth, gender and survey year

South Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Australia	76	13 (17)	45	2 (4)	126	16 (13)	
Other Oceania	0	0 (0)	2	1 (50)	2	1 (50)	
Asia	1	1 (100)	1	1 (100)	2	2 (100)	
UK & Ireland	5	2 (40)	3	1 (33)	8	3 (38)	
Other	1	0 (0)	2	0 (0)	3	0 (0)	
p value		0.110		0.002		0.002	
2022							
Australia	127	14 (11)	72	11 (15)	206	25 (12)	
Other Oceania	2	0 (0)	2	1 (50)	4	1 (25)	
Asia	5	1 (20)	2	0 (0)	7	1 (14)	
UK & Ireland	5	1 (20)	8	1 (13)	13	2 (15)	
Other	3	1 (33)	2	0 (0)	5	1 (20)	
p value		0.288		0.680		0.560	
2023							
Australia	110	7 (6)	74	0 (0)	191	8 (4)	
Other Oceania	5	1 (20)	3	1 (33)	8	2 (25)	
Asia	2	0 (0)	0	0 (0)	2	0 (0)	
UK & Ireland	5	1 (20)	3	0 (0)	8	1 (13)	
Other	3	0 (0)	0	0 (0)	3	0 (0)	
p value		0.294		0.075		0.093	
2024							
Australia	99	8 (8)	92	4 (4)	196	12 (6)	
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)	
Asia	4	0 (0)	0	0 (0)	4	0 (0)	
UK & Ireland	3	0 (0)	3	0 (0)	6	0 (0)	
Other	1	0 (0)	1	0 (0)	2	0 (0)	
p value		0.874		0.973		0.932	
2025							
Australia	108	7 (6)	75	5 (7)	187	12 (6)	
Other Oceania	2	0 (0)	2	0 (0)	4	0 (0)	
Asia	9	0 (0)	1	0 (0)	10	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	5	1 (20)	2	0 (0)	7	1 (14)	
p value		0.516		0.949		0.634	

Tasmania

Table 7.1.1 Number (%) of respondents by demographic characteristics and survey year

Tasmania	2021*	2022	2023	2024	2025
Number of sites	4	4	4	3	4
N° surveyed	N=95	N=91	N=78	N=88	N=79
Response rate (%)	62%	38%	30%	39%	24%
Gender (%)					
Male	51 (54)	60 (66)	49 (63)	61 (69)	49 (62)
Female	44 (46)	29 (32)	28 (36)	26 (30)	30 (38)
Other	0 (0)	2 (2)	0 (0)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	
Age (years)					
Median age	45	44	43	44	45
Age range	20-67	24-62	26-67	18-62	24-67
<25 years	2 (2)	1 (1)	0 (0)	5 (6)	1 (1)
25+ years	91 (96)	90 (99)	77 (99)	83 (94)	78 (99)
Not reported	2 (2)	0 (0)	1 (1)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	81 (85)	77 (85)	60 (77)	74 (84)	65 (82)
Bisexual	9 (9)	9 (10)	12 (15)	10 (11)	12 (15)
Gay/Lesbian	1 (1)	3 (3)	2 (3)	3 (3)	2 (3)
Other	2 (2)	2 (2)	2 (3)	1 (1)	0 (0)
Not reported	2 (2)	0 (0)	2 (3)	0 (0)	
Aboriginal and Torres Strait Islander origin (%)					
No	72 (76)	63 (69)	61 (78)	59 (67)	57 (72)
Yes	20 (21)	25 (27)	17 (22)	29 (33)	21 (27)
Not reported	3 (3)	3 (3)	0 (0)	0 (0)	1 (1)
Region/country of birth (%)					
Australia	86 (91)	87 (96)	73 (94)	80 (91)	75 (95)
Other Oceania	0 (0)	1 (1)	1 (1)	2 (2)	0 (0)
Asia	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
UK & Ireland	0 (0)	1 (1)	1 (1)	3 (3)	2 (3)
Other	6 (6)	1 (1)	3 (4)	1 (1)	1 (1)
Not reported	2 (2)	1 (1)	0 (0)	2 (2)	1 (1)
Main language spoken at home by parents (%)					
English	90 (95)	90 (99)	75 (96)	86 (98)	78 (99)
Non-English	4 (4)	1 (1)	2 (3)	1 (1)	0 (0)
Not reported	1 (1)	0 (0)	1 (1)	1 (1)	1 (1)
Age at first injection and time since first injection (years)					
Median age at first injection	20	19	20	18.5	20
Age range at first injection	12-55	10-56	11-49	10-50	12-57
N° not reported	2	2	3	0	0
Median yrs since first injection	21.5	25	22	22	23
Range yrs since first injection	1-48	2-46	<1-47	<1-49	<1-45
<3 years since first injection	5 (5)	2 (2)	7 (9)	8 (9)	4 (5)
3+ years since first injection	87 (92)	87 (96)	68 (87)	80 (91)	75 (95)
Not reported	3 (3)	2 (2)	3 (4)	0 (0)	0 (0)

* Implementation of the 2021 ANSPS was impacted by the COVID-19 pandemic

Table 7.1.2 Number (%) of respondents by last drug injected, frequency of injecting, overdose, imprisonment, injection in prison and survey year

Tasmania	2021	2022	2023	2024	2025
N° surveyed	N=95	N=91	N=78	N=88	N=79
Drug last injected (%)					
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	49 (52)	50 (55)	47 (60)	68 (77)	58 (73)
Heroin	7 (7)	3 (3)	2 (3)	2 (2)	4 (5)
Pharm. opioids	14 (15)	21 (23)	9 (12)	6 (7)	5 (6)
Methadone	9 (9)	6 (7)	6 (8)	2 (2)	3 (4)
Buprenorphine	4 (4)	6 (7)	6 (8)	2 (2)	0 (0)
Buprenorphine/naloxone	4 (4)	1 (1)	0 (0)	0 (0)	0 (0)
PIEDs	2 (2)	0 (0)	3 (4)	2 (2)	5 (6)
More than one	3 (3)	3 (3)	2 (3)	5 (6)	3 (4)
Other	2 (2)	1 (1)	2 (3)	1 (1)	0 (0)
Not reported	1 (1)	0 (0)	1 (1)	0 (0)	1 (1)
Ever injected opioids (%)					
No	32 (34)	16 (18)	23 (29)	29 (33)	25 (32)
Yes	63 (66)	75 (82)	54 (69)	58 (66)	54 (68)
Not reported	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Frequency of injection last month (%)					
Not last month	10 (11)	2 (2)	6 (8)	5 (6)	2 (3)
Less than weekly	32 (34)	14 (15)	20 (26)	18 (20)	14 (18)
Weekly not daily	20 (21)	26 (29)	25 (32)	26 (30)	22 (28)
Daily or more	31 (33)	49 (54)	23 (29)	36 (41)	40 (51)
Not reported	2 (2)	0 (0)	4 (5)	3 (3)	1 (1)
Present when someone injected for the first time in the last 12 months (%)					
No	78 (82)	75 (82)	69 (88)	70 (80)	66 (84)
Yes	14 (15)	16 (18)	7 (9)	16 (18)	11 (14)
Not reported	3 (3)	0 (0)	2 (3)	2 (2)	2 (3)
Overdosed in last 12 months (%)					
No	85 (89)	83 (91)	69 (88)	76 (86)	72 (91)
Yes	5 (5)	8 (9)	7 (9)	8 (9)	5 (6)
Not reported	5 (5)	0 (0)	2 (3)	4 (5)	2 (3)
Imprisonment last year (%)					
No	82 (86)	75 (82)	67 (86)	60 (68)	70 (89)
Yes	8 (8)	14 (15)	9 (12)	24 (27)	7 (9)
Not reported	5 (5)	2 (2)	2 (3)	4 (5)	2 (3)
Injected while in prison last year					
N° in prison last year	N=8	N=14	N=9	N=24	N=9
No	6 (75)	10 (71)	7 (78)	18 (75)	5 (71)
Yes	2 (25)	4 (29)	2 (22)	6 (25)	2 (29)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Table 7.1.3 Number (%) of respondents by injecting behaviour in the last month and survey year

Tasmania	2021	2022	2023	2024	2025
N° injected last month	N=83	N=89	N=68	N=80	N=76
Places injected last month (%)					
All private	62 (75)	49 (55)	45 (66)	40 (50)	52 (68)
Any public	21 (25)	40 (45)	23 (34)	40 (50)	24 (32)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	71 (86)	75 (84)	54 (79)	60 (75)	60 (79)
Most of the time	8 (10)	12 (13)	10 (15)	17 (21)	13 (17)
Half of the time	0 (0)	1 (1)	3 (4)	1 (1)	1 (1)
Some of the time	0 (0)	1 (1)	0 (0)	0 (0)	2 (3)
Not last month	2 (2)	0 (0)	1 (1)	0 (0)	0 (0)
Not reported	2 (2)	0 (0)	0 (0)	2 (3)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	76 (92)	76 (85)	65 (96)	66 (83)	65 (86)
Once	2 (2)	3 (3)	1 (1)	4 (5)	5 (7)
Twice	4 (5)	6 (7)	1 (1)	7 (9)	1 (1)
3-5 times	0 (0)	1 (1)	1 (1)	1 (1)	2 (3)
>5 times	1 (1)	3 (3)	0 (0)	2 (3)	2 (3)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Number of people needle & syringe was re-used after last month (%)					
None	76 (92)	76 (85)	65 (96)	66 (83)	65 (86)
One	2 (2)	3 (3)	2 (3)	4 (5)	4 (5)
Two	1 (1)	1 (1)	0 (0)	3 (4)	0 (0)
Three to five	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)
More than five	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Don't know	3 (4)	4 (4)	1 (1)	6 (8)	6 (8)
Not reported	1 (1)	2 (2)	0 (0)	1 (1)	1 (1)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	2 (2)	2 (2)	0 (0)	7 (9)	2 (3)
Casual sex partner	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Close friend	2 (2)	3 (3)	2 (3)	4 (5)	0 (0)
Acquaintance	0 (0)	2 (2)	1 (1)	0 (0)	4 (5)
Other	1 (1)	3 (3)	0 (0)	0 (0)	1 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	11 (13)	20 (22)	3 (4)	8 (10)	5 (7)
Water	19 (23)	13 (15)	15 (22)	17 (21)	10 (13)
Filter	9 (11)	5 (6)	6 (9)	4 (5)	0 (0)
Drug mix	5 (6)	4 (4)	1 (1)	7 (9)	6 (8)
None	58 (70)	54 (61)	48 (71)	56 (70)	61 (80)
Injected by someone after that person injected themselves or others last month (%)					
No	73 (88)	71 (80)	65 (96)	68 (85)	65 (86)
Yes	9 (11)	18 (20)	3 (4)	11 (14)	11 (14)
Not reported	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)
Source of needle acquisition (%)					
Needle Syringe Program	72 (87)	86 (97)	61 (90)	73 (91)	67 (88)
Chemist/Pharmacy	19 (23)	27 (30)	17 (25)	15 (19)	22 (29)
Personal sources	5 (6)	12 (13)	4 (6)	9 (11)	6 (8)
Dispensing/Vending Machine	7 (8)	19 (21)	5 (7)	9 (11)	16 (21)
Other sources	1 (1)	0 (0)	0 (0)	4 (5)	0 (0)

Table 7.1.4 Number (%) of respondents by treatment for drug use and survey year

Tasmania	2021	2022	2023	2024	2025
N° surveyed	N=95	N=91	N=78	N=88	N=79
Ever any treatment/therapy for drug use (%)					
No	33 (35)	23 (25)	22 (28)	35 (40)	26 (33)
Yes	62 (65)	68 (75)	56 (72)	53 (60)	53 (67)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	10 (11)	12 (13)	7 (9)	7 (8)	6 (8)
Previously	18 (19)	24 (26)	19 (24)	16 (18)	14 (18)
Never	62 (65)	55 (60)	49 (63)	61 (69)	58 (73)
Not reported	5 (5)	0 (0)	3 (4)	4 (5)	1 (1)
History of buprenorphine (Subutex®) treatment (%)					
Currently	12 (13)	14 (15)	10 (13)	9 (10)	7 (9)
Previously	16 (17)	16 (18)	14 (18)	18 (20)	12 (15)
Never	64 (67)	59 (65)	51 (65)	57 (65)	58 (73)
Not reported	3 (3)	2 (2)	3 (4)	4 (5)	2 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	6 (6)	9 (10)	6 (8)	5 (6)	4 (5)
Previously	16 (17)	16 (18)	11 (14)	13 (15)	12 (15)
Never	71 (75)	66 (73)	61 (78)	69 (78)	63 (80)
Not reported	2 (2)	0 (0)	0 (0)	1 (1)	
History of depot buprenorphine treatment (%)					
Currently	1 (1)	3 (3)	2 (3)	9 (10)	6 (8)
Previously	7 (7)	10 (11)	5 (6)	8 (9)	5 (6)
Never	84 (88)	78 (86)	69 (88)	67 (76)	66 (84)
Not reported	3 (3)	0 (0)	2 (3)	4 (5)	2 (3)

Table 7.1.5 Number (%) of respondents by sexual behaviour in the month prior to survey and survey year

Tasmania	2021	2022	2023	2024	2025
N° surveyed	N=95	N=91	N=78	N=88	N=79
Sex with a regular partner last month (%)					
No	34 (36)	43 (47)	33 (42)	41 (47)	31 (39)
Yes	30 (32)	36 (40)	36 (46)	37 (42)	38 (48)
Not reported	31 (33)	12 (13)	9 (12)	10 (11)	10 (13)
Condom used with regular partner last month (%)					
N° surveyed	N=30	N=36	N=36	N=37	N=38
Never	23 (77)	30 (83)	29 (81)	31 (84)	32 (84)
Sometimes	3 (10)	2 (6)	1 (3)	1 (3)	4 (11)
Every time	1 (3)	4 (11)	3 (8)	3 (8)	0 (0)
Not reported	3 (10)	0 (0)	3 (8)	2 (5)	2 (5)
Sex with other partner(s) last month (%)					
No	57 (60)	69 (76)	59 (76)	60 (68)	62 (78)
Yes	5 (5)	9 (10)	9 (12)	16 (18)	5 (6)
Not reported	33 (35)	13 (14)	10 (13)	12 (14)	12 (15)
Condom used with other partner(s) last month (%)					
N° surveyed	N=5	N=9	N=9	N=16	N=5
Never	3 (60)	4 (44)	4 (44)	13 (81)	3 (60)
Sometimes	1 (20)	3 (33)	3 (33)	3 (19)	0 (0)
Every time	0 (0)	2 (22)	1 (11)	0 (0)	1 (20)
Not reported	1 (20)	0 (0)	1 (11)	0 (0)	1 (20)
Sex work last month (%)					
No	57 (60)	72 (79)	69 (88)	70 (80)	61 (77)
Yes	6 (6)	6 (7)	1 (1)	3 (3)	1 (1)
Not reported	32 (34)	13 (14)	8 (10)	15 (17)	17 (22)
Condom used at last sex work (%)					
Yes	3 (50)	4 (67)	1 (100)	2 (67)	1 (100)

Table 7.1.6 Number (%) of respondents by testing for HIV and HCV, HCV treatment by survey year

Tasmania	2021	2022	2023	2024	2025
N° surveyed	N=95	N=91	N=78	N=88	N=79
Previous HIV test (%)					
Yes, ever	71 (75)	77 (85)	64 (82)	66 (75)	65 (82)
Yes, last year	40 (42)	50 (55)	30 (38)	37 (42)	35 (44)
>1 year ago	31 (33)	27 (30)	34 (44)	29 (33)	30 (38)
Never tested	19 (20)	12 (13)	11 (14)	19 (22)	12 (15)
Not reported	5 (5)	2 (2)	3 (4)	3 (3)	2 (3)
Previous HCV test (%)					
Yes, ever	79 (83)	75 (82)	62 (79)	74 (84)	75 (95)
Yes, last year	52 (55)	52 (57)	37 (47)	41 (47)	44 (56)
>1 year ago	27 (28)	23 (25)	25 (32)	33 (38)	31 (39)
Never tested	7 (7)	6 (7)	8 (10)	10 (11)	3 (4)
Not reported	9 (9)	10 (11)	8 (10)	4 (5)	1 (1)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=19	N=17	N=12	N=18	N=12
Antiviral treatment	11 (42)	15 (88)	11 (92)	18 (100)	10 (83)
No antiviral treatment	8 (58)	2 (12)	1 (8)	0 (0)	2 (17)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)^{**}					
N° self-reported HCV diagnosis	N=9	N=7	N=3	N=5	N=5
Antiviral treatment	1 (11)	4 (57)	2 (67)	3 (60)	3 (60)
No antiviral treatment	8 (89)	3 (43)	1 (33)	2 (40)	2 (40)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance^{*} excludes people who reported treatment induced clearance more than 12 months previously

HIV antibody prevalence

Table 7.2.1 HIV antibody prevalence by gender and survey year

Tasmania	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021	49	0 (0.0)	42	0 (0.0)	91	0 (0.0)
2022	59	0 (0.0)	29	0 (0.0)	90	0 (0.0)
2023	37	1 (2.7)	25	0 (0.0)	63	1 (1.6)
2024	60	0 (0.0)	25	0 (0.0)	86	0 (0.0)
2025	49	1 (2.0)	30	0 (0.0)	79	1 (1.3)
X ² p trend		0.324		--		0.295

HCV antibody prevalence

Table 7.3.1 HCV antibody prevalence by gender and survey year

Tasmania	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	49	18 (37)	42	9 (21)	91	27 (30)
2022	59	21 (36)	29	6 (21)	90	28 (31)
2023*	37	11 (30)	25	11 (44)	63	22 (35)
2024	60	15 (25)	25	13 (52)	86	28 (33)
2025	49	16 (33)	30	9 (30)	79	25 (32)
X ² p trend^		0.711		0.265		0.685

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

^ X² p trend calculated on years 2023-2025 only

Table 7.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Tasmania	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	44	16 (36)	33	6 (18)	77	22 (29)
Bisexual	3	0 (0)	6	2 (33)	9	2 (22)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.219		0.260		0.147
2022						
Heterosexual	56	20 (36)	19	2 (11)	76	23 (30)
Bisexual	2	1 (50)	7	2 (29)	9	3 (33)
Homosexual	1	0 (0)	2	1 (50)	3	1 (33)
p value		1.000		0.085		0.733
2023						
Heterosexual	33	11 (33)	17	8 (47)	50	19 (38)
Bisexual	3	0 (0)	6	2 (33)	9	2 (22)
Homosexual	0	0 (0)	2	1 (50)	2	1 (50)
p value		0.675		0.825		0.699
2024						
Heterosexual	55	15 (27)	17	9 (53)	72	24 (33)
Bisexual	4	0 (0)	5	3 (60)	10	3 (30)
Homosexual	1	0 (0)	2	1 (50)	3	1 (33)
p value		0.403		0.748		0.912
2025						
Heterosexual	45	15 (33)	20	5 (25)	65	20 (31)
Bisexual	3	1 (33)	9	3 (33)	12	4 (33)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.781		0.270		0.839

Table 7.3.3 HCV antibody prevalence by age group, gender and survey year

Tasmania	Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<25 years	0	0 (0)	2	0 (0)	2	0 (0)
25-34 years	7	2 (29)	7	1 (14)	14	3 (21)
35-44 years	15	5 (33)	12	1 (8)	27	6 (22)
45+ years	27	11 (41)	19	6 (32)	46	17 (37)
p value		0.847		0.489		0.437
2022						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	11	2 (18)	6	0 (0)	17	2 (12)
35-44 years	17	7 (41)	10	2 (20)	28	10 (36)
45+ years	31	12 (39)	12	4 (33)	44	16 (36)
p value		0.418		0.494		0.200
2023						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	6	0 (0)	4	2 (50)	10	2 (20)
35-44 years	12	2 (17)	10	5 (50)	22	7 (32)
45+ years	19	9 (47)	11	4 (36)	30	13 (43)
p value		0.044		0.869		0.400
2024						
<25 years	4	0 (0)	0	0 (0)	4	0 (0)
25-34 years	9	2 (22)	5	1 (20)	14	3 (21)
35-44 years	19	2 (11)	12	5 (42)	31	7 (23)
45+ years	28	11 (39)	8	7 (88)	37	18 (49)
p value		0.088		0.037		0.037
2025						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	8	2 (25)	0	0 (0)	8	2 (25)
35-44 years	12	2 (17)	17	3 (18)	29	5 (17)
45+ years	29	12 (41)	12	6 (50)	41	18 (44)
p value		0.271		0.139		0.100

Table 7.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Tasmania	Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	2	0 (0)	3	0 (0)	5	0 (0)
3 to 10 years	2	0 (0)	5	0 (0)	7	0 (0)
11+ years	45	18 (40)	31	8 (26)	76	26 (34)
p value		0.394		0.607		0.067
2022						
<3 years	0	0 (0)	2	0 (0)	2	0 (0)
3 to 10 years	3	0 (0)	7	0 (0)	10	0 (0)
11+ years	55	20 (36)	19	6 (32)	76	27 (36)
p value		0.544		0.226		0.029
2023						
<3 years	1	0 (0)	3	0 (0)	4	0 (0)
3 to 10 years	5	0 (0)	3	1 (33)	8	1 (13)
11+ years	29	10 (34)	19	10 (53)	48	20 (42)
p value		0.377		0.407		0.091
2024						
<3 years	5	0 (0)	2	0 (0)	7	0 (0)
3 to 10 years	7	1 (14)	3	0 (0)	10	1 (10)
11+ years	48	14 (29)	20	13 (65)	69	27 (39)
p value		0.281		0.034		0.029
2025						
<3 years	1	0 (0)	3	0 (0)	4	0 (0)
3 to 10 years	5	1 (20)	4	0 (0)	9	1 (11)
11+ years	43	15 (35)	23	9 (39)	66	24 (36)
p value		0.623		0.141		0.117

Table 7.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Tasmania	<3 years		3+ years		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	5	0 (0)	68	22 (32)	75	22 (29)
Receptive sharing	0	0 (0)	5	2 (40)	5	2 (40)
p value		--		1.000		0.633
2022						
No receptive sharing	2	0 (0)	71	21 (30)	75	22 (29)
Receptive sharing	0	0 (0)	13	5 (38)	13	5 (38)
p value		--		0.524		0.510
2023						
No receptive sharing	4	0 (0)	49	19 (39)	55	20 (36)
Receptive sharing	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.523		0.536
2024						
No receptive sharing	5	0 (0)	59	23 (39)	64	23 (36)
Receptive sharing	2	0 (0)	12	3 (25)	14	3 (21)
p value		--		0.359		0.297
2025						
No receptive sharing	4	0 (0)	61	20 (33)	65	20 (31)
Receptive sharing	0	0 (0)	10	5 (50)	10	5 (50)
p value		--		0.291		0.230

Table 7.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Tasmania	<3 years		3+ years		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Methamphetamine	4	0 (0)	40	8 (20)	44	8 (18)
Pharmaceutical opioids	1	0 (0)	13	5 (38)	14	5 (36)
OAT*	0	0 (0)	15	6 (40)	16	6 (38)
Other drugs	0	0 (0)	13	6 (46)	14	6 (43)
p value		--		0.206		0.194
2022						
Methamphetamine	0	0 (0)	48	14 (29)	49	15 (31)
Pharmaceutical opioids	1	0 (0)	20	5 (25)	21	5 (24)
OAT*	1	0 (0)	11	6 (55)	13	6 (46)
Other drugs	0	0 (0)	7	2 (29)	7	2 (29)
p value		--		0.354		0.589
2023						
Methamphetamine	4	0 (0)	30	9 (30)	35	9 (26)
Pharmaceutical opioids	0	0 (0)	8	5 (63)	9	6 (67)
OAT*	0	0 (0)	11	5 (45)	11	5 (45)
Other drugs	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		0.333		0.114
2024						
Methamphetamine	3	0 (0)	60	18 (30)	63	18 (29)
Pharmaceutical opioids	2	0 (0)	4	4 (100)	6	4 (67)
OAT*	0	0 (0)	4	3 (75)	4	3 (75)
Other drugs	2	0 (0)	8	2 (25)	10	2 (20)
p value		--		0.011		0.054
2025						
Methamphetamine	2	0 (0)	56	19 (34)	58	19 (33)
Pharmaceutical opioids	0	0 (0)	5	2 (40)	5	2 (40)
OAT*	0	0 (0)	3	2 (67)	3	2 (67)
Other drugs	2	0 (0)	9	1 (11)	11	1 (9)
p value		--		0.305		0.211

*OAT = methadone, buprenorphine or buprenorphine/naloxone

Table 7.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Tasmania	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	3	0 (0)	47	11 (23)	51	11 (22)
Daily or more	2	0 (0)	26	13 (50)	29	13 (45)
Not last month	0	0 (0)	9	1 (11)	9	1 (11)
p value		--		0.032		0.048
2022						
Less than daily	0	0 (0)	39	11 (28)	40	11 (28)
Daily or more	2	0 (0)	45	15 (33)	48	16 (33)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.676		0.608
2023						
Less than daily	3	0 (0)	32	12 (38)	37	13 (35)
Daily or more	1	0 (0)	19	7 (37)	20	7 (35)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
2024						
Less than daily	5	0 (0)	38	13 (34)	43	13 (30)
Daily or more	2	0 (0)	33	13 (39)	35	13 (37)
Not last month	0	0 (0)	5	1 (20)	5	1 (20)
p value		--		0.680		0.670
2025						
Less than daily	2	0 (0)	34	9 (26)	36	9 (25)
Daily or more	2	0 (0)	38	16 (42)	40	16 (40)
Not last month	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.222		0.232

Table 7.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Tasmania	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	3	0 (0)	73	23 (32)	79	24 (30)
Imprisonment	1	0 (0)	6	3 (50)	7	3 (43)
p value		--		0.389		0.673
2022						
No imprisonment	2	0 (0)	70	19 (27)	74	20 (27)
Imprisonment	0	0 (0)	14	7 (50)	14	7 (50)
p value		--		0.091		0.087
2023						
No imprisonment	4	0 (0)	49	19 (39)	56	20 (36)
Imprisonment	0	0 (0)	5	1 (20)	5	1 (20)
p value		--		0.640		0.651
2024						
No imprisonment	4	0 (0)	55	21 (38)	59	21 (36)
Imprisonment	3	0 (0)	21	6 (29)	24	6 (25)
p value		--		0.434		0.350
2025						
No imprisonment	4	0 (0)	66	21 (32)	70	21 (30)
Imprisonment	0	0 (0)	7	4 (57)	7	4 (57)
p value		--		0.179		0.144

Table 7.3.9 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Tasmania		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
English speaking	45	16 (36)	41	9 (22)	86	25 (29)	
Non-English speaking	4	2 (50)	0	0 (0)	4	2 (50)	
p value		0.618		--		0.580	
2022							
English speaking	58	20 (34)	29	6 (21)	89	27 (30)	
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)	
p value		0.356		--		0.311	
2023							
English speaking	36	11 (31)	24	11 (46)	61	22 (36)	
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)	
p value		1.000		1.000		0.538	
2024							
English speaking	59	15 (25)	24	13 (54)	84	28 (33)	
Non-English speaking	0	0 (0)	1	0 (0)	1	0 (0)	
p value		--		1.000		0.481	
2025							
English speaking	48	16 (33)	30	9 (30)	78	25 (32)	
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	

Table 7.3.10 HCV antibody prevalence by region/country of birth, gender and survey year

Tasmania	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Australia	42	15 (36)	40	8 (20)	82	23 (28)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	1	1 (100)	1	1 (100)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	5	2 (40)	1	0 (0)	6	2 (33)
p value		1.000		0.387		0.415
2022						
Australia	56	19 (34)	28	6 (21)	86	26 (30)
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.575		1.000		0.667
2023						
Australia	34	10 (29)	24	11 (46)	59	21 (36)
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.665		1.000		1.000
2024						
Australia	55	14 (25)	23	13 (57)	78	27 (35)
Other Oceania	1	0 (0)	1	0 (0)	2	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	3	0 (0)	0	0 (0)	3	0 (0)
Other	0	0 (0)	0	0 (0)	1	0 (0)
p value		0.513		0.267		0.382
2025						
Australia	45	15 (33)	30	9 (30)	75	24 (32)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	3	1 (33)	0	0 (0)	3	1 (33)
p value		1.000		--		0.961

HCV RNA prevalence

Table 7.4.1 HCV RNA prevalence by gender and survey year

Tasmania	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	42	6 (14)	35	3 (9)	77	9 (12)
2022	55	5 (9)	29	0 (0)	86	6 (7)
2023	37	0 (0)	25	2 (8)	63	2 (3)
2024	59	4 (7)	24	1 (4)	84	5 (6)
2025	45	3 (7)	30	2 (7)	75	5 (7)
X ² p trend		0.172		0.968		0.228

Totals include respondents where gender was reported as other or not reported

Table 7.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Tasmania	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	38	5 (13)	27	2 (7)	65	7 (11)
Bisexual	2	0 (0)	6	0 (0)	8	0 (0)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.583		0.759		0.586
2022						
Heterosexual	52	4 (8)	19	0 (0)	72	5 (7)
Bisexual	2	1 (50)	7	0 (0)	9	1 (11)
Homosexual	1	0 (0)	2	0 (0)	3	0 (0)
p value		0.253		--		0.668
2023						
Heterosexual	33	0 (0)	17	1 (6)	50	1 (2)
Bisexual	3	0 (0)	6	1 (17)	9	1 (11)
Homosexual	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.547		0.352
2024						
Heterosexual	54	4 (7)	16	0 (0)	70	4 (6)
Bisexual	4	0 (0)	5	1 (20)	10	1 (10)
Homosexual	1	0 (0)	2	0 (0)	3	0 (0)
p value		0.820		0.265		0.907
2025						
Heterosexual	41	2 (5)	20	1 (5)	61	3 (5)
Bisexual	3	1 (33)	9	1 (11)	12	2 (17)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.156		0.800		0.306

Table 7.4.3 HCV RNA prevalence by age group, gender and survey year

Tasmania	Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<25 years	0	0 (0)	2	0 (0)	2	0 (0)
25-34 years	6	0 (0)	6	0 (0)	12	0 (0)
35-44 years	13	0 (0)	9	0 (0)	22	0 (0)
45+ years	23	6 (26)	16	2 (13)	39	8 (21)
p value		0.056		0.520		0.041
2022						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	10	1 (10)	6	0 (0)	16	1 (6)
35-44 years	16	0 (0)	10	0 (0)	27	1 (4)
45+ years	29	4 (14)	12	0 (0)	42	4 (10)
p value		0.373		--		0.863
2023						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	6	0 (0)	4	1 (25)	10	1 (10)
35-44 years	12	0 (0)	10	0 (0)	22	0 (0)
45+ years	19	0 (0)	11	1 (9)	30	1 (3)
p value		--		0.300		0.421
2024						
<25 years	4	0 (0)	0	0 (0)	4	0 (0)
25-34 years	9	0 (0)	5	0 (0)	14	0 (0)
35-44 years	19	0 (0)	11	0 (0)	30	0 (0)
45+ years	27	4 (15)	8	1 (13)	36	5 (14)
p value		0.166		0.352		0.069
2025						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	8	0 (0)	0	0 (0)	8	0 (0)
35-44 years	11	1 (9)	17	0 (0)	28	1 (4)
45+ years	26	2 (8)	12	2 (17)	38	4 (11)
p value		0.698		0.200		0.576

Table 7.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Tasmania	Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	2	0 (0)	3	0 (0)	5	0 (0)
11+ years	39	6 (15)	27	2 (7)	66	8 (12)
p value		0.764		0.821		0.581
2022						
<3 years	0	0 (0)	2	0 (0)	2	0 (0)
3 to 10 years	3	0 (0)	7	0 (0)	10	0 (0)
11+ years	51	5 (10)	19	0 (0)	72	6 (8)
p value		1.000		--		1.000
2023						
<3 years	1	0 (0)	3	0 (0)	4	0 (0)
3 to 10 years	5	0 (0)	3	1 (33)	8	1 (13)
11+ years	29	0 (0)	19	1 (5)	48	1 (2)
p value		--		0.430		0.363
2024						
<3 years	5	0 (0)	2	0 (0)	7	0 (0)
3 to 10 years	7	0 (0)	3	0 (0)	10	0 (0)
11+ years	47	4 (9)	19	1 (5)	67	5 (7)
p value		0.578		0.872		0.509
2025						
<3 years	1	0 (0)	3	0 (0)	4	0 (0)
3 to 10 years	5	1 (20)	4	0 (0)	9	1 (11)
11+ years	39	2 (5)	23	2 (9)	62	4 (6)
p value		0.439		0.722		0.750

Table 7.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Tasmania	Male		Female		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	37	5 (14)	25	1 (4)	62	6 (10)
Receptive sharing	2	0 (0)	3	1 (33)	5	1 (20)
p value		0.578		0.062		0.468
2022						
No receptive sharing	45	5 (11)	26	0 (0)	72	5 (7)
Receptive sharing	8	0 (0)	3	0 (0)	12	1 (8)
p value		1.000		--		1.000
2023						
No receptive sharing	33	0 (0)	22	2 (9)	55	2 (4)
Receptive sharing	1	0 (0)	1	0 (0)	2	0 (0)
p value		--		1.000		1.000
2024						
No receptive sharing	44	4 (9)	18	1 (6)	63	5 (8)
Receptive sharing	9	0 (0)	4	0 (0)	13	0 (0)
p value		0.347		0.629		0.293
2025						
No receptive sharing	37	2 (5)	24	2 (8)	61	4 (7)
Receptive sharing	6	1 (17)	4	0 (0)	10	1 (10)
p value		0.315		0.549		0.693

Table 7.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Tasmania	Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Methamphetamine	12	0 (0)	21	2 (10)	33	2 (6)
Pharm. Opioids	11	3 (27)	3	0 (0)	14	3 (21)
OAT	11	1 (9)	3	0 (0)	14	1 (7)
Other drugs	7	2 (29)	6	0 (0)	13	2 (15)
p value		0.185		0.749		0.409
2022						
Methamphetamine	28	4 (14)	17	0 (0)	46	4 (9)
Pharm. Opioids	16	1 (6)	3	0 (0)	20	2 (10)
OAT	6	0 (0)	7	0 (0)	13	0 (0)
Other drugs	5	0 (0)	2	0 (0)	7	0 (0)
p value		0.538		--		0.574
2023						
Methamphetamine	15	0 (0)	20	2 (10)	35	2 (6)
Pharm. Opioids	7	0 (0)	2	0 (0)	9	0 (0)
OAT	9	0 (0)	2	0 (0)	11	0 (0)
Other drugs	4	0 (0)	0	0 (0)	4	0 (0)
p value		--		0.804		0.701
2024						
Methamphetamine	44	3 (7)	17	0 (0)	62	3 (5)
Pharm. Opioids	4	1 (25)	1	0 (0)	5	1 (20)
OAT	1	0 (0)	3	0 (0)	4	0 (0)
Other drugs	8	0 (0)	2	1 (50)	10	1 (10)
p value		0.446		0.012		0.502
2025						
Methamphetamine	30	3 (10)	24	1 (4)	54	4 (7)
Pharm. Opioids	5	0 (0)	0	0 (0)	5	0 (0)
OAT	2	0 (0)	1	1 (100)	3	1 (33)
Other drugs	7	0 (0)	4	0 (0)	11	0 (0)
p value		0.682		0.001		0.212

OAT: methadone, buprenorphine or buprenorphine/naloxone

Table 7.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Tasmania	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	20	1 (5)	21	2 (10)	41	3 (7)
Daily or more	19	4 (21)	7	0 (0)	26	4 (15)
Not last month	3	1 (33)	5	0 (0)	8	1 (13)
p value		0.222		0.544		0.572
2022						
Less than daily	25	2 (8)	14	0 (0)	40	2 (5)
Daily or more	28	3 (11)	15	0 (0)	44	4 (9)
Not last month	2	0 (0)	0	0 (0)	2	0 (0)
p value		1.000		--		0.722
2023						
Less than daily	21	0 (0)	16	2 (13)	37	2 (5)
Daily or more	13	0 (0)	7	0 (0)	20	0 (0)
Not last month	1	0 (0)	1	0 (0)	2	0 (0)
p value		--		1.000		0.568
2024						
Less than daily	32	3 (9)	9	1 (11)	42	4 (10)
Daily or more	21	1 (5)	13	0 (0)	34	1 (3)
Not last month	4	0 (0)	1	0 (0)	5	0 (0)
p value		0.691		0.443		0.416
2025						
Less than daily	18	0 (0)	15	2 (13)	33	2 (6)
Daily or more	25	3 (12)	14	0 (0)	39	3 (8)
Not last month	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.294		0.343		0.894

Table 7.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Tasmania	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	36	6 (17)	32	3 (9)	68	9 (13)
Imprisonment	4	0 (0)	2	0 (0)	6	0 (0)
p value		0.376		0.650		0.342
2022						
No imprisonment	44	4 (9)	24	0 (0)	70	5 (7)
Imprisonment	10	1 (10)	4	0 (0)	14	1 (7)
p value		1.000		--		1.000
2023						
No imprisonment	31	0 (0)	24	2 (8)	56	2 (4)
Imprisonment	5	0 (0)	0	0 (0)	5	0 (0)
p value		--		--		1.000
2024						
No imprisonment	39	3 (8)	18	1 (6)	58	4 (7)
Imprisonment	18	0 (0)	5	0 (0)	23	0 (0)
p value		0.227		0.590		0.573
2025						
No imprisonment	40	3 (8)	26	2 (8)	66	5 (8)
Imprisonment	4	0 (0)	3	0 (0)	7	0 (0)
p value		0.570		0.619		0.451

Table 7.4.9 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Tasmania	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
English speaking	39	6 (15)	35	3 (9)	74	9 (12)
Non-English speaking	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.463		--		0.520
2022						
English speaking	54	5 (9)	29	0 (0)	85	6 (7)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000
2023						
English speaking	36	0 (0)	24	2 (8)	61	2 (3)
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)
p value		--		1.000		1.000
2024						
English speaking	58	4 (7)	23	1 (4)	82	5 (6)
Non-English speaking	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.831		0.799
2025						
English speaking	44	3 (7)	30	2 (7)	74	5 (7)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

Table 7.4.10 HCV RNA prevalence by region/country of birth, gender and survey year

Tasmania		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Australia	35	6 (17)	34	3 (9)	69	9 (13)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	1	0 (0)	1	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	5	0 (0)	0	0 (0)	5	0 (0)	
p value		0.315		0.756		0.641	
2022							
Australia	52	5 (10)	28	0 (0)	82	6 (7)	
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)	
Other	1	0 (0)	0	0 (0)	1	0 (0)	
p value		1.000		--		1.000	
2023							
Australia	34	0 (0)	24	2 (8)	59	2 (3)	
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)	
Other	2	0 (0)	0	0 (0)	2	0 (0)	
p value		--		1.000		1.000	
2024							
Australia	54	3 (6)	22	1 (5)	76	4 (5)	
Other Oceania	1	0 (0)	1	0 (0)	2	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	3	0 (0)	0	0 (0)	3	0 (0)	
Other	0	0 (0)	0	0 (0)	1	0 (0)	
p value		0.889		0.827		0.954	
2025							
Australia	41	2 (5)	30	2 (7)	71	4 (6)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	3	1 (33)	0	0 (0)	3	1 (33)	
p value		0.059		--		0.061	

Victoria

Table 8.1.1 Number (%) of respondents by demographic characteristics and survey year

Victoria	2021*	2022	2023	2024	2025
Number of sites	3	5	6	6	6
N° surveyed	N=40	N=122	N=228	N=216	N=247
Response rate (%)	44%	43%	59%	57%	53%
Gender (%)					
Male	28 (70)	78 (64)	156 (68)	147 (68)	165 (67)
Female	11 (28)	43 (35)	68 (30)	63 (29)	75 (30)
Other	1 (3)	1 (1)	3 (1)	6 (3)	6 (2)
Not reported	0 (0)	0 (0)	1 (<1)	0 (0)	1 (<1)
Age (years)					
Median age	46	46	44.5	46	46
Age range	29-62	25-66	20-77	23-70	22-70
<25 years	0 (0)	0 (0)	2 (1)	2 (1)	2 (1)
25+ years	40 (100)	121 (99)	222 (97)	214 (99)	243 (98)
Not reported	0 (0)	1 (1)	4 (2)	0 (0)	2 (1)
Sexual identity (%)					
Heterosexual	30 (75)	92 (75)	184 (81)	170 (79)	208 (84)
Bisexual	7 (18)	14 (11)	19 (8)	22 (10)	21 (9)
Gay/Lesbian	1 (3)	9 (7)	11 (5)	11 (5)	9 (4)
Other	2 (5)	7 (6)	14 (6)	12 (6)	3 (1)
Not reported	0 (0)	0 (0)	0 (0)	1 (<1)	6 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	31 (78)	101 (83)	157 (69)	166 (77)	179 (72)
Yes	9 (23)	19 (16)	69 (30)	47 (22)	65 (26)
Not reported	0 (0)	2 (2)	2 (1)	3 (1)	3 (1)
Region/country of birth (%)					
Australia	33 (83)	96 (79)	199 (87)	185 (86)	221 (89)
Other Oceania	2 (5)	3 (2)	6 (3)	1 (<1)	6 (2)
Asia	0 (0)	0 (0)	4 (2)	2 (1)	3 (1)
UK & Ireland	2 (5)	6 (5)	6 (3)	11 (5)	5 (2)
Other	3 (8)	12 (10)	11 (5)	13 (6)	7 (3)
Not reported	0 (0)	5 (4)	2 (1)	4 (2)	5 (2)
Main language spoken at home by parents (%)					
English	36 (90)	103 (84)	201 (88)	187 (87)	228 (92)
Non-English	4 (10)	16 (13)	26 (11)	27 (13)	17 (7)
Not reported	0 (0)	3 (2)	1 (<1)	2 (1)	2 (1)
Age at first injection and time since first injection (years)					
Median age at first injection	18	18	18	19	18
Age range at first injection	13-50	11-50	11-71	11-64	10-59
N° not reported	0	5	7	8	6
Median yrs since first injection	27.5	27	26	28	27
Range yrs since first injection	<1-41	<1-52	<1-49	2-52	1-55
<3 years since first injection	2 (5)	2 (2)	6 (3)	4 (2)	9 (4)
3+ years since first injection	38 (95)	115 (94)	213 (93)	204 (94)	231 (94)
Not reported	0 (0)	5 (4)	9 (4)	8 (4)	7 (3)

* Implementation of the 2021 ANSPS was impacted by the COVID-19 pandemic

Table 8.1.2 Number (%) of respondents by last drug injected, frequency of injecting, overdose, imprisonment, injection in prison and survey year

Victoria	2021	2022	2023	2024	2025
N° surveyed	N=40	N=122	N=228	N=216	N=247
Drug last injected (%)					
Cocaine	0 (0)	1 (1)	1 (<1)	0 (0)	3 (1)
Methamphetamine	18 (45)	35 (29)	62 (27)	70 (32)	96 (39)
Heroin	16 (40)	70 (57)	144 (63)	112 (52)	110 (45)
Pharm. opioids	1 (3)	0 (0)	3 (1)	1 (<1)	1 (<1)
Methadone	0 (0)	1 (1)	1 (<1)	2 (1)	3 (1)
Buprenorphine	1 (3)	3 (2)	0 (0)	6 (3)	2 (1)
Buprenorphine/naloxone	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)
PIEDs	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)
More than one	3 (8)	9 (7)	13 (6)	22 (10)	29 (12)
Other	1 (3)	2 (2)	2 (1)	1 (<1)	0 (0)
Not reported	0 (0)	1 (1)	1 (<1)	0 (0)	3 (1)
Ever injected opioids (%)					
No	6 (15)	5 (4)	12 (5)	20 (9)	26 (11)
Yes	34 (85)	117 (96)	215 (94)	196 (91)	218 (88)
Not reported	0 (0)	0 (0)	1 (<1)	0 (0)	3 (1)
Frequency of injection last month (%)					
Not last month	2 (5)	10 (8)	20 (9)	11 (5)	18 (7)
Less than weekly	10 (25)	16 (13)	24 (11)	19 (9)	29 (12)
Weekly not daily	6 (15)	20 (16)	36 (16)	39 (18)	33 (13)
Daily or more	22 (55)	73 (60)	148 (65)	144 (67)	157 (64)
Not reported	0 (0)	3 (2)	0 (0)	3 (1)	10 (4)
Present when someone injected for the first time in the last 12 months (%)					
No	28 (70)	90 (74)	199 (87)	179 (83)	209 (85)
Yes	7 (18)	25 (20)	21 (9)	34 (16)	33 (13)
Not reported	5 (13)	7 (6)	8 (4)	3 (1)	5 (2)
Overdosed in last 12 months (%)					
No	30 (75)	85 (70)	163 (71)	158 (73)	188 (76)
Yes	4 (10)	28 (23)	54 (24)	50 (23)	53 (21)
Not reported	6 (15)	9 (7)	11 (5)	8 (4)	6 (2)
Imprisonment last year (%)					
No	34 (85)	93 (76)	185 (81)	183 (85)	213 (86)
Yes	2 (5)	15 (12)	32 (14)	21 (10)	21 (9)
Not reported	4 (10)	14 (11)	11 (5)	12 (6)	13 (5)
Injected while in prison last year					
N° in prison last year	N=2	N=15	N=32	N=15	N=32
No	2 (100)	10 (67)	23 (72)	16 (76)	17 (81)
Yes	0 (0)	5 (33)	8 (25)	4 (19)	3 (14)
Not reported	0 (0)	0 (0)	1 (3)	1 (5)	1 (5)

Table 8.1.3 Number (%) of respondents by injecting behaviour in the last month and survey year

Victoria	2021	2022	2023	2024	2025
N° injected last month	N=38	N=109	N=208	N=202	N=219
Places injected last month (%)					
All private	18 (47)	42 (39)	67 (32)	87 (43)	87 (40)
Any public	20 (53)	65 (60)	141 (68)	115 (57)	129 (59)
Not reported	0 (0)	2 (2)	0 (0)	0 (0)	3 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	34 (89)	82 (75)	163 (78)	159 (79)	158 (72)
Most of the time	2 (5)	21 (19)	35 (17)	37 (18)	50 (23)
Half of the time	0 (0)	3 (3)	6 (3)	1 (1)	3 (1)
Some of the time	0 (0)	1 (1)	3 (1)	3 (1)	4 (2)
Not last month	2 (5)	1 (1)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (1)	1 (<1)	2 (1)	4 (2)
Re-used someone else's used needle & syringe last month (%)					
None	35 (92)	84 (77)	175 (84)	176 (87)	191 (87)
Once	0 (0)	7 (6)	9 (4)	12 (6)	7 (3)
Twice	2 (5)	8 (7)	12 (6)	5 (2)	5 (2)
3-5 times	0 (0)	3 (3)	6 (3)	5 (2)	4 (2)
>5 times	1 (3)	6 (6)	4 (2)	4 (2)	7 (3)
Not reported	0 (0)	1 (1)	2 (1)	0 (0)	5 (2)
Number of people needle & syringe was re-used after last month (%)					
None	34 (89)	84 (77)	175 (84)	176 (87)	191 (87)
One	1 (3)	4 (4)	15 (7)	10 (5)	11 (5)
Two	0 (0)	3 (3)	2 (1)	1 (1)	3 (1)
Three to five	0 (0)	4 (4)	2 (1)	0 (0)	2 (1)
More than five	0 (0)	2 (2)	1 (<1)	5 (2)	0 (0)
Don't know	2 (5)	4 (4)	4 (2)	7 (3)	4 (2)
Not reported	1 (3)	8 (7)	9 (4)	3 (1)	8 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	0 (0)	4 (4)	4 (2)	12 (6)	8 (4)
Casual sex partner	0 (0)	1 (1)	1 (<1)	1 (1)	3 (1)
Close friend	1 (3)	4 (4)	7 (3)	6 (3)	6 (3)
Acquaintance	0 (0)	4 (4)	9 (4)	2 (1)	5 (2)
Other	0 (0)	2 (2)	0 (0)	2 (1)	1 (<1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	9 (24)	30 (28)	57 (27)	55 (27)	69 (32)
Water	4 (11)	22 (20)	44 (21)	41 (20)	49 (22)
Filter	5 (13)	12 (11)	19 (9)	20 (10)	29 (13)
Drug mix	3 (8)	9 (8)	26 (13)	28 (14)	25 (11)
None	28 (74)	71 (65)	137 (66)	133 (66)	141 (64)
Injected by someone after that person injected themselves or others last month (%)					
No	35 (92)	85 (78)	169 (81)	170 (84)	182 (83)
Yes	3 (8)	19 (17)	39 (19)	32 (16)	34 (16)
Not reported	0 (0)	5 (5)	0 (0)	0 (0)	3 (1)
Source of needle acquisition (%)					
Needle Syringe Program	31 (82)	92 (84)	199 (96)	183 (91)	200 (91)
Chemist/Pharmacy	4 (11)	10 (9)	11 (5)	24 (12)	30 (14)
Personal sources	5 (13)	10 (9)	12 (6)	25 (12)	32 (15)
Dispensing/Vending Machine	16 (42)	28 (26)	59 (28)	41 (20)	59 (27)
Other sources	0 (0)	5 (5)	1 (<1)	11 (5)	2 (1)

Table 8.1.4 Number (%) of respondents by treatment for drug use and survey year

Victoria	2021	2022	2023	2024	2025
N° surveyed	N=40	N=122	N=228	N=216	N=247
Ever any treatment/therapy for drug use (%)					
No	6 (15)	13 (11)	23 (10)	23 (11)	36 (15)
Yes	34 (85)	108 (89)	205 (90)	193 (89)	209 (85)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	2 (1)
History of methadone maintenance treatment (%)					
Currently	16 (40)	37 (30)	61 (27)	69 (32)	66 (27)
Previously	12 (30)	51 (42)	101 (44)	78 (36)	81 (33)
Never	11 (28)	30 (25)	62 (27)	62 (29)	90 (36)
Not reported	1 (3)	4 (3)	4 (2)	7 (3)	10 (4)
History of buprenorphine (Subutex®) treatment (%)					
Currently	4 (10)	16 (13)	12 (5)	19 (9)	22 (9)
Previously	14 (35)	53 (43)	83 (36)	88 (41)	96 (39)
Never	21 (53)	49 (40)	125 (55)	104 (48)	119 (48)
Not reported	1 (3)	4 (3)	8 (4)	5 (2)	10 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	3 (8)	8 (7)	13 (6)	15 (7)	16 (6)
Previously	14 (35)	56 (46)	93 (41)	92 (43)	93 (38)
Never	23 (58)	56 (46)	119 (52)	108 (50)	134 (54)
Not reported	0 (0)	2 (2)	3 (1)	1 (<1)	4 (2)
History of depot buprenorphine treatment (%)					
Currently	2 (5)	16 (13)	28 (12)	36 (17)	32 (13)
Previously	5 (13)	26 (21)	48 (21)	42 (19)	47 (19)
Never	32 (80)	75 (61)	144 (63)	134 (62)	155 (63)
Not reported	1 (3)	5 (4)	8 (4)	4 (2)	13 (5)

Table 8.1.5 Number (%) of respondents by sexual behaviour in the month prior to survey and survey year

Victoria	2021	2022	2023	2024	2025
N° surveyed	N=40	N=122	N=228	N=216	N=247
Sex with a regular partner last month (%)					
No	31 (78)	74 (61)	147 (64)	144 (67)	175 (71)
Yes	6 (15)	39 (32)	75 (33)	64 (30)	63 (26)
Not reported	3 (8)	9 (7)	6 (3)	8 (4)	9 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=6	N=39	N=75	N=64	N=63
Never	5 (83)	29 (74)	61 (81)	49 (77)	47 (75)
Sometimes	0 (0)	4 (10)	7 (9)	5 (8)	6 (10)
Every time	1 (17)	4 (10)	4 (5)	6 (9)	6 (10)
Not reported	0 (0)	2 (5)	3 (4)	4 (6)	4 (6)
Sex with other partner(s) last month (%)					
No	25 (63)	94 (77)	179 (79)	181 (84)	199 (81)
Yes	8 (20)	19 (16)	31 (14)	26 (12)	33 (13)
Not reported	7 (18)	9 (7)	18 (8)	9 (4)	15 (6)
Condom used with other partner(s) last month (%)					
N° surveyed	N=8	N=19	N=31	N=26	N=33
Never	2 (25)	9 (47)	13 (42)	14 (54)	15 (45)
Sometimes	1 (13)	6 (32)	11 (35)	5 (19)	12 (36)
Every time	4 (50)	4 (21)	7 (23)	5 (19)	5 (15)
Not reported	1 (13)	0 (0)	0 (0)	2 (8)	1 (3)
Sex work last month (%)					
No	30 (75)	102 (84)	204 (89)	201 (93)	216 (87)
Yes	5 (13)	8 (7)	15 (7)	7 (3)	14 (6)
Not reported	5 (13)	12 (10)	9 (4)	8 (4)	17 (7)
Condom used at last sex work (%)					
Yes	4 (80)	6 (75)	8 (53)	6 (86)	9 (64)

Table 8.1.6 Number (%) of respondents by testing for HIV and HCV, HCV treatment by survey year

Victoria	2021	2022	2023	2024	2025
N° surveyed	N=40	N=122	N=228	N=216	N=247
Previous HIV test (%)					
Yes, ever	35 (88)	100 (82)	198 (87)	188 (87)	210 (85)
Yes, last year	12 (30)	58 (48)	122 (54)	123 (57)	129 (52)
>1 year ago	23 (58)	42 (34)	76 (33)	65 (30)	81 (33)
Never tested	1 (3)	13 (11)	24 (11)	20 (9)	27 (11)
Not reported	4 (10)	9 (7)	6 (3)	8 (4)	10 (4)
Previous HCV test (%)					
Yes, ever	33 (83)	104 (85)	200 (88)	192 (89)	213 (86)
Yes, last year	17 (43)	66 (54)	146 (64)	132 (61)	131 (53)
>1 year ago	17 (43)	38 (31)	54 (24)	60 (28)	82 (33)
Never tested	1 (3)	8 (7)	15 (7)	6 (3)	13 (5)
Not reported	5 (13)	10 (8)	13 (6)	18 (8)	21 (9)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=11	N=21	N=42	N=60	N=69
Antiviral treatment	5 (45)	15 (71)	32 (76)	48 (80)	58 (84)
No antiviral treatment	6 (55)	6 (29)	10 (24)	12 (20)	11 (16)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)^{**}					
N° self-reported HCV diagnosis	N=10	N=14	N=29	N=24	N=31
Antiviral treatment	2 (20)	5 (36)	15 (52)	7 (29)	16 (52)
No antiviral treatment	8 (80)	9 (64)	14 (48)	17 (71)	15 (48)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance^{*} excludes people who reported treatment induced clearance more than 12 months previously

HIV antibody prevalence

Table 8.2.1 HIV antibody prevalence by gender and survey year

Victoria	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021	25	1 (4.0)	11	0 (0.0)	37	2 (5.4)
2022	68	1 (1.5)	41	1 (2.4)	109	2 (1.8)
2023	80	3 (3.8)	38	1 (2.6)	120	4 (3.3)
2024	135	2 (1.5)	60	2 (3.3)	200	4 (2.0)
2025	161	1 (0.6)	75	0 (0.0)	243	2 (0.8)
X ² p trend		0.163		0.513		0.082

HCV antibody prevalence

Table 8.3.1 HCV antibody prevalence by gender and survey year

Victoria	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	25	8 (32)	11	8 (73)	37	16 (43)
2022	64	19 (30)	39	18 (46)	103	37 (36)
2023*	80	46 (58)	38	23 (61)	120	70 (58)
2024	136	72 (53)	60	31 (52)	201	106 (53)
2025	161	77 (48)	75	40 (53)	243	119 (49)
X ² p trend^		0.145		0.543		0.094

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

^ X² p trend calculated on years 2023-2025 only

Table 8.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Victoria	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	22	8 (36)	4	4 (100)	27	12 (44)
Bisexual	1	0 (0)	6	3 (50)	7	3 (43)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		0.273		1.000
2022						
Heterosexual	56	16 (29)	22	9 (41)	78	25 (32)
Bisexual	2	1 (50)	10	2 (20)	12	3 (25)
Homosexual	4	1 (25)	3	3 (100)	7	4 (57)
p value		0.723		0.018		0.076
2023						
Heterosexual	69	44 (64)	30	17 (57)	99	61 (62)
Bisexual	4	1 (25)	5	4 (80)	9	5 (56)
Homosexual	4	1 (25)	0	0 (0)	5	1 (20)
p value		0.029		0.888		0.334
2024						
Heterosexual	120	65 (54)	39	21 (54)	159	86 (54)
Bisexual	7	4 (57)	11	5 (45)	20	11 (55)
Homosexual	5	1 (20)	4	2 (50)	10	3 (30)
p value		0.678		0.269		0.208
2025						
Heterosexual	142	72 (51)	61	30 (49)	205	102 (50)
Bisexual	10	3 (30)	9	6 (67)	21	9 (43)
Homosexual	4	0 (0)	3	2 (67)	8	3 (38)
p value		0.132		0.544		0.231

Table 8.3.3 HCV antibody prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	1	0 (0)	2	0 (0)
35-44 years	6	2 (33)	4	2 (50)	10	4 (40)
45+ years	19	6 (32)	6	6 (100)	25	12 (48)
p value		1.000		0.061		0.542
2022						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	5	2 (40)	6	2 (33)	11	4 (36)
35-44 years	16	7 (44)	17	8 (47)	33	15 (45)
45+ years	43	10 (23)	15	8 (53)	58	18 (31)
p value		0.248		0.76		0.361
2023						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	3	1 (33)	3	2 (67)	6	3 (50)
35-44 years	35	19 (54)	15	10 (67)	52	30 (58)
45+ years	39	25 (64)	19	10 (53)	58	35 (60)
p value		0.412		0.775		0.710
2024						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	9	4 (44)	7	3 (43)	18	8 (44)
35-44 years	42	25 (60)	15	8 (53)	58	33 (57)
45+ years	85	43 (51)	38	20 (53)	125	65 (52)
p value		0.554		0.883		0.629
2025						
<25 years	1	0 (0)	1	0 (0)	2	0 (0)
25-34 years	13	3 (23)	6	1 (17)	20	4 (20)
35-44 years	45	14 (31)	21	12 (57)	69	27 (39)
45+ years	101	60 (59)	46	26 (57)	150	87 (58)
p value		0.002		0.197		0.001

Table 8.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Victoria	Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3 to 10 years	4	1 (25)	1	1 (100)	6	2 (33)
11+ years	20	7 (35)	9	7 (78)	29	14 (48)
p value		1		0.491		0.575
2022						
<3 years	2	1 (50)	0	0 (0)	2	1 (50)
3 to 10 years	3	0 (0)	3	0 (0)	6	0 (0)
11+ years	56	18 (32)	34	17 (50)	90	35 (39)
p value		0.588		0.234		0.095
2023						
<3 years	2	0 (0)	2	0 (0)	4	0 (0)
3 to 10 years	8	2 (25)	2	1 (50)	10	3 (30)
11+ years	68	43 (63)	32	20 (63)	102	64 (63)
p value		0.025		0.310		0.006
2024						
<3 years	3	1 (33)	1	0 (0)	4	1 (25)
3 to 10 years	9	2 (22)	4	0 (0)	13	2 (15)
11+ years	121	68 (56)	52	30 (58)	178	101 (57)
p value		0.112		0.048		0.008
2025						
<3 years	3	0 (0)	5	0 (0)	9	0 (0)
3 to 10 years	9	1 (11)	8	3 (38)	18	4 (22)
11+ years	145	75 (52)	59	35 (59)	209	112 (54)
p value		0.015		0.025		<0.001

Table 8.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	2	0 (0)	30	14 (47)	32	14 (44)
Receptive sharing	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		0.601		0.582
2022						
No receptive sharing	2	1 (50)	66	26 (39)	71	27 (38)
Receptive sharing	0	0 (0)	19	3 (16)	21	4 (19)
p value		--		0.970		0.123
2023						
No receptive sharing	4	0 (0)	81	50 (62)	87	52 (60)
Receptive sharing	0	0 (0)	16	9 (56)	18	10 (56)
p value		--		0.682		0.741
2024						
No receptive sharing	4	1 (25)	157	81 (52)	166	84 (51)
Receptive sharing	0	0 (0)	21	14 (67)	22	14 (64)
p value		--		0.193		0.250
2025						
No receptive sharing	7	0 (0)	177	88 (50)	187	90 (48)
Receptive sharing	0	0 (0)	22	13 (59)	23	13 (57)
p value		--		0.407		0.447

Table 8.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heroin	0	0 (0)	15	6 (40)	15	6 (40)
Methamphetamine	2	0 (0)	14	7 (50)	16	7 (44)
Other opioids	0	0 (0)	2	1 (50)	2	1 (50)
Other drugs	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.951		0.981
2022						
Heroin	0	0 (0)	57	26 (46)	60	26 (43)
Methamphetamine	1	0 (0)	25	6 (24)	28	7 (25)
Other opioids	1	1 (100)	2	1 (50)	3	2 (67)
Other drugs	0	0 (0)	9	2 (22)	9	2 (22)
p value		0.157		0.206		0.192
2023						
Heroin	1	0 (0)	71	46 (65)	74	48 (65)
Methamphetamine	3	0 (0)	30	16 (53)	34	17 (50)
Other opioids	0	0 (0)	3	1 (33)	4	1 (25)
Other drugs	0	0 (0)	8	4 (50)	8	4 (50)
p value		--		0.484		0.228
2024						
Heroin	1	1 (100)	103	60 (58)	108	62 (57)
Methamphetamine	3	0 (0)	58	23 (40)	63	24 (38)
Other opioids	0	0 (0)	9	8 (89)	9	8 (89)
Other drugs	0	0 (0)	19	10 (53)	19	10 (53)
p value		0.046		0.019		0.011
2025						
Heroin	0	0 (0)	104	65 (63)	106	65 (61)
Methamphetamine	8	0 (0)	81	30 (37)	92	33 (36)
Other opioids	0	0 (0)	4	3 (75)	4	3 (75)
Other drugs	1	0 (0)	27	11 (41)	28	11 (39)
p value		--		0.003		0.002

Table 8.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	0	0 (0)	15	7 (47)	15	7 (47)
Daily or more	2	0 (0)	18	9 (50)	20	9 (45)
Not last month	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.641		0.657
2022						
Less than daily	1	0 (0)	24	9 (38)	27	9 (33)
Daily or more	1	1 (100)	62	21 (34)	66	23 (35)
Not last month	0	0 (0)	7	5 (71)	7	5 (71)
p value		1.000		0.179		0.183
2023						
Less than daily	2	0 (0)	29	21 (72)	32	21 (66)
Daily or more	2	0 (0)	69	39 (57)	74	42 (57)
Not last month	0	0 (0)	14	7 (50)	14	7 (50)
p value		--		0.248		0.556
2024						
Less than daily	1	1 (100)	53	25 (47)	55	26 (47)
Daily or more	3	0 (0)	125	70 (56)	133	72 (54)
Not last month	0	0 (0)	11	6 (55)	11	6 (55)
p value		0.046		0.557		0.684
2025						
Less than daily	1	0 (0)	60	26 (43)	62	27 (44)
Daily or more	7	0 (0)	143	78 (55)	153	79 (52)
Not last month	1	0 (0)	16	7 (44)	18	8 (44)
p value		--		0.293		0.519

Table 8.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	2	0 (0)	30	12 (40)	32	12 (38)
Imprisonment	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
2022						
No imprisonment	1	0 (0)	74	26 (35)	79	26 (33)
Imprisonment	1	1 (100)	12	3 (25)	14	5 (36)
p value		1.000		0.743		1.000
2023						
No imprisonment	4	0 (0)	90	55 (61)	98	58 (59)
Imprisonment	0	0 (0)	15	9 (60)	15	9 (60)
p value		--		0.935		0.952
2024						
No imprisonment	4	1 (25)	159	85 (53)	169	88 (52)
Imprisonment	0	0 (0)	20	11 (55)	20	11 (55)
p value		--		0.896		0.804
2025						
No imprisonment	8	0 (0)	194	102 (53)	209	105 (50)
Imprisonment	0	0 (0)	21	9 (43)	21	9 (43)
p value		--		0.397		0.519

Table 8.3.9 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Victoria		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
English speaking	21	6 (29)	11	8 (73)	33	14 (42)	
Non-English speaking	4	2 (50)	0	0 (0)	4	2 (50)	
p value		0.570		--		1.000	
2022							
English speaking	53	17 (32)	36	17 (42)	89	34 (38)	
Non-English speaking	9	2 (22)	3	1 (33)	12	3 (25)	
p value		0.709		1.000		0.373	
2023							
English speaking	71	40 (56)	36	21 (58)	109	62 (57)	
Non-English speaking	9	6 (67)	2	2 (100)	11	8 (73)	
p value		0.726		0.509		0.357	
2024							
English speaking	114	59 (52)	56	31 (55)	175	93 (53)	
Non-English speaking	20	12 (60)	4	0 (0)	24	12 (50)	
p value		0.496		0.032		0.772	
2025							
English speaking	147	69 (47)	71	36 (51)	224	107 (48)	
Non-English speaking	12	7 (58)	4	4 (100)	17	11 (65)	
p value		0.447		0.055		0.178	

Table 8.3.10 HCV antibody prevalence by region/country of birth, gender and survey year

Victoria	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Australia	20	7 (35)	10	8 (80)	30	15 (50)
Other Oceania	0	0 (0)	1	0 (0)	2	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	0 (0)	0	0 (0)	2	0 (0)
Other	3	1 (33)	0	0 (0)	3	1 (33)
p value		1.000		0.273		0.435
2022						
Australia	48	17 (35)	32	15 (47)	80	32 (40)
Other Oceania	1	0 (0)	2	1 (50)	3	1 (33)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	4	1 (25)	2	0 (0)	6	1 (17)
Other	8	1 (13)	1	0 (0)	9	1 (11)
p value		0.716		0.746		0.270
2023						
Australia	73	42 (58)	34	20 (59)	109	63 (58)
Other Oceania	0	0 (0)	1	1 (100)	1	1 (100)
Asia	2	1 (50)	0	0 (0)	2	1 (50)
UK & Ireland	0	0 (0)	1	1 (100)	1	1 (100)
Other	5	3 (60)	2	1 (50)	7	4 (57)
p value		1.000		1.000		1.000
2024						
Australia	116	60 (52)	52	29 (56)	173	92 (53)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	1	0 (0)	1	0 (0)	2	0 (0)
UK & Ireland	6	3 (50)	3	1 (33)	9	4 (44)
Other	9	6 (67)	3	0 (0)	12	6 (50)
p value		0.596		0.171		0.492
2025						
Australia	142	71 (50)	69	37 (54)	217	110 (51)
Other Oceania	4	1 (25)	2	0 (0)	6	1 (17)
Asia	2	1 (50)	1	1 (100)	3	2 (67)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	9	4 (44)	1	1 (100)	11	5 (45)
p value		0.788		0.257		0.372

HCV RNA prevalence

Table 8.4.1 HCV RNA prevalence by gender and survey year

Victoria	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	19	0 (0)	8	4 (50)	28	5 (18)
2022	37	6 (16)	29	2 (7)	66	8 (12)
2023	76	8 (11)	35	8 (23)	113	16 (14)
2024	134	8 (6)	60	5 (8)	199	13 (7)
2025	141	12 (9)	68	3 (4)	216	15 (7)
X ² p trend		0.695		0.003		0.009

Totals include respondents where gender was reported as other or not reported

Table 8.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Victoria	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	16	0 (0)	3	1 (33)	20	2 (10)
Bisexual	1	0 (0)	4	2 (50)	5	2 (40)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		0.659		0.228
2022						
Heterosexual	34	6 (18)	18	1 (6)	52	7 (13)
Bisexual	1	0 (0)	5	0 (0)	6	0 (0)
Homosexual	2	0 (0)	2	1 (50)	4	1 (25)
p value		1.000		0.401		0.729
2023						
Heterosexual	65	8 (12)	27	7 (26)	92	15 (16)
Bisexual	4	0 (0)	5	1 (20)	9	1 (11)
Homosexual	4	0 (0)	0	0 (0)	5	0 (0)
p value		1.000		1.000		1.000
2024						
Heterosexual	118	8 (7)	39	3 (8)	157	11 (7)
Bisexual	7	0 (0)	11	1 (9)	20	1 (5)
Homosexual	5	0 (0)	4	0 (0)	10	0 (0)
p value		0.886		0.561		0.823
2025						
Heterosexual	124	11 (9)	57	3 (5)	183	14 (8)
Bisexual	9	1 (11)	8	0 (0)	19	1 (5)
Homosexual	3	0 (0)	1	0 (0)	5	0 (0)
p value		0.986		0.908		0.960

Table 8.4.3 HCV RNA prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	1	0 (0)	2	1 (50)
35-44 years	4	0 (0)	2	1 (50)	6	1 (17)
45+ years	15	0 (0)	5	3 (60)	20	3 (15)
p value		--		0.549		0.466
2022						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	1 (50)	3	1 (33)	5	2 (40)
35-44 years	10	1 (10)	11	1 (9)	21	2 (10)
45+ years	25	4 (16)	14	0 (0)	39	4 (10)
p value		0.408		0.095		0.164
2023						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	3	1 (33)	3	1 (33)	6	2 (33)
35-44 years	33	4 (12)	14	3 (21)	49	7 (14)
45+ years	37	2 (5)	17	3 (18)	54	5 (9)
p value		0.279		0.839		0.298
2024						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	9	1 (11)	7	0 (0)	18	1 (5)
35-44 years	41	1 (2)	15	2 (13)	57	3 (5)
45+ years	84	6 (7)	38	3 (8)	124	9 (7)
p value		0.463		0.566		0.867
2025						
<25 years	1	0 (0)	1	0 (0)	2	0 (0)
25-34 years	10	0 (0)	5	0 (0)	16	0 (0)
35-44 years	40	2 (5)	18	2 (11)	61	4 (7)
45+ years	90	10 (11)	43	1 (2)	136	11 (8)
p value		0.487		0.458		0.654

Table 8.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	3	0 (0)	1	1 (100)	5	2 (40)
11+ years	15	0 (0)	7	3 (43)	22	3 (14)
p value		--		0.285		0.340
2022						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	2	0 (0)	2	0 (0)	4	0 (0)
11+ years	34	5 (15)	25	1 (4)	59	6 (10)
p value		0.182		1.000		0.161
2023						
<3 years	2	0 (0)	2	0 (0)	4	0 (0)
3 to 10 years	8	0 (0)	2	2 (100)	10	2 (20)
11+ years	64	7 (11)	29	5 (17)	95	12 (13)
p value		1.000		0.079		0.782
2024						
<3 years	2	0 (0)	1	0 (0)	3	0 (0)
3 to 10 years	9	0 (0)	4	0 (0)	13	0 (0)
11+ years	120	8 (7)	52	5 (10)	177	13 (7)
p value		0.677		0.768		0.533
2025						
<3 years	3	0 (0)	4	0 (0)	8	0 (0)
3 to 10 years	8	0 (0)	8	0 (0)	17	0 (0)
11+ years	128	12 (9)	54	3 (6)	187	15 (8)
p value		0.569		0.705		0.340

Table 8.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Victoria Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	18	0 (0)	6	3 (50)	25	4 (16)
Receptive sharing	1	0 (0)	1	1 (100)	2	1 (50)
p value		--		0.350		0.234
2022						
No receptive sharing	27	5 (19)	22	0 (0)	49	5 (10)
Receptive sharing	7	0 (0)	5	1 (20)	12	1 (8)
p value		0.559		0.185		1.000
2023						
No receptive sharing	55	6 (11)	24	4 (17)	81	10 (12)
Receptive sharing	12	1 (8)	6	3 (50)	18	4 (22)
p value		1.000		0.120		0.277
2024						
No receptive sharing	111	6 (5)	51	4 (8)	165	10 (6)
Receptive sharing	11	2 (18)	8	0 (0)	21	2 (10)
p value		0.102		0.412		0.543
2025						
No receptive sharing	114	8 (7)	50	2 (4)	168	10 (6)
Receptive sharing	14	2 (14)	5	1 (20)	20	3 (15)
p value		0.339		0.133		0.132

Table 8.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Victoria Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heroin	9	0 (0)	3	0 (0)	13	1 (8)
Methamphetamine	8	0 (0)	4	3 (75)	12	3 (25)
Other opioids	1	0 (0)	0	0 (0)	1	0 (0)
Other drugs	1	0 (0)	1	1 (100)	2	1 (50)
p value		--		0.082		0.398
2022						
Heroin	22	3 (14)	15	0 (0)	37	3 (8)
Methamphetamine	10	1 (10)	11	2 (18)	21	3 (14)
Other opioids	2	1 (50)	1	0 (0)	3	1 (33)
Other drugs	2	1 (50)	2	0 (0)	4	1 (25)
p value		0.300		0.319		0.474
2023						
Heroin	47	6 (13)	21	5 (24)	69	11 (16)
Methamphetamine	17	1 (6)	14	3 (21)	32	4 (13)
Other opioids	4	0 (0)	0	0 (0)	4	0 (0)
Other drugs	8	1 (13)	0	0 (0)	8	1 (13)
p value		0.767		0.869		0.818
2024						
Heroin	80	2 (3)	27	2 (7)	107	4 (4)
Methamphetamine	37	3 (8)	22	2 (9)	62	5 (8)
Other opioids	8	2 (25)	1	0 (0)	9	2 (22)
Other drugs	8	1 (13)	9	0 (0)	19	1 (5)
p value		0.052		0.818		0.134
2025						
Heroin	60	4 (7)	32	2 (6)	95	6 (6)
Methamphetamine	52	5 (10)	28	0 (0)	82	5 (6)
Other opioids	2	0 (0)	2	0 (0)	4	0 (0)
Other drugs	20	1 (5)	4	0 (0)	26	1 (4)
p value		0.864		0.534		0.922

Table 8.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Victoria	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	9	0 (0)	2	2 (100)	11	2 (18)
Daily or more	10	0 (0)	5	2 (40)	16	3 (19)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.202		0.893
2022						
Less than daily	6	1 (17)	10	0 (0)	16	1 (6)
Daily or more	28	4 (14)	17	1 (6)	45	5 (11)
Not last month	2	1 (50)	2	1 (50)	4	2 (50)
p value		0.346		0.135		0.109
2023						
Less than daily	21	2 (10)	9	3 (33)	31	5 (16)
Daily or more	47	5 (11)	21	4 (19)	69	9 (13)
Not last month	8	1 (13)	5	1 (20)	13	2 (15)
p value		1.000		0.844		0.925
2024						
Less than daily	40	3 (8)	13	2 (15)	54	5 (9)
Daily or more	82	5 (6)	46	2 (4)	132	7 (5)
Not last month	11	0 (0)	0	0 (0)	11	0 (0)
p value		0.650		0.162		0.406
2025						
Less than daily	36	2 (6)	20	1 (5)	58	3 (5)
Daily or more	93	9 (10)	38	2 (5)	135	11 (8)
Not last month	6	0 (0)	10	0 (0)	17	0 (0)
p value		0.564		0.762		0.387

Table 8.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Victoria	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	19	0 (0)	4	3 (75)	24	4 (17)
Imprisonment	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.171		0.656
2022						
No imprisonment	28	5 (18)	20	1 (5)	48	6 (13)
Imprisonment	6	1 (17)	5	1 (20)	11	2 (18)
p value		1.000		0.367		0.635
2023						
No imprisonment	59	7 (12)	31	8 (26)	92	15 (16)
Imprisonment	12	1 (8)	2	0 (0)	14	1 (7)
p value		1.000		1.000		0.689
2024						
No imprisonment	111	7 (6)	52	5 (10)	167	12 (7)
Imprisonment	14	0 (0)	6	0 (0)	20	0 (0)
p value		0.334		0.427		0.215
2025						
No imprisonment	123	12 (10)	63	3 (5)	191	15 (8)
Imprisonment	14	0 (0)	4	0 (0)	18	0 (0)
p value		0.221		0.655		0.217

Table 8.4.9 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
English speaking	16	0 (0)	8	4 (50)	25	5 (20)
Non-English speaking	3	0 (0)	0	0 (0)	3	0 (0)
p value		--		--		0.393
2022						
English speaking	31	5 (16)	26	1 (4)	57	6 (11)
Non-English speaking	5	1 (20)	3	1 (33)	8	2 (25)
p value		1.000		0.200		0.254
2023						
English speaking	67	8 (12)	33	8 (24)	102	16 (16)
Non-English speaking	9	0 (0)	2	0 (0)	11	0 (0)
p value		0.585		1.000		0.359
2024						
English speaking	112	7 (6)	56	5 (9)	173	12 (7)
Non-English speaking	20	1 (5)	4	0 (0)	24	1 (4)
p value		0.829		0.533		0.609
2025						
English speaking	129	10 (8)	64	1 (2)	199	11 (6)
Non-English speaking	11	2 (18)	4	2 (50)	16	4 (25)
p value		0.236		<0.001		0.003

Table 8.4.10 HCV RNA prevalence by region/country of birth, gender and survey year

Victoria		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Australia	14	0 (0)	8	4 (50)	22	4 (18)	
Other Oceania	0	0 (0)	0	0 (0)	1	1 (100)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	2	0 (0)	0	0 (0)	2	0 (0)	
Other	3	0 (0)	0	0 (0)	3	0 (0)	
p value		--		--		0.128	
2022							
Australia	30	6 (20)	24	1 (4)	54	7 (13)	
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	2	0 (0)	3	0 (0)	
Other	5	0 (0)	0	0 (0)	5	0 (0)	
p value		0.634		1.000		1.000	
2023							
Australia	69	8 (12)	31	8 (26)	102	16 (16)	
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)	
Asia	2	0 (0)	0	0 (0)	2	0 (0)	
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)	
Other	5	0 (0)	2	0 (0)	7	0 (0)	
p value		1.000		1.000		0.780	
2024							
Australia	114	8 (7)	52	5 (10)	171	13 (8)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	1	0 (0)	1	0 (0)	2	0 (0)	
UK & Ireland	6	0 (0)	3	0 (0)	9	0 (0)	
Other	9	0 (0)	3	0 (0)	12	0 (0)	
p value		0.866		0.865		0.744	
2025							
Australia	123	10 (8)	63	2 (3)	192	12 (6)	
Other Oceania	3	0 (0)	1	0 (0)	4	0 (0)	
Asia	2	0 (0)	1	1 (100)	3	1 (33)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	9	2 (22)	1	0 (0)	11	2 (18)	
p value		0.461		<0.001		0.129	

Western Australia

Table 9.1.1 Number (%) of respondents by demographic characteristics and survey year

Western Australia	2021*	2022	2023	2024	2025
Number of sites	4	4	4	4	4
N° surveyed	N=485	N=421	N=469	N=306	N=369
Response rate (%)	68%	62%	75%	64%	67%
Gender (%)					
Male	292 (60)	265 (63)	291 (62)	195 (64)	236 (64)
Female	187 (39)	151 (36)	172 (37)	104 (34)	126 (34)
Other*	4 (1)	4 (1)	4 (1)	7 (2)	1 (<1)
Not reported	2 (<1)	1 (<1)	2 (<1)	0 (0)	6 (2)
Age (years)					
Median age	44	43	45	44	47
Age range	23-66	18-73	20-74	18-68	17-69
<25 years	7 (1)	11 (3)	4 (1)	8 (3)	10 (3)
25+ years	472 (97)	404 (96)	459 (98)	298 (97)	358 (97)
Not reported	6 (1)	6 (1)	6 (1)	0 (0)	1 (<1)
Sexual identity (%)					
Heterosexual	397 (82)	344 (82)	384 (82)	243 (79)	315 (85)
Bisexual	49 (10)	34 (8)	38 (8)	28 (9)	23 (6)
Gay/Lesbian	16 (3)	12 (3)	8 (2)	9 (3)	9 (2)
Other	18 (4)	27 (6)	31 (7)	25 (8)	3 (1)
Not reported	5 (1)	4 (1)	8 (2)	1 (<1)	19 (5)
Aboriginal and Torres Strait Islander origin (%)					
No	306 (63)	279 (66)	286 (61)	197 (64)	236 (64)
Yes	150 (31)	139 (33)	174 (37)	106 (35)	121 (33)
Not reported	29 (6)	3 (1)	9 (2)	3 (1)	12 (3)
Region/country of birth (%)					
Australia	401 (83)	365 (87)	406 (87)	256 (84)	321 (87)
Other Oceania	22 (5)	12 (3)	17 (4)	10 (3)	20 (5)
Asia	4 (1)	5 (1)	4 (1)	7 (2)	1 (<1)
UK & Ireland	27 (6)	16 (4)	17 (4)	14 (5)	10 (3)
Other	14 (3)	18 (4)	14 (3)	18 (6)	8 (2)
Not reported	17 (4)	5 (1)	11 (2)	1 (<1)	9 (2)
Main language spoken at home by parents (%)					
English	462 (95)	396 (94)	432 (92)	282 (92)	346 (94)
Non-English	17 (4)	22 (5)	30 (6)	20 (7)	16 (4)
Not reported	6 (1)	3 (1)	7 (1)	4 (1)	7 (2)
Age at first injection and time since first injection (years)					
Median age at first injection	19	19	18	19	19
Age range at first injection	10-85	10-72	10-72	11-60	10-55
N° not reported	17	27	16	7	16
Median yrs since first injection	23	22	25	24	26
Range yrs since first injection	<1-49	<1-51	<1-49	<1-51	<1-54
<3 years since first injection	17 (4)	16 (4)	28 (6)	18 (6)	16 (4)
3+ years since first injection	448 (92)	378 (90)	425 (91)	281 (92)	337 (91)
Not reported	20 (4)	27 (6)	16 (3)	7 (2)	16 (4)

* Implementation of the 2021 ANSPS was impacted by the COVID-19 pandemic

Table 9.1.2 Number (%) of respondents by last drug injected, frequency of injecting, overdose, imprisonment, injection in prison and survey year

Western Australia	2021	2022	2023	2024	2025
N° surveyed	N=485	N=421	N=469	N=306	N=369
Drug last injected (%)					
Cocaine	1 (<1)	1 (<1)	0 (0)	0 (0)	2 (1)
Methamphetamine	282 (58)	283 (67)	320 (68)	204 (67)	269 (73)
Heroin	86 (18)	64 (15)	72 (15)	43 (14)	46 (12)
Pharm. opioids	12 (2)	6 (1)	5 (1)	3 (1)	0 (0)
Methadone	21 (4)	14 (3)	13 (3)	2 (1)	1 (<1)
Buprenorphine	21 (4)	8 (2)	6 (1)	4 (1)	2 (1)
Buprenorphine/naloxone	17 (4)	9 (2)	7 (1)	3 (1)	0 (0)
PIEDs	9 (2)	16 (4)	3 (1)	5 (2)	6 (2)
More than one	32 (7)	16 (4)	37 (8)	37 (12)	36 (10)
Other	3 (1)	2 (<1)	2 (<1)	3 (1)	0 (0)
Not reported	1 (<1)	2 (<1)	4 (1)	2 (1)	7 (2)
Ever injected opioids (%)					
No	154 (32)	151 (36)	168 (36)	108 (35)	154 (42)
Yes	327 (67)	270 (64)	300 (64)	196 (64)	212 (57)
Not reported	4 (1)	0 (0)	1 (<1)	2 (1)	3 (1)
Frequency of injection last month (%)					
Not last month	40 (8)	29 (7)	30 (6)	14 (5)	15 (4)
Less than weekly	98 (20)	69 (16)	72 (15)	36 (12)	31 (8)
Weekly not daily	121 (25)	85 (20)	89 (19)	46 (15)	61 (17)
Daily or more	215 (44)	229 (54)	265 (57)	204 (67)	248 (67)
Not reported	11 (2)	9 (2)	13 (3)	6 (2)	14 (4)
Present when someone injected for the first time in the last 12 months (%)					
No	395 (81)	334 (79)	354 (75)	245 (80)	264 (72)
Yes	83 (17)	79 (19)	92 (20)	51 (17)	86 (23)
Not reported	7 (1)	8 (2)	23 (5)	10 (3)	19 (5)
Overdosed in last 12 months (%)					
No	412 (85)	352 (84)	377 (80)	243 (79)	288 (78)
Yes	63 (13)	63 (15)	68 (15)	51 (17)	62 (17)
Not reported	10 (2)	6 (1)	24 (5)	12 (4)	19 (5)
Imprisonment last year (%)					
No	395 (81)	343 (81)	371 (79)	225 (74)	284 (77)
Yes	61 (13)	57 (14)	60 (13)	57 (19)	58 (16)
Not reported	29 (6)	21 (5)	38 (8)	24 (8)	27 (7)
Injected while in prison last year					
N° in prison last year	N=61	N=57	N=60	N=57	N=58
No	45 (74)	33 (58)	39 (65)	41 (72)	37 (64)
Yes	14 (23)	22 (39)	19 (32)	15 (26)	20 (34)
Not reported	2 (3)	2 (4)	2 (3)	1 (2)	1 (2)

Table 9.1.3 Number (%) of respondents by injecting behaviour in the last month and survey year

Western Australia	2021	2022	2023	2024	2025
N° injected last month	N=434	N=383	N=426	N=286	N=340
Places injected last month (%)					
All private	183 (42)	153 (40)	169 (40)	94 (33)	131 (39)
Any public	247 (57)	228 (60)	253 (59)	188 (66)	209 (61)
Not reported	4 (1)	2 (1)	4 (1)	4 (1)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	269 (62)	234 (61)	254 (60)	146 (51)	227 (67)
Most of the time	126 (29)	113 (30)	122 (29)	94 (33)	85 (25)
Half of the time	14 (3)	16 (4)	27 (6)	15 (5)	11 (3)
Some of the time	17 (4)	11 (3)	13 (3)	16 (6)	9 (3)
Not last month	3 (1)	5 (1)	3 (1)	3 (1)	2 (1)
Not reported	5 (1)	4 (1)	7 (2)	12 (4)	6 (2)
Re-used someone else's used needle & syringe last month (%)					
None	321 (74)	265 (69)	287 (67)	168 (59)	246 (72)
Once	34 (8)	34 (9)	32 (8)	28 (10)	21 (6)
Twice	27 (6)	37 (10)	38 (9)	34 (12)	27 (8)
3-5 times	22 (5)	27 (7)	40 (9)	31 (11)	21 (6)
>5 times	26 (6)	20 (5)	25 (6)	21 (7)	23 (7)
Not reported	4 (1)	0 (0)	4 (1)	4 (1)	2 (1)
Number of people needle & syringe was re-used after last month (%)					
None	321 (74)	265 (69)	287 (67)	168 (59)	246 (72)
One	49 (11)	62 (16)	56 (13)	51 (18)	36 (11)
Two	17 (4)	14 (4)	14 (3)	15 (5)	9 (3)
Three to five	11 (3)	8 (2)	13 (3)	7 (2)	8 (2)
More than five	7 (2)	5 (1)	7 (2)	6 (2)	10 (3)
Don't know	18 (4)	14 (4)	23 (5)	23 (8)	23 (7)
Not reported	11 (3)	15 (4)	26 (6)	16 (6)	8 (2)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	43 (10)	49 (13)	42 (10)	43 (15)	31 (9)
Casual sex partner	6 (1)	4 (1)	8 (2)	6 (2)	5 (1)
Close friend	33 (8)	43 (11)	40 (9)	42 (15)	28 (8)
Acquaintance	26 (6)	15 (4)	16 (4)	19 (7)	18 (5)
Other	6 (1)	8 (2)	9 (2)	17 (6)	4 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	94 (22)	60 (16)	98 (23)	59 (21)	63 (19)
Water	130 (30)	87 (23)	152 (36)	116 (41)	101 (30)
Filter	46 (11)	33 (9)	55 (13)	42 (15)	24 (7)
Drug mix	56 (13)	46 (12)	73 (17)	51 (18)	43 (13)
None	255 (59)	243 (63)	222 (52)	151 (53)	197 (58)
Injected by someone after that person injected themselves or others last month (%)					
No	327 (75)	301 (79)	313 (73)	208 (73)	250 (74)
Yes	103 (24)	82 (21)	108 (25)	73 (26)	88 (26)
Not reported	4 (1)	0 (0)	5 (1)	5 (2)	2 (1)
Source of needle acquisition (%)					
Needle Syringe Program	350 (81)	295 (77)	319 (75)	239 (84)	273 (80)
Chemist/Pharmacy	153 (35)	126 (33)	142 (33)	112 (39)	107 (31)
Personal sources	57 (13)	54 (14)	61 (14)	58 (20)	56 (16)
Dispensing/Vending Machine	4 (1)	10 (3)	8 (2)	7 (2)	11 (3)
Other sources	8 (2)	11 (3)	7 (2)	10 (4)	3 (1)

Table 9.1.4 Number (%) of respondents by treatment for drug use and survey year

Western Australia	2021	2022	2023	2024	2025
N° surveyed	N=485	N=421	N=469	N=306	N=369
Ever any treatment/therapy for drug use (%)					
No	205 (42)	174 (41)	202 (43)	121 (40)	172 (47)
Yes	280 (58)	247 (59)	267 (57)	185 (60)	196 (53)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
History of methadone maintenance treatment (%)					
Currently	59 (12)	46 (11)	39 (8)	23 (8)	28 (8)
Previously	70 (14)	74 (18)	86 (18)	50 (16)	56 (15)
Never	345 (71)	293 (70)	317 (68)	222 (73)	266 (72)
Not reported	11 (2)	8 (2)	27 (6)	11 (4)	19 (5)
History of buprenorphine (Subutex®) treatment (%)					
Currently	33 (7)	21 (5)	34 (7)	19 (6)	22 (6)
Previously	81 (17)	78 (19)	91 (19)	62 (20)	52 (14)
Never	358 (74)	315 (75)	322 (69)	214 (70)	276 (75)
Not reported	13 (3)	7 (2)	22 (5)	11 (4)	19 (5)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	30 (6)	26 (6)	32 (7)	19 (6)	11 (3)
Previously	76 (16)	70 (17)	91 (19)	51 (17)	53 (14)
Never	372 (77)	323 (77)	341 (73)	234 (76)	297 (80)
Not reported	7 (1)	2 (<1)	5 (1)	2 (1)	8 (2)
History of depot buprenorphine treatment (%)					
Currently	16 (3)	22 (5)	29 (6)	14 (5)	19 (5)
Previously	30 (6)	36 (9)	37 (8)	37 (12)	36 (10)
Never	427 (88)	353 (84)	380 (81)	247 (81)	293 (79)
Not reported	12 (2)	10 (2)	23 (5)	8 (3)	21 (6)

Table 9.1.5 Number (%) of respondents by sexual behaviour in the month prior to survey and survey year

Western Australia	2021	2022	2023	2024	2025
N° surveyed	N=485	N=421	N=469	N=306	N=369
Sex with a regular partner last month (%)					
No	226 (47)	203 (48)	219 (47)	165 (54)	176 (48)
Yes	242 (50)	200 (48)	219 (47)	131 (43)	171 (46)
Not reported	17 (4)	18 (4)	31 (7)	10 (3)	22 (6)
Condom used with regular partner last month (%)					
N° surveyed	N=242	N=200	N=219	N=131	N=171
Never	192 (79)	154 (77)	160 (73)	97 (74)	130 (76)
Sometimes	16 (7)	19 (10)	30 (14)	12 (9)	16 (9)
Every time	20 (8)	16 (8)	16 (7)	15 (11)	13 (8)
Not reported	14 (6)	11 (6)	13 (6)	7 (5)	12 (7)
Sex with other partner(s) last month (%)					
No	389 (80)	327 (78)	359 (77)	226 (74)	279 (76)
Yes	72 (15)	77 (18)	78 (17)	59 (19)	68 (18)
Not reported	24 (5)	17 (4)	32 (7)	21 (7)	22 (6)
Condom used with other partner(s) last month (%)					
N° surveyed	N=72	N=77	N=78	N=59	N=68
Never	41 (57)	42 (55)	46 (59)	38 (64)	46 (68)
Sometimes	14 (19)	19 (25)	16 (21)	10 (17)	11 (16)
Every time	13 (18)	12 (16)	16 (21)	7 (12)	7 (10)
Not reported	4 (6)	4 (5)	0 (0)	4 (7)	4 (6)
Sex work last month (%)					
No	432 (89)	379 (90)	405 (86)	267 (87)	319 (86)
Yes	26 (5)	26 (6)	30 (6)	19 (6)	31 (8)
Not reported	27 (6)	16 (4)	34 (7)	20 (7)	19 (5)
Condom used at last sex work (%)					
Yes	11 (42)	16 (62)	16 (53)	8 (42)	14 (45)

Table 9.1.6 Number (%) of respondents by testing for HIV and HCV, HCV treatment by survey year

Western Australia	2021	2022	2023	2024	2025
N° surveyed	N=485	N=421	N=469	N=306	N=369
Previous HIV test (%)					
Yes, ever	370 (76)	311 (74)	342 (73)	229 (75)	266 (72)
Yes, last year	216 (45)	187 (44)	212 (45)	139 (45)	161 (44)
>1 year ago	154 (32)	124 (29)	130 (28)	90 (29)	105 (28)
Never tested	92 (19)	98 (23)	95 (20)	62 (20)	87 (24)
Not reported	23 (5)	12 (3)	32 (7)	15 (5)	16 (4)
Previous HCV test (%)					
Yes, ever	377 (78)	337 (80)	357 (76)	246 (80)	267 (72)
Yes, last year	258 (53)	219 (52)	226 (48)	154 (50)	172 (47)
>1 year ago	119 (25)	118 (28)	131 (28)	92 (30)	95 (26)
Never tested	63 (13)	44 (10)	58 (12)	33 (11)	58 (16)
Not reported	45 (9)	40 (10)	54 (12)	27 (9)	44 (12)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=110	N=83	N=93	N=67	N=60
Antiviral treatment	58 (53)	48 (58)	60 (65)	50 (75)	38 (63)
No antiviral treatment	52 (47)	35 (42)	33 (35)	17 (25)	22 (37)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=86	N=62	N=67	N=40	N=42
Antiviral treatment	22 (26)	17 (27)	23 (34)	19 (48)	12 (29)
No antiviral treatment	64 (74)	45 (73)	44 (66)	21 (53)	30 (71)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

HIV antibody prevalence

Table 9.2.1 HIV antibody prevalence by gender and survey year

Western Australia	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021	289	5 (1.7)	187	1 (0.5)	482	6 (1.2)
2022	265	3 (1.1)	151	1 (0.7)	421	4 (1.0)
2023	259	3 (1.2)	150	1 (0.7)	415	4 (1.0)
2024	194	2 (1.0)	103	0 (0.0)	304	3 (1.0)
2025	234	5 (2.1)	126	0 (0.0)	367	5 (1.4)
X ² p trend		0.787		0.354		0.900

Table 9.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Western Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
Heterosexual	258	3 (1.2)	136	1 (0.7)	395	4 (1.0)
Bisexual	12	0 (0.0)	36	0 (0.0)	49	0 (0.0)
Homosexual	9	2 (22.2)	5	0 (0.0)	15	2 (13.3)
p value		0.038		1.000		0.067
2022						
Heterosexual	233	1 (0.4)	110	1 (0.9)	344	2 (0.6)
Bisexual	12	0 (0.0)	21	0 (0.0)	34	0 (0.0)
Homosexual	7	1 (14.3)	5	0 (0.0)	12	1 (8.3)
p value		0.018		1.000		0.058
2023						
Heterosexual	231	1 (0.4)	108	1 (0.9)	341	2 (0.6)
Bisexual	8	0 (0.0)	26	0 (0.0)	34	0 (0.0)
Homosexual	5	1 (20.0)	0	0 (0.0)	5	1 (20.0)
p value		0.016		1.000		0.032
2024						
Heterosexual	167	1 (0.6)	75	0 (0.0)	242	1 (0.4)
Bisexual	5	0 (0.0)	18	0 (0.0)	28	1 (3.6)
Homosexual	8	1 (12.5)	1	0 (0.0)	9	1 (11.1)
p value		0.094		--		0.054
2025						
Heterosexual	208	3 (1.4)	103	0 (0.0)	314	3 (1.0)
Bisexual	8	0 (0.0)	14	0 (0.0)	23	0 (0.0)
Homosexual	6	2 (33.3)	1	0 (0.0)	9	2 (22.2)
p value		<0.001		--		<0.001

Table 9.2.3 HIV antibody prevalence by age group, gender and survey year

Western Australia		Male		Female		Total	
Age group	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
<25 years	4	1 (25.0)	3	0 (0.0)	7	1 (14.3)	
25-34 years	31	1 (3.2)	28	0 (0.0)	61	1 (1.6)	
35-44 years	103	0 (0.0)	83	0 (0.0)	189	0 (0.0)	
45+ years	147	3 (2.0)	71	1 (1.4)	219	4 (1.8)	
p value		0.018		0.551		0.016	
2022							
<25 years	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)	
25-34 years	42	1 (2.4)	19	0 (0.0)	62	1 (1.6)	
35-44 years	98	1 (1.0)	66	0 (0.0)	166	1 (0.6)	
45+ years	114	1 (0.9)	60	1 (1.7)	176	2 (1.1)	
p value		0.604		0.604		0.604	
2023							
<25 years	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)	
25-34 years	40	0 (0.0)	27	0 (0.0)	67	0 (0.0)	
35-44 years	70	0 (0.0)	48	0 (0.0)	120	0 (0.0)	
45+ years	146	3 (2.1)	71	1 (1.4)	220	4 (1.8)	
p value		0.735		1.000		0.312	
2024							
<25 years	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)	
25-34 years	31	1 (3.2)	24	0 (0.0)	57	2 (3.5)	
35-44 years	44	0 (0.0)	45	0 (0.0)	90	0 (0.0)	
45+ years	115	1 (0.9)	30	0 (0.0)	149	1 (0.7)	
p value		0.574		--		0.184	
2025							
<25 years	6	0 (0.0)	3	0 (0.0)	10	0 (0.0)	
25-34 years	22	0 (0.0)	19	0 (0.0)	41	0 (0.0)	
35-44 years	58	1 (1.7)	37	0 (0.0)	96	1 (1.0)	
45+ years	147	4 (2.7)	67	0 (0.0)	219	4 (1.8)	
p value		0.827		--		0.771	

Table 9.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Western Australia	Male		Female		Total	
Last drug injected	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
Heroin	48	2 (4.2)	36	1 (2.8)	86	3 (3.5)
Methamphetamine	168	3 (1.8)	112	0 (0.0)	281	3 (1.1)
Other opioids	44	0 (0.0)	24	0 (0.0)	69	0 (0.0)
Other drugs	29	0 (0.0)	15	0 (0.0)	45	0 (0.0)
p value		0.468		0.401		0.259
2022						
Heroin	41	0 (0.0)	22	1 (4.6)	64	1 (1.6)
Methamphetamine	167	2 (1.2)	114	0 (0.0)	283	2 (0.7)
Other opioids	27	0 (0.0)	8	0 (0.0)	37	0 (0.0)
Other drugs	30	1 (3.3)	5	0 (0.0)	35	1 (2.9)
p value		0.566		0.235		0.317
2023						
Heroin	41	0 (0.0)	19	1 (5.3)	61	1 (1.6)
Methamphetamine	167	0 (0.0)	110	0 (0.0)	279	0 (0.0)
Other opioids	22	3 (13.6)	7	0 (0.0)	30	3 (10.0)
Other drugs	26	0 (0.0)	14	0 (0.0)	41	0 (0.0)
p value		0.001		0.267		<0.001
2024						
Heroin	31	0 (0.0)	10	0 (0.0)	43	1 (2.3)
Methamphetamine	126	2 (1.6)	71	0 (0.0)	202	2 (1.0)
Other opioids	8	0 (0.0)	4	0 (0.0)	12	0 (0.0)
Other drugs	28	0 (0.0)	17	0 (0.0)	45	0 (0.0)
p value		0.783		--		0.718
2025						
Heroin	30	0 (0.0)	15	0 (0.0)	46	0 (0.0)
Methamphetamine	163	3 (1.8)	101	0 (0.0)	267	3 (1.1)
Other opioids	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
Other drugs	34	1 (2.9)	8	0 (0.0)	44	1 (2.3)
p value		0.835		--		0.779

Table 9.2.5 HIV antibody prevalence by years of injection, gender and survey year

Western Australia		Male		Female		Total	
Years of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
<3 years	13	0 (0.0)	3	0 (0.0)	17	0 (0.0)	
3 to 10 years	38	3 (7.9)	35	0 (0.0)	73	3 (4.1)	
11 + years	224	2 (0.9)	144	1 (0.7)	372	3 (0.8)	
p value		0.039		1.000		0.099	
2022							
<3 years	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)	
3 to 10 years	37	1 (2.7)	17	0 (0.0)	55	1 (1.8)	
11 + years	199	2 (1.0)	120	1 (0.8)	323	3 (0.9)	
p value		0.479		1.000		0.550	
2023							
<3 years	16	0 (0.0)	9	0 (0.0)	25	0 (0.0)	
3 to 10 years	28	0 (0.0)	27	0 (0.0)	56	0 (0.0)	
11 + years	204	3 (1.5)	112	1 (0.9)	319	4 (1.3)	
p value		1.000		1.000		1.000	
2024							
<3 years	7	0 (0.0)	11	0 (0.0)	18	0 (0.0)	
3 to 10 years	29	2 (6.9)	13	0 (0.0)	44	3 (6.8)	
11 + years	154	0 (0.0)	77	0 (0.0)	235	0 (0.0)	
p value		0.004		--		<0.001	
2025							
<3 years	9	0 (0.0)	6	0 (0.0)	16	0 (0.0)	
3 to 10 years	22	1 (4.6)	21	0 (0.0)	43	1 (2.3)	
11 + years	193	4 (2.1)	96	0 (0.0)	292	4 (1.4)	
p value		0.681		--		0.784	

Table 9.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Western Australia		Male		Female		Total	
Receptively shared syringe last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
No receptive sharing	184	5 (2.7)	133	1 (0.8)	318	6 (1.9)	
Receptive sharing	68	0 (0.0)	38	0 (0.0)	109	0 (0.0)	
p value		0.328		1.000		0.345	
2022							
No receptive sharing	165	3 (1.8)	98	0 (0.0)	265	3 (1.1)	
Receptive sharing	74	0 (0.0)	41	0 (0.0)	118	0 (0.0)	
p value		0.554		--		0.556	
2023							
No receptive sharing	151	2 (1.3)	93	0 (0.0)	249	2 (0.8)	
Receptive sharing	83	1 (1.2)	40	0 (0.0)	123	1 (0.8)	
p value		1.000		--		1.000	
2024							
No receptive sharing	111	1 (0.9)	55	0 (0.0)	166	1 (0.6)	
Receptive sharing	69	1 (1.5)	40	0 (0.0)	114	2 (1.8)	
p value		0.733		--		0.358	
2025							
No receptive sharing	162	5 (3.1)	81	0 (0.0)	246	5 (2.0)	
Receptive sharing	54	0 (0.0)	33	0 (0.0)	90	0 (0.0)	
p value		0.191		--		0.173	

Table 9.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Western Australia	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
Less than daily	130	4 (3.1)	84	0 (0.0)	216	4 (1.9)
Daily or more	124	1 (0.8)	89	1 (1.1)	215	2 (0.9)
Not last month	28	0 (0.0)	12	0 (0.0)	40	0 (0.0)
p value		0.504		1.000		0.816
2022						
Less than daily	91	2 (2.2)	60	0 (0.0)	154	2 (1.3)
Daily or more	148	1 (0.7)	79	0 (0.0)	229	1 (0.4)
Not last month	21	0 (0.0)	8	1 (12.5)	29	1 (3.5)
p value		0.658		0.054		0.259
2023						
Less than daily	99	0 (0.0)	45	0 (0.0)	145	0 (0.0)
Daily or more	137	3 (2.2)	90	0 (0.0)	231	3 (1.3)
Not last month	17	0 (0.0)	11	1 (9.1)	28	1 (3.6)
p value		0.405		0.075		0.106
2024						
Less than daily	51	1 (2.0)	30	0 (0.0)	82	1 (1.2)
Daily or more	132	1 (0.8)	65	0 (0.0)	202	2 (1.0)
Not last month	8	0 (0.0)	5	0 (0.0)	14	0 (0.0)
p value		0.740		--		0.914
2025						
Less than daily	56	1 (1.8)	34	0 (0.0)	92	1 (1.1)
Daily or more	161	4 (2.5)	81	0 (0.0)	246	4 (1.6)
Not last month	8	0 (0.0)	7	0 (0.0)	15	0 (0.0)
p value		0.869		--		0.833

Table 9.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Western Australia	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2021						
No imprisonment	222	3 (1.4)	166	1 (0.6)	392	4 (1.0)
Imprisonment	47	1 (2.1)	13	0 (0.0)	61	1 (1.6)
p value		0.538		1.000		0.516
2022						
No imprisonment	203	3 (1.5)	135	1 (0.7)	343	4 (1.2)
Imprisonment	47	0 (0.0)	10	0 (0.0)	57	0 (0.0)
p value		1.000		1.000		1.000
2023						
No imprisonment	203	1 (0.5)	121	1 (0.8)	329	2 (0.6)
Imprisonment	40	2 (5.0)	16	0 (0.0)	56	2 (3.6)
p value		0.071		1.000		0.103
2024						
No imprisonment	138	1 (0.7)	80	0 (0.0)	223	2 (0.9)
Imprisonment	38	1 (2.6)	18	0 (0.0)	57	1 (1.8)
p value		0.326		--		0.575
2025						
No imprisonment	171	5 (2.9)	108	0 (0.0)	283	5 (1.8)
Imprisonment	44	0 (0.0)	11	0 (0.0)	57	0 (0.0)
p value		0.251		--		0.312

Table 9.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Western Australia		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
No condom use	99	3 (3.0)	90	0 (0.0)	192	3 (1.6)	
Condom use	19	0 (0.0)	16	0 (0.0)	36	0 (0.0)	
p value		1.000		--		1.000	
2022							
No condom use	88	1 (1.1)	64	0 (0.0)	154	1 (0.7)	
Condom use	22	0 (0.0)	42	0 (0.0)	35	0 (0.0)	
p value		1.000		--		1.000	
2023							
No condom use	79	1 (1.3)	62	0 (0.0)	143	1 (0.7)	
Condom use	19	0 (0.0)	20	0 (0.0)	39	0 (0.0)	
p value		1.000		--		1.000	
2024							
No condom use	52	2 (3.9)	43	0 (0.0)	96	2 (2.1)	
Condom use	14	0 (0.0)	13	0 (0.0)	27	0 (0.0)	
p value		0.456		--		0.450	
2025							
No condom use	79	4 (5.1)	49	0 (0.0)	130	4 (3.1)	
Condom use	15	0 (0.0)	14	0 (0.0)	29	0 (0.0)	
p value		0.373		--		0.339	

Table 9.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Western Australia		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
No sex work	263	3 (1.1)	162	1 (0.6)	430	4 (0.9)	
Sex work	11	1 (9.1)	15	0 (0.0)	26	1 (3.9)	
p value		0.152		1.000		0.255	
2022							
No sex work	243	3 (1.2)	132	1 (0.8)	379	4 (1.1)	
Sex work	12	0 (0.0)	13	0 (0.0)	26	0 (0.0)	
p value		1.000		1.000		1.000	
2023							
No sex work	229	3 (1.3)	128	1 (0.8)	360	4 (1.1)	
Sex work	13	0 (0.0)	12	0 (0.0)	27	0 (0.0)	
p value		1.000		1.000		1.000	
2024							
No sex work	170	1 (0.6)	91	0 (0.0)	265	2 (0.8)	
Sex work	12	1 (8.3)	6	0 (0.0)	19	1 (5.3)	
p value		0.013		--		0.063	
2025							
No sex work	203	4 (2.0)	110	0 (0.0)	317	4 (1.3)	
Sex work	20	1 (5.0)	8	0 (0.0)	31	1 (3.2)	
p value		0.383		--		0.380	

Table 9.2.11 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Western Australia		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
English speaking	274	4 (1.5)	179	1 (0.6)	459	5 (1.1)	
Non-English speaking	11	1 (9.1)	6	0 (0.0)	17	1 (5.9)	
p value		0.180		1.000		0.197	
2022							
English speaking	248	2 (0.8)	143	1 (0.7)	396	3 (0.8)	
Non-English speaking	16	1 (6.3)	6	0 (0.0)	22	1 (4.6)	
p value		0.172		1.000		0.195	
2023							
English speaking	238	3 (1.3)	138	1 (0.7)	381	4 (1.1)	
Non-English speaking	17	0 (0.0)	10	0 (0.0)	28	0 (0.0)	
p value		1.000		1.000		1.000	
2024							
English speaking	178	1 (0.6)	96	0 (0.0)	280	2 (0.7)	
Non-English speaking	12	1 (8.3)	7	0 (0.0)	20	1 (5.0)	
p value		0.011		--		0.063	
2025							
English speaking	222	4 (1.8)	116	0 (0.0)	344	4 (1.2)	
Non-English speaking	9	1 (11.1)	7	0 (0.0)	16	1 (6.3)	
p value		0.060		--		0.089	

Table 9.2.12 HIV antibody prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2021							
Australia	235	3 (1.3)	158	1 (0.6)	399	4 (1.0)	
Other Oceania	11	0 (0.0)	11	0 (0.0)	22	0 (0.0)	
Asia	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)	
UK & Ireland	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)	
Other	9	2 (22.2)	5	0 (0.0)	14	2 (14.3)	
p value		0.037		1.000		0.058	
2022							
Australia	228	2 (0.9)	133	1 (0.8)	365	3 (0.8)	
Other Oceania	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)	
Asia	1	0 (0.0)	4	0 (0.0)	5	0 (0.0)	
UK & Ireland	8	0 (0.0)	7	0 (0.0)	16	0 (0.0)	
Other	15	1 (6.7)	3	0 (0.0)	18	1 (5.6)	
p value		0.334		1.000		0.409	
2023							
Australia	225	3 (1.3)	132	1 (0.8)	362	4 (1.1)	
Other Oceania	7	0 (0.0)	8	0 (0.0)	15	0 (0.0)	
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
UK & Ireland	11	0 (0.0)	2	0 (0.0)	14	0 (0.0)	
Other	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)	
p value		1.000		1.000		1.000	
2024							
Australia	159	2 (1.3)	93	0 (0.0)	255	3 (1.2)	
Other Oceania	8	0 (0.0)	2	0 (0.0)	10	0 (0.0)	
Asia	5	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
UK & Ireland	7	0 (0.0)	4	0 (0.0)	13	0 (0.0)	
Other	14	0 (0.0)	3	0 (0.0)	18	0 (0.0)	
p value		0.980		--		0.966	
2025							
Australia	206	5 (2.4)	109	0 (0.0)	320	5 (1.6)	
Other Oceania	10	0 (0.0)	10	0 (0.0)	20	0 (0.0)	
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
UK & Ireland	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
Other	14	0 (0.0)	3	0 (0.0)	17	0 (0.0)	
p value		0.892		--		0.896	

HCV antibody prevalence

Table 9.3.1 HCV antibody prevalence by gender and survey year

Western Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021	289	120 (42)	187	68 (36)	482	192 (40)
2022	265	105 (40)	151	44 (29)	421	151 (36)
2023*	259	141 (54)	150	71 (47)	415	213 (51)
2024	194	87 (45)	103	32 (31)	304	123 (40)
2025	234	83 (35)	126	40 (32)	367	124 (34)
X ² p trend^		<0.001		0.006		<0.001

* Antibody testing assay changed in 2023. See Appendix B: Methodological Notes

^ X² p trend calculated on years 2023-2025 only

Table 9.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Western Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heterosexual	257	113 (44)	136	43 (32)	394	157 (40)
Bisexual	12	4 (33)	36	19 (53)	49	23 (47)
Homosexual	10	1 (10)	5	2 (40)	16	3 (19)
p value		0.089		0.050		0.378
2022						
Heterosexual	233	94 (40)	110	36 (33)	344	131 (38)
Bisexual	12	4 (33)	21	2 (10)	34	6 (18)
Homosexual	7	2 (29)	5	0 (0)	12	2 (17)
p value		0.987		0.079		0.164
2023						
Heterosexual	231	124 (54)	108	54 (50)	341	178 (52)
Bisexual	8	6 (75)	26	9 (35)	34	15 (44)
Homosexual	5	1 (20)	0	0 (0)	5	1 (20)
p value		0.097		0.698		0.323
2024						
Heterosexual	167	80 (48)	75	24 (32)	242	104 (43)
Bisexual	5	0 (0)	18	5 (28)	28	7 (25)
Homosexual	8	1 (13)	1	0 (0)	9	1 (11)
p value		0.040		0.664		0.097
2025						
Heterosexual	208	72 (35)	103	31 (30)	314	104 (33)
Bisexual	8	4 (50)	14	3 (21)	23	7 (30)
Homosexual	6	1 (17)	1	1 (100)	9	2 (22)
p value		0.150		0.116		0.230

Table 9.3.3 HCV antibody prevalence by age group, gender and survey year

Western Australia		Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
<25 years	4	1 (25)	3	1 (33)	7	2 (29)	
25-34 years	31	7 (23)	28	9 (32)	61	17 (28)	
35-44 years	103	41 (40)	83	25 (30)	189	68 (36)	
45+ years	147	71 (48)	71	32 (45)	219	104 (47)	
p value		0.039		0.236		0.013	
2022							
<25 years	8	4 (50)	3	0 (0)	11	4 (36)	
25-34 years	42	13 (31)	19	4 (21)	62	17 (27)	
35-44 years	98	34 (35)	66	23 (35)	166	58 (35)	
45+ years	114	53 (46)	60	17 (28)	176	71 (40)	
p value		0.173		0.533		0.328	
2023							
<25 years	1	1 (100)	2	1 (50)	3	2 (67)	
25-34 years	40	13 (33)	27	11 (41)	67	24 (36)	
35-44 years	70	34 (49)	48	25 (52)	120	59 (49)	
45+ years	146	91 (62)	71	33 (46)	220	124 (56)	
p value		0.002		0.826		0.018	
2024							
<25 years	4	0 (0)	4	0 (0)	8	0 (0)	
25-34 years	31	8 (26)	24	7 (29)	57	16 (28)	
35-44 years	44	24 (55)	45	14 (31)	90	38 (42)	
45+ years	115	55 (48)	30	11 (37)	149	69 (46)	
p value		0.020		0.516		0.010	
2025							
<25 years	6	0 (0)	3	1 (33)	10	2 (20)	
25-34 years	22	6 (27)	19	7 (37)	41	13 (32)	
35-44 years	58	18 (31)	37	8 (22)	96	26 (27)	
45+ years	147	59 (40)	67	24 (36)	219	83 (38)	
p value		0.120		0.476		0.212	

Table 9.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	13	0 (0)	3	1 (33)	17	1 (6)
3 to 10 years	38	9 (24)	35	10 (29)	73	19 (26)
11+ years	224	107 (48)	144	54 (38)	372	164 (44)
p value		<0.001		0.746		<0.001
2022						
<3 years	11	2 (18)	5	0 (0)	16	2 (13)
3 to 10 years	37	7 (19)	17	3 (18)	55	10 (18)
11+ years	199	88 (44)	120	38 (32)	323	128 (40)
p value		0.004		0.265		0.001
2023						
<3 years	16	1 (6)	9	2 (22)	25	3 (12)
3 to 10 years	28	8 (29)	27	9 (33)	56	17 (30)
11+ years	204	125 (61)	112	59 (53)	319	184 (58)
p value		<0.001		0.056		<0.001
2024						
<3 years	7	0 (0)	11	0 (0)	18	0 (0)
3 to 10 years	29	8 (28)	13	2 (15)	44	11 (25)
11+ years	154	77 (50)	77	29 (38)	235	108 (46)
p value		0.004		0.018		<0.001
2025						
<3 years	9	0 (0)	6	0 (0)	16	0 (0)
3 to 10 years	22	3 (14)	21	3 (14)	43	6 (14)
11+ years	193	78 (40)	96	35 (36)	292	113 (39)
p value		0.003		0.034		<0.001

Table 9.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Western Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	9	0 (0)	298	116 (39)	319	119 (37)
Receptive sharing	2	1 (50)	102	54 (53)	108	58 (54)
p value		0.182		0.013		0.003
2022						
No receptive sharing	10	0 (0)	235	78 (33)	265	85 (32)
Receptive sharing	3	2 (67)	110	51 (46)	118	56 (47)
p value		0.038		0.018		0.004
2023						
No receptive sharing	18	2 (11)	222	115 (52)	249	121 (49)
Receptive sharing	6	1 (17)	113	68 (60)	123	72 (59)
p value		1.000		0.145		0.071
2024						
No receptive sharing	11	0 (0)	151	57 (38)	166	59 (36)
Receptive sharing	5	0 (0)	108	53 (49)	114	53 (46)
p value		--		0.069		0.066
2025						
No receptive sharing	12	0 (0)	225	72 (32)	246	74 (30)
Receptive sharing	4	0 (0)	82	36 (44)	90	39 (43)
p value		--		0.053		0.023

Table 9.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Heroin	2	1 (50)	82	45 (55)	85	47 (55)
Methamphetamine	8	0 (0)	257	82 (32)	274	85 (31)
Other opioids	3	0 (0)	62	33 (53)	68	35 (51)
Other drugs	3	0 (0)	36	19 (53)	44	20 (45)
p value		0.058		<0.000		<0.000
2022						
Heroin	1	0 (0)	61	25 (41)	63	26 (41)
Methamphetamine	9	2 (22)	249	81 (33)	277	90 (32)
Other opioids	1	0 (0)	31	22 (71)	36	25 (69)
Other drugs	5	0 (0)	26	7 (27)	34	7 (21)
p value		0.620		<0.001		<0.001
2023						
Heroin	1	0 (0)	55	41 (75)	58	42 (72)
Methamphetamine	19	2 (11)	248	114 (46)	275	120 (44)
Other opioids	0	0 (0)	30	22 (73)	30	22 (73)
Other drugs	4	1 (25)	31	20 (65)	38	23 (61)
p value		0.676		<0.001		<0.001
2024						
Heroin	4	0 (0)	37	20 (54)	42	20 (48)
Methamphetamine	9	0 (0)	186	72 (39)	199	76 (38)
Other opioids	1	0 (0)	11	6 (55)	12	6 (50)
Other drugs	3	0 (0)	38	18 (47)	43	18 (42)
p value		--		0.248		0.614
2025						
Heroin	1	0 (0)	43	28 (65)	46	29 (63)
Methamphetamine	12	0 (0)	240	65 (27)	259	67 (26)
Other opioids	0	0 (0)	3	1 (33)	3	1 (33)
Other drugs	2	0 (0)	35	18 (51)	40	19 (48)
p value		--		<0.001		<0.001

Table 9.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
Less than daily	9	0 (0)	201	74 (37)	217	77 (35)
Daily or more	3	1 (33)	201	96 (48)	214	101 (47)
Not last month	4	0 (0)	35	9 (26)	40	9 (23)
p value		0.187		0.013		0.003
2022						
Less than daily	8	0 (0)	140	46 (33)	154	49 (32)
Daily or more	5	2 (40)	205	83 (40)	229	92 (40)
Not last month	3	0 (0)	24	7 (29)	29	8 (28)
p value		0.108		0.255		0.151
2023						
Less than daily	13	1 (8)	130	67 (52)	145	70 (48)
Daily or more	11	2 (18)	209	117 (56)	231	124 (54)
Not last month	0	0 (0)	28	14 (50)	28	14 (50)
p value		0.576		0.661		0.586
2024						
Less than daily	4	0 (0)	78	28 (36)	82	28 (34)
Daily or more	12	0 (0)	185	83 (45)	202	85 (42)
Not last month	2	0 (0)	10	5 (50)	14	7 (50)
p value		--		0.360		0.349
2025						
Less than daily	3	0 (0)	85	25 (29)	92	26 (28)
Daily or more	13	0 (0)	224	85 (38)	246	89 (36)
Not last month	0	0 (0)	15	4 (27)	15	4 (27)
p value		--		0.291		0.329

Table 9.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No imprisonment	15	1 (7)	364	147 (40)	392	151 (39)
Imprisonment	2	0 (0)	55	27 (49)	61	30 (49)
p value		1.000		0.242		0.114
2022						
No imprisonment	15	1 (7)	310	106 (34)	343	115 (34)
Imprisonment	1	1 (100)	50	25 (50)	57	29 (51)
p value		0.125		0.031		0.012
2023						
No imprisonment	15	2 (13)	303	155 (51)	329	163 (50)
Imprisonment	7	0 (0)	47	35 (74)	56	36 (64)
p value		1.000		0.003		0.041
2024						
No imprisonment	15	0 (0)	202	79 (39)	223	83 (37)
Imprisonment	2	0 (0)	55	31 (56)	57	31 (54)
p value		--		0.022		0.019
2025						
No imprisonment	15	0 (0)	262	83 (32)	283	85 (30)
Imprisonment	1	0 (0)	48	21 (44)	57	24 (42)
p value		--		0.103		0.075

Table 9.3.9 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Western Australia		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
English speaking	274	113 (41)	179	64 (36)	459	181 (39)	
Non-English speaking	11	4 (36)	6	3 (50)	17	7 (41)	
p value		1.000		0.669		0.885	
2022							
English speaking	248	96 (39)	143	42 (29)	396	140 (35)	
Non-English speaking	16	8 (50)	6	2 (33)	22	10 (45)	
p value		0.370		1.000		0.336	
2023							
English speaking	238	134 (56)	138	64 (46)	381	199 (52)	
Non-English speaking	17	5 (29)	10	6 (60)	28	11 (39)	
p value		0.031		0.518		0.186	
2024							
English speaking	178	81 (46)	96	29 (30)	280	113 (40)	
Non-English speaking	12	4 (33)	7	3 (43)	20	8 (40)	
p value		0.412		0.485		0.975	
2025							
English speaking	222	79 (36)	116	36 (31)	344	115 (33)	
Non-English speaking	9	3 (33)	7	3 (43)	16	6 (38)	
p value		0.890		0.514		0.736	

Table 9.3.10 HCV antibody prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Australia	235	98 (42)	158	61 (39)	399	163 (41)	
Other Oceania	11	6 (55)	11	3 (27)	22	9 (41)	
Asia	2	0 (0)	2	0 (0)	4	0 (0)	
UK & Ireland	19	6 (32)	7	0 (0)	26	6 (23)	
Other	9	4 (44)	5	2 (40)	14	6 (43)	
p value		0.654		0.194		0.219	
2022							
Australia	228	85 (37)	133	39 (29)	365	126 (35)	
Other Oceania	9	6 (67)	3	1 (33)	12	7 (58)	
Asia	1	0 (0)	4	1 (25)	5	1 (20)	
UK & Ireland	8	3 (38)	7	1 (14)	16	4 (25)	
Other	15	10 (67)	3	1 (33)	18	11 (61)	
p value		0.059		0.973		0.054	
2023							
Australia	225	125 (56)	132	59 (45)	362	185 (51)	
Other Oceania	7	1 (14)	8	5 (63)	15	6 (40)	
Asia	2	1 (50)	1	0 (0)	3	1 (33)	
UK & Ireland	11	7 (64)	2	1 (50)	14	8 (57)	
Other	9	5 (56)	3	2 (67)	12	7 (58)	
p value		0.242		0.763		0.821	
2024							
Australia	159	70 (44)	93	30 (32)	255	101 (40)	
Other Oceania	8	3 (38)	2	0 (0)	10	3 (30)	
Asia	5	4 (80)	1	1 (100)	7	6 (59)	
UK & Ireland	7	2 (29)	4	0 (0)	13	3 (23)	
Other	14	8 (57)	3	1 (33)	18	10 (56)	
p value		0.365		0.288		0.044	
2025							
Australia	206	76 (37)	109	34 (31)	320	110 (34)	
Other Oceania	10	2 (20)	10	5 (50)	20	7 (35)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	14	4 (29)	3	0 (0)	17	4 (24)	
p value		0.558		0.231		0.712	

HCV RNA prevalence

Table 9.4.1 HCV RNA prevalence by gender and survey year

Western Australia		Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021	286	75 (26)	177	27 (15)	469	103 (22)	
2022	260	56 (22)	150	17 (11)	415	74 (18)	
2023	259	63 (24)	150	21 (14)	415	84 (20)	
2024	183	29 (16)	98	10 (10)	288	40 (14)	
2025	225	26 (12)	125	14 (11)	357	40 (11)	
X ² p trend		<0.001		0.295		<0.001	

Totals include respondents where gender was reported as other or not reported

Table 9.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Western Australia		Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Heterosexual	255	70 (27)	128	18 (14)	384	88 (23)	
Bisexual	12	2 (17)	35	5 (14)	48	7 (15)	
Homosexual	9	1 (11)	5	2 (40)	15	3 (20)	
p value		0.404		0.277		0.414	
2022							
Heterosexual	228	48 (21)	109	13 (12)	338	61 (18)	
Bisexual	12	2 (17)	21	1 (5)	34	3 (9)	
Homosexual	7	2 (29)	5	0 (0)	12	2 (17)	
p value		0.720		0.227		0.183	
2023							
Heterosexual	231	57 (25)	108	15 (14)	341	72 (21)	
Bisexual	8	5 (63)	26	3 (12)	34	8 (24)	
Homosexual	5	1 (20)	0	0 (0)	5	1 (20)	
p value		0.100		0.548		0.913	
2024							
Heterosexual	159	27 (17)	73	7 (10)	232	34 (15)	
Bisexual	4	0 (0)	17	2 (12)	26	3 (12)	
Homosexual	8	1 (13)	1	0 (0)	9	1 (11)	
p value		0.595		0.050		0.302	
2025							
Heterosexual	201	24 (12)	103	11 (11)	307	35 (11)	
Bisexual	7	1 (14)	13	1 (8)	21	2 (10)	
Homosexual	6	0 (0)	1	0 (0)	9	0 (0)	
p value		0.748		0.039		0.218	

Table 9.4.3 HCV RNA prevalence by age group, gender and survey year

Western Australia		Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
<25 years	4	1 (25)	3	1 (33)	7	2 (29)	
25-34 years	30	5 (17)	26	5 (19)	58	11 (19)	
35-44 years	101	27 (27)	76	8 (11)	180	35 (19)	
45+ years	147	42 (29)	70	13 (19)	218	55 (25)	
p value		0.612		0.399		0.482	
2022							
<25 years	8	2 (25)	3	0 (0)	11	2 (18)	
25-34 years	42	7 (17)	19	1 (5)	62	8 (13)	
35-44 years	96	19 (20)	66	7 (11)	164	26 (16)	
45+ years	111	28 (25)	59	9 (15)	172	38 (22)	
p value		0.641		0.694		0.311	
2023							
<25 years	1	0 (0)	2	0 (0)	3	0 (0)	
25-34 years	40	8 (20)	27	6 (22)	67	14 (21)	
35-44 years	70	14 (20)	48	5 (10)	120	19 (16)	
45+ years	146	40 (27)	71	10 (14)	220	50 (23)	
p value		0.583		0.545		0.426	
2024							
<25 years	4	0 (0)	4	0 (0)	8	0 (0)	
25-34 years	31	4 (13)	24	3 (13)	57	7 (12)	
35-44 years	43	7 (16)	43	4 (9)	87	11 (13)	
45+ years	105	18 (17)	27	3 (11)	136	22 (16)	
p value		0.779		0.884		0.548	
2025							
<25 years	6	1 (17)	3	0 (0)	10	1 (10)	
25-34 years	22	3 (14)	19	4 (21)	41	7 (17)	
35-44 years	56	5 (9)	36	2 (6)	93	7 (8)	
45+ years	140	17 (12)	67	8 (12)	212	25 (12)	
p value		0.881		0.331		0.429	

Table 9.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Western Australia	Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
<3 years	13	0 (0)	3	0 (0)	17	0 (0)
3 to 10 years	36	11 (31)	31	6 (19)	67	17 (25)
11+ years	223	62 (28)	138	18 (13)	365	80 (22)
p value		0.077		0.513		0.072
2022						
<3 years	11	1 (9)	5	0 (0)	16	1 (6)
3 to 10 years	36	5 (14)	16	2 (13)	53	7 (13)
11+ years	195	44 (23)	120	14 (12)	319	59 (19)
p value		0.421		1.000		0.377
2023						
<3 years	16	0 (0)	9	2 (22)	25	2 (8)
3 to 10 years	28	6 (21)	27	5 (19)	56	11 (20)
11+ years	204	54 (26)	112	14 (13)	319	68 (21)
p value		0.029		0.429		0.302
2024						
<3 years	7	0 (0)	11	1 (9)	18	1 (6)
3 to 10 years	28	4 (14)	13	0 (0)	43	4 (9)
11+ years	145	25 (17)	72	9 (13)	221	35 (16)
p value		0.461		0.393		0.295
2025						
<3 years	9	0 (0)	6	0 (0)	16	0 (0)
3 to 10 years	21	2 (10)	21	1 (5)	42	3 (7)
11+ years	185	22 (12)	95	13 (14)	283	35 (12)
p value		0.525		0.339		0.211

Table 9.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Western Australia	Male		Female		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2021						
No receptive sharing	182	46 (25)	125	16 (13)	308	62 (20)
Receptive sharing	67	23 (34)	36	9 (25)	106	32 (30)
p value		0.157		0.075		0.033
2022						
No receptive sharing	163	32 (20)	97	7 (7)	262	39 (15)
Receptive sharing	71	22 (31)	41	9 (22)	115	32 (28)
p value		0.058		0.013		0.003
2023						
No receptive sharing	151	38 (25)	93	13 (14)	249	51 (20)
Receptive sharing	83	22 (27)	40	5 (13)	123	27 (22)
p value		0.822		0.819		0.743
2024						
No receptive sharing	103	17 (17)	52	5 (10)	155	22 (14)
Receptive sharing	66	11 (17)	38	3 (8)	109	15 (14)
p value		0.978		0.777		0.921
2025						
No receptive sharing	155	12 (8)	80	8 (10)	238	20 (8)
Receptive sharing	52	10 (19)	33	2 (6)	88	12 (14)
p value		0.020		0.503		0.159

Table 9.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Western Australia		Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Heroin	48	14 (29)	33	7 (21)	83	21 (25)	
Methamphetamine	159	44 (28)	104	13 (13)	264	57 (22)	
Other opioids	43	13 (30)	23	3 (13)	67	16 (24)	
Other drugs	29	1 (3)	15	4 (27)	44	5 (11)	
p value		0.035		0.379		0.308	
2022							
Heroin	40	4 (10)	21	2 (10)	62	6 (10)	
Methamphetamine	160	39 (24)	110	13 (12)	272	53 (19)	
Other opioids	26	8 (31)	8	1 (13)	36	9 (25)	
Other drugs	29	4 (14)	5	0 (0)	34	4 (12)	
p value		0.100		0.861		0.142	
2023							
Heroin	39	8 (21)	18	6 (33)	58	14 (24)	
Methamphetamine	165	41 (25)	108	12 (11)	275	53 (19)	
Other opioids	22	7 (32)	7	0 (0)	30	7 (23)	
Other drugs	24	6 (25)	13	3 (23)	38	9 (24)	
p value		0.809		0.043		0.779	
2024							
Heroin	31	5 (16)	9	1 (11)	42	7 (17)	
Methamphetamine	115	20 (17)	65	2 (3)	185	22 (12)	
Other opioids	8	2 (25)	3	1 (33)	11	3 (27)	
Other drugs	25	2 (8)	17	4 (24)	42	6 (14)	
p value		0.612		0.020		0.463	
2025							
Heroin	29	3 (10)	15	0 (0)	45	3 (7)	
Methamphetamine	150	15 (10)	98	12 (12)	251	27 (11)	
Other opioids	2	0 (0)	1	0 (0)	3	0 (0)	
Other drugs	31	5 (16)	6	0 (0)	39	5 (13)	
p value		0.740		0.393		0.728	

Table 9.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Western Australia		Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Less than daily	131	36 (27)	82	11 (13)	215	47 (22)	
Daily or more	120	33 (28)	81	15 (19)	203	48 (24)	
Not last month	28	3 (11)	12	1 (8)	40	4 (10)	
p value		0.157		0.519		0.158	
2022							
Less than daily	91	21 (23)	60	7 (12)	154	29 (19)	
Daily or more	143	33 (23)	78	9 (12)	223	42 (19)	
Not last month	21	1 (5)	8	0 (0)	29	1 (3)	
p value		0.134		0.832		0.093	
2023							
Less than daily	99	22 (22)	45	4 (9)	145	26 (18)	
Daily or more	137	39 (28)	90	14 (16)	231	53 (23)	
Not last month	17	1 (6)	11	3 (27)	28	4 (14)	
p value		0.098		0.224		0.381	
2024							
Less than daily	48	8 (17)	28	2 (7)	77	10 (13)	
Daily or more	124	21 (17)	62	6 (10)	191	28 (15)	
Not last month	8	0 (0)	5	0 (0)	14	0 (0)	
p value		0.447		0.724		0.297	
2025							
Less than daily	53	6 (11)	34	3 (9)	89	9 (10)	
Daily or more	155	17 (11)	80	8 (10)	239	25 (10)	
Not last month	8	1 (13)	7	1 (14)	15	2 (13)	
p value		0.989		0.907		0.931	

Table 9.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Western Australia		Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
No imprisonment	220	58 (26)	156	21 (13)	380	80 (21)	
Imprisonment	47	12 (26)	13	4 (31)	61	16 (26)	
p value		0.906		0.091		0.363	
2022							
No imprisonment	199	40 (20)	134	15 (11)	338	56 (17)	
Imprisonment	46	12 (26)	10	2 (20)	56	14 (25)	
p value		0.371		0.335		0.126	
2023							
No imprisonment	203	50 (25)	121	16 (13)	329	66 (20)	
Imprisonment	40	7 (18)	16	1 (6)	56	8 (14)	
p value		0.331		0.692		0.311	
2024							
No imprisonment	131	19 (15)	77	8 (10)	213	27 (13)	
Imprisonment	35	8 (23)	16	1 (6)	52	10 (19)	
p value		0.234		0.610		0.221	
2025							
No imprisonment	162	12 (7)	107	12 (11)	273	24 (9)	
Imprisonment	44	9 (20)	11	0 (0)	57	9 (16)	
p value		0.011		0.241		0.109	

Table 9.4.9 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Western Australia		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
English speaking	271	70 (26)	170	24 (14)	447	95 (21)	
Non-English speaking	11	4 (36)	6	2 (33)	17	6 (35)	
p value		0.436		0.192		0.169	
2022							
English speaking	243	52 (21)	142	15 (11)	390	68 (17)	
Non-English speaking	16	3 (19)	6	1 (17)	22	4 (18)	
p value		1.000		0.503		1.000	
2023							
English speaking	238	62 (26)	138	16 (12)	381	78 (20)	
Non-English speaking	17	1 (6)	10	5 (50)	28	6 (21)	
p value		0.080		0.001		0.904	
2024							
English speaking	168	27 (16)	91	8 (9)	265	36 (14)	
Non-English speaking	12	2 (17)	7	2 (29)	20	4 (20)	
p value		0.957		0.096		0.426	
2025							
English speaking	213	25 (12)	115	13 (11)	334	38 (11)	
Non-English speaking	9	1 (11)	7	1 (14)	16	2 (13)	
p value		0.954		0.810		0.890	

Table 9.4.10 HCV RNA prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2021							
Australia	234	61 (26)	152	23 (15)	392	85 (22)	
Other Oceania	11	6 (55)	9	2 (22)	20	8 (40)	
Asia	2	0 (0)	2	1 (50)	4	1 (25)	
UK & Ireland	18	3 (17)	6	0 (0)	24	3 (13)	
Other	8	2 (25)	5	0 (0)	13	2 (15)	
p value		0.196		0.374		0.250	
2022							
Australia	223	44 (20)	132	14 (11)	359	59 (16)	
Other Oceania	9	4 (44)	3	0 (0)	12	4 (33)	
Asia	1	0 (0)	4	1 (25)	5	1 (20)	
UK & Ireland	8	2 (25)	7	1 (14)	16	3 (19)	
Other	15	6 (40)	3	1 (33)	18	7 (39)	
p value		0.112		0.349		0.072	
2023							
Australia	225	55 (24)	132	18 (14)	362	73 (20)	
Other Oceania	7	0 (0)	8	0 (0)	15	0 (0)	
Asia	2	0 (0)	1	0 (0)	3	0 (0)	
UK & Ireland	11	5 (45)	2	0 (0)	14	5 (36)	
Other	9	2 (22)	3	1 (33)	12	3 (25)	
p value		0.272		0.526		0.109	
2024							
Australia	149	22 (15)	89	8 (9)	241	30 (12)	
Other Oceania	8	1 (13)	2	0 (0)	10	1 (10)	
Asia	4	2 (50)	1	1 (100)	6	3 (50)	
UK & Ireland	7	1 (14)	3	0 (0)	12	2 (17)	
Other	14	3 (21)	3	1 (33)	18	4 (22)	
p value		0.404		0.024		0.085	
2025							
Australia	198	23 (12)	108	13 (12)	311	36 (12)	
Other Oceania	9	1 (11)	10	1 (10)	19	2 (11)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	14	2 (14)	3	0 (0)	17	2 (12)	
p value		0.973		0.803		0.985	

Appendix A: Participating NSP services

Year	'21	'22	'23	'24	'25
Number of NSP sites	37	53	55	54	53
Australian Capital Territory	1	1	1	1	1
Directions Health, Canberra	✓	✓	✓	✓	✓
New South Wales	3	18	19	19	18
ACON Hunter		✓	✓	✓	✓
Ballina Harm Reduction Services		✓	✓	✓	✓
Blacktown HIV/Hepatitis C Prevention Service		✓	✓	✓	✓
Byron/Tweed Harm Reduction Services		✓	✓	✓	✓
Canterbury Harm Minimisation Program		✓	✓	✓	✓
Central Coast NSP		✓	✓	✓	✓
Coffs Harbour/ Grafton/ Kempsey Harm Reduction Services		✓	✓	✓	✓
First Step Program, Port Kembla			✓	✓	✓
Health ConneXions, Liverpool		✓	✓	✓	✓
Hunter Harm Reduction Services		✓	✓	✓	✓
Kelly Close Needle Syringe Program, Mt Druitt		✓	✓	✓	✓
Kirketon Road Centre	✓	✓	✓	✓	✓
KRC Kellett St		✓	✓	✓	✓
KRC South, Sutherland	✓	✓	✓	✓	✓
Nimbin/Lismore Harm Reduction Services		✓	✓	✓	✓
NSW Users and AIDS Association (NUAA)	✓	✓	✓	✓	
Parramatta HIV/Hepatitis C Prevention Service		✓	✓	✓	✓
Redfern Harm Minimisation Program		✓	✓	✓	✓
Exchange on Parker (formerly South Court Primary Care NSP)		✓	✓	✓	✓
Northern Territory	3	3	3	3	3
Northern Territory AIDS & Hepatitis Council, Alice Springs	✓	✓	✓	✓	✓
Northern Territory AIDS & Hepatitis Council, Darwin	✓	✓	✓	✓	✓
Northern Territory AIDS & Hepatitis Council, Palmerston	✓	✓	✓	✓	✓
Queensland	11	10	10	10	9
Biala Community Alcohol and Drug Services, Brisbane	✓	✓	✓	✓	✓
Bundaberg AODS NSP				✓	
Cairns ATODS NSP	✓	✓	✓	✓	✓
Inala Alcohol and Drugs Service	✓	✓			
Kobi Place (formerly Kobi House), Toowoomba	✓		✓		✓
Queensland Injectors Health Network, Brisbane	✓	✓	✓	✓	✓
Queensland Injectors Health Network, Gold Coast	✓	✓	✓	✓	✓
Queensland Injectors Health Network, Sunshine Coast	✓	✓	✓	✓	✓
Rockhampton AODS NSP	✓	✓	✓	✓	✓
Townsville ATODS NSP	✓	✓	✓	✓	✓
West Moreton Sexual Health Service	✓	✓	✓	✓	
Youth Link, Cairns	✓	✓	✓	✓	✓

Year	'21	'22	'23	'24	'25
Number of NSP sites	37	53	55	54	53
South Australia	8	8	8	8	8
Community Access & Services SA (CASSA)	✓	✓	✓	✓	✓
Kurlana Tampawardli, Hendon	✓	✓	✓	✓	✓
Noarlunga Primary Health (formerly SAVIVE Noarlunga)	✓	✓	✓	✓	✓
Northern DASSA Elizabeth	✓	✓	✓	✓	✓
Nunkuwarrin Yunti Community Health Centre	✓	✓	✓	✓	✓
Streetlink Youth Services	✓	✓	✓	✓	✓
Watto Purrinna, Port Adelaide (formerly SAVIVE Port Adelaide)	✓	✓	✓	✓	✓
West Coast Youth, Port Lincoln	✓	✓	✓	✓	✓
Tasmania	4	4	4	3	4
Clarence Integrated Care Centre	✓	✓	✓		✓
Glenorchy NSP Service	✓	✓	✓	✓	✓
Hobart NSP Service	✓	✓	✓	✓	✓
Salvation Army Launceston	✓	✓	✓	✓	✓
Victoria	3	5	6	6	6
Barwon Health Drug and Alcohol Services	✓	✓	✓	✓	✓
Health Information Exchange, St Kilda	✓	✓	✓	✓	✓
Health Works, Footscray	✓	✓	✓	✓	✓
Innerspace, Collingwood		✓	✓	✓	✓
North Richmond NSP Services		✓	✓	✓	✓
SHARPS, Frankston			✓	✓	✓
Western Australia	4	4	4	4	4
HepatitisWA	✓	✓	✓	✓	✓
Peer Based Harm Reduction WA (formerly WASUA) - Perth	✓	✓	✓	✓	✓
Peer Based Harm Reduction WA (formerly WASUA) - Bunbury	✓	✓	✓	✓	✓
WAAC	✓	✓	✓	✓	✓

Appendix B: Methodological notes

Ethics approval

Ethical approvals for the study were obtained from Human Research Ethics Committees associated with the investigators and participating sites. ANSPS has national ethics approval through the National Mutual Acceptance Scheme with lead HREC Sydney LHD (RPAH Zone, Protocol X18-0053 & 2019_ETH07546). Verbal rather than written informed consent was obtained to assure the anonymity of participants.

Recording responses to invitation to participate

NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey period and this data was used to determine response rates. Some clients visited the site more than once during the survey week, and only one attendance per person was included in the response rate denominator.

Analysis

Data presented in this report were analysed using Stata, Version 19 (Stata Corporation, College Station TX). Where data showed a linear relationship over time, chi square (Cochran-Armitage) tests for trend were used to assess temporal trends in HIV/HCV antibody and HCV RNA prevalence. Associations between demographic and behavioural variables and HIV/HCV antibody and HCV RNA prevalence were assessed using the χ^2 test or Fisher's exact test where frequencies were less than five.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as other. Time since first injection was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection. Tables reporting HIV antibody prevalence stratified by demographic and drug use characteristics are not included in this report for states and territories or survey years where the number of HIV antibody positive participants was less than 5 in all years.

Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". The symbol "--" shown in some tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. The vast majority of survey questions were consistent over all survey years.

HIV and HCV antibody laboratory testing

Laboratory assays

Up until 2023 ANSPS samples were tested for HIV antibodies using the Murex HIV-1.2.0 ELISA (Diasorin, Italy) and the HIV confirmatory Western blot (New-Lav Blot-1, Bio-rad France). The assay used for HCV antibody detection was the Monolisa anti-HCV Plus Version 3 (Bio-rad, France) and for HCV RNA the Aptima HCV Quant Dx assay (Hologic, USA).

From 2023 the serological testing platform changed to the Abbott Alinity i [Abbott Diagnostics, Chicago USA] using the HIV antigen/antibody combo and HCV antibody assays. The required dried blood spot (DBS) size for this assay is 12mm versus 6mm from the previous year's assays, which increased the number of 2023 DBS samples graded as insufficient to 16.34% compared to 1.45%

the previous year. For the 2024 survey, the antibody testing protocol was optimised to include the use of an automated punching instrument which utilised three 6mm spots per sample.

Utilising the HIV and HCV screening platform (Alinity i) available at SydPath, St Vincent's Hospital, Sydney, there was an increase in HCV antibody prevalence (from 32% in 2022 to 45% in 2023 and 39% in 2024), likely due to the augmented quantity of sample volume and template introduced into the test, alongside the enhanced assay sensitivity characteristics of the latest generation HCV antibody analyser and assay. It should be noted, however, that HCV Ab prevalence remains lower compared to ANSPS results in the pre-DAA era.

In all years capillary blood was obtained by finger-prick using disposable, single-use lancets [BD] and a Whatman 903 protein-saver card [Interpath]. DBS samples were kept at room temperature at the survey sites and couriered to St Vincent's Centre for Applied Medical Research, Sydney every second or third day. When received, the DBS cards were stored in gas impermeable bags [ThermoFisher] containing two grams of desiccant packs [Desicco] and stored at minus 80 degrees Celsius until processing.

Laboratory testing methods prior to 2023

Prior to processing 6mm DBS discs were excised using an automated DBS puncher (BSD Electronics, Australia) with a blank spot punched in between each sample. Spots were punched into an unbound 96-well plate and eluted in 200uL of PBS, 5% Tween20 and 5% skim milk powder solution overnight at 2-8 degrees Celsius.

HIV antibody was detected using the Murex HIV-1.2.0 ELISA (Diasorin, Italy) and repeatedly reactive specimens were subjected to Western blot confirmatory testing (New LAV Blot-1, Bio-rad, France). A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 3 EIA, Bio-rad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

Laboratory 2023 testing methods

As stated above, from 2023 the serological testing platform changed to the Abbott Alinity i [Abbott Diagnostics, Chicago USA] using the HIV antigen/antibody combo and HCV antibody assays. The required DBS size for this assay is 12mm versus 6mm from the previous year's assays. DBS were excised using a 12mm stainless steel hole puncher and flame sterilised between each sample. Spots were placed into an aliquot containing 750uL of a PBS and 5% Tween20 solution. Samples were eluted at 1000rpm for 30 minutes at room temperature [PoCD] then centrifuged at 10,000g and 4 degrees Celsius [ThermoFisher] for 10 minutes prior to testing.

The serology analysis was completed on the Abbott Alinity i, HIV antigen/antibody combo and HCV antibody assays simultaneously. Specimens with an HIV and/or HCV sample to cutoff ratio (S/CO) >1.0 were repeated in duplicate. A Western blot was performed to confirm HIV reactive screening results (New LAV blot 1, Bio-Rad). Specimens were considered HCV antibody positive with a S/CO of >1.0 from at least 2 out of the 3 results.

Laboratory testing methods from 2024

From the 2024 survey onwards, the only modification to the testing process was the punching protocol for the antibody testing. Three 6mm spots were utilised per sample for both the HIV Ag/Ab

and HCV antibody testing on the Abbott Alinity i analyser. Spots were excised using an automated DBS puncher (BSD Electronics) with a blank spot punched in between each sample. All other testing methodologies and procedures remain unchanged from 2023.

HCV RNA laboratory testing

In 2015, HCV RNA was detected and quantified using a modified Abbott RealTime™ (Illinois, United States) HCV RNA assay. The Abbott RealTime HCV RNA assay involves specimen extraction automation using the Abbott M2000SP coupled with the M2000RT Realtime PCR instrument. A bias (+1.91 Log10) applied post run gave a quantifiable DBS HCV viral load (VL) result with a lower limit of detection of 977IU/mL (plasma equivalency). A qualitative result of <12IU/mL detected (trace/equivocal) was applied to samples <977IU/mL (plasma equivalency).

In all subsequent years (2016 to 2025), HCV RNA was detected and quantified on the Hologic Panther™ using the Aptima™ HCV Quant Dx assay (Hologic, Inc. San Diego, Calif) which has a limit of quantitation (LOQ) 10 IU/mL and an upper limit of quantitation of 10^8 IU/mL in plasma.

An offboard DBS elution protocol was applied prior to sampling. A 12mm spot was excised with a stainless steel hole puncher and flame sterilised between each sample. Spots were placed into an aliquot containing 1mL Hologic Specimen Transfer Media and eluted for 30 minutes at room temperature on an orbital rocker [Ratek]. Samples were centrifuged at 3000g for 2 mins then placed onboard the analyser.

To correct for haematocrit, all post run DBS viral load results on the Aptima assay were multiplied by a plasma conversion factor of 36.36. This calculation was based on the following assumptions: 45% haematocrit average per DBS, 50uL DBS volume and 1000uL Aptima transport media volume. A qualitative result of <10IU/mL detected (trace/equivocal) was applied to samples <400IU/mL (plasma equivalency).

Appendix C: List of tables

1. Demographic characteristics and drug use

Table 1.1.1	Number (%) of respondents by demographic characteristics and survey year
Table 1.1.2	Number (%) of respondents by last drug injected, frequency of injecting, overdose, imprisonment, injection in prison and survey year
Table 1.1.3	Number (%) of respondents by injecting behaviour in the last month and survey year
Table 1.1.4	Number (%) of respondents by treatment for drug use and survey year
Table 1.1.5	Number (%) of respondents by sexual behaviour in the month prior to survey and survey year
Table 1.1.6	Number (%) of respondents by testing for HIV and HCV, HCV treatment by survey year

2. HIV antibody prevalence

Table 1.2.1	HIV antibody prevalence by gender and survey year
Table 1.2.2	HIV antibody prevalence by sexual identity, gender and survey year
Table 1.2.3	HIV antibody prevalence by age group, gender and survey year
Table 1.2.4	HIV antibody prevalence by last drug injected, gender and survey year
Table 1.2.5	HIV antibody prevalence by years of injection, gender and survey year
Table 1.2.6	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year
Table 1.2.7	HIV antibody prevalence by frequency of drug injection last month, gender and survey year
Table 1.2.8	HIV antibody prevalence by imprisonment last year, gender and survey year
Table 1.2.9	HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year
Table 1.2.10	HIV antibody prevalence by sex work last month, gender and survey year
Table 1.2.11	HIV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.2.12	HIV antibody prevalence by region/country of birth, gender and survey year

3. HCV antibody prevalence

Table 1.3.1	HCV antibody prevalence by gender and survey year
Table 1.3.2	HCV antibody prevalence by sexual identity, gender and survey year
Table 1.3.3	HCV antibody prevalence by age group, gender and survey year
Table 1.3.4	HCV antibody prevalence by years since first injection, gender and survey year
Table 1.3.5	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year
Table 1.3.6	HCV antibody prevalence by last drug injected, years since first injection and survey year
Table 1.3.7	HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year
Table 1.3.8	HCV antibody prevalence by imprisonment last year, years since first injection and survey year
Table 1.3.9	HCV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.3.10	HCV antibody prevalence by region/country of birth, gender and survey year

4.	HCV RNA prevalence
Table 1.4.1	HCV RNA prevalence by gender and survey year
Table 1.4.2	HCV RNA prevalence by sexual identity, gender and survey year
Table 1.4.3	HCV RNA prevalence by age group, gender and survey year
Table 1.4.4	HCV RNA prevalence by years since first injection, gender and survey year
Table 1.4.5	HCV RNA prevalence by re-use of someone else’s used needle and syringe last month, gender and survey year
Table 1.4.6	HCV RNA prevalence by last drug injected, gender and survey year
Table 1.4.7	HCV RNA prevalence by frequency of drug injection last month, gender and survey year
Table 1.4.8	HCV RNA prevalence by imprisonment last year, gender and survey year
Table 1.4.9	HCV RNA prevalence by main language spoken at home by parents, gender and survey year
Table 1.4.10	HCV RNA prevalence by region/country of birth, gender and survey year

